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Increasing evidence implicates a persistent enteroviral infection of β-cells as a 
potential trigger for the development of Type 1 diabetes (T1D). In support of 
this, findings presented in this thesis demonstrate that interferon-stimulated 
genes are upregulated in pancreas samples from T1D donors, but absent from 
donors without T1D, despite evidence of viral protein in their islets. The reasons 
for this exaggerated response are unclear but may be related to altered 
regulation of the viral recognition protein, MDA5. Protein phosphatase 1, 
regulatory, inhibitory, subunit 1A (PPP1R1A) is a largely unstudied molecule 
and has a restricted tissue distribution, but is highly expressed in β-cells. 
PPP1R1A specifically regulates protein phosphatase 1 (PP1) which has a 
central role in coordinating MDA5 activity. Findings presented in this thesis 
demonstrate that PPP1R1A is depleted from β-cells in T1D.  
To explore the impact of PPP1R1A on β-cell function, clonal lines of tetracycline 
inducible β-cells were developed using the PPP1R1A-deficient 1.1B4 cells as a 
host line for the Flp-In T-REx system. Two cell lines were generated which 
express either wild-type (WT) PPP1R1A or a phosphorylation-null (T35A) 
mutant form, upon addition of tetracycline. During the development of these Flp-
In T-REx lines, I made the discovery that the parental 1.1B4 line was 
contaminated with an unidentified rat cell line. Data are presented on how this 
contamination was discovered and the steps taken to re-derive and characterise 
new human 1.1B4 cells lines. These findings have resulted in the withdrawal of 
1.1B4 (and other related cell lines) from the European Collection of 
Authenticated Cell Cultures (ECACC) and a change in international practice for 
the authentication of cell lines.  
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Despite these difficulties, the Flp-In T-REx PPP1R1A cell lines and other human 
cell lines available, were used to explore (1) the role of PPP1R1A in cell cycle 
progression and (2) the role of PPP1R1A in regulation of secretion from β-cells. 
Cell cycle progression was found to be reliant upon the timing of sequential 
PPP1R1A phosphorylation and dephosphorylation. Phosphorylation of 
PPP1R1A is critical for successful completion of the cell cycle and sustained 
phosphorylation of PPP1R1A resulted in apoptosis. Previous studies had 
identified PPP1R1A as a critical component necessary for insulin secretion. The 
studies reported in this thesis demonstrate that PPP1R1A could also play a 
previously unrecognised role in regulating constitutive secretion of molecules 
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1.1 Diabetes Mellitus 
Diabetes Mellitus is a term used to encompass a group of diseases 
characterised by overt hyperglycaemia. This can be a result of insufficient 
insulin secretion by pancreatic β-cells, or impaired insulin action on targeting 
muscles, or a combination of both (American_Diabetes_Association, 2013). 
Chronic hyperglycaemia can result in a number of complications including 
retinopathy, nephropathy, peripheral neuropathy and autonomic neuropathy. 
Prolonged or repeated episodes of hyperglycaemia can lead to amputation, 
blindness and kidney failure thus the ability to recognise the symptoms of 
hyperglycaemia (polyuria, polydipsia, polyphagia and weight loss) are of 
importance to aid in early diagnosis. Unfortunately, some people with diabetes 
must rely on lifelong administration of exogenous insulin to regulate blood 
glucose levels, however, the precise mode of management of diabetes largely 
depends on the classification of diabetes that one falls into. This can sometimes 
be difficult to tell as symptoms of Type 1 – and Type 2 diabetes can be similar, 
and individuals can be misdiagnosed (Thomas and Philipson, 2015). There are 
two main classifications of Diabetes; Type 1 diabetes and Type 2 diabetes, 
each of which can require very different management strategies.  
Although Type 1, and Type 2 diabetes are the most common forms of diabetes, 
there are other forms which are less common, including gestational diabetes 
mellitus, maturity onset diabetes of the young (MODY), and neonatal diabetes. 
These forms are described below. 
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1.1.1 Gestational diabetes mellitus 
Gestational diabetes affects ~ 16% of pregnant women in the UK (Diabetes UK 
https://www.diabetes.org.uk/diabetes-the-basics/gestational-diabetes (accessed 
11/12/10)), and is one of the most common complications of pregnancy (Petra 
et al., 2019). Gestational diabetes is diagnosed via a blood test during 
pregnancy, and often resolves after giving birth. During pregnancy, insulin 
sensitivity is decreased to allow more glucose to cross the placenta for foetal 
development (Simpson et al., 2018), caused by increased concentrations of 
hormones, such as oestrogen, progesterone and human placental lactogen 
(Sonagra et al., 2014). This decrease in insulin sensitivity is counteracted by an 
increase in β-cell mass and insulin secretion. Failure of maternal β-cells to 
compensate for the increased demand for insulin results in gestational diabetes 
mellitus (Simpson et al., 2018). Gestational diabetes is either treated with 
insulin injections or oral agents such as metformin. Gestational diabetes 
mellitus has been shown to affect both the mother and offspring, both of whom 
have increased risk of developing T2D in later life (Simpson et al., 2018, Petra 
et al., 2019).  
1.1.2 Monogenic diabetes 
Monogenic forms of diabetes include maturity onset diabetes of the young 
(MODY) and neonatal diabetes.  
1.1.2.1 Maturity onset diabetes of the young (MODY) 
MODY is a monogenic disorder caused by specific genetic mutations, rather 
than by an interplay between genetics and environment, unlike other forms of 




diabetes/mody; accessed 11/12/19). MODY is rare, and it is estimated that only 
1-2% of people with diabetes in the UK have a form of MODY. There are four 
common genes in which mutations result in MODY; HNF1-α, HNF4-α, HNF1-β 
and Glucokinase, however, currently there are as many as 14 genes in which 
mutations can be associated with MODY (Urakami, 2019). Of the four main 
genes, ~70% of MODY cases are caused by mutations in HNF1-α. HNF1-α is a 
transcription factor which is important during embryonic development (as are 
HNF1-β and HNF4-α), however in mature β-cells, HNF1-α is also important in 
regulating insulin expression, and mutations in HNF1-α have been shown to 
influence the glucose transport protein (GLUT2), as well as various metabolic 
enzymes (McDonald and Ellard, 2013). Mutations in HNF4-α have a similar 
impact on β-cell function to mutations in HNF1-α, and patients present with a 
similar progressive β-cell loss (McDonald and Ellard, 2013). One of the key 
differences between HNF1-α and HNF4-α MODY subtypes is that HNF1-α 
MODY is associated with glycosuria, whereas HNF4-α MODY is not (Urakami, 
2019). HNF1-β MODY results in insulin resistance in addition to β-cell 
dysfunction, unlike HNF1-α and HNF4-α MODY which both cause β-cell 
dysfunction. Glucokinase is the rate-limiting enzyme in β-cell glucose 
metabolism, responsible for phosphorylating glucose to glucose-6-phosphate, 
thus mutations in glucokinase alter the glucose sensitivity of β-cells, since, 
phosphorylation (metabolism) of glucose may be impaired or require a higher 
concentration to attain equivalent ATP synthesis and insulin secretion 
(McDonald and Ellard, 2013). These four genes account for ~80% of MODY 
cases. Other, rarer forms of MODY involve INS, KCNJ11 and ABCC8.  
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1.1.2.2 Neonatal diabetes  
Neonatal diabetes is defined as diabetes diagnosed within the first 6 months of 
life, and results from mutations in a single gene. The mode of inheritance can 
either be dominant or recessive, or may be via a de novo mutation (Hattersley 
et al., 2009). Mutations in genes which impact insulin resistance have only 
rarely been reported (Musso et al., 2004), more frequently, mutations occur in 
genes which regulate β-cell function (Musso et al., 2004, Hattersley et al., 
2009). Most common causes are the result of mutations in the INS, KCNJ11, 
ABCC8, EIF2AK3, FOXP3 or GCK genes (Hattersley et al., 2009, Barbetti and 
D'Annunzio, 2018).  
Collectively, these forms of diabetes; Gestational diabetes mellitus, Neonatal 
diabetes, and MODY only account for ~2% of all diabetes cases in the UK 
(https://www.diabetes.org.uk/; accessed 24/2/20). The other 98% of diabetes 
cases are contributed by Type 1 and Type 2 diabetes 
(https://www.diabetes.org.uk/; accessed 24/2/20). These are described further 
in the following sections.  
1.2 Type 2 diabetes 
The incidence of Type 2 diabetes (T2D) is rising globally, and accounts for 
~90% of all diabetes cases (https://www.idf.org/aboutdiabetes/type-2-
diabetes.html; accessed 11/12/19). T2D culminates as a result of an interplay 
between genetic and environmental risk factors (Fletcher et al., 2002). GWAS 
studies have identified 143 risk variants associated with T2D (Xue et al., 2018). 
Type 2 diabetes is characterised by insulin resistance, thereby applying 
pressure on β-cells to produce more insulin, and leading ultimately to β-cell 
failure. T2D is associated with high BMI and body fat percentage, although T2D 
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can also affect individuals who have a normal BMI (Han et al., 2019). 
Maintaining a healthy, balanced diet can often prevent T2D, and adherence to a 
highly calorie restrictive diet can even reverse the condition (McCombie et al., 
2017).  
Type 2 diabetes is initially treated by administration of metformin tablets with 
lifestyle intervention (Fonseca and Kulkarni, 2008), if this is unsuccessful, 
second-line drugs including sulfonylurea and Glitazone are trialled, or basal 
insulin can be administered with metformin. If these are unsuccessful alone, 
they may be trialled as combination therapies, with or without insulin injections 
(Fonseca and Kulkarni, 2008).  
1.3 Type 1 diabetes  
An estimated 400,000 people are living with Type 1 diabetes in the UK alone, 
with over 29,000 of them being children (https://jdrf.org.uk/information-
support/about-type-1-diabetes/facts-and-figures/ accessed 12/11/19). Incidence 
is increasing by ~4% per annum. This cannot be explained by genetics alone, 
especially given that 85% of individuals diagnosed with T1D have no family 
history of the disease (https://jdrf.org.uk/information-support/about-type-1-
diabetes/facts-and-figures/ accessed 12/11/19). All individuals with T1D rely on 
lifelong administration of exogenous insulin to lower their blood glucose levels, 
in order to avoid the associated diabetic complications already described. On 
the other hand, if the insulin requirement is miscalculated, and too much insulin 
is administered, this drops blood glucose levels too low, and subjects become 
hypoglycaemic. If blood glucose levels remain low for too long, patients can 
have even more serious outcomes such as fainting, coma or death.   
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Type 1 diabetes is an autoimmune disease, where the pancreatic β-cells are 
selectively targeted by immune mediated mechanisms. CD8+, CD4+ T cells and 
CD20+ B cells predominate in the immune cell infiltrate in young children (Leete 
et al., 2016). The proportion of these different immune cells varies according to 
the age at diagnosis. In children diagnosed under the age of 7 years, large 
numbers of immune cells infiltrate the pancreas. Regardless of the immune 
profile of an inflamed islet, the most frequently observed immune cells are 
CD8+ (Willcox et al., 2009), however, the proportion of B cells in each inflamed 
islet varied depending on age at diagnosis. Those diagnosed under the age of 7 
years have a higher ratio of CD20+:CD4+ cells in inflamed islets compared to 
those diagnosed over the age of 13 years (Leete et al., 2016, Leete et al., 
2018). The more aggressive immune cell profile in those diagnosed <7 years is 
reflected in the many fewer residual insulin containing islets (ICIs), compared to 
the proportion in those diagnosed >13 years, who can have a large number of 
residual ICIs at diagnosis. These findings have resulted in the identification of 
two endotypes of T1D; T1DE1 and T1DE2 (Leete et al., 2020). This could be 
important when considering immunotherapies for the treatment of T1D. Children 
diagnosed <7 (T1DE1) may respond better to an immunotherapy targeting B 
cells (CD20 cells) whereas those diagnosed >13 (T1DE2) may respond less 
well to this type of therapy. There is evidence for poor response to anti-B-cell 
therapy (anti-CD20; Rituximab) in T1D patients, however the patients enrolled 
in the clinical trial were aged between 8 and 40, with a new T1D diagnosis 
(Pescovitz et al., 2009), thus would fall mainly into the TIDE2 category, which is 




1.3.1 A brief overview of genetic links and Type 1 diabetes 
There are over 60 genetic loci associated with T1D and approximately half of 
the genetic risk is conferred by the Human Leukocyte Antigen (HLA) region on 
chromosome 6p21 (Bakay et al., 2019). HLA molecules are important in antigen 
presentation to immune cells, and immune cell activation. The highest risk for 
T1D comes from specific class II HLA genes, particularly in the DR and DQ loci, 
with individuals heterozygous for DRB1*03 and DRB1*04 (DR3/DR4) at highest 
risk of disease (Noble, 2015). Class I HLA also confers risk for T1D, as 
individuals carrying the HLA-A*24 allele have reduced residual β-cell function, 
compared to those with alternative HLA-A alleles (Nakanishi et al., 1993). 
Although the HLA region confers the highest degree of T1D risk, it is not the 
only genomic region conferring risk. Due to the polygenic association with T1D, 
a Type 1 diabetes genetic risk score can be employed to monitor ‘at-risk’ 
individuals, and to aid accurate diagnosis (Oram et al., 2016). The Type 1 
diabetes genetic risk score takes into account 30 single nucleotide 
polymorphisms (SNPs), including various SNPs in the HLA region as well as 
other SNPs from outside the HLA region (Sharp et al., 2018). 80% of T1D 
candidate genes are expressed in β-cells, and pathway analysis of these genes 
revealed that the three top pathway hits were “interferon signalling”, “role of 
JAK1, JAK2 and TYK2 in interferon signalling” and “role of pattern recognition 
receptors in recognition of bacteria and virus” (Marroqui et al., 2015). This 
suggests that T1D candidate genes are important in cellular response to viral 




1.3.2 A brief overview of islet autoantibodies 
Autoantibodies are antibodies produced by B cells that recognise self-proteins. 
The development of Type 1 diabetes is often preceded by the detection of 
particular autoantibodies circulating in the blood. There are four main 
autoantigens recognised in T1D; Insulin (IAA), glutamic acid decarboxylase 2 
(GAD65), protein tyrosine phosphatase like protein (IA-2) and zinc transporter 8 
(ZnT8) (Palmer et al., 1983, Rabin et al., 1992, Baekkeskov et al., 1990, 
Wenzlau et al., 2007), although more recently, a fifth autoantigen has been 
identified; tetraspanin protein family member 7 (TSPAN7) (McLaughlin et al., 
2016). All of these proteins are expressed in β-cells (Lampasona and Liberati, 
2016). In a report by Ziegler et al. (2013), it was found that nearly 8% of at-risk 
children who were autoantibody negative at enrolment, seroconverted to 
autoantibody positive during follow up, furthermore over 90% of children who 
developed diabetes had been positive for autoantibodies previously. The 
development of islet autoantibodies is associated with genetic predisposition, 
particularly with HLA haplotypes. In particular, GADA and IAA or IA-2A are 
associated with DR3 and DR4 haplotypes, respectively (Giannopoulou et al., 
2015). Individuals who seroconvert to multiple autoantibodies are at greatest 
risk of T1D development (Lampasona and Liberati, 2016). The mechanism of 
development of islet autoantibodies and their role in disease development is yet 
to be fully elucidated, however autoantibodies remain a key marker and 




1.3.3 Role of a virus infection? 
As mentioned previously, the incidence of Type 1 diabetes is rising, particularly 
in children under 5 years old, where there is an ~5% increase per year 
(https://jdrf.org.uk/information-support/about-type-1-diabetes/facts-and-figures/). 
This increase cannot be accounted for by genetics alone, therefore an 
environmental trigger must be involved. One of the potential environmental 
triggers for the development of T1D is a viral infection, enteroviruses in 
particular have been strongly implicated (Krogvold et al., 2015, Morgan and 
Richardson, 2014, Richardson and Morgan, 2018, Richardson et al., 2009, 
Rodriguez-Calvo et al., 2016). Enteroviruses are non-enveloped, single-
stranded, positive sense RNA viruses, belonging to the Picornaviridae family. 
They are commonly circulating viruses, transmitted via the faecal-oral route. 
Infections are often asymptomatic, however a spectrum of symptoms can result, 
including myocarditis at the most severe end (Rodriguez-Calvo et al., 2016). 
Their genome consists of a 5’ untranslated region (UTR), a coding region then a 
3’ UTR. The coding region encodes 11 viral proteins including VP1 – VP4, 
polymerases and proteases. An association between enteroviruses and T1D 
has been suggested since 1969, when Gamble et al. (1969) found higher 
antibody titres of Coxsackie B virus in sera from individuals who had been 
diagnosed with insulin-dependent diabetes within three months, compared to 
controls or individuals who had been diagnosed for longer than three months. 
There is also some association between viral infections and the appearance of 
islet autoantibodies; Coxsackievirus (CV) B1 and CVB5 infections are 
associated with IAA as the first autoantibody, however there are no reported 
associations linking CVB with the appearance of GADA (Sioofy-Khojine et al., 
2018). Given that IAA and GADA are associated with different HLA haplotypes, 
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it is unclear whether particular haplotypes (i.e. HLA-DR4) make an individual 
more prone to viral infections or whether the development of IAA antibodies is 
due to viral infection mechanisms. It could be speculated that since the 
enteroviral receptor, Coxsackie and Adenovirus receptor (CAR), colocalises 
with insulin in β-cells, (Ifie et al., 2018), that this contributes to the association 
with IAA and CVB1 and CVB5 in some studies, since IAA is associated with 
insulin granules, and GADA is not. On the other hand, other studies have not 
shown an association between CVB1 and HLA genotype (Oikarinen et al., 
2014). 
Several epidemiological studies have also shown associations between T1D 
and enteroviral (EV) infections. In the Type 1 Diabetes Prediction and 
Prevention (DIPP) study it was found that EV infection (detected in stool 
samples) was found frequently in children, months before autoantibodies were 
detected (Honkanen et al., 2017). Additionally, the DIPP study found that not all 
coxsackieviruses are pathogenic, in fact they found that CVB1 is pathogenic, 
but that CVB3 and CVB6 are associated with reduced risk of islet autoimmunity, 
and could potentially protect against autoimmunity triggered by CVB1. In The 
Diabetes and Autoimmunity Study in the Young (DAISY), 2,365 genetically 
predisposed children were followed, and blood or rectal swabs were collected 
every 3-6 months after autoantibodies were detected, until a diagnosis of Type 
1 diabetes had been made. The DAISY study found that autoantibody positive 
individuals who progressed faster to T1D, were those with EV RNA in blood 
(Stene et al., 2010), suggesting that viral infection may trigger or augment 
autoimmunity in some individuals. Recent results from 383 children with islet 
autoimmunity and 112 children with T1D, enrolled in the Environmental 
Determinants of Diabetes in the Young (TEDDY) study imply that persistent 
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enteroviral B infection, rather than an acute enteroviral infection, is associated 
with development of islet autoimmunity (Vehik et al., 2019). This was concluded 
by analysing nucleic acid extracted from stools and subjected to next generation 
sequencing. In addition, samples from each stool were cultivated on virus-
susceptible cells, the nucleic acids extracted and subjected to next generation 
sequencing (Vehik et al., 2019).  
Few studies have utilised pancreas samples to assess viral infection in 
individuals with T1D. Access to pancreatic tissue / islets is very rare, especially 
from individuals diagnosed soon after the onset of T1D. However, in The 
Diabetes Virus Detection (DiViD) study, pancreas tissue collected soon (<9 
weeks) after diagnosis of T1D from 6 living adults revealed that VP1 (via 
immunostaining) was found in the islets of all 6 cases, and EV RNA (via PCR 
and sequencing) could be detected in four out of the six patients (Krogvold et 
al., 2015). Furthermore, using a different cohort of T1D pancreata from cadaver 
donors, VP1 was detected in 44 out of 72 young recent-onset T1D individuals, 
compared to only 3 out of 50 neonatal controls (Richardson et al., 2009).  
In a large meta-analysis of observational molecular studies, a significant 
association between EV and T1D was found, where the odds of EV infection in 
children at diagnosis of T1D was 10 x more than controls, and in children with 
autoimmunity, a 3-fold higher risk of EV infection was found (compared to 
controls) (Yeung et al., 2011). Furthermore, it was shown that there was a high 
association (odds ratio 11) between EV infection and established T1D (Yeung 
et al., 2011), suggesting that the EV infection could be persistent, since EV 
infection could be detected in pancreata with established T1D. Further evidence 
supports the hypothesis of a persistent enteroviral infection as a trigger for the 
development of T1D. The viral protein, VP1 can be detected in pancreas 
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samples from people with a T1D duration of 10 years in samples from the 
nPOD cohort (Dunne et al., 2019). Enteroviruses usually result in acute 
infections, and are not typically associated with persistent infection. Persistent 
infection may be promoted by a 5’ deletion of the viral genome, which gives rise 
to a replication deficient virus with a non-lytic capacity (Bouin et al., 2019, Bouin 
et al., 2016). Although there is much evidence associating EV infection with 
T1D, causality of T1D is still a question which remains unanswered – are 
individuals who develop T1D more prone to EV infection, so evidence of viral 
infection is an effect, rather than cause? One such study which tried to address 
this question evaluated the histopathology of T1D pancreata, and it was found 
that in VP1 positive insulin-containing islets (ICIs), >60% were not inflamed 
(Willcox et al., 2011), suggesting that VP1 infection precedes the infiltration of 
immune cells, which selectively target pancreatic β-cells. Due to the increasing 
evidence implicating enteroviral infections as a potential trigger for T1D, at least 
in some individuals, ProventionBio are developing a vaccine against 
Coxsackievirus, in the hope that a large proportion of T1D cases can be 
prevented (https://www.proventionbio.com/prv-101/). This method of prevention 
of T1D onset will target ‘at-risk’ individuals, i.e. those with high HLA-
susceptibility and those with a first-degree relative with T1D.  
In an Italian study, enteroviral RNA was detected in the blood of individuals 
newly diagnosed with T1D (79%), their parents (63%) and siblings (60%), more 
commonly than in relevant controls (3%) (Salvatoni et al., 2013). This indicates 
that, although many people become infected with virus, not everyone will 
develop T1D, suggesting that the way the β-cells respond to viral infection may 
be of most importance.  
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1.3.4 Other potential triggers of T1D 
1.3.4.1 Cow’s Milk 
For decades, associations have been made between the early introduction of 
cow’s milk into the diet with increased risk of T1D (Borch-Johnsen et al., 1984, 
Virtanen et al., 1991). In children at increased risk of T1D, the presence of islet 
autoimmunity was measured as part of the Diabetes Autoimmunity Study in the 
Young (DAISY). It  was found that, in children with a high risk HLA-DR genotype 
(HLA-DR3/4) cow’s milk intake had no effect on progression to T1D and islet 
autoimmunity, however, among children with low / moderate risk HLA-DR 
genotypes, the risk of T1D and islet autoimmunity was increased (Lamb et al., 
2015). Similar results were found in a subgroup of children enrolled in the Trial 
to Reduce Insulin-Dependent Diabetes Mellitus in the genetically at-risk 
(TRIGR). All children in this study had HLA-conferred T1D susceptibility, and an 
affected first degree relative. It was found that children with early exposure to 
cow’s milk proteins who later developed T1D, had aberrant humoral responses 
to cow’s milk proteins, compared to HLA-matched unaffected controls, 
suggesting that exposure to cow’s milk proteins can affect the adaptive immune 
response in children. The mechanisms are thought to involve molecular 
mimicry, between proteins found in cow’s milk and human proteins. For 
example, it has been proposed that bovine insulin can be detected in cow’s milk 
and an immune reaction towards this is developed, however these antibodies 
cross-react with human insulin in at-risk children (Vaarala, 2002, Paronen et al., 
2000). In the Type 1 Diabetes Prediction and Prevention Project (DIPP), a 
prospective population-based cohort study, new born children were screened 
for HLA genotype, and were monitored every 3 – 6 months for growth, 
autoantibodies and viral infections, as well as being given food questionnaires 
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for parents to fill out (Virtanen et al., 2006). Data from 3,565 children were 
analysed, and it was found that there was no association between age of 
introduction to cow’s milk and β-cell autoimmunity (Virtanen et al., 2006). 
Although there is evidence to suggest that Cow’s milk may be associated with 
the onset of T1D in some children, there is limited strong evidence.  
1.3.4.2 Vitamin D 
Vitamin D deficiency has been suggested to have an impact on the 
development of Type 1 diabetes, particularly in genetically predisposed 
children. One of the greatest sources of vitamin D is from sunlight. Since 
Finland has the highest global incidence of T1D (~60 cases per 100,000) 
(https://www.diabetes.org.uk/about_us/news_landing_page/uk-has-worlds-5th-
highest-rate-of-type-1-diabetes-in-children/list-of-countries-by-incidence-of-type-
1-diabetes-ages-0-to-14), it is hypothesised that the low hours of sunlight 
contribute to T1D incidence rates in Finland and Sweden (Dahlquist and 
Mustonen, 1994). Arguing against this, is evidence that  the incidence of T1D 
between other neighbouring populations; Karelian Republic of Russia and 
Finland are remarkably different, despite similar HLA-DQ T1D risk genotypes, 
similar geographical locations and sunlight hours (Kondrashova et al., 2005). 
This suggests that sunlight (and vitamin D) exposure may not be significant to 
trigger T1D. Due to the hypothesis that vitamin D deficiency contributes to T1D 
incidence in countries with low sunlight hours, vitamin D supplementation has 
been investigated as a means to protect against the onset of T1D. Vitamin D 
supplementation in early childhood has been found to be protective against T1D 
(Hyppönen et al., 2001, Zipitis and Akobeng, 2008, Harris, 2002, Stene et al., 
2000). Supplementation of Cod-liver oil, containing vitamin D during pregnancy 
has been also been associated with reduced risk of T1D in offspring, however 
46 
 
this could be due to ω-3 fatty acids in cod-liver oil, rather than vitamin D (Stene 
et al., 2000). Clinical intervention studies have also assessed the relationship 
between vitamin D supplementation (in conjunction with insulin therapy) in 
patients with T1D, with a range of observations reported (Infante et al., 2019). 
For example, some studies have reported an increase in regulatory T cells 
when vitamin D was supplemented (Gabbay et al., 2012, Treiber et al., 2015, 
Bogdanou et al., 2017) alongside a decrease in HbA1c levels (Gabbay et al., 
2012, Bogdanou et al., 2017, Giri et al., 2017, Panjiyar et al., 2018). On the 
contrary, other trials reported no significant changes in HbA1c levels between 
vitamin D-treated and control groups (Sharma et al., 2017, Haller et al., 2013, 
Perchard et al., 2017, Bizzarri et al., 2010, Pitocco et al., 2006). Differences in 
outcome after vitamin D supplementation could be due to the different forms of 
vitamin D supplemented (i.e. cholecalciferol vs calcidol), or differences between 
the concentrations of vitamin D achieved. Storm et al. (1983) investigated 
vitamin D metabolism between 5 groups of individuals with Type 1 diabetes, 
and found that vitamin D metabolism was not affected in adult-onset, insulin-
dependent diabetes, implying that aberrant metabolism of vitamin D is unlikely 
to be a contributing factor to T1D development, however, a larger study cohort 
with a wider age-range and controlled vitamin D form and concentration should 
be investigated.  
1.3.4.3 Hygiene hypothesis and Gut microbiota 
The hygiene hypothesis originally suggested that allergies were prevented by 
infections transmitted by “unhygienic contact” (Barker, 1985). More recently, 
non-harmful microorganisms, such as commensals and microflora are included 
in the hypothesis, and allergy as an outcome has been extended to include 
inflammatory diseases (Ege, 2017). The hygiene hypothesis states that the 
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decreased frequency of infections, through improved hygiene and medicine, 
results in an increased frequency of inflammatory diseases such as T1D 
(Jakobsen and Szereday, 2018, Bach, 2018). The geographical map of 
infectious diseases shows inverse correlation with the incidence rates of 
childhood T1D. This is also true more locally, where in a region as small as 
Northern Ireland the incidence of T1D is lowest in areas of poor hygiene 
(Jakobsen and Szereday, 2018, Bach and Chatenoud, 2012).  
In contrast to the hygiene hypothesis, the role of intestinal microbiota is thought 
to be related to the diversity of the microbiome, since this helps shape the 
immune system (Dunne et al., 2014, Arpaia et al., 2013, Wen et al., 2008, 
Koenig et al., 2011). The diversity of flora in individuals with T1D has been 
shown to differ from the flora of individuals without T1D. The intestinal flora of 
children with T1D consists of a higher proportion of Bacteroidetes phyla (which 
are gram negative) and a lower proportion of Firmicutes phyla (which are gram 
positive), which was the opposite of children without T1D (Boerner and 
Sarvetnick, 2011). In contrast, another study found that there were no 
differences between the bacterial profiles of individuals with T1D who had good 
glycaemic control and who were physically active (Stewart et al., 2017). This 
study had a small cohort of just 10 individuals in each group, each of which 
were matched for age, gender, BMI, peak oxygen uptake and exercise habits. 
This finding suggested that observations linking bacterial profiles of individuals 
with T1D development may be an effect, rather than cause of T1D. In another 
effort to understand whether the microbial profile differs between people with β-
cell autoimmunity and those without, de Goffau et al. (2013) took into account 
HLA genotype, early feeding history, age and sex when analysing the 
microbiota in faecal samples from 18 individuals who had at least two diabetes-
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associated autoantibodies, compared to those with no autoantibodies. It was 
found that there were a lower proportion of some groups of bacterial species in 
children with T1D associated autoantibodies. More longitudinal studies are 
needed to fully understand the role of gut microbiota in the development and 
pathogenesis of T1D.  
 
1.4 Pancreas in health 
1.4.1 Structure and function 
The pancreas is situated in the abdominal cavity, behind the stomach. During 
embryonic development, the pancreas is formed from buds, firstly the dorsal 
bud, followed by two ventral buds. The dorsal bud and the right ventral bud fuse 
at approximately 6 weeks gestation (Pan and Brissova, 2014). The dorsal bud 
forms into the upper part of the pancreas head, the neck, body and the tail, 
whereas the ventral bud forms the inferior part of the pancreas head (Pan and 
Brissova, 2014, Van Hoe and Claikens, 1999). Originating in the tail of the 
pancreas, the pancreatic duct runs along the length of the organ, and connects 
to the common bile duct, draining in to the duodenum (Henry et al., 2019). The 
pancreas is both an exocrine and endocrine organ, meaning it secretes 
molecules both into ducts (exocrine) and directly into the blood (endocrine). The 
exocrine pancreas is composed of acinar cells which are arranged around 
central lumens, and pancreatic ductal cells which form the duct walls. Acinar 
cells synthesise and secrete digestive enzymes, including trypsinogen, 
chymotrypsinogen, elastase, amylase, lipase, carbopeptidase and 
phospholipase A. These enzymes are secreted with water and bicarbonate ions 
into the pancreatic ducts, eventually reaching the duodenum.  
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The endocrine pancreas is organised into islets of Langerhans. These were first 
described in 1868, in the PhD thesis of Paul Langerhans (Langerhans, 1868), 
however it took until 1893 before these ‘islands of cells’ were found to control 
the blood glucose level, and were named Islets of Langerhans (Laguesse, 
1893). Pancreatic islets of Langerhans are composed of five different endocrine 
cell types; α-, β-, δ-, PP- and ε-cells (Arrojo e Drigo et al., 2015, Orci and Unger, 
1975, Brissova et al., 2005, Ekblad and Sundler, 2002, Roscioni et al., 2016), 
each of which secrete a specific hormone; glucagon, insulin, somatostatin, 
pancreatic polypeptide and ghrelin, respectively. Insulin and glucagon are 
paramount in regulating blood glucose concentrations, whereas the other 
hormones fine-tune this response. The function of each hormone is described in 
Table 1-1. Pancreatic β-cells are the predominant cell type within the islets and 
comprise 28-75% of each islet (Brissova et al., 2005), with α-cells being the 
next most abundant, comprising 10-65% of each islet (Brissova et al., 2005). In 
rodent models, the islet architecture is uniform with α- and δ-cells around the 
periphery of the islet, and β-cells in the islet core, whereas in human islets, each 
cell type is more dispersed across the islet (Figure 1-1) (Brissova et al., 2005, 







Hormone Function Target organ 
α-cell Glucagon Raises blood glucose 
levels 
Liver and adipose tissue 
β-cell Insulin Lowers blood glucose 
levels 
Liver then skeletal 
muscle and adipose 
δ-cell Somatostatin Inhibits secretion of insulin 
and glucagon 
α- and β- cells 
PP-cell Pancreatic 
Polypeptide 
Suppression of secretion 
by exocrine pancreas and 
bile secretion 
Pancreas 
ε-cell Ghrelin Stimulates appetite and 
suppresses insulin release 
Brain, pancreas 
Table 1-1 The five different cell types present in pancreatic islets of Langerhans 
 
 
Surrounding the islets of Langerhans, is an extracellular matrix, which consists 
of both a basement membrane and interstitial matrix (Korpos et al., 2013). The 
extracellular matrix is constituted of laminins, collagens, heparan sulphate / 
heparan sulphate proteoglycans (Bogdani et al., 2014). The basement 
membrane is composed mainly of glycoproteins, and its main role is to separate 
tissue compartments (i.e. separating the exocrine form the endocrine tissue) 
(Bogdani et al., 2014, Korpos et al., 2013). The interstitial matrix is composed 
mainly of fibrillar collagens and is located on the exocrine side of the basement 
membrane, surrounding the islet (Bogdani et al., 2014, Korpos et al., 2013). The 
extracellular matrix surrounding pancreatic islets of Langerhans acts to protect 
the islets from immune cell invasion and to help keep the islet structure in place 





Figure 1-1 Schematic diagram showing cell layout in (A) human islets and (B) 
rodent islets 
Schematic diagram showing the distribution of cell type in (A) human islets 
and (B) rodent islets, and the basement membrane surrounding the islets. 
Cells in human islets (A) are dispersed across the islet, whereas in rodent 
islets (B) α- and δ-cells are localised around the islet periphery, whereas 
β-cells are localised in the islets core.   
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As mentioned previously, the endocrine portion of the pancreas secretes 
hormones into the blood, therefore pancreatic blood flow regulation is of 
importance. Each islet is supplied with blood from up to five arterioles, which 
branch into capillaries (Ballian and Brunicardi, 2007), and lead ultimately to the 
hepatic portal vein (Rorsman and Ashcroft, 2018). Despite the pancreatic islets 
of Langerhans only composing ~1% of the pancreas mass, they receive 5 – 
15% of the organ’s blood supply (Ballian and Brunicardi, 2007), with some 
suggesting up to 20% (Rorsman and Ashcroft, 2018). The regulation of islet 
blood flow is achieved by innervation from the central nervous system, 
particularly the vagus nerve, which when stimulated results in islet vasodilation 
(Ballian and Brunicardi, 2007), thereby increasing blood supply to the islets 
when glucose is elevated, improving the capacity of these cells to sense 
glucose and secrete insulin in response.  
1.4.2 Cellular secretory pathways 
There are two main pathways by which molecules can be secreted (Figure 1-2); 
the constitutive pathway, which is present in all cell types; and the regulated 
secretory pathway, which is only present in specialised secretory cells, such as 
neurons and β-cells (Chang et al., 1998). There are three key characteristics of 
the constitutive secretory pathway; (1) The constitutive secretory pathway is not 
activated by an action potential, (2) the rate limiting step of this pathway is at 
transcription / translation, (3) there is no intracellular storage of cargo-filled 
secretory vesicles (Revelo et al., 2019) (Figure 1-2). Upon transcriptional 
stimulation, mRNA destined to be a secreted protein is trafficked to the 
endoplasmic reticulum (ER) where the mRNA is translated into proteins. The 
proteins are then transported to the appropriate cellular compartment. Proteins 
for constitutive secretion are trafficked to the Golgi, where they may be modified 
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in ways such as O-linked glycosylation, then proteins are packaged and sent to 
the plasma membrane for secretion (Revelo et al., 2019, Stanley and Lacy, 
2010). Most proteins destined for the plasma membrane, or to be secreted 
including cytokines and interferons, are routed through this constitutive 
secretory pathway (Chang et al., 1998, Stanley and Lacy, 2010). 
The regulated secretory pathway, as the name suggests, is much more highly 
regulated. In comparison to the constitutive secretory pathway components (1) 
alterations in cell membrane potential, strong enough to elicit an action potential 
is essential for release of vesicular contents, (2) the rate limiting step is not 
transcription / translation, but exocytosis is, (3) secretory granules are stored in 
the cytosol until an appropriate stimulus is detected (Revelo et al., 2019). 
Examples of molecules secreted via the regulated pathway include insulin, 
(Figure 1-3) and neurotransmitters e.g. ACh, GABA and dopamine. Insulin 





Figure 1-2 Differences between regulated and constitutive secretory pathways – 
adapted from Stanley and Lacy (2010) – Pathways for cytokine secretion 
Proteins secreted via the regulated secretory pathway (A) are transcribed, 
and translated constitutively, although this can also be augmented by 
appropriate stimuli. They are processed through the endoplasmic 
reticulum (ER) and Golgi apparatus. They are then stored in granules until 
an appropriate stimulus triggers fusion with the plasma membrane and 
exocytosis of storage granule contents. In contrast, proteins secreted via 
the constitutive secretory pathway (B) are not transcribed until an 
appropriate stimulus signals to do so. The gene is then transcribed and 
translated and processed through the ER and Golgi apparatus. Once the 
protein has been trafficked through the golgi, it is immediately secreted. 
The rate limiting step in this pathway is gene transcription, whereas the 
rate limiting step in regulated secretion is an appropriate stimulus 




1.4.2.1 Insulin synthesis and processing 
Humans have one gene for insulin, INS, which is located on chromosome 11. 
Insulin transcription and translation are regulated by blood glucose levels 
(Poitout et al., 2006). The main transcription factors controlling the INS gene are 
MafA, PDX1 and NeuroD1 (Tokarz et al., 2018, Andrali et al., 2008). Elevated 
glucose concentrations can promote the binding of PDX1 to transcriptional 
control elements (Poitout et al., 2006). Once the INS gene has been 
transcribed, it is translated into a 110 amino acid precursor, preproinsulin 
(Guest, 2019, Tokarz et al., 2018, Patzelt et al., 1978). Whilst it is in the rough 
ER, preproinsulin is cleaved to form proinsulin, by a signal peptidase, which 
cleaves off the N-terminal signal peptide (Patzelt et al., 1978). Proinsulin is then 
able to be folded by chaperone proteins, linking the A and B chains by three 
sets of disulphide bonds (Guest, 2019, Tokarz et al., 2018) in the Golgi 
apparatus where it is then sorted into Zn2+ and Ca2+ rich secretory granules. 
The proinsulin forms hexamers in association with Zn2+ and Ca2+ (Dunn, 2005). 
As these immature secretory granules become increasingly acidic, proinsulin is 
further processed (Orci et al., 1987) and C-peptide is cleaved by the 
prohormone convertases PC1/3 and PC2 (Guest, 2019). Carboxypeptidase E 
can then cleave basic amino acids on the C-terminus of proinsulin, resulting in 
mature insulin A and B chains which are linked by disulphide bridges (Tokarz et 
al., 2018, Hutton, 1994). Hexameric insulin is not very soluble, thus is 
crystallised in the secretory vesicles (Dunn, 2005). Upon exocytosis of insulin 
vesicles, crystalline insulin hexamers dissolve to produce insulin monomers, 
which can act on target tissues. A single pancreatic β-cell can contain more 
than 10,000 insulin granules (Dean, 1973, Rorsman and Renstrom, 2003). 
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1.4.2.2 Insulin secretion  
Insulin secretion from pancreatic β-cells is highly regulated, and only achieved 
under conditions of elevated blood glucose concentrations, beyond the fasting 
blood glucose concentration of 4 – 5 mM. It is maximal at glucose 
concentrations >20 mM (Rorsman and Ashcroft, 2018). Glucose enters the 
pancreatic β-cell via facilitated diffusion through glucose transporter 1 (GLUT1) 
in humans or GLUT2 in rodents (Henquin, 2000). Glucose is then metabolised 
through glycolysis. The first step is the phosphorylation of glucose to glucose – 
6 – phosphate, catalysed by the ‘glucose sensor’, glucokinase. In most other 
cell types this step is carried out by hexokinase, which has a lower Km for 
glucose than glucokinase (Middleton, 1990). The higher concentration of 
glucose needed for phosphorylation by glucokinase limits the stimulated release 
of insulin to situations when blood glucose concentrations are elevated above 
basal levels. The final product of glycolysis is pyruvate, which enters the TCA 
cycle for oxidation and yields the reducing agent, NADH, which drives the 
electron transport chain to yield an increase in ATP. The increase in ATP 
increases the ATP/ADP ratio, and closes ATP-sensitive K+ (KATP) channels. 
KATP channel closure restricts K+ efflux which depolarises the cell, resulting in 
activation of L-type voltage-dependent calcium channels (VDCCs), allowing an 
influx of calcium (Ca2+) into the cell. Ca2+ influx stimulates exocytosis of insulin 
granules. This pathway of insulin secretion can be amplified in many ways. One 
such method is by an upregulation of cyclic adenosine monophosphate (cAMP) 
within the β-cell. cAMP can be increased by Gs-protein-coupled receptors 
(GPCRs) in response to incretin hormones such as, glucagon-like-peptide 1 
(GLP1) and gastric inhibitory polypeptide (GIP). GLP1 and GIP are released 
from the gut in response to glucose, and help to modulate the release of insulin 
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upon food intake (MacDonald et al., 2002). They cannot stimulate insulin 
secretion in the absence of glucose, however, they potentiate insulin secretion 
when glucose concentrations are elevated. Refer to Figure 1-3 for an overview. 
Activation of muscarinic Gq-protein coupled receptors (e.g. by acetylcholine) 
can also augment insulin secretion (Figure 1-3). This is triggered by elevated 
phosphatidylinositol (PI) being incorporated into phosphatidylinositol 
bisphosphate (PI(4,5)P2), which results in elevated 2nd messengers inositol 
trisphosphate (IP3) or diacylglycerol (DAG). DAG activates protein kinase C 
(PKC) which augments insulin granule release (Turk et al., 1993, Yamazaki et 
al., 2010). Alternatively, IP3 can bind specific receptors on the ER membrane, 
triggering calcium to be released from the ER stores (Suh et al., 2008, Ahren, 
2000).  
Glucose stimulated insulin secretion (GSIS) happens in two phases, termed the 
first phase, and second phases (Grodsky, 1972). First phase secretion occurs in 
the initial few minutes after stimulation, whereas the second phase of insulin 
secretion is more gradual and occurs over the next 60 minutes and can be 
sustained (Grodsky, 1972). The first phase of insulin secretion is due to 
exocytosis of granules in the ‘readily releasable pools’ (RRP). These are 
granules which contain mature insulin and are in close proximity (~100-200 nm) 
to the cell plasma membrane (Kalwat and Cobb, 2017). It is thought that the 
RRP constitutes ~5-15% of the granules in a cell (Hou et al., 2009, Kalwat and 
Cobb, 2017). Once the RRP of granules has been depleted, the rate of insulin 
secretion is slower as granules have to be recruited from intracellular sites. The 
second pool of granules is then mobilised and secreted, which marks the 
second phase of insulin secretion. Both phases of insulin secretion occur 
through the same sequence of events; glucose entry, increased glucose 
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metabolism, increase in ATP/ADP ratio, closure of KATP channels, opening of 
VDCC, calcium influx and mobilisation of secretory vesicles. An increase of 
cAMP within the cell through activation of GPCRs, amplifies the glucose 





Figure 1-3 Pathway of insulin secretion 
Glucose enters the cell via the glucose transporter, GLUT1. Once glucose 
has entered the cell it is metabolised, initially through glycolysis, which 
yields pyruvate. Pyruvate can then enter the Krebs cycle, where NADH is 
yielded. NADH acts as a reducing equivalent, which drives the electron 
transport chain, generating ATP. An increase in ATP increases the 
ATP:ADP ratio. This increase in ATP:ADP ratio closes ATP sensitive 
potassium channels (KATP) on the cell membrane, depolarising the cell 
membrane, which results in the opening of voltage gated calcium 
channels, allowing calcium influx. This influx of calcium triggers exocytosis 
of insulin containing granules. Insulin secretion can be augmented by an 
increase in intracellular cAMP by means of Gs-protein coupled receptor 
(GPCR) signalling for example by the incretin hormones GIP and GLP-1 
binding their respective receptors on the β-cell membrane. Insulin 
secretion can also be augmented by Gq-coupled protein receptors (e.g. by 
acetylcholine). This results in an increase in phospholipase C (PLC) 
activity, which elevates the second messengers diacylglycerol (DAG) and 
inositol trisphosphate (IP3). DAG increases PKC activity and IP3 binds IP3 
receptors on the ER membrane which releases Ca2+ from the intracellular 
ER stores into the cytoplasm. These mechanisms augment insulin 
secretion, however are insufficient to trigger insulin secretion in the 
absence of glucose.  
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1.5 How can we study the pancreas? 
1.5.1 Animal models 
To study Type 1 diabetes, there are two commonly used animal models; the 
Non-Obese Diabetic (NOD) mouse and the Bio-Breeding diabetes-prone (BB) 
rat. These animal models have similarities to human diabetes, and are useful in 
understanding some processes in diabetes pathology, as their pancreas can be 
examined longitudinally through the disease process. This can itself cause 
confusion, as rodent pancreas has a different composition to human pancreas, 
with arrangement of cell type etc., where rodent pancreas has α-cells located at 
the islet periphery, and β-cells are in the centre of the islet, whereas human 
islets have a more heterogeneous arrangement of cells (Figure 1-1). In addition, 
the inflammatory profile of diabetic rodents is much different to that of humans, 
where there are many more infiltrating immune cells in rodent diabetes (In't 
Veld, 2014). Due to these differences, rodent models of Type 1 diabetes have 
their limitations. Diabetes in the described rodent models can be reversed by 
several reagents which are not effective in the human disease including various 
immunotherapies (Lenzen, 2017, Ben Nasr et al., 2015). 
1.5.2 Tissue biobanks 
Human pancreas material is rare, thus much of the functional studies on the 
pancreas are derived from animal models, this is partially due to the positioning 
of the pancreas within the body – in the middle of the abdominal cavity, behind 
the stomach making it inaccessible. More importantly, the majority of the 
pancreas produces and secretes digestive enzymes, and if after biopsy the 
lesion is not adequately sealed, the digestive enzymes can leak out and lead to 
extreme adverse consequences. There are a limited number of human 
pancreas samples available to study, and even fewer from individuals with Type 
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1 diabetes (<600 across all cohorts) (Morgan and Richardson, 2018). There 
were three main collections available for study in my work; the Exeter Archival 
Diabetes Biobank (EADB), the Network for Pancreatic Organ Donors with 
Diabetes (nPOD) and the Diabetes Virus Detection Study (DiViD) cohorts. Each 
of these collections has unique advantages and when used carefully, can 
enhance the understanding of healthy pancreas and T1D pancreas pathology.  
1.5.2.1 EADB 
The EADB collection is an archival collection housed in Exeter, assembled by 
Professor Alan Foulis between 1980 and the mid 1990’s (Foulis et al., 1986, 
Morgan and Richardson, 2018). Many of the pancreas samples were collected 
post-mortem, meaning that the tissue is of variable quality, and the fixation 
method of the samples was not standardised. However, the EADB collection 
contains the largest number of pancreas tissue samples collected from children 
under 10 years of age with recent onset T1D (Morgan and Richardson, 2018), 
thus a great deal can be learned from this collection of pancreas tissue, and it is 
an invaluable resource.  
1.5.2.2 nPOD 
The nPOD biobank was established in 2007 by the Juvenile Diabetes Research 
Foundation (JDRF) (Campbell-Thompson et al., 2012), and includes T1D 
patients, non-diabetic autoantibody positive individuals, autoantibody negative 
non-diabetic individuals and also individuals with disorders relevant to β-cell 
function. In addition to pancreas samples, serum, blood and lymph-nodes were 
also collected. Each donor has been further analysed for T1D autoantibodies, c-
peptide levels and HLA genotype. The nPOD biobank currently comprises a 
total of 514 donors, 167 of which are T1D (ages 4.4 – 93 years) 
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(https://www.jdrfnpod.org/for-investigators/donor-groups/ Accessed 17.12.19). 
All samples collected by nPOD are processed in an optimised standardised 
manner.  
1.5.2.3 DiViD 
The DiViD study collected pancreas tail resection biopsies from 6 living 
participants (3 male, 3 female) with newly diagnosed Type 1 diabetes (3-9 
weeks). Unfortunately, due to post-operative complications, no further 
individuals were recruited to the study. These samples provide an invaluable 
resource to learn about Type 1 diabetes soon after diagnosis, however, all the 
participants were adults (ages 24 – 35), and there are no samples from 
individuals without Type 1 diabetes available to make direct comparisons 
(Krogvold et al., 2014). For non-diabetic comparisons, nPOD samples are often 
used, since the processing of the nPOD and DiViD samples was done similarly. 
Additional information such as age and BMI can also be matched between 
nPOD and DiViD samples. 
1.5.3 In-vitro β-cell models 
1.5.3.1 Human islets 
The gold standard for studying β-cell biology is the isolated human islet 
(Persaud et al., 2010), however these have their disadvantages. Isolated 
human islets are prioritised for transplantation in the UK, rather than for 
research, and are often only used in research if they do not meet the criteria for 
transplantation, thus are rarely obtainable. Isolated human islets can also be 
highly variable. The status of the donor will impact the data obtained when 
using the islets, i.e. age, gender, BMI and clinical history, in addition to the way 
in which the islets were isolated from the donor, also impacts on the data 
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obtained when using the islets (Persaud et al., 2010). Isolated human islets are 
only viable for a limited period do not replicate in culture, therefore long duration 
experiments cannot be carried out.  
1.5.3.2 Clonal β-cell lines 
Since isolated human islets are not routinely obtainable, most β-cell research is 
carried out using clonal β-cell lines. There are very few human β-cell lines 
commonly used, these include EndoC-βH1 (Ravassard et al., 2011) and 1.1B4 
cells (McCluskey et al., 2011), and these cell lines have only been available in 
the last decade. The processes by which these cell lines were created is 
discussed in section 2.1. EndoC-βH1 cells are notoriously fastidious and are 
challenging to manipulate e.g. transfect or genetically modify. However they are 
comparable to isolated human islets, so are considered the “next best” to 
isolated human islets. More recently there have been advancements on the 
EndoC-βH1 cells, resulting in the EndoC-βH2 (Scharfmann et al., 2014) and 
EndoC-βH3 (Benazra et al., 2015) cell lines. EndoC-βH2 cells were developed 
using similar methods to the EndoC-βH1 cells and proliferate due to inserted 
immortalising transgenes. These transgenes are then silenced via use of Cre-
loxP (described in more detail in chapter 4), which resulted in decreased cell 
proliferation and enhanced β-cell gene expression (Scharfmann et al., 2014). 
The EndoC-βH3 cells are a revised version of the EndoC-βH2 cells which have 
an additional Cre site. They have been transduced with tamoxifen sensitive Cre, 
where the addition of tamoxifen silences the immortalising transgenes, again 
resulting in arrested proliferation and enhanced insulin expression and secretion 
(Benazra et al., 2015).  
There are many more rodent β-cell lines than human β-cell lines available, 
including MIN6, INS-1, INS-1 832/13 and BRIN-BD11. The development of 
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these cell lines is discussed further in section 2.1. Rodent β-cell lines are often 
used for in vitro studies, since EndoC-βH1 cells are challenging, and the 
alternative human β-cells, 1.1B4 cells, have low insulin content. MIN6, INS-1 
and INS-1 832/13 cells offer promising alternatives, since these display high 
insulin expression, β-cell gene expression, and some of these lines are robustly 
glucose responsive. 
Most β-cell lines are capable of forming pseudoislets (3D aggregates of cells) in 
culture. Pseudoislet formation often enhances β-cell characteristics, such as 
gene expression and insulin secretion, thus are also useful models to study β-
cell physiology (Persaud et al., 2010).  
1.5.3.3 Stem cell derived β-cells 
Stem-cell derived β-cells are not only useful in the field of diabetes research, 
but also potentially in the future treatment of diabetes, since β-cells selectively 
destroyed in T1D could be replaced by patient derived stem cells. There are a 
few reports of stem cell derived β-cells, the first of which was by Rezania et al. 
(2014) where human embryonic stem cells and induced pluripotent stem cells 
were differentiated into insulin expressing cells, resembling β-cells. One of the 
major limitations to current protocols for stem-cell derived β-cells is that the 
differentiated cells resemble immature β-cells, rather than functionally mature β-
cells (Odorico et al., 2018, Balboa et al., 2019). Patient derived induced 
pluripotent stem cells (iPSCs) have been successfully used to study the impact 
of neonatal diabetes-causing genetic mutations in the INS gene on β-cell 
function (Balboa et al., 2018). Furthermore, these patient derived iPSCs were 
corrected by use of CRISPR-Cas9 technology to generate isogenic controls 
however, the cells (either containing the INS mutation, or corrected) did not 
differentiate to mature β-cells (Balboa et al., 2018). Once this hurdle of 
65 
 
immature β-cells has been overcome, stem-cell derived β-cells will be of much 




1.6 Protein phosphatase 1, regulatory (inhibitory) subunit, 1A (PPP1R1A) 
Most eukaryotic proteins require post-translational modifications to be active or 
carry out a specific role, a common dynamic post-translational modification 
undergone by proteins is phosphorylation. Kinases phosphorylate proteins and 
phosphatases dephosphorylate proteins at specific sites. There are up to 5 
times more kinases than there are phosphatases (Fardilha et al., 2012), thus 
whilst kinases are more specific, phosphatases have a much broader scope of 
target proteins. The regulatory proteins phosphatases associate with, largely 
dictate the protein target of the phosphatase, i.e. protein phosphatase 1 (PP1) 
has many target proteins, but dependent on the regulatory subunit it associates 
with, it will dephosphorylate (or be inhibited from dephosphorylating) a more 
limited set of protein targets. Work described in this thesis focusses on a 
regulatory protein of PP1; Protein phosphatase 1, regulatory, inhibitory subunit, 
1A (PPP1R1A). 
Although PPP1R1A is the gene name, there are several other protein names 
used, including; Protein Phosphatase Inhibitor 1, IPP-1, Inhibitor 1 and I1.  
PPP1R1A was identified and isolated from rabbit skeletal muscle by Huang and 
Glinsmann (1976), who identified inhibitor-1 and inhibitor-2 as inhibitors of 
phosphorylase phosphatase, which we now know as protein phosphatase 1 
(PP1). Huang and Glinsmann (1976) revealed that PPP1R1A (inhibitor-1) acts 
to inhibit this phosphatase, in a reaction requiring phosphorylation by a PKA. By 




1.6.1 Regulation of PPP1R1A 
The transcription factor for PPP1R1A has not been directly studied, however, 
computer predicted transcription factors include HOXA9, C/EBPβ, FOXO3(b), 
FOXO3a, HEN1 and Meis-1 (https://genecards.weizmann.ac.il/v3/cgi-
bin/carddisp.pl?gene=PPP1R1A&search=3af8b31e4d14744e11c5890bbe8058
db; accessed Feb 2020).  
The molecular weight of PPP1R1A (in humans) is ~19 kDa. The protein 
sequence of PPP1R1A has little ordered structure and is very rich in proline and 
glutamic acid (Nimmo and Cohen, 1978). For PPP1R1A to be active (binding 
and inhibiting PP1), PPP1R1A must be phosphorylated at Threonine35 (Huang 
and Glinsmann, 1976, Foulkes and Cohen, 1979, Endo et al., 1996). The 
protein responsible for phosphorylating PPP1R1A is protein kinase A (PKA), 
which is activated by increased intracellular levels of cAMP. Few studies have 
been carried out examining the phosphatase for Thr35, however in the brain, 
dephosphorylation of PPP1R1A at Thr35 is carried out by PP2A (Mulkey et al., 
1994, Nguyen et al., 2007). In the brain, PPP1R1A can also be phosphorylated 
at Serine6 by cdk5, and again, PP2A is thought to be the phosphatase for this 
site (Nguyen et al., 2007). Other potential phosphorylation sites include Serine 
67 (Bibb et al., 2001) and Serine 65 (Nguyen et al., 2007). These serine 
phosphorylation sites do not directly affect the binding affinity of PPP1R1A to 
PP1, but there is some evidence to suggest that they help to stabilise the 
phosphorylation at Thr35, since mutation of one or both of Ser6 and / or Ser67 
resulted in decreased Thr35 phosphorylation by >75% (Nguyen et al., 2007).  
The binding of PP1 to PPP1R1A occurs at aa8RKIQF12 (Endo et al., 1996), near 
the N terminus of the protein. 
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The phosphorylation sites and PP1 binding site of PPP1R1A is represented 
schematically in Figure 1-4.   
 
In rabbit skeletal muscle, the basal phosphorylation of PPP1R1A is ~31%, and 
this increases up to 70% after injection of adrenaline (Tao et al., 1978, Foulkes 
and Cohen, 1979, Khatra et al., 1980), it was noted that PPP1R1A is 
phosphorylated at a similar rate as glycogen synthase in skeletal muscle. Since 
PP1 is known to be involved in the regulation of glycogen metabolism in skeletal 
muscle, it was hypothesised that PPP1R1A regulated PP1 activity and resultant 
glycogen metabolism (Foulkes and Cohen, 1979). Since PPP1R1A is 
expressed in skeletal muscle and skeletal muscle is a target of insulin, the effect 
of insulin on PPP1R1A was investigated. It was found that insulin reduced the 
degree of PPP1R1A phosphorylation, to stimulate glycogen synthesis (Foulkes 
et al., 1980, Khatra et al., 1980, Nemenoff et al., 1983). It was hypothesised that 
insulin reduced PPP1R1A phosphorylation by decreasing cAMP (and PKA) 
activity or by inducing protein phosphatase 1 to dephosphorylate PPP1R1A.   
 
Figure 1-4 Schematic diagram of the binding site for PP1 and phosphorylation 
sites on PPP1R1A 
The purple bar represents PPP1R1A. Each coloured line represents the 
approximate position of amino acids which can become phosphorylated, 




1.6.2 Expression of PPP1R1A 
The expression profile of PPP1R1A has been mainly investigated in animal 
models, including mice, rats, rabbits and guinea-pigs. Across these animal 
models, PPP1R1A is expressed in rat skeletal muscle (Khatra et al., 1980, 
Foulkes et al., 1980), brain (Snyder et al., 1992) and adipose tissue (Nemenoff 
et al., 1983), guinea-pig heart (Gupta et al., 1996), rabbit liver (MacDougall et 
al., 1989), and kidney tubules (Higuchi et al., 2000) and pancreas of mice (Lilja 
et al., 2005). The expression profile of PPP1R1A in humans has not been 
widely studied, however appears to be more restricted, with low expression 
limited to adipocyte stem cells, but not mature adipocytes (Satish et al., 2015), 
cardiac cells (El-Armouche et al., 2004, Meyer-Roxlau et al., 2017), brain 
(Bossers et al., 2010) and isolated human islets (Jiang et al., 2013).   
Adipogenic stem cells were matured into adipocytes over a period of 21 days. 
Of interest, the mRNA expression of PPP1R1A at day 7 was increased by >4-
fold, but had returned to below baseline at day 21 (Satish et al., 2015), 
suggesting that PPP1R1A is important for the maturation of adipocytes, but not 
for the functioning of mature adipocytes, which is contradictory to earlier reports 
(Nemenoff et al., 1983). Alternatively, these authors have assessed rabbit 
protein expression of PPP1R1A and human mRNA expression of PPP1R1A, 
respectively, which could explain differences in results obtained between the 
two studies.  
An organ where PPP1R1A is highly expressed is the brain. In animal models, 
PPP1R1A is expressed within medium-sized neurons in the dorsal striatum 
(Gustafson et al., 1991), olfactory bulb, cortex, and dentate gyrus of the 
hippocampus (Nguyen et al., 2007). PPP1R1A has been deemed a central 
regulator of synaptic plasticity and holds a key position in neuronal signal 
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transduction (Nguyen et al., 2007). It has also been shown that during the 
progression of Alzheimer’s disease, the mRNA level of PPP1R1A is reduced in 
the first half of disease duration, before it is increased in later disease stages 
(Bossers et al., 2010), which could impact neuronal function in the disease.  
Pancreatic expression of PPP1R1A is restricted to the islets of Langerhans, 
specifically to β-cells (Jiang et al., 2013, Lilja et al., 2005), and it is a conserved 
β-cell marker across human and rodent β-cells (Martens et al., 2011). In fact, 
the expression of PPP1R1A is so restricted to the pancreatic β-cells that it has 
been suggested to be a biomarker for pancreatic β-cell destruction in diabetes 
(Jiang et al., 2013). Extracellular PPP1R1A could be detected in damaged rat 
and human islets, and streptozotocin induced diabetes in rats lead to decreased 
β-cell PPP1R1A and an increase in plasma levels of PPP1R1A (Jiang et al., 
2013). Although this was successful as a proof-of-principal investigation, a 
major limitation of PPP1R1A as a biomarker for pancreatic β-cell destruction is 
that it is filtered quickly by the kidney, due to its low molecular weight (<20 kDa) 
and has a half-life of ~15 minutes (Jiang et al., 2013). Therefore, may not be of 
use clinically, other than to measure real-time β-cell destruction. PPP1R1A 
expression, as alluded to, is reduced in Type 2 diabetes (Solimena et al., 2018, 
Taneera et al., 2015), however, there are no known SNPs in PPP1R1A 
associated with T2D. Exposing human islets to high concentrations of glucose 
(>18.9 mM) for 24 or 48 hours induces expression of PPP1R1A (Taneera et al., 
2015, Solimena et al., 2018). Both of these studies (Solimena et al., 2018, 
Taneera et al., 2015) also showed that silencing PPP1R1A in INS-1 832/13 
cells reduced insulin secretion, in response to glucose, although the 
mechanisms by which this was achieved was not discussed. As well as insulin 
secretion, PPP1R1A can impact the phosphorylation status of eukaryotic 
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translation initiation factor 2α (eIF2α) in HEK293 cells and in brains of squirrels 
(Connor et al., 2001), since eIF2α is a substrate for PP1. Vander Mierde et al. 
(2007) showed that incubation of MIN6 cells or mouse islets with up to 10 mM 
glucose decreased eIF2α phosphorylation, and that this was dependent on 
formation of a trimeric complex between PP1/PPP1R1A/eIF2α. The 
phosphorylation status of eIF2α is central to alleviating the unfolded protein 
response (UPR), which can ultimately lead to cell death, thus PPP1R1A could 
be critical in maintaining cell viability. 
There is increasing evidence suggesting that β-cells are heterogeneous, with 
regard to gene expression and insulin secretion (Farack et al., 2019, Dorrell et 
al., 2016, Avrahami et al., 2017, Roscioni et al., 2016). One of the hypotheses is 
that there are leader β-cells (“hub cells”) and follower β-cells, the hub cells 
coordinate the islet response to glucose and if the hub cells are damaged then 
the islet does not respond appropriately to glucose (Johnston et al., 2016). Hub 
cells are transcriptionally immature β-cells, however may be targeted in 
diabetes, resulting in whole islet failure (Johnston et al., 2016). Further to this, 
Dorrell et al. (2016) describe four antigenically distinct β-cell subtypes; termed 
β1-4. These subtypes are based on their expression of alpha-N-
acetylneuraminide alpha-2,8-sialyltransferase (ST8SIA1) and the tetraspanin, 
CD9. Of note, both of these proteins are also expressed on α- and δ-cells. It is 
unclear whether any of the β-cell subtypes described by Dorrell et al. (2016) 
corresponds to either the hub or follower cells described by Johnston et al. 
(2016). The four identified β-cell subtypes were either negative for both 
ST8SIA1 and CD9, positive for either ST8SIA1 or CD9 or positive for both. The 
PPP1R1A expression of these cell types was not homogenous, β1 and β3 β-
cells are negative for CD9, and these are the subtypes which had lowest 
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PPP1R1A expression (regardless of ST8SIA1A expression), and β2 and β4 β-
cells are positive for CD9, and these are the β-cells which had highest 
PPP1R1A expression (Dorrell et al., 2016). The β1 subtype has lowest basal 
insulin secretion and highest stimulated secretion, whereas the β4 subtype has 
highest basal secretion and lowest glucose stimulated insulin secretion, with β2 
and β3, subtypes between these two extremes. Since PPP1R1A is expressed 
most highly in subtypes β2 and β4, this does not directly support PPP1R1A 
playing a role in insulin secretion (Solimena et al., 2018, Taneera et al., 2015).  
1.6.3 PPP1R1A isoforms 
There are three known isoforms of PPP1R1A (Figure 1-5). These have been 
identified from human brain and liver, they include the full length isoform and 
two splice variants (Liu et al., 2002). The names of these isoforms is somewhat 
confusing as they are given different names in different databases. In the paper 
where they are initially described (Endo et al., 1996), they are termed isoform-
1α and isoform-1β, whereas in NCBI database they are termed Variant 4 and 
Variant 2, respectively and in ENSEMBL only variant 2 (V2) is documented. The 
function of each of these known isoforms is unknown. All isoforms however, 
retain the PP1 binding site (8RKIQF12) and Thr35 phosphorylation site.  
Since there is no clear evidence for the role of PPP1R1A in pancreatic β-cells, 





Figure 1-5 PPP1R1A isoforms and the exons they each contain 
Schematic diagram of the exons (coloured squares) that each of the 
PPP1R1A isoforms contain and the nomenclature for each isoform from 






1.6.4 PPP1R1A and regulation of antiviral responses  
A potential role of PPP1R1A, which may or may not be cell type specific, is 
regulation of the way in which cells respond to viral infection. Melanoma 
differentiation-associated protein 5 (MDA5) is a viral sensor protein, which 
recognises dsRNA, a molecule generated by some viruses during their 
replication cycle. For MDA5 to trigger an intracellular signalling cascade in 
response to viral infection, MDA5 must be in its ‘active’ (dephosphorylated) 
state. The protein responsible for dephosphorylating and activating MDA5 is 
PP1 (Wies et al., 2013). Under circumstances of minimal PPP1R1A expression, 
PP1 is free to dephosphorylate and activate MDA5, however in the presence of 
PPP1R1A, PP1 is inhibited, and thus cannot dephosphorylate and activate 
MDA5. Given the links between viral infection and onset of T1D (discussed in 
section 1.3.3), it was considered important to investigate whether the loss of 
PPP1R1A in T1D, could aid in perpetuating the antiviral response. This 




Figure 1-6 Proposed mechanism of PPP1R1A regulated IFN release from virally 
infected pancreatic β-cells 
When enterovirus infects cells, at some point during its replication cycle it 
will produce dsRNA. dsRNA is recognised and sensed by MDA5. MDA5 
triggers an intracellular signalling cascade which ultimately results in the 
release of Type 1 IFN from the cell. In order to regulate the release of IFN 
from the cell, MDA5 activity is regulated. MDA5 must be dephosphorylated 
in order to be active. In an inactive state it is phosphorylated. The protein 
responsible for activation and dephosphorylation of MDA5 is PP1. PP1s 
activity is also regulated by PPP1R1A, in the presence of PPP1R1A, PP1 
is inhibited, maintaining MDA5 in its inactive state. In the absence of 
PPP1R1A (as in the schematic on the right), PP1 is free to 
dephosphorylate and activate MDA5, resulting in Type 1 IFN release from 




1.7 Project aims 
The overarching broad aim of this study was to contribute to the ongoing efforts 
to investigate how PPP1R1A expression may influence the development of 
T1D. More specifically, how PPP1R1A may influence the way in which cells 
may respond to a viral infection, culminating in the development of Type 1 
diabetes.  
The first steps in this aim were; 
(1) To utilise human pancreas samples to investigate and compare the 
expression of interferon-stimulated genes in donors with Type 1 
diabetes, auto-antibody positive (but no diabetes), and no diabetes (auto-
antibody negative). The expression of proteins which have been 
previously demonstrated to have increased RNA expression in Type 1 
diabetes will be examined by immunofluorescence, and compared 
between donor groups. These proteins include; MxA, STAT1 and IRF1. 
(2) Evaluate the expression of a potential modulator of host response to viral 
infection, PPP1R1A, in human pancreas samples from individuals with or 
without Type 1 diabetes, across a wide range of ages and diabetes 
duration. This will be achieved by immunofluorescence staining, and 
analysis of the percentage of different cell types that express PPP1R1A, 
and the intensity at which they do.   
These studies in human pancreas tissue will be consolidated by in vitro studies. 
This will be achieved by; 
(3) Developing and characterising a cell line with tetracycline-inducible 
expression of PPP1R1A, or a non-phosphorylatable mutant form of 
PPP1R1A, using the Flp-In T-REx kit (Invitrogen Cat# 650001).  
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1.7.1 Aims to investigate the role of PPP1R1A in regulation of response to viral 
infection 
A persistent enteroviral infection will be established in the cells with tetracycline-
inducible expression of PPP1R1A. PPP1R1A expression will either be induced 
prior to viral infection, or induced once a persistent viral infection has been 
established. The differences in the way in which cells respond to viral infection 
will be analysed. In addition, PPP1R1A expression will be manipulated and the 
anti-viral responses by these cells will be followed. Questions such as these will 
be investigated; 
Does PPP1R1A expression affect MDA5 phosphorylation status? 
 This can be monitored using an anti-pMDA5 antibody (gift from Prof. 
Michaela Gack, University of Chicago) 
Does PPP1R1A have an effect on viral load? 
 The presence of viral infection can be determined by qPCR, in addition to 
staining for dsRNA and viral proteins, in addition to using flow cytometry. 
Cell supernatants can also be collected and analysed to determine viral 
load. 
Does PPP1R1A expression alter the expression of interferon-stimulated genes 
in β-cell models? 
 Interferon-stimulated genes which have been shown to be upregulated in 
Type 1 diabetes will be examined. These include; MxA, STAT1, HLA-
ABC, IRF1, PKR and MDA5. The expression of these will be determined 
by immunocytochemistry, and Western blotting. 
Does PPP1R1A expression affect cytokine release? 
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 Secreted cytokines can be measured using ELISA for specific 
interferons, such as interferon alpha and lambda.  
If PPP1R1A expression is induced prior to initial viral infection, does viral 
infection deplete PPP1R1A expression? 
 PPP1R1A expression can be detected via Western blotting, 
Immunocytochemistry and RT-qPCR. 
During the development of cells with tetracycline-responsive PPP1R1A 
expression, it was discovered that the 1.1B4 cell line (the chosen cell line in 
which to generate the tetracycline-responsive system) was contaminated with 
rat cells. Upon validation, the 1.1B4 tetracycline responsive cells were 
confirmed to be rat, rather than human.  
This meant that the role PPP1R1A plays in regulating antiviral responses could 
not be studied as human and rat anti-viral pathways are considerably different. 
This finding that the 1.1B4 cell line was contaminated created new aims;  
1.7.2 Revised aims 
(4) To isolate a human cell / cells from the contaminated 1.1B4 cell 
population and expand the clones 
(5) To characterise this ‘new’ human cell line. Characteristics to be 
examined include;  
 Expression of β-cell genes, to be determined by RT-PCR 
 Capability of the cells to secrete in response to canonical insulin 
secretagogues, including: glucose, cAMP agonists, potassium or a 
combination of these stimulants  




 Response to type 1 interferon or the viral mimic, Poly:IC. This will 
be determined by treating the cells, and measuring the expression 
of interferon stimulated genes by Western blotting. 
Using a combination of both of the cell lines generated (cells with inducible 
expression of PPP1R1A and h1.1B4 cells), and other β-cell lines available in 
the lab, alternative roles for PPP1R1A in β-cells were investigated. These 
included; 
(6) The role of PPP1R1A in regulation of cell cycle progression 
 This will be explored using flow cytometry to measure the 
percentage of cells in each stage of the cell cycle after induced 
expression of PPP1R1A, and in response to phosphorylated 
PPP1R1A. Immunocytochemistry will also be utilised to visualise 
mitotic cells after induced expression (and phosphorylation) of 
PPP1R1A. Cells will be co-stained for PPP1R1A or 
phosphorylated PPP1R1A and the widely used proliferative 
marker, Ki67.   
(7) The role of PPP1R1A in regulation of secretion.  
 Insulin secretagogues including: glucose, cAMP agonists and 
potassium, or a combination of these will be used to stimulate the 









2.1 Cell culture 
Cell lines used in these studies include the pancreatic cell lines; 1.1B4 (and 
derivatives of), INS-1E, INS-1 832/13, EndoC-βH1, PANC1, 1.2B4, BRIN-BD11, 
and Min6.  
For the majority of experiments, 1.1B4 cells (or derivatives of) were used. 1.1B4 
cells are reported to be glucose responsive, human pancreatic β-cells, created 
by the electrofusion of immortalised PANC1 cells with human pancreatic β-cells 
(McCluskey et al., 2011). PANC1 cells are derived from a human carcinoma of 
the ductal cells of the exocrine pancreas (Lieber et al., 1975).  
INS-1E cells are insulin-secreting rat β-cells, isolated from an x-ray induced rat 
transplantable insulinoma (Asfari et al., 1992). INS-1 832/13 cells are a clone 
from INS-1E cells that have been stably transfected with a plasmid containing 
the human proinsulin gene (Hohmeier et al., 2000). BRIN-BD11 cells are 
another glucose-responsive rat beta cell line, produced by the electrofusion of 
RINm5F cells with New England Deaconess Hospital rat pancreatic islet cells 
(McClenaghan et al., 1996). A further glucose-responsive cell line that was used 
in these studies were Min6 cells. These cells were obtained from insulinomas 
generated by targeted expression of the simian virus 40 T antigen gene in 
transgenic mice (Miyazaki et al., 1990). EndoC-βH1 cells were also used in 
these studies. EndoC-βH1 cells are a glucose-responsive, insulin secreting 
human β-cell line. They were produced by transducing a lentiviral vector 
containing SV40LT, under the control of the insulin promoter into human foetal 
pancreatic buds, before being transplanted into SCID mice for maturation 
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(Ravassard et al., 2011). 1.2B4 cells were created by the electrofusion of 
human pancreatic islets with HuP-T3 cells, which are a human pancreatic 




1.1B4, 1.2B4, BRIN-BD11 and Min6 were all cultured in RPMI 1640 media 
containing 11.1 mmol/l D-Glucose (Gibco), supplemented with 100 U/ml 
Penicillin and 100 µg/ml Streptomycin (Gibco), 2 mmol/l L-glutamine (Sigma) 
and 10% FBS (Sigma). INS-1E and INS-1 832/13 media was further 
supplemented with 50 µmol/l beta-mercaptoethanol (Sigma), and INS-1 832/13 
media further supplemented still with addition of 10 mmol/l Hepes (Sigma) and 
1 mmol/l sodium pyruvate (Sigma). 
PANC1 cells were cultured in DMEM media (Gibco) supplemented with 100 
U/ml Penicillin and 100 µg/ml Streptomycin (Gibco), 2 mmol/l L-glutamine 
(Sigma) and 10% FBS (Sigma). 
EndoC-βH1 cells were cultured in 5.5 mmol/l D-glucose DMEM media (Gibco), 
supplemented with 100 U/ml Penicillin and 100 µg/ml Streptomycin (Gibco), 2% 
BSA (fraction V, fatty acid free) (SLS), 50 µmol/l β-mercaptoethanol (Sigma), 
5.5 µg/l Transferrin (Sigma), 6.7 ng/ml sodium selenite (Sigma), 10 mmol/l 
nicotinamide (VWR). T25 flasks were pre-coated with coating medium (4.5 g/l 
glucose, 1% penicillin / streptomycin, 2 µg/ml fibronectin, 1% ECM) for at least 1 
hour prior to seeding freshly split cells. To split the cells, they were washed with 
PBS, then incubated with trypsin / EDTA solution for 3 – 5 minutes. Once cells 
were detached from the flask, the trypsin / EDTA solution was neutralised using 
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warmed neutralisation media (80 % PBS, 20 % FBS), and the solution was 
transferred to a 50 ml centrifuge tube. The cells were pelleted by centrifuging at 
700 x g for 5 minutes. Cells were resuspended in fresh culture medium, and 
seeded at a density of 1.75 x 106 cells per ml. EndoC-βH1 cells were sub-
cultured every 7-9 days, with 50% of the media refreshed every 3-4 days.  
All other cells were passaged every 4 to 5 days, or when they reached 80% 
confluency. Cells were dissociated from the flask by incubating for 5 minutes at 
37°C in 5% CO2 with Trypsin-EDTA (0.05%) (Gibco). Trypsin was neutralised 
with fresh media, and cells were pelleted by centrifugation at 200 x g for 5 
minutes. The pellet was then re-suspended in 10 ml fresh media and typically, 1 
ml of the cell suspension was transferred into a new flask with 19 ml fresh 
media for continued growth. All cell lines were incubated at 37 °C, 5 % CO2 and 
100 % humidity and were mycoplasma negative (tested by using the 
MycoAlert™ Mycoplasma Detection Kit (Lonza)). 
The cell origins and media used are summarised in Table 2-1, and key 
properties of the cells are described in table Table 2-2.
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RPMI 1640 media containing 11.1 mmol/l D-Glucose 
(Gibco), supplemented with 100U/ml Penicillin and 
100µg/ml Streptomycin (Gibco), 2mmol/l L-glutamine 







5.5mmol/l D-glucose DMEM media (Gibco), 
supplemented with 100U/ml Penicillin and 100µg/ml 
Streptomycin (Gibco), 2% BSA (fraction V, fatty acid 
free) (SLS), 50µmol/l β-mercaptoethanol (Sigma), 
5.5µg/l Transferrin (Sigma), 6.7ng/ml sodium selenite 




DMEM media (Gibco) supplemented with 100U/ml 
Penicillin and 100µg/ml Streptomycin (Gibco), 






RPMI 1640 media containing 11.1 mmol/l D-Glucose 
(Gibco), supplemented with 100U/ml Penicillin and 
100µg/ml Streptomycin (Gibco), 2mmol/l L-glutamine 










RPMI 1640 media containing 11.1 mmol/l D-Glucose 
(Gibco), supplemented with 100U/ml Penicillin and 
100µg/ml Streptomycin (Gibco), 2mmol/l L-glutamine 
(Sigma) and 10% FBS (Sigma), 50µmol/l beta-
mercaptoethanol (Sigma), 10mmol/l Hepes (Sigma), 








RPMI 1640 media containing 11.1 mmol/l D-Glucose 
(Gibco), supplemented with 100U/ml Penicillin and 
100µg/ml Streptomycin (Gibco), 2mmol/l L-glutamine 





RPMI 1640 media containing 11.1 mmol/l D-Glucose 
(Gibco), supplemented with 100U/ml Penicillin and 
100µg/ml Streptomycin (Gibco), 2mmol/l L-glutamine 





RPMI 1640 media containing 11.1 mmol/l D-Glucose 
(Gibco), supplemented with 100U/ml Penicillin and 
100µg/ml Streptomycin (Gibco), 2mmol/l L-glutamine 







RPMI 1640 media containing 11.1 mmol/l D-Glucose 
(Gibco), supplemented with 100U/ml Penicillin and 
100µg/ml Streptomycin (Gibco), 2mmol/l L-glutamine 




RPMI 1640 media containing 11.1 mmol/l D-Glucose 
(Gibco), supplemented with 100U/ml Penicillin and 
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100µg/ml Streptomycin (Gibco), 2mmol/l L-glutamine 
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X   Yes No X  
Table 2-2 Significant properties of the cell lines used in this thesis 
Since multiple cell lines were used in this thesis, this table summarises some key features of each cell line including verified 
species, original reference describing the development of the cells, immortalisation method, which cell type they are a model 
of, insulin expression and secretory properties.  
*There is no peer-reviewed article describing the origin of these cells, although they were developed in the Ulster, by Flatt et 
al. Details about the cells can be found at: https://www.phe-
culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=10070103&collection=ecacc_gc (accessed 29/7/20). 
**These cell lines express insulin at the mRNA level, however express no detectable mature insulin at the protein level. 
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2.1.1 Freezing of cells 
When a T75 flask reached ~80 % confluency, cells were split as normal, but 
resuspended in 4 or 5 ml (depending on cell confluency) freezing solution 
(Table 2-3). 1 ml of the cell suspension was then aliquoted into cryovials, and 
stored in CoolCells (BioCision) at -80 °C for 24 hours, before being transferred 
to liquid nitrogen storage.  
2.1.2 Transfections  
Cells were seeded at an assay dependant density into either 24 or 6 well plates, 
depending on the experiment. After seeding, cells were left to adhere to the 
plates for 24 hours, then the media was refreshed. The transfection mix 
consisted of serum-free media (Opti-MEM (Fisher)), liposomal-based 
transfection reagent and cDNA (either in the form of an expression vector, or 
polyinosinic:polycytidylic acid (Poly:IC)). Different cell lines respond differentially 
to transfection reagents, for example, on some cells Avalanche®-Omni gives 
the optimum transfection efficiency, whereas for other cell lines, this transfection 
reagent is highly toxic. Therefore, the transfection reagent used was determined 
by balancing the one with the highest transfection efficiency with the least 
amount of toxicity in the given cell line (Table 2-4). Length of incubation time 
was also considered for optimum transfection efficiency. Transfection mixes 
were gently mixed by pipetting and left for 15 minutes before being added 
dropwise to the cells. The transfection mixture was left on the cells for 14-24 
hours (dependant on the cell line), before the media was changed.   
2.1.3 Pseudoislet preparation 
Pseudoislets are 3-dimensional cell structures, which mimic, in part, the 
arrangement of pancreatic islets. They are formed by cultured β-cell lines when 
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they are grown in ultra-low attachment flasks. Pseudoislets were prepared by 
seeding 20 % of a confluent T75 into a non-adherent T75 flask (Corning). Cells 
were incubated for 3 to 4 days, and harvested once pseudoislets had formed.  
Buffers Recipe 
Freezing 
solution for cells 
30ml FBS (Sigma) + 5ml DMSO (Sigma) 
Whole cell lysis 
buffer 
20mM Tris, 150mM NaCl, 1mM EDTA, 1% Triton-X (10μl/ml 
Protease and phosphatase inhibitor cocktails 2 and 3) 
BCA 49 parts A : 1 part B  
Reagent A: bicinchoninic acid, sodium carbonate, sodium 
tartrate and sodium bicarbonate in 0.1M NaOH (pH11.25) 
Reagent B: 4% (w/v) copper(II) sulphate pentahydrate 
Running Buffer 50mM MOPS, 50mM Tris Base, 0.1% SDS, 1mM EDTA, 
pH7.7 
Transfer Buffer 14.4g Glycine, 3g Tris, 0.8L H2O and 0.2L Methanol 
TBS(T) – 
western blotting 
40g NaCl, 1g KCl, 30g Tris (+0.005% Tween 20 for TBST) 
LDS buffer Purchased from Fisher 
Lithium dodecyl sulphate (pH8.4), Glycerol 
Saline GM 1.10mg/ml D-Glucose (Sigma), 0.40mg/ml KCl (Sigma), 
0.39mg/ml Na2HPO4 (Sigma), 0.15mg/ml KH2PO4 (Sigma), 
NaCl (Sigma), 0.5mM EDTA (Sigma) 
Flow cytometry 
staining solution 
50µg/ml Propidium iodide (Sigma), 100µg/ml RNAase A 
(Thermo Fisher, Life Technologies) in PBS 
TBE Buffer 80mM Tris, 40mM boric acid, 0.2mM EDTA (pH 8.0) 
Krebs Ringer 
Buffer (KRB) 
125mM NaCl, 4.74mM KCl, 1mM CaCl2, 1.2mM KH2PO4, 
1.2mM MgSO4, 5mM NaHCO2, 25mM HEPES 
Antibody dilution 
solution (ADS) 
0.1M lysine, 10% donor calf serum, 0.02% sodium azide, in 
PBS 
TBS – (IHC)  50mM (61g) Tris, 0.9% (90g) NaCl 
STWS 40mM NaHCO3, 170mM MgSO4 , 0.05% Sodium azide 
Citrate (0.01M) 
pH6 
19.2 g Citric acid, pH’d with NaOH 
EDTA (1mM) 
pH8 
3.7g EDTA, pH’d with NaOH 














































ThermoFisher 15338500 3.5 μl/μg DNA 
14 
hours 
Table 2-4 Optimised transfection conditions used for different cell lines 
Conditions for h1.1B4 and 1.2B4 cells were optimised by myself, whereas 
transfection conditions for 1.1B4 and INS-1 832/13 cells were optimised 
by other members of the IBEx group.  
*Length of time refers to the length of time the transfection mixture was left 




2.2 Methods for investigation into gene expression  
2.2.1 RNA extraction 
Once cells reached 70-80% confluency, RNA was extracted using the RNeasy 
mini Kit (Qiagen), according to manufacturer’s instructions. This was carried out 
in an area of the lab dedicated to RNA work to help ensure a sterile 
environment. The section of lab bench where RNA extraction took place was 
cleaned using RNAseZap and all pipette tips used were RNAse free. Briefly, 
cells were lysed using buffer RLT, supplemented with 10 µl / ml β-
mercaptoethanol to inactivate RNAses in the lysate, and then homogenized 
using QiaShredder columns. The eluate was then transferred to the RNeasy 
mini column. To ensure optimum binding conditions of the RNA to the spin 
column, ethanol is added. RNA binds to the column and any contaminants are 
washed away by centrifuging at 8000 x g. RNA is eluted in RNase and DNase 
free water during a final centrifugation step at 8000 x g. RNA was stored at -20 
°C short term or at -80 °C for long term storage. 
2.2.2 DNA Extraction 
DNA was extracted using the Invitrogen PureLink Genomic DNA Mini Kit 
according to the manufacturer’s instructions. Cells were collected by 
trypsinization and centrifugation at 10,000 x g for 5 minutes. The cell pellet was 
resuspended in 200 µl PBS, then Proteinase K was added to digest protein 
contaminants in the sample and aid in efficient lysis of the cells, and RNase A 
was added to degrade RNA in the sample. PureLink Genomic Lysis/Binding 
Buffer was added, vortexed and incubated at 55°C for 10 minutes to aid with 
cell lysis and to bind the DNA to the spin column membrane. 100% ethanol was 
then added to the sample to enhance DNA binding to the column, before 
centrifugation at 10,000 x g for 1 minute. The column was then washed a 
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number of times by centrifugation to purify DNA before elution. DNA was eluted 
in 50 µl Genomic Elution Buffer, again by centrifugation, followed by addition of 
a further 25 µl Genomic Elution Buffer to the column to ensure complete elution 
of the DNA. DNA was stored at -20°C short term or at -80°C for long term 
storage. 
2.2.3 RNA / DNA estimation 
The concentration of RNA or DNA in a sample was measured using the 
Nanodrop 8000 spectrophotometer (ThermoFisher Scientific). 1 µl RNA or DNA 
was pipetted onto the pedestal, and absorbance was measured. A 260/280 ratio 
of ~1.8 is considered as “pure” DNA, and a ratio of ~2.0 is considered as “pure” 
for RNA. A 260/230 ratio is also used as a secondary measurement of nucleic 
acid purity. A 260/230 ratio of ~2.0 - 2.2 is considered acceptable. Lower ratios 
for either 260/280 or 260/230 could indicate the presence of contaminants, such 
as protein for the 260/280 ratio, or carbohydrates for the 260/230 ratio. Samples 
that were not considered pure were discarded. 
2.2.4 cDNA synthesis 
Complimentary DNA (cDNA) synthesis is the conversion of single-stranded 
mRNA into complimentary DNA, which can then be used for polymerase chain 
reactions (PCR). For cDNA synthesis, 1 µg RNA was used with either the RT2 
first strand kit (Qiagen), or the SuperScript VILO cDNA synthesis Kit (Roche). 
Both kits include buffers containing random hexamers, and reverse 
transcriptase, which allow the generation of cDNA from Ribonucleic acid (RNA). 
Following incubation with these, and specific buffers for each kit (as per the 
manufacturers instructions), the samples were heated at 42°C in both cases, 
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then the reaction stopped by increasing the temperature to 95°C or 85°C in the 
RT2, or SuperScript VILO kit, respectively. cDNA was stored at -20°C.  
2.2.5 Primer Design 
Primers were designed using Primer3, which is an online tool 
(http://primer3.ut.ee/). The sequence of the gene of interest is entered, and 
parameters such as primer size (~20 bp) and GC content (40-60%) were 
specified. The primers were designed so that they would amplify a product 
between 200 and 400 bp. The specificity of the primers was checked using the 
online tool available from NCBI, Primer – BLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). If the primers were likely to 
amplify any off target sequence this tool highlights these and the expected size 
of these amplicons. If any off-target sequences were predicted to be amplified, 
an alternative primer set was selected that was not predicted to amplify any off 





Polymerase chain reactions (PCRs) are used to detect the presence of 
predefined specific sequences within (complimentary)DNA. Specific sequences 
are amplified using primers, which are short complimentary nucleotide 
sequences to those of interest. If the target sequence is present, it will be 
amplified. Amplified sequences – amplicons – are loaded into an agarose gel so 
that they can be separated by size, using an electric current. The size of the 
band can be checked against a reference ladder, and sequenced for validation 
of the amplified sequence. 
To perform a PCR, 1 µl cDNA, 1 µl of appropriate forward primer and 1 µl 
reverse primer was added to 22 µl 1x DreamTaq Green PCR Master Mix 
(Thermo Fisher). The Master Mix contains 4 mM MgCl2, DNA Polymerase and 
dNTPs. All PCRs began with an initial denaturation step of 95°C for 10 mins, 
followed by 35 - 40 amplification cycles which consisted of denaturation for 30 
seconds at 95°C, annealing for 30 seconds (at primer specific temperature), 
and an extension for 30 seconds at 72°C. The final step of the PCR was a final 
extension for 5 minutes at 72°C. PCRs were carried out in a thermocycler 
(SimpliAmpTM Thermal Cycler, Life Technologies).  
To separate the amplified products by size, they were separated by gel 
electrophoresis. The samples were loaded onto a 1% agarose (geneflow Cat# 
A4-0700) gel containing 0.005% GelRed (an alternative, safer nucleic acid stain 
to Ethidium Bromide) in TBE buffer (Table 2-3). In order to estimate the size of 
the amplified products, they were run alongside a DNA ladder with 100 bp 
increments (MassRuler Express, Thermo Fisher).  
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The gel was run at 100 V for 40 minutes, or until there was sufficient separation 
of the ladder and of the amplified products. The gel was viewed by using the 
GelMax Imager (UVP), which uses UV transillumination to visualise the bands. 
This system has a built-in digital camera to capture the image acquired under 
transillumination, which was viewed and captured on the GelMax UVP software.  
For confirmation that the amplified product was the expected sequence, the 
amplicon was extracted from the gel and sent to SourceBioscience, Cambridge, 
for sequencing (see section 2.3.1).  
2.3.1 Gel extraction 
For validation that a visualised band was the expected sequence, the band of 
DNA was extracted from the agarose gel, purified, and sent off for sequencing.  
To extract the amplicon from the gel, the gel was viewed using an LED 
transilliminator (dark reader transilliminator (Labtech)), and the sample was 
excised with a clean scalpel. The DNA was extracted from the gel using the 
QIAquick Gel Extraction Kit (Qiagen). The kit enables extraction and purification 
of DNA using column based technology. The excised gel is initially dissolved, 
then the DNA binds to the column under high salt conditions. Purification of the 
DNA is carried out by multiple wash and centrifugation steps (all at 17,900 x g), 
before DNA is eluted in low-salt buffer or water, by centrifugation.  
The returned sequence of the amplicon was opened using FinchTV software 
(version 1.4.0). The software shows how clean the sample is, as well as the 
nucleotide sequence. The returned sequence is then aligned using the online 
NCBI tool, BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=Blast
Search&LINK_LOC=blasthome). BLAST will return the sequence with any 
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matches that is found in the online database and highlight any differences, if 





2.4 Sub-cloning of DNA 
Bacteria, commonly E. coli, can be encouraged to take up exogenous DNA 
(transformation), and upon bacteria multiplication, DNA is alto multiplied. 
Plasmid DNA can be easily extracted and purified, and thus large quantities of 
plasmid DNA can be readily obtained.  
2.4.1 Transformation 
Competent E.coli, DH5α (NEB), were thawed on ice. 50 ng of an appropriate 
plasmid was added and the tube was softly flicked to mix, then incubated again 
on ice for 10 minutes. To allow the DNA to enter the bacteria, a heat shock 
method was used. This was achieved by incubating the bacteria / plasmid at 
42°C for 50 seconds, then on ice for 2 minutes. The bacteria was then added to 
900 µl Luria broth (LB) and incubated with shaking at 37°C for 1 hour. 50 µl of 
this solution was then added to an agar plate containing 100 µg/ml ampicillin 
(Sigma). For all plasmids that were used in these studies, the selection 
antibiotic was ampicillin. The agar plate was then incubated upside down 
overnight at 37°C to promote growth of transformed bacterial colonies.  
Single colonies were picked from the plate and expanded by transferring to 5 ml 
LB + ampicillin, and incubated with shaking at 37°C for 8 hours, then transferred 
to 100 ml LB + ampicillin overnight at 37°C, with shaking to promote growth of 
transformed bacterial colonies.  
Plasmids were extracted from the bacteria using the Plasmid midi kit, or 
Plasmid mini kit (Qiagen) depending on the volume of bacteria from which the 
plasmid was to be extracted from. The plasmid midi kit relies on gravity-flow 
anion-exchange to purify the plasmid from bacterial DNA, and uses isopropanol 
and centrifugation to precipitate DNA; whereas the plasmid mini kit, used for 
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DNA extraction from smaller volumes of bacteria, relies upon column based 
technology. 
Extracted DNA was sent to Source Bioscience for confirmation of sequence (as 
described in section 2.3.1).  
2.4.2 Glycerol stocks 
For long term storage of transformed bacterial colonies, 850 µl of turbid 
bacterial suspension was added to 150 µl glycerol and mixed well before storing 
at -80°C. These colonies could be re-amplified by scraping the top of the frozen 
glycerol suspension and streaking onto an agar plate containing ampicillin.  
2.4.3 Restriction digest 
A restriction digest uses specific restriction enzymes (NEB or Promega) which 
‘cut’ DNA at specific recognition sites, the cut site depends on the enzyme 
used. To perform a restriction digest reaction, 1-10 µg DNA is incubated with 10 
U restriction enzyme(s), 5 µl 10X digestion buffer and approximately 10 µg/ml 
BSA, all made up to 50 µl with nuclease free (nf)H2O. These mixtures are 
incubated at 37°C for 12 hours to ensure complete digestion of DNA. 
To assess the degree of digestion from each reaction, MassRuler DNA Loading 
Dye (6x) (ThermoFisher) was added to each sample, and the products of the 
digestion were separated by gel electrophoresis (section 2.3). Where required, 
DNA was extracted from the gel (as section 2.3.1) for sequencing or ligation 
(section 2.4.4), and the DNA product stored at -20°C.  
2.4.4 DNA ligation 
For the ligation of two DNA fragments, they must have been previously digested 
to produce complimentary ‘sticky’ ends or blunt ends on each DNA strand. 
Following restriction digestion, extracted DNA was ligated by incubation with 1 
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µl ligase enzyme (T4 DNA ligase, Promega) and 1x ligase buffer (Promega). 
The amount of DNA to be ligated was typically composed of two different ratios 
of backbone : insert, these were 1:2 and 1:7 although the backbone : insert ratio 
was altered if initial ligations were unsuccessful. The ligation mix was incubated 
overnight at 4°C to promote complete ligation. The ligation mix can then be 
transformed into competent E.coli (as described in section 2.4.1). Bacteria 
which have taken up successfully ligated plasmid will be expanded (section 
2.4.1). Following expansion of the colonies, a Plasmid mini kit was used to 
extract DNA from the bacteria. Typically, the success of ligation was assessed 
in two ways; either by direct sequencing of the plasmid (Source Bioscience) or, 
for quicker results, by restriction digestion of the product (see section 2.4.3) 
using sites that would be uniquely present / absent in the newly ligated DNA.  
Restriction enzymes were chosen based on their position and compatibility. 
Digest products were then separated by gel electrophoresis to confirm expected 
sizes (described in section 2.3). Digestion experiments would confirm whether 
the gene of interest was successfully inserted into the plasmid, but could not 
always determine whether the orientation of the gene was correct, which is why 
samples were directly sequenced. The primers used for sequencing were 
SourceBioscience stock primers, namely pCMVF (the forward primer for the 
CMV promoter) which was the promoter immediately upstream of the gene of 




2.5 Southern Blotting 
Southern Blotting separates DNA based on fragment size. Briefly, DNA is 
separated by electrophoresis, transferred onto a nitrocellulose membrane, and 
then specific DNA sequences are detected by radioautography traditionally 
(Southern, 1975), but by enzymatic reactions more recently (Zavala et al., 2014, 
Rihn et al., 1995). In the case of enzymatic detection, a biotin labelled probe is 
utilized, and this is detected by streptavidin conjugated to AP. The Southern 
blotting protocol I developed was a combination of the Southern Blotting 




and-northern-blotting.html) and  (Nature_Methods, 2004) 
2.5.1  DNA digestion 
For a Southern Blot to be successful, the DNA must first be fragmented before 
separating by agarose gel electrophoresis. This was achieved by using HindIII 
to digest the DNA, since HindIII has a single cut site in the pFRT/LacZeo 
plasmid which is located within the FRT site, thereby not hindering the LacZ-
Zeocin fusion gene. Cutting the DNA using a restriction enzyme that will not cut 
the LacZ-Zeocin fusion gene is crucial to later stages, as the DNA sequence 
which is going to be detected is the DNA sequence of LacZ. LacZ was selected 
as the DNA sequence to detect, as it should only be present in transfected cells, 
and the number of copies detected directly correlates with the number of 
insertions of the pFRT/LacZeo plasmid, as cells do not have endogenous LacZ 




2.5.2 Transfer onto nylon membrane 
Prior to the transfer of the DNA onto the membrane, the DNA must have been 
denatured in 3 x 15 minute washes of denaturing solution (1.5M NaCl, 0.5M 
NaOH, pH 13) with constant agitation. The gel was then washed 2 x with 
ddH2O.  
Charged nylon membrane (Sigma) was cut to the appropriate size, soaked in 
ddH2O then soaked in alkaline transfer buffer (0.4M NaOH, 1M NaCl) for 5 
minutes.  
The transfer relies upon the electrostatic forces between the negatively charged 
DNA in the gel and the positively charged nylon membrane. A container was 
prepared with alkaline transfer buffer (0.4M NaOH, 1M NaCl) and a raised 
platform in the centre. To create a clean environment, a piece of cling film is 
placed on top of the platform, but ensuring that the cling film is not in contact 
with the transfer buffer. On top of this, a piece of transfer buffer-soaked blotting 
paper is placed, with the edges submerged in the transfer buffer surrounding 
the platform. Next, was the gel, then the pre-soaked positively charged nylon 
membrane, then a stack of soaked blotting paper, ensuring there are no air 
bubbles between any of the layers thus far, followed by a large pile of paper 
towels, with a weight (2 x T75 flasks filled with water). This assembly (Figure 
2-1) was stood for 24 hours (at room temperature) with the paper towels 
replaced when they get wet. Once the 24 hours were complete, the success of 
the transfer can be checked by visualising the gel in the GelMax imager (as 




Figure 2-1 Transfer set-up for Southern Blotting 
The transfer for Southern Blotting relies upon the electrostatic forces between the DNA and nylon membrane, therefore unlike 
with Western blotting, there is no need for a current. A weight of 400g (water inside T75 culture flasks) acts to keep close contact 
between the DNA and the membrane. The blotting paper and paper towels prevent the system from drying out.   
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2.5.3 Making the probe 
The aim of carrying out the Southern blot is to determine how many times the 
pFRT/lacZeo vector had inserted into the cells’ genome, therefore, the probe 
that was used was designed to recognise a portion of the lacZ sequence, since 
the number of times this sequence is detected should directly indicate how 
many times the vector has inserted into the cells’ genome. Additionally, this 
fragment should not be digestible by HindIII.  
To make the probe, the LacZ sequence within the pFRT/LacZeo plasmid was 
amplified using primers. The primers used have been previously described by 
Takaoka et al. (2011) and are directed against LacZ: LacZ forward, 5’-
GCGTTACCCAACTTAATCG -3’; and LacZ reverse, 5’-
TGTGAGCGAGTAACAACC -3’ (PCR product; 320 bp). The reaction took place 
over 30 cycles, and the annealing temperature was 60°C. The amplified product 
was isolated by gel electrophoresis then extracted from the gel and sent for 
sequencing. Upon confirmation that it was the expected sequence the extracted 
DNA was used to create the probe. To create the probe, the Biotin DecaLabel 
DNA Labelling kit (ThermoFisher Scientific) was used according to the 
manufacturer’s instructions. The kit uses random decamers (rather than 
hexamers) which increases the annealing efficiency with DNA at 37°C. Klenow 
Fragment exo- is also used, which is an N-terminal truncation of DNA 
polymerase I meaning that it retains its polymerase activity, but loses its 
exonuclease activity, thus DNA polymerase I can replicate the DNA sequence, 
amplifying it, and amplicons will not be degraded by the usual exonuclease 
activity of DNA polymerase I. The end result of the process yields a Biotin-




To hybridize the probe to the DNA sequences, the PerfectHyb plus buffer was 
used (Sigma), which removes the need to carry out the pre-hybridization 
(blocking) step due to buffer components. The buffer was heated to 49°C and 7 
ul of probe was added. The membrane was placed in a glass dish DNA-side-up 
and the hybridization buffer and probe mix was added. This was incubated for 3 
hours at 68°C. After hybridization, the membrane was washed 3 x in decreasing 
SSPE % washes for 20 minutes each at room temperature, with shaking. SSPE 
contains 0.02 M EDTA and 2.98 M NaCl in 0.2 M PBS (pH 7.4). 
2.5.5 Detection 
For detection, the Biotin Chromogenic Detection kit (ThermoFisher Scientific) 
was used, this relies upon the binding of alkaline-phosphatase-labelled-
streptavidin to biotin. 
All steps were carried out at room temperature, on a plate shaker with moderate 
shaking. The membrane was initially blocked with the provided blocking solution 
for 30 minutes, then incubated with Streptavidin-AP for 30 minutes. The 
membrane was then washed 2 x with provided washing buffer for 15 minutes, 
before being incubated with detection buffer for 10 minutes. The membrane was 
incubated overnight with 10 ml substrate solution and protected from light. To 
stop the reaction, the membrane was washed 2 x with ddH2O. The result was 





2.6 Western Blotting 
Western blotting was first described in 1979 (Towbin et al., 1979), and is a 
technique widely used to analyse the expression of proteins within samples 
(Burnette, 1981). Proteins are isolated from the sample and separated 
according to size and charge, by loading them into a Sodium Dodecyl Sulphate-
poly acrylamide gel and passing an electrical current through the gel (gel 
electrophoresis). The now separated proteins are then transferred onto a 
microporous membrane, and proteins of interest can be detected using specific 
antibodies, a process termed blotting (Kurien and Scofield, 2015). Originally, x-
rays were used to detect antibodies (Burnette, 1981), however, enzymatic 
reactions and fluorescence are now more commonly used (Ni et al., 2017).    
2.6.1 Whole cell protein extraction 
Cells were washed in ice cold PBS. PBS was aspirated thoroughly to ensure all 
the liquid was removed from each well. 0.5 ml lysis buffer (Table 2-3) was 
added per T75 flask; 0.2 ml per T25; or 100 µl per well of a 6-well plate. 10 µl/ml 
each of protease and phosphatase inhibitor cocktails 2 and 3 were added to 
lysis buffer just before use. These inhibitors ensure that endogenous proteases 
and phosphatases in the cell are neutralised to preserve the both the amount of 
protein and phosphorylation status of proteins within the cells when extraction 
takes place.   
The cells were incubated in the lysis buffer + inhibitors on ice for approximately 
20 minutes. Cells were scraped off the growth surface using a rubber policeman 
and contents transferred to 1.5 ml microcentrifuge tubes (on ice). Samples were 
vortexed 4 times for 15 seconds, with 5 seconds on ice between each vortex. 
To pellet the cell debris, samples were centrifuged at 2,500 x g for 10 minutes 
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at 4 °C. The supernatant containing the extracted protein was transferred into a 
new tube and stored at -20 °C for short term storage, or -80 °C for long term 
storage. 
2.6.2 Protein estimation 
In order to estimate the concentration of protein in each sample the 
bicinchoninic acid (BCA) assay was used (ThermoFisher). The BCA assay 
detects protein via colorimetric analysis of reduction of copper ions. The 
reaction works in two phases. The first phase of the reaction is the biuret 
reaction, where copper chelates with protein in an alkaline environment to form 
a light blue complex. In the second phase of the reaction, BCA reacts with the 
reduced copper ion that was formed in phase 1, resulting in a purple colour 
proportional to the amount of protein in the sample, with absorbance measured 
at 562 nm. Bovine serum albumin (BSA) was used to make a standard curve of 
0, 200, 400, 600, 800, 1000 and 1,200 µg/ml, using lysis buffer as a diluent. In a 
96 well plate, each sample was diluted 1:5 and 1:10 with lysis buffer. 10 µl of 
each diluted sample or standard was pipetted into a new well in duplicate, then 
200 µl BCA reagent (49 parts reagent A with 1 part reagent B) was added to 
each of these duplicated wells. The plate was incubated at room temperature 
on a plate shaker for 10 – 15 minutes for the reaction, resulting in colour 
change, to take place. The absorbance was then measured at 562 nm using a 
Pherastar plate reader (Pherastar FS, BMG Labtech), and the concentration of 
each protein sample was calculated by comparing with the BSA standard curve.  
2.6.3 Gel electrophoresis 
Gel electrophoresis is the separation of proteins within a sample. The proteins 
are separated using an according to size and charge using Sodium Dodecyl 
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Sulphate-poly acrylamide gel electrophoresis (SDS-PAGE). The percentage of 
the poly acrylamide gels used is dependent upon the size of the proteins of 
interest. Higher percentage gels are used for smaller proteins, whereas lower 
percentage gels are used when larger proteins are of interest. Gradient gels are 
useful if multiple proteins of varying sizes are to be analysed on a single blot.  
Each sample was prepared for Western blotting with 65% protein extract / lysis 
buffer; 25% LDS buffer (4x) (Fisher); 10% β-mercaptoethanol. The LDS buffer 
contains lithium dodecyl sulphate (pH8) to allow for maximal activity of the 
reducing agent, as well as glycerol (to increase the density of the sample and to 
help with accurate loading), and the dyes; Coomassie G250 and Phenol Red, 
which are necessary to determine how far down the gel the samples have run. 
The β-mercaptoethanol helps to denature proteins to their primary structure, so 
that they migrate more evenly down the gel. The amount of protein was 
normalised for each set of samples, with typically 30 ug of protein sample 
loaded per blot. 
Samples were mixed by pipetting, then heated at 70°C for 10 minutes before 
loading onto the gel. 
Pre-cast 4 - 12 % Bis-Tris gels were purchased from Invitrogen, and secured 
into an Invitrogen XCell SureLock tank, with a spacer used if only a single gel 
was run. 20 µl each sample was added per well, alongside 5 µl protein ladder. 
The samples and ladder were loaded using a gel loading tip to increase loading 
accuracy. The gels were run for 120 minutes at 120 V, or until the dye front 
reached the bottom of the gel.  
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2.6.4 Transferring protein onto Polyvinylidene difluoride (PVDF) membrane 
PVDF membrane (Sigma) was cut to size, removed from its protective cover, 
and briefly permeabilised in methanol. The membrane was then washed 3 times 
in water and left to soak in transfer buffer (Table 2-3) until ready for use. 2 
pieces of blotting paper per gel to be transferred, were also cut to size and 
soaked in transfer buffer. 
On a clean surface, the gel was placed on top of a single piece of pre-soaked 
blotting paper. The wells and the bottom of the gel were carefully cut off using a 
clean scalpel, and discarded. The soaked PVDF membrane was placed on top 
of the gel and the other piece of blotting paper placed on top of the membrane. 
The sandwich was gently rolled to get rid of any bubbles between the layers 
before being placed gel side down on top of 2 soaked sponges inside the 
transfer cassette. Finally, 2 additional transfer buffer-soaked sponges were 
placed on top of the gel - membrane sandwich. The lid of the cassette was 
placed on top, and then the whole cassette slotted into the Invitrogen XCell 
SureLock tank, and secured with a clamp. The inside of the cassette was filled 
with transfer buffer, and the outside of the cassette was filled with water to keep 
the system cool. The transfer was run at 30 V for 120 minutes. 
 
2.6.5 Blotting the membrane 
Once the transfer was complete, the membrane was removed from the transfer 
cassette and placed into a 50 ml falcon tube with the protein side inwards. A 
blocking solution of 5% milk, 5% BSA or 2.5% milk with 2.5% BSA in TBST 
(Table 2-3) was added to the tube, depending on the primary antibody used. 
The membrane was left to incubate with 5 ml blocking solution for 1 hour at 
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room temperature on a roller. Primary antibody diluted in 3 ml of blocking 
solution was added to the membrane and incubated overnight at 4°C (Table 
2-3), followed by 1 hour at room temperature the following day. Membranes 
were washed 3 times in TBST for 15 minutes (each wash) before being 
incubated with the appropriate secondary antibody (Table 2-5) for 1 hour at 
room temperature. The secondary antibodies were either conjugated to a 
fluorescent tag (Invitrogen) or to alkaline phosphatase (AP) (Sigma). This was 
again followed by 3 x 15 minute TBST washes before detection.  
2.6.6 Loading controls 
To confirm that equal amounts of protein was loaded per sample, either β-actin 
or GAPDH were detected and used as a loading control. Either β-actin or 
GAPDH antibodies were incubated in 5% milk either overnight at 4°C or for 2 
hours at room temperature (Table 2-6). 
2.6.7 Detection of the membrane 
For detection of membranes probed with secondary antibodies conjugated to a 
fluorescent tag, membranes were placed protein side down into the Licor 
Odyssey CLx scanner. Auto settings for 700 nm and 800 nm channels were 
used to detect each blot. 
For detection of membranes probed with secondary antibodies conjugated to an 
alkaline phosphatase (AP) tag, excess TBST was removed from the membrane 
by gently placing the corner of the membrane onto white roll, then placing the 
membrane protein side up onto cling film. 1 ml of the detection reagent, CDP 
Star (C0712, Sigma) was pipetted onto the membrane and this was left to 
incubate at room temperature for 5 minutes, before the excess was drained off. 
The membrane was wrapped in a fresh piece of cling film, ensuring there were 
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no creases or bubbles over the membrane. Immediately before detection, a 
luminescent pen was used to carefully mark the ladder at appropriate sizes 
relevant to the protein of interest. The membrane was then placed under light 
for 1 minute to activate the luminescent pen before the blot was placed protein 
side down onto the scanner. Blots were scanned using the high sensitivity mode 
of the Licor C-DiGit scanner. 
Analysis was performed using Image Studio Lite Ver 5.2 software regardless of 
scanner used to capture the image.  
2.6.8 Stripping the membrane 
Stripping the membrane removes any pre-bound primary and secondary 
antibodies, allowing for subsequent re-probing and detection of antibodies 
raised in the same species or of proteins that are a similar molecular weight.  
Membranes were washed twice in TBST for 5 minutes. ReBlot Plus Strong 
Antibody Stripping Solution (10x; #2504, Merck) was diluted to a 1x strength in 
ddH2O, and 3 ml diluted ReBlot Plus Strong Antibody Stripping Solution was 
used per membrane. The solution was left to incubate for 13 minutes on a roller 
at room temperature. Blots were then washed twice in TBST for 5 minutes 
















Rabbit IgG AP Sigma #3687 Goat 1/25,000 1 hr Western Blotting 
Mouse IgG AP Sigma #A3562 Goat 1/25,000 1 hr Western Blotting 
Rabbit IgG 800 ThermoFisher #SA5-10036 Goat 1/5000 1 hr Western Blotting 
Mouse IgG 680 ThermoFisher #35519 Goat 1/5000 1 hr Western Blotting 
Rabbit IgG 488 Life Technologies #A11034 Goat 1/400 1 hr IF / ICC 
Rabbit IgG 555 Life Technologies #A21429 Goat 1/400 1 hr IF / ICC 
Mouse IgG 488 Life Technologies #A32723 Goat 1/400 1 hr IF / ICC 
Mouse IgG 555 Abcam ab150114 Goat 1/400 1 hr IF / ICC 
Rat IgG 488 Life Technologies #A11006 Goat 1/400 1 hr IF / ICC 
Rat IgG 555 Abcam ab150158 Goat 1/400 1 hr IF / ICC 
Guinea-pig IgG 555 Life Technologies A21435 Goat 1/400 1 hr IF / ICC 
Guinea-pig IgG 647 Life Technologies A21450 Goat 1/400 1 hr IF / ICC 
Goat IgG 488 Life Technologies A11055 Donkey 1/400 1 hr IF / ICC 
Rabbit / Mouse 
IgG 
HRP Agilent K5007 Goat N/A 30 mins IHC 
Table 2-5 Secondary antibodies used in this thesis.  
 




Table 2-6 Primary antibodies used for protein detection by Western blotting 
Reactive against Catalogue number Raised in Dilution Diluent Incubation time 
PPP1R1A Ab40877 Rabbit 1/1000 5% milk 
1hr at RT or 
Overnight at 4 °C 
pThr35 PPP1R1A Sc-14267 Rabbit 1/200 5% milk Overnight at 4°C 
MDA5 ALX-210-935-C100 Rabbit 1/500 2.5% milk & 2.5% BSA Overnight at 4°C 
IRF1 8478 Rabbit 1/1000 2.5% milk & 2.5% BSA Overnight at 4°C 
PKR 3072 Rabbit 1/1000 2.5% milk & 2.5% BSA Overnight at 4°C 
ISG15 Ab92345 Rabbit 1/1000 2.5% milk & 2.5% BSA Overnight at 4°C 
STAT1 Ab2415 Rabbit 1/200 2.5% milk & 2.5% BSA Overnight at 4°C 
pSTAT1 (Y705) Ab29045 Mouse 1/1000 2.5% milk & 2.5% BSA Overnight at 4°C 
TYK2 Ab57678 Mouse 1/500 2.5% milk & 2.5% BSA Overnight at 4°C 
GAPDH 60004-1 Mouse 1/10,000 
5% milk or 5% BSA or 2.5% 
milk & 2.5% BSA 
1hr at RT or 
Overnight at 4 °C 
113 
 
2.7 Flow cytometry for cell cycle analysis 
Flow cytometry uses lasers to rapidly measure parameters of single cells in 
solution such as cell size and granularity, and can also measure labelled 
fluorescent signals. Specific cell populations can then be analysed based on 
these parameters (McKinnon, 2018). Data obtained using flow cytometry are 
displayed as dot plots or histograms, plotting one parameter against another. 
Populations can be selected for further analysis, or specifically excluded from 
analyses (McKinnon, 2018). In respect to using flow cytometry to analyse cell 
cycle, propidium iodide is used to fluorescently label DNA (Pozarowski and 
Darzynkiewicz, 2004).  
As a cell progresses through the cell cycle, the amount of DNA within that cell 
will change. Cell cycle analysis by flow cytometry uses the fluorescent dye, 
Propidium iodide (PI, Sigma Cat#P4170) which when a cell is permeabilised, 
can enter and bind to DNA. PI provides a proxy of the amount of DNA present 
within the cell as it binds in proportion to the amount of DNA present. The 
fluorescent signal from PI is detected by the flow cytometer, and plotted as a 
histogram. 
Cells were collected from the cell culture dish by using Trypsin-EDTA, and 
pelleted at 2500 x g for 5 minutes. The supernatant was removed, and cells 
resuspended in 250 µl cold saline GM (Table 2-3). 750 µl of cold 95% ethanol 
was added to each sample and the samples were incubated on ice for at least 
30 minutes.  
Cells were then pelleted, the ethanol fixative removed before resuspending in 1 
ml staining solution (Table 2-3) and incubated for at least 1 hour at room 
temperature. RNase A (Life Technologies) is added to ensure that the 
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fluorescence signal will be from PI stained-DNA alone, and not RNA as the 
RNase A will digest single stranded RNA (ssRNA) (Pozarowski and 
Darzynkiewicz, 2004).  
Cells were then transferred into a FACS tube (Sarstedt) and analysed by flow 
cytometry (BD Accuri C6 Flow Cytometer). 25,000 events (cells) were counted 
per sample. The flow cytometer detects the fluorescence signal of the PI 
stained DNA. Cells undergoing apoptosis will have fragmented DNA, 
(Darzynkiewicz et al., 1992). Cells in G2/M will have nearly twice as much DNA 
as those in G1. Cells undergoing the S phase of the cell cycle will be increasing 
their DNA amount, until it doubles, in which case they will be in G2/M phase 
(Figure 2-2). The intensity of the signal from the PI stain will be proportional to 
the amount of DNA in each cell and can thus distinguish which phase of the cell 




Figure 2-2 DNA changes within a cell during cell cycle progression 
In G1, cells will have 1n of DNA. During the S phase, DNA replicates, 
creating 2n of the DNA. This remains at 2n through G2 and M phases of 
the cell cycle, until towards the end of the M phase where the one cell with 
2n DNA undergoes cytokinesis, and becomes two daughter cells, each 
with 1n of DNA. 
 
The size and granularity of each cell that passes through the laser is also 
detected. Initially, each cell is plotted as forward scatter (FSC) vs side scatter 
(SSC) (Figure 2.3(A)), which relates to the size of the cell (i.e. FSC) vs 
granularity of the cell (i.e. SSC) determined by the scattering of the light as the 
cell passes through the flow cytometer, this plot helps exclude any debris. The 
debris will display on the plot in the lower left corner, close to the apoptotic cell 
population (Figure 2-3(A)). Doublets are then excluded by plotting forward 
scatter height (FSC-H) vs forward scatter area (FSC-A) (Figure 2-3(B)). Cells to 
the right of the main cell population are considered doublets. The removal of 
doublets in this assay is important because doublets can appear as false 
positives of cells with twice the amount of DNA i.e. G2/M phase cells. The 
fluorescence intensity is then taken into consideration on the population which 
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excludes debris and doublets. The fluorescence intensity, termed PE-A, is 
plotted against the number of cells with that fluorescent intensity. Results are 
displayed as a histogram (Figure 2-3 (C)). The BD CSampler Plus software was 
used for analysis.  
 
Figure 2-3 Examples of plots of cell cycle analysis by flow cytometry 
Cell cycle stage was analysed in 1.1B4 Flp-In T-REx cells, using PI 
staining to give a histogram indicating the proportion of cells in different 
stages of the cell cycle. (A) shows PI positive staining plotted as FSC-A vs 
SSC-A. Black dots inside the black circle indicate debris in the sample. 
Cells within the red polygon were included in subsequent analysis, 
however, at this stage doublets are also included. (B) allows for doublet 
discrimination, by plotting FSC-A vs FSC-H. Events to the right of the 
polygon are doublets, which were excluded from further analysis. (C) is a 
typical histogram. The early apoptotic population of cells is labelled M6 and 
shows as a sub-G1 peak. The purple population are cells in the G0/G1 
phase of the cell cycle, the blue section of cells are in the S phase, and 
cells in G2/M phase are shown in the yellow/orange population on the right 





2.8 Secretion assay 
Since many of the cell lines used in these studies have very little / no insulin 
expression, insulin secretion could not be measured directly. As a surrogate to 
investigate the glucose sensitivity of these cells, human growth hormone (hGH) 
was transfected into cells, then the concentration of secreted human growth 
hormone in response to appropriate stimuli was measured. In cells which have 
a regulated secretory pathway, such as pancreatic β-cells, hGH can be used as 
a surrogate to measure insulin secretion, since hGH is also routed through the 
regulated secretory pathway (Figure 1-2 and Figure 1-3). Human growth 
hormone has been used as a marker of secretory granules and regulated 
secretion from neurons (Fisher and Burgoyne, 1999) in addition to secretion 
from pancreatic β-cells (Min6 cells) (da Silva Xavier et al., 2003). Furthermore, it 
has been shown to be display similar secretory patterns to insulin secretion in 
response to relevant stimuli (da Silva Xavier et al., 2003). In addition, Varadi 
and Rutter (2002) have demonstrated colocalisation of transfected human 
growth hormone and endogenous insulin in INS-1 and Min6 cells, confirming it 
is secreted via the regulated secretory pathway (discussed in section 1.4.2). 
Cells were seeded in 24-well plates at a density of 0.8x105 cells per well for the 
Flp-In T-REx, 1.2B4 and INS-1 832/13 cells, or 0.5x105 cells per well for the 
h1.1B4 and PANC1 cells. After allowing 24 hours for the cells to settle and 
adhere to the culture plate, they were transiently transfected (see section 2.1.2, 
Table 2-4) with a plasmid encoding hGH (da Silva Xavier et al., 2003), using 
transfection conditions described in section 2.1.2. In each condition, 0.5 µg hGH 
plasmid, or 2.5 µg hGH plus 2.5 µg plasmid encoding EV, WT or T35A 
PPP1R1A was transfected into the cells for the optimised length of time before 
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the media was refreshed. After a further 24 hours, the cells were incubated with 
various stimulants. 
Cells were first washed with 500 µl pre-warmed Krebs Ringer Buffer (KRB) 
(Table 2-3), before being pre-incubated with 500 µl KRB containing 0.1% BSA 
for 1.5 hours at 37°C to encourage cells to be secreting at a basal rate. The 
cells were then incubated with 300 µl KRB containing 0.1% BSA plus any 
stimulatory conditions (described in Chapters 5 and 6) for 1 hour at 37°C.  
After 1 hour incubation with the stimulation solutions, the supernatant was 
removed and stored at -20°C until used for analysis.  
 
2.9 ELISA 
The method of enzyme-linked Immunosorbent assay (ELISA) was first 
described by Engvall and Perlmann (1972), since then the method has been 
slightly adapted for use in plates rather than tubes, however the principal 
remains the same. To measure the concentration of hGH in the supernatants, a 
hGH ELISA kit (Roche Cat# 11585878001) was used. The kit exploits the 
sandwich ELISA principal (Figure 2-4), where antibodies against hGH are pre-
bound to the surface of each well in microplate modules. The supernatants 
collected from the transfected cells (see section 2.1.2) were transferred to the 
microplate modules and incubated for 1 hour at 37°C, any hGH in the samples 
will bind to the antibody-coated microplate module surface. The microplate 
modules were then washed 5 times with the provided wash buffer (PBS + 
Tween-20) to remove any un-bound sample. In the next step, a digoxigenin-
labelled antibody to human growth hormone (anti-hGH-DIG) was added, this will 
directly bind to the Human growth hormone which has bound to the antibody on 
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the microplate module surface. After 1hr incubation with the anti-hGH-DIG at 
37°C the plate was again washed 5 times with washing buffer, then an antibody 
conjugated to peroxidase against digoxigenin (anti-DIG-POD) was added and 
incubated at 37°C for a further 1 hour, this will bind to the digoxigenin. Again, 
the plate was then washed 5 times with washing buffer to ensure there was no 
residual unbound anti-DIG-POD. Finally, the peroxidase substrate, 2,2'-azino-
bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) was added. ABTS is 
cleaved by peroxidase, yielding a soluble green reaction product. The colour 
change in each sample is proportional to the amount of hGH is the supernatant. 
The absorbance was measured by a microplate reader (Pherastar FS). Two 
readings are made – one at 405 nm, and a reference wavelength of 490 nm, 
which is subtracted from the 405 nm reading to take into account any variation 
in the microplate modules. The concentration of hGH in each sample is 
calculated by referring to the calibration curve of a set of standards which are 






Figure 2-4 hGH ELISA principal 
The hGH is based on the sandwich ELISA. A microplate is supplied with 
pre-bound antibodies to hGH (anti-hGH). Upon addition of either a hGH 
standard, or culture medium containing hGH, hGH binds to the antibody 
coating the microplate surface. Next, a digoxigenin-labelled (DIG) antibody 
(anti-hGH-DIG) is added, which binds the hGH. The next step in the 
process requires addition of an antibody reactive to digoxigenin, this 
antibody is conjugated to peroxidase (anti-DIG-POD). In the final step, the 
peroxidase substrate, ATBS, is added. Peroxidase catalyses the reaction 
which cleaves the substrate, resulting in a colour change. The colour 
change is proportional to the concentration of hGH in each sample. The 





2.10 Immunofluorescence staining 
Immunofluorescence staining is a technique which uses antibodies that target 
specific protein epitopes, allowing visualisation of that protein epitope within a 
sample. It is useful to determine the cellular localisation of proteins, whereas 
Western blotting (section 2.6) allows for easier quantification of protein 
abundance, it does not indicate the cellular localisation of the protein of interest.  
2.10.1 Coverslip sterilization and preparation 
Coverslips needed to be sterilised prior to use, since cells are seeded onto 
them, in order to be immunostained. 13 mm round coverslips were washed 3 
times for 45 minutes each in 100 % ethanol, before placing in a final wash of 
100 % ethanol for storage. A single coverslip was placed in each well of a 24 
well plate, and then washed with 100 µl PBS to remove any residual ethanol. 
Cells were then seeded onto the coverslips at a density of 0.5x105 cells per 
well. To fix the cells onto the coverslips, the media was removed and then the 
cells were gently washed with warmed PBS, before being incubated with 250 µl 
4% PFA for 10 minutes. Each coverslip was washed 3 times with PBS. The final 
wash was left on the cells to stop them from drying out. Each plate was sealed 
with parafilm and stored at 4°C until ready for immunostaining.  
2.10.2 Coverslip Immunostaining 
For immunostaining, coverslips were carefully removed from the 24 well plate, 
and placed cell side up onto upturned 1.5 ml microcentrifuge tube lids which 
have been stuck down in a petri dish. To permeabilise the cells, 150 µl ADS + 
0.2% Triton (ADST; Table 2-3) was carefully pipetted onto each coverslip, and 
left to incubate at room temperature for 30 mins. ADST was removed following 
permiabilization, and coverslips were probed with primary antibody (at an 
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antibody specific concentration) diluted in ADST overnight at 4°C. Before 
incubation with secondary antibody (Table 2-5), the coverslip was washed 5 x in 
PBS. Fluorescently-tagged secondary antibodies (Life Technologies) were 
diluted 1:400 in ADST for 1 hour at room temperature. DAPI was used at 
1:1000 with the final secondary antibody incubation to stain the nuclei. To 
remove residual or unbound secondary antibody, the coverslips were washed in 
PBS 5 times, before excess liquid was removed prior to mounting. To mount 
onto slides, 15 µl Fluorescent mounting media (Dako) was pipetted onto a 
microscope slide and the coverslips were mounted cell side down onto the 
mounting media. The slides were left to dry for at least 24 hours at room 
temperature before being viewed with a fluorescent upright microscope (Leica 
DM400 B LED Fluorescence). Slides were stored medium term at 4°C, or at -





Immunohistochemistry is much like immunofluorescence staining, however 
utilises histological samples, rather than cultured cells.  
Most reagents used for staining, other than primary antibodies were purchased 
from Agilent (formally called Dako). Fluorescent Alexa Fluor secondary 
antibodies were purchased either from Life Technologies or Abcam.  
Formalin-fixed paraffin embedded (FFPE) tissue sections from three different 
cohorts were available to use for these studies; The Exeter Archival Diabetes 
Biobank (EADB); The Network for Pancreatic Organ Donors with Diabetes 
(nPOD); and the Diabetes Virus Detection Study (DiViD) cohorts. Each cohort 
has unique advantages and disadvantages (Table 2-7). The EADB tissue is a 
collection of largely post-mortem tissue, collected from around the UK by Prof. 
Alan Foulis (Glasgow, which is now housed at the University of Exeter), 
whereas the nPOD tissue is an active collection from organ donors in America. 
The Norwegian DiViD collection consists of pancreas resections from 6 
individuals who had been recently diagnosed with T1D.  
 
Advantages Disadvantages 
EADB Young onset, short duration 
cases 
Short duration cases 
Limited medical history  
Different fixative methods 
Autopsy samples 
nPOD Standardised fixation methods 
Organ donors 
Medical records available 
Few young onset, short duration 
cases 
Few short duration cases 
DiViD Biopsy samples 
At onset of T1D 
Narrow age range (24-35y) 
No controls 
Table 2-7 Table comparing the three tissue collections available for these 
studies; EADB, nPOD and DiViD 
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2.11.1 Immunohistochemistry – detection by HRP (IHC-HRP) 
To remove the wax from tissue sections, they were submerged twice in 
Histoclear (SLS) for 5 minutes, or for slides that were post-fixed in mercuric 
chloride (HgCl2), these were de-waxed by submerging in 0.5% iodine and 
xylene solution for 5 minutes, followed by 5 minutes in xylene. To rehydrate the 
sections, they were placed in a series of coplin jars containing 50 ml ethanol at 
decreasing percentages; 100%, 90%, 70%, then finally 100% methanol for 1 
minute each, before the alcohol was washed off in double distilled water for 5 
minutes.  
To remove the crosslinks that were formed during the fixation process of the 
tissue, Heat Induced Epitope Retrieval (HIER) was carried out using Citrate 
buffer (10 mM, pH6) unless otherwise stated. For PD-L1 staining (Chapter 3) 
Universal HIER Antigen Retrieval Reagent (Abcam) was used, and for staining 
involving p21 (Chapter 6), a double antigen retrieval method was necessary, 
where slides were first subject to Citrate (pH6) antigen retrieval, then after 
cooling, were subject to antigen retrieval with 1 mM EDTA (pH8). To carry out 
HIER, a pressure cooker was filled with 1 L antigen retrieval buffer, and slides 
placed in a metal rack ensuring they were completely submerged in buffer. The 
lid was secured onto the pressure cooker (ensuring the vents were closed) and 
the slides were microwaved on full power for 20 minutes.  
Once slides had cooled (20 minutes), excess buffer was removed from around 
the tissue and the tissue section was incubated with a blocking agent for 5 
minutes. For most antibodies, the blocking agent used was 5% normal goat 
serum (NGS) diluted in TBS, however for some antibodies 5% BSA was used 
as an alternative, this was dependant on the species that the primary antibody 
was raised in. Slides were then incubated with primary antibody (Table 2-8), 
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diluted at an assay dependent concentration in antibody diluent (Agilent 
Cat#S0809). Following 3 x TBS washes, slides were then incubated with a 
peroxidase block for 5 minutes to inhibit the activity of any endogenous 
peroxidase activity in the tissue. The secondary antibody (Table 2-5) is part of 
the Dako REALTM EnVisionTM Detection System (Cat #K5007) and is capable of 
recognising both mouse and rabbit primary antibodies (Reagent A). It consists 
of a dextran backbone conjugated to multiple horse-radish peroxidase (HRP) 
molecules, which acts to amplify the signal. This was incubated on the section 
for 30 minutes, before washing off in TBS. 3,3’-diaminobenzidine (DAB) working 
solution (1 part DAKO Real DAB+ Chromogen (bottle C) to 50 parts DAKO Real 
substrate buffer (Bottle B) which contains DAB and hydrogen peroxide (H2O2)) 
were incubated for exactly 10 minutes, before being washed in ddH2O for 5 
minutes. Haematoxylin was used as a counterstain for nuclei, slides were then 
washed under a tap of running water followed by submersion in STWS (Table 
2-3) for blueing. They were then washed in ddH2O, then immersed in 2% 
copper sulphate in 0.9% saline solution for 5 minutes; this helps to intensify the 
DAB stain. Slides were finally dehydrated by immersing them in increasing 
concentrations of ethanol, from 50% to 70%, 90% then 2 x 100% for 5 minutes 
each. 
To allow the DPX (used for mounting) into the section, and to remove excess 
alcohol, slides were incubated twice in Histoclear for 5 minutes each. A 
sufficient amount of DPX was added onto the section, then a glass coverslip 
was mounted onto the section. Excess DPX was removed and slides were left 




Antigen Catalogue # Raised in Dilution Incubation time 
Protein Kinase 
R (PKR) 
ab32052 Rabbit 1/700 Overnight 
MxA MABF938 Mouse 1/500 Overnight 
STAT1 ab2415 Rabbit 1/100 (IF) 
Overnight then 1 hr 
at RT 
Insulin A0564 Guinea-Pig 1/363  1 hour 
Insulin IR00261-2 Guinea-Pig 1/5 1 hour 




Rabbit 1/2000 Overnight 
PPP1R1A Ab40877 Rabbit 1/250 
2 hours at room 
temperature 
HLA-ABC Ab70328 Mouse 1/1000 1 hour 
VP1 M7064 Mouse 1/2000 Overnight 
IRF1 #8478 Rabbit 1/100 
Overnight then 1 hr 
at RT 
CD45 M0701 Mouse 1/2000 Overnight 
HLA-F Ab126624 Rabbit 1/400 1 hour 
MDA5 #4544 Goat 1/50 
Overnight then 1 hr 
at RT 
PDL1 ab205921 Rabbit 1/100 
Overnight then 1 hr 
at RT 
P21 Ab109520 Rabbit 1/200 











SC-14267 Rabbit 1/75 
Overnight then 1hr 
at RT 




Immunofluorescence staining was employed when multiple antigens were to be 
co-stained on the same section. The initial preparation of the slides for 
immunofluorescence is carried out in the same way as with IHC-HRP staining, 
up to the point of primary antibody incubation. After incubation with primary 
antibody for the appropriate length of time, slides were washed 3 times in TBS, 
before being incubated with the appropriate secondary antibody for 1 hour at 
room temperature, this time conjugated to a fluorescent tag. All fluorescent 
secondary antibodies (Table 2-5) were diluted 1/400 in antibody diluent. As 
soon as the first fluorescent secondary antibody has been incubated with the 
slide, the remainder of the protocol is carried out with exposure to as little light 
as possible. A maximum of 3 antigens can be sequentially detected via 
immunofluorescence on the same section, provided that the primary antibody 
for each required antigen is raised in a different species. Additionally to exploit 
detection of multiple antigens on the same section, each secondary antibody 
must be conjugated to a different fluorochrome that is excited by, and emits at a 
different wavelength of light. To stain the nucleus, DAPI is added at a 
concentration of 1:1000 at the same time as the final secondary antibody. The 
secondary antibodies used were typically conjugated to fluorescent tags that 
fluoresce at wavelengths of 488 nm, 555 nm and 647 nm, whilst DAPI 
fluoresces at 405 nm. Slides were mounted using fluorescent mounting 
medium, and are left to dry in the absence of light at least overnight before 
being viewed by a fluorescent microscope. Either the Leica DM4000 B LED 
Fluorescence microscope, or the Leica DMi8 TCS SP8 Confocal microscope 




2.11.3 Immunofluorescence – TSA and TSA superboost 
TSA and TSA superboost kits were purchased from Thermo Fischer Scientific.  
For some antibodies, detection by HRP was successful, however, on occasion 
the sensitivity for detection using standard fluorescence approaches was too 
low. This is due to there being a single fluorochrome conjugated to each 
antibody. To overcome this hurdle, either the TSA kit, or the TSA SuperBoost kit 
was used, these approaches amplify the fluorescent signal by exploiting the 
catalytic activity of HRP, much like the way in which the signal is amplified using 
IHC-HRP methodology (section 2.11.1). TSA kits provide tyramide Alexa Fluors 
which fluoresce at wavelengths of 488, 555 and 647 nm, allowing for amplified 
detection of multiple antigens on the same tissue section.  
For carrying out immunofluorescence staining using a TSA kit, slides are 
prepared as described in section 2.11.1, up to and including the point of primary 
antibody incubation, with the exception that PBS is used instead of TBS for 
washes (as per manufacturer’s instructions). Before the addition of the 
secondary antibody, sections were incubated with Peroxidase blocking solution 
(Dako Cat#S202386-2) to inhibit any endogenous tissue peroxidases, then the 
slides were washed 3 times in PBS. The secondary antibodies provided in TSA 
kits are conjugated to HRP, and for the SuperBoost kit, the secondary 
antibodies are conjugated to multiple HRP molecules, thus amplifying the 
signal. Secondary antibodies were incubated on the tissue section for 1 hour at 
room temperature followed by 3 PBS washes. Freshly prepared tyramide 
working solution was incubated with the sample for up to 10 minutes; the 
tyramide working solution consists of Alexa FluorTM and H2O2, in reaction buffer 
(all components are provided with the TSA kit). To stop the enzymatic reaction 
between the HRP labelled secondary antibody and the tyramide, an equal 
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volume of stop solution was applied to each slide, then washed 3 times in PBS. 
Subsequent antigens can be detected either by standard immunofluorescence, 
or by using the TSA kit. TSA is also a useful method to co-stain the same 
section with antibodies which are raised in the same species. The antibody 
which is probed for first is detected via the TSA kit. The TSA kit results in an 
irreversible reaction leaving a deposit on the section. The antibodies can then 
be stripped off the section by placing in a pressure cooker, submerging in 
relevant antigen retrieval buffer, and microwaving on full power for 10 minutes, 
followed by 6 minutes on simmer. This process leaves the first tyramide deposit 
where the original antibody was bound, but removes any traces of the primary 
and secondary antibodies that were used. The section can then be probed with 
subsequent antibodies using either standard immunofluorescence or TSA 
methods. Similarly as with standard immunofluorescence staining, DAPI (diluted 
1:1000) is used to stain the nuclei of cells. Sections are left to dry for at least 24 
hours before being viewed using a fluorescent microscope (described in section 
2.11.2). 
2.12 Electron microscopy 
Cells were plated in 10 cm culture dishes, and incubated until they were 80% 
confluent. Cells were washed in warmed PBS before being fixed with 4% PFA 
supplemented with 0.1% glutaraldehyde for 10 minutes. Cells were then gently 
scraped, with care taken not to damage any, and transferred to a 1.5 ml 
eppendorf tube. The cells were then pelleted by centrifugation at 3,500 x g for 
30 minutes, taking care to situate the eppendorf such that the pellet will be at 
the bottom of the tube, not the side – this was achieved by using white roll to 
encase the eppendorf in a 50 ml tube. The PFA was carefully removed and 200 
µl warm 12% gelatine in PBS was added to each eppendorf and incubated at 
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37°C for 10 minutes. The cells were centrifuged for 5 minutes at room 
temperature at 6000 rpm to mix the cells with the gelatine. The gelatine was 
then solidified by placing the eppendorfs on ice. 300 µl 4% PFA (without 
glutaraldehyde) was added on top of the gelatine to keep the pellet moist. This 
preparation was stored at 4°C before shipment to Professor Varpu Marjomӓki 
(University of Jyvӓskylӓ) for analysis by thin frozen sectioning and EM analysis. 
Sections were probed for insulin (5 nm labelling) and pro-insulin (10 nm 
labelling), further described in Chapter 5. For further details, refer to Ifie et al. 
(2018).  
2.13 Patch Clamp and calcium imaging 
Patch clamping is used to measure the electrical activity within cells, and to 
measure the membrane potential of cells. During the process on insulin 
secretion, the cell membrane must depolarise. Patch clamping is used to 
measure the voltage changes across the cell membrane. Another important 
component of insulin secretion is calcium influx, which was measured using a 
calcium specific dye. 
Cells were seeded at a density of 0.5x105 cells per well, onto 13 mm round 
coverslips placed in 24 well plates. Cells were left to adhere for 48 hours before 
whole-cell patch clamping or calcium imaging was performed, in collaboration 
with Dr Kyle Wedgewood (University of Exeter). Fura-2, was used to detected 
intracellular calcium concentrations. Cells were incubated with the 
acetoxymethyl (AM) ester form of Fura-2 for 45 minutes to allow the dye to 
enter the cells, before being viewed using a Differential Interface Contrast (DIC) 
microscope (Scientifica). The ratio of Ca2+ bound (~340 nm) to Ca2+ unbound 






3 Evidence of a differential host response to virus in Type 1 
diabetes 
3.1 Introduction 
Since the 1920’s there have been hypotheses that a viral infection might play a 
role in the development of Type 1 diabetes (Gundersen, 1927), and there is 
increasing evidence to support the rationale that a persistent enteroviral 
infection may be a potential trigger for the initiation of disease pathogenesis 
(Dunne et al., 2019).  
Despite increasing evidence to support the relationship between enteroviral 
infection and initiation of disease, direct evidence of enteroviral infection within 
pancreas has been harder to gather. However, recent technological advances 
such as RT-PCR, immunohistochemistry, electron microscopy and whole cell ex 
vivo nucleotide sequencing have uncovered evidence supporting this 
relationship in pancreatic samples from individuals with newly diagnosed T1D. 
Identification of both enteroviral capsid protein (VP1) and enteroviral RNA 
(Krogvold et al., 2015, Dotta et al., 2007, Richardson et al., 2013, Richardson et 
al., 2009, Oikarinen et al., 2018) within T1D β-cells have been significant 
advances in support of this theory.  
In an earlier study (Yoon et al., 1979) diabetogenic enterovirus was isolated 
from the pancreas of a 10 year old boy who died shortly after being admitted to 
hospital for flu-like symptoms. Upon autopsy, it was found he had immune 
infiltration in his pancreatic Islets of Langerhans, and islet necrosis (Yoon et al., 
1979). Inoculation of the isolated enterovirus (Coxsackievirus B4) into mice 
resulted in diabetes (Yoon et al., 1979). More recently, enterovirus was isolated 
from islets of a T1D patient, which was capable of infecting β-cells from non-
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diabetic patients (Dotta et al., 2007) although this finding has been challenged 
due to sequence similarities between the isolated virus and reference laboratory 
strains of the virus (Tracy et al., 2010). 
Upon viral infection, both infected cells, and circulating immune cells secrete 
interferons (IFNs), which act as key mediators of the host defence mechanism 
against viruses. Appropriate interferon signalling is critical for an effective 
immune response, however, inappropriate interferon signalling is associated 
with monogenic diseases, falling under the umbrella term – Type 1 
interferonopathies. These are characterised by an overproduction and over-
secretion of type 1 interferons (T1 IFN). Type 1 interferonopathies cause a 
range of debilitating conditions, including “skin vasculopathy with chilblains and 
livedo reticularis, interstitial lung disease and panniculitis” (Volpi et al., 2016); 
and arise as a result of a dysfunction in the innate immune system due to 
mutations in interferon-stimulated genes (ISGs). Type 1 interferonopathies 
result in a T1 IFN signature which causes autoimmune traits (Jean-Baptiste et 
al., 2017). A T1 IFN signature can also be identified in the blood of at-risk 
children prior to a clinical diagnosis of diabetes (Ferreira et al., 2014, Kallionpaa 
et al., 2014, Richardson and Horwitz, 2014), further demonstrating the 
importance of understanding ISG activity and IFN signalling in T1D.  
RNA analysis of laser capture micro-dissected islets from the recently 
diagnosed DiViD cohort of T1D live donors revealed that in T1D there is 
increased expression of a range of ISGs; including those which are associated 
with type 1 interferonopathies, when compared to islets collected from people 
without diabetes (Lundberg et al., 2016). These data provided further indirect 
evidence of the presence of viral infection in T1D. More specifically, 
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upregulation of; HLA-A, STAT1, EIF2AK2, MX1, and IRF1 (amongst other 
ISGs) was detected at the mRNA level (Lundberg et al., 2016). These findings 
are supported by evidence of upregulation of the protein products of these 
genes in Type 1 diabetes (Colli et al., 2018, Richardson et al., 2016).  
Residual insulin containing islets (ICIs) in donors with T1D hyperexpress class I 
human leukocyte antigen (HLA) – A, B or C (HLA-ABC), which is known to be a 
hallmark feature of T1D, and can be upregulated in response to interferons 
(Richardson et al., 2016, Foulis et al., 1987, Pujol-Borrell et al., 1986). HLA 
proteins are key components in immune surveillance and response in humans. 
Residual ICIs which have HLA-ABC hyperexpression, also have upregulated 
STAT1 (Richardson et al., 2016), suggesting that a common pathway (i.e. 
interferon signalling) may upregulate both STAT1 and HLA-ABC expression in 
this disease. STAT1 is essential in mediating antiviral responses to interferons 
(Figure 3-1). Elevated STAT1, at the protein level in T1D islets provides further 
indirect evidence, strengthening the hypothesis that interferon signalling is 




Figure 3-1 Schematic diagram showing interferon signalling 
Type I, II and III interferons have specific receptors, which are associated 
with specific janus kinases, essential for mediating downstream signalling 
pathways. The type I IFN and type III IFN receptors are associated with 
the janus kinases JAK1 and TYK2. These autophosphorylate upon ligand-
receptor binding and mediate STAT1 and STAT2 phosphorylation and 
subsequent dimerisation. These then associate with IRF9 to form the 
ISGF3 complex, which can mediate DNA binding at ISRE sites. The type 
II IFN receptor is associated with the janus kinases JAK1 and JAK2. These 
autophosphorylate upon ligand-receptor binding and mediate STAT1 
dimerisation. STAT1 homodimers bind GAS on DNA, and mediate 





The importance of IFN and immune signalling in T1D has also been 
acknowledged in many genetic studies, since many candidate genes for T1D 
susceptibility are related to immunological processes (Marroqui et al., 2015). 
Polymorphisms in these genes can modulate the risk of developing T1D, 
suggesting that the immune system plays an important role in the development 
of the disease. For example, variation in the HLA region (Noble et al., 2010, 
Valdes et al., 2005) incurs the greatest weighting of genetic risk scores for T1D 
(Sharp et al., 2019, Redondo et al., 2018) and polymorphisms in other 
interferon-stimulated genes, such as IFIH1 (Smyth et al., 2006) and TYK2 
(Wallace et al., 2010), also modulate T1D risk. TYK2 encodes a Janus Kinase 
receptor subunit, necessary for autocrine and paracrine interferon signalling and 
activation of downstream IFN transcription factors (Marroqui et al., 2015), 
(Figure 3-1) and IFIH1 encodes the pattern recognition receptor (PRR), 
melanoma differentiation-associated protein 5 (MDA5). MDA5 senses dsRNA, 
which is produced by RNA and DNA viruses, once they have entered the cell 
(Weber et al., 2006). Upon MDA5 binding of viral dsRNA, an intracellular 
signalling pathway is triggered, ultimately resulting in the secretion of interferons 
(IFNs) (Reikine et al., 2014) (Figure 3-2). Our lab has previously examined 
MDA5, which is constitutively expressed in α-cells in individuals with and 
without T1D, but is intriguingly found to be upregulated in residual β-cells in T1D 





Figure 3-2 Intracellular antiviral signalling pathways 
Coxsackie B viruses gain entry to β-cells via the Coxsackie and 
Adenovirus Receptor (CAR; encoded by the CXADR gene). Recent 
studies have shown that beta cells express a specific isoform of CAR 
called CAR-SIV, which is localised to insulin granules. Once the virus is 
inside the cell, it will produce dsRNA as part of its replication cycle. dsRNA 
is detected and bound by MDA5. Upon dsRNA binding, MDA5 will 
translocate to the adaptor protein, MAVS. MAVS either resides on 
peroxisomes or mitochondria. Depending on where MDA5 translocates to 
a signalling pathway will be established, ultimately leading to the 
production of interferons. Protein kinase R (PKR) can also detect viral 
dsRNA. Upon PKR activation, it will phosphorylate eIF2α, which shuts off 




Since excessive IFN signalling can have negative outcomes such as the 
debilitating manifestations of type 1 interferonopathies, there are a number of 
regulatory mechanisms in place, to coordinate IFN signalling. To restrict the 
likelihood of MDA5 triggering inappropriate interferon signalling, its 
phosphorylation status is of upmost importance. For MDA5 to be ‘active’ and 
trigger the intracellular signalling pathway, it must be in its de-phosphorylated 
state. MDA5 phosphorylation at Serine-88 maintains the protein in its inactive 
state (Wies et al., 2013, Wallach and Kovalenko, 2013), whereas when MDA5 is 
dephosphorylated, (i.e. in its ‘active’ state), it can trigger interferon signalling 
pathways (Figure 3-2, Figure 3-3 and Figure 3-4). The protein responsible for 
dephosphorylating MDA5 is protein phosphatase 1 (PP1) (Wies et al., 2013), 
which itself is also tightly regulated. One of the many regulatory proteins of PP1 
is Protein Phosphatase 1, Regulatory, Inhibitory, Subunit 1A (PPP1R1A) 
(Figure 3-4). In view of the evidence of viral signatures in the pancreas, 
upregulation of MDA5 in T1D β-cells, and the evidence for increased levels of 
ISG activity in T1D; investigation into the regulatory pathways involved in 
modulating MDA5 initiated interferon signalling is justified and may have 




Figure 3-3 MDA5 activation by dephosphorylation 
MDA5 is phosphorylated on the CARD and C-terminal domains. Upon 
dsRNA binding, it is dephosphorylated on the CARD domain at Ser88 by 
PP1. This activates MDA5, so it can be polyubiquitinated, and translocated 
to the adaptor protein MAVS, which resides either on mitochondria or 
peroxisomes.  





Figure 3-4 Proposed mechanism of PPP1R1A regulated IFN release from virally 
infected pancreatic β-cells 
When a virus infects a cell, at some point during its replication cycle it will 
produce dsRNA (Richardson et al., 2010). dsRNA is recognised and 
sensed by MDA5. MDA5 triggers an intracellular signalling cascade which 
ultimately results in the release of Type 1 IFN from the cell. In order to 
regulate the release of IFN from the cell, MDA5 activity is regulated. MDA5 
must be dephosphorylated in order to be active. In an inactive state it is 
phosphorylated. The protein responsible for activation and 
dephosphorylation of MDA5 is PP1. PP1s activity is also regulated by 
PPP1R1A, in the presence of PPP1R1A, PP1 is inhibited, maintaining 
MDA5 in its inactive state. In the absence of PPP1R1A, PP1 is free to 
dephosphorylate and activate MDA5, resulting in Type 1 IFN release from 




In addition to previously described viral RNA analysis in serum (Krogvold et al., 
2015), VP1 positive β-cells have been observed in the islets of individuals both 
with and without Type 1 diabetes (Richardson et al., 2013) (Figure 3-5), 
although this is a more frequent observation in donors with T1D than those 
without (69.5% vs 13.6%). Understanding if the host response differs between 
individuals with and without T1D will be important for understanding the role that 
β-cells play, in response to viruses that may trigger this condition.  
 
Figure 3-5 Percentage of cases from the EADB (UK) and nPOD cohorts with 
VP1 positive cells in islets 
The proportion of cases of islets with intense VP1 staining. White 
bars are non-diabetic controls (EADB n=50; nPOD n=12), hashed 
bars are T1D cases with residual ICIs (EADB n=72; nPOD n=10); 
black bars are T1D cases with only IDIs (nPOD n=7)  




Therefore, the aims of this chapter are to investigate whether the host response 
to viral infection differs between individuals with and without T1D. This will be 
achieved by examining the expression of the proteins encoded by the ISGs; 
EIF2AK2 [PKR], STAT1 [STAT1] and MX1 [MxA] in pancreas samples from 
VP1 positive donors with and without T1D, and in islet autoantibody (AAb+) 
donors without diabetes.  
Using the expression of these proteins, the intracellular (within the same cells) 
and intercellular (between the surrounding cells) responses will be compared 
between VP1 positive T1D donors and VP1 positive donors without T1D.  
Expression of IRF1, will also be explored in pancreas samples from donors with 
or without T1D, since this has only been shown to be elevated at the mRNA 
level in T1D.  
Finally, novel mechanisms for an altered regulation of ISGs in T1D will be 
examined, by assessing the expression of the MDA5 regulatory protein, 
PPP1R1A, where levels will be compared between donors with T1D and those 




3.1.1 Preliminary findings relevant to this chapter 
3.1.1.1 PKR expression correlates with VP1 positive staining, regardless of donor status 
Enteroviral VP1 can be detected in the islets of donors both with and without 
T1D (Richardson et al., 2013). However, T1D donors are both more frequently 
VP1 positive, and they tend to have higher numbers of VP1+ cells within their 
islets when compared to donors without T1D. The observation that VP1 can be 
detected in β-cells of individuals with no diabetes suggests that the presence of 
virus alone is not sufficient to trigger the development of T1D. The link between 
enteroviral infection and T1D development likely involves a multi-step process 
where the balance between the virus, the host response to virus (likely 
controlled by genetic factors) and the immune system determines the ultimate 
outcome. 
PKR is a pattern recognition receptor (PRR), which detects dsRNA produced by 
the majority of viruses during their replication cycle. As a direct result of PKR 
activation (by binding dsRNA) eIF2α is phosphorylated, which inhibits cap-
dependent protein translation (Figure 3-2). This is effective as a viral defence 
mechanism, since viruses rely on host machinery to synthesise viral proteins. 
With translation inhibited, viruses cannot produce proteins needed for viral 
spreading or infection.  
It has been previously reported that PKR and VP1 are expressed in the same 
cells in T1D donors (Richardson et al., 2013). The present study was part of a 
much larger study, which included 12 donors with T1D, 7 AAb+ donors and 12 
donors with no diabetes. In each of these donors it was confirmed that VP1 and 
PKR were detected in the same cells, which was indicative of an intracellular 
anti-viral response (Ylipaasto et al., 2005, Schulte et al., 2012).  
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3.1.1.2 MDA5 is upregulated in select β-cells in T1D  
Given previously discussed evidence (section 3.1) of increased interferon 
signalling in T1D, the genetic links between T1D and IFIH1 (Smyth et al., 2006), 
and the evidence presented later in this chapter (sections 3.3.1 and 3.3.2) 
which supports the presence of an interferon signature in the islets of 
individuals with T1D, the expression of the viral recognition protein, MDA5, was 
investigated. MDA5 was found to be expressed strongly in a subset of 
endocrine cells via IHC-HRP (staining carried out by Prof. Sarah Richardson) 
(Figure 3-6). The expression of MDA5 in the islets was further examined (in 
collaboration with Dr Pia Leete) by immunostaining for MDA5, insulin and 
glucagon in 7 donors with T1D and 6 donors without. In donors without T1D, 
MDA5 was expressed at high levels in the α-cells (Figure 3-7). In contrast, β-
cells expressed relatively low or undetectable levels of MDA5. This is in 
agreement with single cell transcriptome data from 
(http://sandberg.cmb.ki.se/pancreas/) which demonstrates that α-cells have 
higher IFIH1 gene expression when compared to β-cells (Figure 3-8). However, 
examination of MDA5 in the islets of individuals with T1D, revealed that unlike 
individuals without T1D, a subset of β-cells expressed higher MDA5 (Figure 
3-7). MDA5 itself is an ISG, and therefore it is perhaps unsurprising, that 
expression is upregulated in the islets of individuals with T1D, whom display 
multiple indicators of an interferon response. This data is also in keeping with 
data obtained from Lundberg et al. (2016), who demonstrate elevated IFIH1 in 





Figure 3-6 MDA5 is upregulated in a subset of endocrine cells in Type 1 
diabetes 
In a pancreas sample obtained from a donor with Type 1 diabetes, MDA5 
(indicated by presence of brown staining), was found to be upregulated in 
a subset of endocrine cells.  







Figure 3-7 MDA5 is upregulated in β-cells in Type 1 diabetes 
In people without Type 1 diabetes, MDA5 (anti-MDA5; green) can be 
detected, however is more frequently detected in α- (anti-glucagon; red) 
than β-cells (anti-insulin; light blue) (yellow arrow).  
In people with Type 1 diabetes, MDA5 is upregulated, and is upregulated 
more specifically in β-cells. MDA5 positive cells are not VP1 positive. 





Figure 3-8 Screenshot from the Sandberg transcriptomics data, demonstrating 
IFIH1 is most strongly expressed in α-cell, not β-cells 
Transcriptomic data demonstrates that α-cells express IFIH1 ordinarily, 
and that β-cells have low expression of IFIH1 
(http://sandberg.cmb.ki.se/pancreas/)  
 
Having demonstrated that MDA5 is upregulated in a subset of β-cells from 
individuals with T1D, and knowing that MDA5 activity is strictly regulated to 
prevent inappropriate downstream signalling, the expression of PPP1R1A, a 
negative regulator of PP1, which in turn directly regulates MDA5 activity, was 
assessed. PPP1R1A was decided upon due to its tissue distribution, being most 
highly expressed in pancreatic islets (Jiang et al., 2013, Lilja et al., 2005). 
Where PPP1R1A expression is high, PP1 activity will be low, therefore, MDA5 
activity will also be low, since PP1 will not be available to activate it. Under 
circumstances where PPP1R1A is depleted, PP1 will be available to activate 




3.1.1.3 Expression of PPP1R1A in the pancreas  
Initially, human pancreas tissue was immunostained for PPP1R1A, using 
immunohistochemistry. PPP1R1A was strongly detected in the pancreatic islets 
in donors without T1D (Figure 3-9) (S. Dhayal, unpublished) and this is in 
keeping with the staining observed in the human protein atlas 
(https://www.proteinatlas.org/ENSG00000135447-PPP1R1A). In donors with 
T1D, the expression of PPP1R1A appeared to be depleted from select cells 
within the islets (Figure 3-9) (S. Dhayal, unpublished). To further explore the cell 
type in which PPP1R1A was expressed, an immunofluorescence approach was 
employed.  
 
Figure 3-9 PPP1R1A is selectively expressed in islets 
In people without Type 1 diabetes, PPP1R1A is highly expressed (left 
image), however in people with Type 1 diabetes (right image), PPP1R1A 
is no longer highly expressed, and is depleted from many islet cells. 





FFPE pancreas tissue sections (Table 3-1 and Table 3-2) were immunostained 
(as described in sections 2.11.1, 2.11.2 and 2.11.3). All cases studied were VP1 
positive. Antibodies used are detailed in Table 2-5 and Table 2-8. Citrate (pH6) 
was used for HIER, other than for when PDL1 staining was carried out, in which 
case Universal antigen retrieval buffer was used. 5% NGS was used as the 
blocking reagent for all the antibodies.  
For analyses of staining, the expression of the protein(s) of interest were scored 
in each residual ICI of T1D cases, and in 12 random islets of each donor 
without diabetes. For MxA analyses, the area of each islet expressing MxA was 
scored on a scale of 0 – 4 (0=absent, 1=<25%, 2=25-50%, 3=50-75% and 
4=>75% of the islet area expressing MxA). STAT1 was scored on a scale of 0 – 
3 for intensity (0=absent, 1 = weak, 2 = medium, 3 = strong). IRF1 was scored 
as -, +, ++ or +++, based on the number of ICIs with IRF1 intra-islet positivity.  
PPP1R1A expression was scored both based on intensity of fluorescence, as 
well as the islet area (or number of positive endocrine cells), and was examined 
in the context of both α- and β-cells (as defined by glucagon and insulin 
positivity, respectively). Similarly to the MxA scoring profile, percentages of 
insulin and glucagon positive cells per islet which were positive for PPP1R1A 
were calculated, and these percentages were converted to scores (0-4) by the 
same means as MxA scores. Cross validation was carried out, and each set of 
staining was scored three times, with previous scores blinded, and subsequent 
scoring several days apart. This was to help eliminate biased scoring; to aid in 
this, in instances where scoring differed considerably between sessions, a 
second or third opinion was sought.   
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6228-04 PB 13-772 T1D 13 Male 0 
6046-08 PB 15-160 T1D 18.8 Female 8 
6070-02 PB 10-118 T1D 22.6 Female 7 
6070-06 PT 13-162 T1D 22.6 Female 7 
6101-10 PT 13-790 Aab+ 64.8 Male N/A 
6184-04 PT 13-179 Aab+ 47.6 Female N/A 
6151-10 PT 13-790 Aab+ 30 Male N/A 
6102-10 PT 14-018 NDC 45.1 Female N/A 
6213-04 PB 13-050 NDC 24 Female N/A 
6019-04 PT 14-005 NDC 42 Male N/A 
6160-03 PH 14-149 NDC 22.1 Male N/A 
6099-01 PB 14-139 NDC 14.2 Male N/A 
6099-06 PB 17-101 NDC 14.2 Male N/A 
6047-02 PH 14-139 NDC 7.8 Male N/A 
6095-04 PT 14-139 NDC 40 Male N/A 
6024-08PT 14-139 NDC 21 Male N/A 
DiViD1 N/A T1D 25 Female 4 weeks 
DiViD2 N/A T1D 24 Male 3 weeks 
DiViD3 N/A T1D 34 Female 9 weeks 
DiViD4 N/A T1D 31 Male 5 weeks 
DiViD5 N/A T1D 24 Female 5 weeks 
DiViD6 N/A T1D 35 Male 5 weeks 
Table 3-1 Details of nPOD and DiViD samples utilised in the study 
The first 4 digits of the sample number are the patient ID, the second 2 
numbers indicate the block number. PH = Pan head, PB = Pan body and 
PT = Pan tail. T1D = Type 1 diabetes,  NDC = Non-diabetic control, Aab+ 





Sample Identity Age 
Duration of 
T1D 
SC115 T1D 1.3y At onset 
SC41 B T1D 4y 3 weeks 
SC119 T1D 4y 2 weeks 
242/89 NDC 3y N/A 
21/89 NDC 4y N/A 
184/90 NDC 5y N/A 
E261 T1D 18y 3 weeks 
E124B T1D 17y Recent 
E556 T1D 18y 4 months 
146/66 NDC 18y N/A 
191/67 NDC 25y N/A 
333/66 NDC 16y N/A 
E560 T1D 42y 18 months 
12495 Neonate 
Paediatric 
1 week N/A 
12424 Neonate 
Paediatric 
3 weeks N/A 
18/88 NDC 68y N/A 
113/66 NDC 80y N/A 
Table 3-2 Details of the EADB cohort samples that were utilised in this study.  






3.3.1 Donors with VP1 positive β-cells have evidence of a host response 
To determine if there are differences in response to viral infection between 
donors with and without diabetes (including islet autoantibody positive 
individuals without diabetes), the expression of a series of host response 
proteins (PKR, MxA, STAT1 and IRF1) was assessed in previously 
characterised VP1+ donors (Richardson 2013; unpublished data – nPOD-V 
working group). 
In the present study, PKR positive β-cells could be identified in each donor 
studied, this included 3 donors with T1D, 3 donors with no T1D, but AAb+, and 
4 donors with no diabetes. This confirmed that each donor had virally infected 
β-cells, and suggests that there is an intracellular anti-viral response within the 
β-cells that involves the upregulation of PKR.  
Since PKR positive β-cells can be detected in all donor types (regardless of 
T1D status), the host response to virus was further investigated, by assessing 





MxA is not expressed in PKR positive islets from donors without T1D 
The ISG MX1 encodes MX dynamin like GTPase1 (MxA). MxA is unique to the 
other discussed ISGs as MxA is only upregulated in response to interferons 
type I and III (Haller and Kochs, 2011). At the mRNA level, MX1 has been 
shown to be upregulated in T1D, and not expressed at the transcript level in 
islets from donors without T1D (Lundberg et al., 2016), however the protein 
expression of MxA in T1D has not been established. To ensure that islets were 
PKR positive, MxA was co-stained with PKR (and insulin, to label β-cells) in 4 
donors without T1D (6102-10 PT, 6213-04 PB, 6019-04 PT and 6160-03 PH), 3 
AAb+ donors (6101-10 PT, 6184-04 PT and 6151-10 PT) and 3 individuals with 
T1D (6228-04, 6046-08 PB and 6070-02 PB). PKR positive β-cells were 
identified in each donor, which corroborated previous findings that each donor 
was VP1 positive.  
MxA was only expressed in donors with T1D (Figure 3-10), and was not 
detected in any islets from donors with no diabetes, including the AAb+ donors 




Figure 3-10 Expression of host response proteins, MxA and PKR, in a VP1 
positive islet from an individual with T1D (6228-04) 
Representative immunofluorescence images of (A) MxA (anti-MxA; 
green), (B) PKR (anti-PKR; red) and (C) Insulin (anti-insulin; light blue). 
Overlay of MxA and PKR (D) and MxA, PKR and insulin (E). (F) Overlay 
of all channels, including nuclei (DAPI; dark blue). (G) Zoomed in image of 
MxA, PKR and insulin showing a PKR, MxA dual positive β-cell. The cells 
surrounding the PKR positive cells are also strongly MxA positive. Data 




Figure 3-11 Expression of host response proteins, PKR and MxA, in a VP1 
positive islet from an individual without T1D (6102-10) 
Representative immunofluorescence images of (A) MxA (anti-MxA; 
green), (B) PKR (anti-PKR; red) and (C) Insulin (anti-insulin; light blue). 
Overlay of MxA and PKR (D) and MxA, PKR and insulin (E). (F) Overlay 
with all channels, including nuclei (DAPI; dark blue). (G) Zoomed in image 
of MxA, PKR and insulin showing a PKR positive β-cell, with no 
surrounding MxA positivity. Data are representative of images from 3 




3.3.1.1 STAT1 is elevated in PKR positive islets in T1D, but not in no diabetes, including 
AAb+ donors 
It has previously been demonstrated that in T1D, expression of STAT1 is 
elevated at both the RNA (Lundberg et al., 2016, Richardson et al., 2016), and 
protein levels (Richardson et al., 2016) and that STAT1 expression correlates 
with hyperexpression of HLA-ABC (Richardson et al., 2016). The expression of 
STAT1 was characterised in AAb+ individuals for the first time, as well as 
directly comparing the expression of STAT1 between VP1 positive donors with 
and without T1D. For STAT1 analyses, the serial section to PKR/MxA was 
used, and sections were labelled with STAT1/MxA/Insulin, to establish whether 
STAT1 and MxA are co-expressed in the same islets.  
STAT1 and MxA were only identified in donors with T1D (Figure 3-12), and 
were not detected in AAb+ or no diabetes donors (Figure 3-13), despite islets 
having PKR/VP1 positive cells. Similarly to STAT1 and HLA-ABC, STAT1 and 
MxA expression was highly correlated. To quantify these data, MxA and STAT1 
expression was scored in each residual ICI from T1D donors, and in 12 islets 
from each donor with no diabetes, and AAb+ donors (Figure 3-14). MxA was 
scored for staining intensity and for area covered, and STAT1 was scored for 
the staining intensity, since STAT1 is expressed across the whole islet. Plotting 
MxA against STAT1 scores confirmed that STAT1 and MxA expression are 





Figure 3-12 Expression of host response proteins, MxA and STAT1, in a VP1 
positive islet from an individual with T1D (6228-04) 
Representative immunofluorescence images of (A) MxA (anti-MxA; 
green), (B) STAT1 (anti-STAT1; red) and (C) Insulin (anti-insulin; light 
blue). Overlay of MxA and STAT1 (D) and MxA, STAT1 and insulin (E). (F) 
Overlay of all channels, including nuclei (DAPI; dark blue). (G) Zoomed in 
image of MxA, PKR and insulin showing a PKR, MxA dual positive β-cell. 
The cells surrounding the STAT1 positive cells are also strongly MxA 





Figure 3-13 Expression of host response proteins, MxA and STAT1, in a VP1 
positive islet from an individual without T1D (6102-10) 
Representative immunofluorescence images of (A) MxA (anti-MxA; 
green), (B) STAT1 (anti-STAT1; red) and (C) Insulin (anti-insulin; light 
blue). Overlay of MxA and STAT1 (D) and MxA, STAT1 and insulin (E). (F) 
Overlay with all channels, including nuclei (DAPI; dark blue). Data are 





Figure 3-14 The relationship between number of STAT1 and MxA expression 
within an islet. 
All insulin containing islets (ICIs) were analysed in T1D samples (n=47 
islets) and 12 islets were analysed in each of the Aab+ and control samples 
(Total islets n=72). Each islet was scored for STAT1 and MxA expression. 
Data is plotted as mean score (± SEM). T1D is represented by red circles, 




3.3.2 Expression of IRF1 in pancreas sections from donors with or without diabetes, 
and its correlation with other host response and immune markers 
Previous studies have reported an upregulation of IRF1 at the mRNA level in 
T1D (Lundberg et al., 2016) and it has also been implicated as a key 
transcription factor in modulating cytokine-induced β-cell death in NOD mouse 
models (Gysemans et al., 2009). However the protein expression of IRF1 in 
human pancreas samples has not been investigated. Therefore, the expression 
of IRF1 was investigated across pancreas samples from 5 non-diabetic controls 
(6099-01, 6047-02, 6095-04, 6024-08 and 6160-02) and 8 T1D samples (6228-
04, DiViD1-6 and E560). The presence of IRF1 in distinct endocrine cell types 
was explored as well as any relationship with the expression of the enteroviral 
capsid protein, VP1, other ISGs, and immune markers, in an effort to explore 
the relationship of IRF1 with other features of T1D.  
Overall, IRF1 expression was only ever observed in the nucleus of cells, and 
was not identified in any islets of donors without T1D (0/6; 0%). In donors with 
T1D all eight donors (8/8; 100%) examined contained IRF1+ cells (Table 3-3). 










E560 T1D ++ 
VP1, Insulin, Glucagon, synaptophysin, 
HLA-ABC, STAT1, HLA-F, CD45 
DiViD1 T1D ++ PDL1 
DiViD2 T1D + PDL1 
DiViD3 T1D +++ Glucagon, PDL1 
DiViD4 T1D ++ PDL1 
DiViD5 T1D ++ PDL1 
DiViD6 T1D + Glucagon, PDL1 



































Table 3-3 Table of all donors analysed for IRF1 expression, the expression of 
IRF1 and details of what was co-stained with IRF1 in each donor 
The donor ID is listed in the left hand column. The expression of intra-islet 





3.3.2.1 Endocrine cell localisation of IRF1 within the islets 
IRF1 was co-stained with insulin and glucagon, to identify which endocrine cell 
type expressed IRF1 in T1D donors (EADB donor E560 and the 6 DiViD 
samples). IRF1 expression was observed in both α- and β-cells (Figure 3-15 
and Figure 3-16), as determined by expression in the nucleus of cells 
expressing insulin and glucagon, and in select acinar cells around the periphery 
of the islet (Figure 3-15). This was true in both the EADB organ donor case, 
E560 and in the DiViD donors. Areas of ICIs had clusters of IRF1 positive cells. 
IRF1 was not evenly distributed around islets, but was often concentrated in 
one area of the islet (Figure 3-15 and Figure 3-16). Examination of the entire 




Figure 3-15 Expression of IRF1 in a residual insulin containing islet from an 
individual with T1D (E560 – EADB organ donor) 
Representative immunofluorescence images of (A) IRF1 (anti-IRF1; 
green), (B) Overlay of IRF1 and glucagon (anti-glucagon; red) and (C) 
Overlay of IRF1 and insulin (anti-insulin; light blue). (D) Zoomed in image 
of IRF1 and glucagon, showing IRF1 positivity in the nuclei of an α-cell 
(white arrow). (E) Zoomed in image of IRF1 and insulin, showing IRF1 
staining in the nuclei of a β-cell (white arrow) and a β-cell with no IRF1 
(yellow arrow). (F) Overlay of all channels, including nuclei (DAPI; dark 
blue) IRF1 was detected in the nuclei of some exocrine cells (white arrow). 




Figure 3-16 Expression of IRF1, insulin and glucagon in a residual insulin 
containing islet from an individual with T1D (DiViD3 live donor, DiViD cohort) 
Representative immunofluorescence images of (A) IRF1 (anti-IRF1; 
green), (B) glucagon (anti-glucagon; red) and (C) Insulin (anti-insulin; light 
blue). Overlay of IRF1 and glucagon (D), overlay of IRF1, glucagon and 
insulin (E) and overlay of all channels, including nuclei (DAPI; dark blue) 
(F). (G) Zoomed in image of IRF1, glucagon and insulin showing IRF1 
positive β-cells (white arrow) and IRF1 positive α-cells (yellow arrows). 





Figure 3-17 Expression of IRF1 in an insulin deficient islet from an individual with 
T1D (E560) 
Representative immunofluorescence images of (A) IRF1 (anti-IRF1; 
green), (B) glucagon (anti-glucagon; red) and (C) insulin (anti-insulin; light 
blue). (D) Overlay of all channels, including nuclei (DAPI; dark blue). Data 




As IRF1 expression was identified in select cells around the islet periphery 
whose identity was unclear, IRF1 was co-stained with synaptophysin, to 
determine whether these IRF1 positive cells could be hormone negative 
endocrine cells (Md Moin et al., 2017, Md Moin et al., 2016) rather than acinar 
cells. Synaptophysin is a neuroendocrine cell marker and recognises 
specialised secretory cells, including all endocrine cells of the islets 
(Wiedenmann et al., 1986). The IRF1 positive cells at the periphery of the islets 
did not stain positively for synaptophysin therefore do not appear to be hormone 




Figure 3-18 Expression of the endocrine cell marker, synaptophysin, and IRF1 in 
an islet from an individual with T1D (E560) 
Representative immunofluorescence images of (A) IRF1 (anti-IRF1; 
green), (B) synaptophysin (anti-synaptophysin; red) and (C) Insulin (anti-
insulin; light blue). Overlay of IRF1 and synaptophysin (D), overlay of IRF1, 
synaptophysin and insulin (E) and overlay of all channels, including nuclei 
(DAPI; dark blue) (F). (G) Zoomed in image of IRF1 and synaptophysin 
showing IRF1 positive endocrine cells (white arrow), and IRF1 positive 




3.3.2.2 Correlation of IRF1 with the enteroviral protein, VP1 
Enteroviral VP1 is present in select β-cells and this is deemed a marker of 
infected cells, therefore, if viral infection is directly triggering IRF1 expression, it 
would be expected that IRF1 is expressed in the same cells as those which 
stain positively for VP1. Alternatively, if a signal released from the infected cells 
is driving IRF1 expression, the cells surrounding VP1 + cells would be expected 
to be positive. To determine if this was the case the T1D sample, E560 was 
immunostained for VP1, IRF1 and insulin, as it had previously been shown to 
have multiple VP1 positive β-cells. Some islets which had VP1 positive β-cells 
were also positive for IRF1 (Figure 3-19). Although IRF1 staining did not directly 
co-localise with VP1 in β-cells, it was uncommon to observe an islet which had 
IRF1 positive cells and no VP1 positive cells. In contrast though, islets were 
observed that contained VP1 positive cells, with no IRF1 expression (Figure 
3-20). The few islets with the IRF1+, VP1- phenotype had very few residual β-
cells. Therefore, although IRF1 expression did not co-localise with VP1 in β-
cells, the presence of IRF1 was frequently associated with the presence of the 





Figure 3-19 Expression of the viral protein, VP1, and IRF1 in an islet from an 
individual with T1D (E560) 
Representative immunofluorescence images of (A) IRF1 (anti-IRF1; 
green), (B) VP1 (anti-VP1; red) and (C) Insulin (anti-insulin; light blue). 
Overlay of IRF1 and VP1 (D), overlay of IRF1, VP1 and insulin (E) and 
overlay of all channels, including nuclei (DAPI; dark blue) (F). (G) Zoomed 
in image of IRF1 and VP1 showing dual VP1 IRF1 positive β-cells (white 
arrow), and some VP1 negative, IRF1 positive β-cells (yellow arrow). Scale 




Figure 3-20 Expression of the viral protein, VP1, and IRF1 in an islet from an 
individual with T1D (E560) 
Representative immunofluorescence images of (A) IRF1 (anti-IRF1; 
green), (B) VP1 (anti-VP1; red) and (C) Insulin (anti-insulin; light blue). 
Overlay of IRF1 and VP1 (D) overlay of IRF1, VP1 and insulin (E) and 
overlay of all channels, including nuclei (DAPI; dark blue) (F). (G) Zoomed 
in image of IRF1 and VP1 showing VP1 positive IRF1 negative β-cells 




3.3.2.3 Correlation of IRF1 and the ISGs, STAT1 and HLA-ABC 
STAT1 and HLA-ABC are ISGs which are both upregulated at the mRNA and 
protein levels in T1D (Lundberg et al., 2016, Richardson et al., 2016, Foulis et 
al., 1987, Pujol-Borrell et al., 1986), and as discussed earlier in this chapter, 
they are not upregulated in VP1 positive islets in no diabetes, or most AAb+ 
donors. To investigate whether IRF1 expression correlated with STAT1 or HLA-
ABC hyperexpression, IRF1 was co-stained with STAT1 and insulin or HLA-
ABC and insulin, in the EADB T1D sample, E560. Both STAT1 and HLA-ABC 
are upregulated in multiple cells across the entire islet, whereas IRF1 tended to 
be localised to distinct clusters of cells either in or around the periphery of the 
islet. STAT1 was upregulated in all residual ICIs, and in select islets, IRF1 was 
also upregulated (Figure 3-21). However, in other ICIs which expressed STAT1, 
IRF1 was not observed (Figure 3-22). Similar observations were also made 
when examining the relationship between IRF1 and HLA-ABC. This is not 
surprising, since the expression of STAT1 and HLA-ABC have been previously 
demonstrated to correlate strongly (Richardson et al., 2016). Furthermore, IRF1 
was observed outside of the HLA-ABC ‘halo’ which can be observed around 
some islets (Figure 3-23). The non-classical HLA, HLA-F, which has also been 
demonstrated to be upregulated in ICIs of T1D donors (Wyatt et al., 2019, 
Richardson et al., 2016) was also investigated in relation to IRF1 expression. 
IRF1 and HLA-F shared the same association pattern as IRF1 and STAT1 or 
HLA-ABC, where HLA-F was expressed in ICIs across the whole islet, and 
could be detected in islets and cells which did not express IRF1 (Figure 3-24). 
These data suggest that IRF1 is regulated in a different manner to STAT1, HLA-





Figure 3-21 Expression of host response proteins, IRF1 and STAT1 in an islet 
from an individual with T1D (E560) 
Representative immunofluorescence images of (A) IRF1 (anti-IRF1; 
green), (B) STAT1 (anti-STAT1; red) and (C) Insulin (anti-insulin; light 
blue). Overlay of IRF1 and STAT1 (D) overlay of IRF1, STAT1 and insulin 
(E) and overlay of all channels, including nuclei (DAPI; dark blue) (F). (G) 
Zoomed in image of IRF1 and STAT1 showing dual IRF1 and STAT1 
positive β-cells (white arrow) some IRF1 negative, STAT1 positive β-cells 
(yellow arrow) and some IRF1 positive, STAT1 negative exocrine cells 





Figure 3-22 Expression of host response proteins, IRF1 and STAT1 in an islet 
from an individual with T1D (E560) 
Representative immunofluorescence images of (A) IRF1 (anti-IRF1; 
green), (B) STAT1 (anti-STAT1; red) and (C) Insulin (anti-insulin; light 
blue). Overlay of IRF1 and STAT1 (D) overlay of IRF1, STAT1 and insulin 
(E) and overlay of all channels, including nuclei (DAPI; dark blue) (F). 





Figure 3-23 Expression of host response proteins, IRF1 and HLA-ABC in islet 
from an individual with T1D (E560) 
Representative immunofluorescence images of (A) IRF1 (anti-IRF1; 
green), (B) HLA-ABC (anti-HLA-ABC; red) and (C) Insulin (anti-insulin; 
light blue). Overlay of IRF1, HLA-ABC and insulin (D) and Overlay of all 
channels, including nuclei (DAPI; dark blue) (E). (F) Zoomed in image of 
IRF1, HLA-ABC and insulin showing dual IRF1 and HLA-ABC positive β-
cells (white arrow) an IRF1 negative, HLA-ABC positive β-cell (yellow 
arrow) and some IRF1 positive, HLA-ABC negative exocrine cells (pink 




Figure 3-24 Expression of host response proteins, IRF1 and HLA-F in islet from 
an individual with T1D (E560) 
Representative immunofluorescence images of (A) IRF1 (anti-IRF1; 
green), (B) HLA-F (anti-HLA-F; red) and (C) IRF1 and Insulin (anti-insulin; 
light blue). Overlay of IRF1 and HLA-F (D) overlay of IRF1, HLA-F and 
insulin (E) and overlay of all channels, including nuclei (DAPI; dark blue) 
(F). (G) Zoomed in image of IRF1, HLA-F and insulin showing dual IRF1 
and HLA-F positive β-cells (white arrow) some IRF1 negative, HLA-F 
positive β-cells (yellow arrow) and some IRF1 positive, HLA-F negative 




3.3.2.4 Correlation of IRF1 and immune markers; CD45 and PDL1 
To determine whether the expression of IRF1 correlated with the presence of 
immune cells, sections were co-stained with IRF1, the pan-immune cell marker, 
CD45, and insulin to identify the residual ICIs. CD45 labels all immune cell 
subtypes, including T-cells and B-cells, which are the most commonly observed 
immune cells in the infiltrate of T1D donors (Leete et al., 2016, Willcox et al., 
2009). Immunostaining of 5 non-diabetic samples (6099-01, 6047-02, 6095-04, 
6024-08 and 6160-02) and 2 T1D samples (6228-04 and E560) were 
performed. In samples from individuals with no diabetes, as expected, IRF1 was 
not observed in the islets, and was rarely observed in the exocrine pancreas 
(Figure 3-25). Importantly though, when it was observed in the exocrine 
pancreas, CD45 was also expressed on neighbouring cells (Figure 3-25), an 
observation also seen in T1D donors. In highly inflamed T1D islets, indicated by 
multiple CD45+ cells in and around the islet, levels of IRF1 expression were 
elevated (Figure 3-26). The T1D donor, 6228-04, had many islets with evidence 
of insulitis. In those islets with evidence of immune cells infiltrating within the 
islet core, IRF1 expression was highly expressed inside the islet (intra-islet) 
(Figure 3-26). In contrast, in the less inflamed islets, IRF1 expression tended to 
be localised to the peri-islet regions. This pattern of IRF1 expression was also 
observed in the DiViD cases, where cases with a larger degree of immune 
infiltration had increased expression of IRF1, compared to donors with less 
inflammation. Collectively, this suggests that IRF1 expression is strongly 





Figure 3-25 Expression of the pan-immune cell marker, CD45, and IRF1 in the 
exocrine pancreas of an individual without T1D (6024-08) 
Representative immunofluorescence images of (A) IRF1 (anti-IRF1; 
green), (B) CD45 (anti-CD45; red) and (C) Insulin (anti-insulin; light blue). 
Overlay of IRF1 and CD45 (D), overlay of IRF1, CD45 and insulin (E) and 







Figure 3-26 Expression of the pan-immune cell marker, CD45, and IRF1 in an 
islet from an individual with T1D (6228-04) 
Representative immunofluorescence images of (A) IRF1 (anti-IRF1; 
green), (B) CD45 (anti-CD45; red) and (C) Insulin (anti-insulin; light blue). 
Overlay of IRF1 and CD45 (D), overlay of IRF1, CD45 and insulin (E) and 
overlay of all channels, including nuclei (DAPI; dark blue) (F). (G) Zoomed 
in image of IRF1, CD45 and insulin showing IRF1 positive β-cells with 




3.3.2.4.1 Examination of the relationship between IRF1, insulitis and the immune 
checkpoint inhibitor, PDL1, in T1D 
Recent advances in cancer immunotherapies include targeting the immune 
checkpoint inhibitors, programmed death receptor-1 (PD-1) and its ligand 
programmed death-ligand 1 (PDL1). PD-1 is expressed on cytotoxic T-cells, 
and binds to its ligand, PDL1, which is upregulated on tumour cells. When PD-1 
is bound to PDL1, the programmed death response of the T cell is inhibited and 
the cell expressing the PDL1 is spared from T-cell mediated cytotoxicity. 
Targeting either PD-1 or PDL1 with antibody therapies prevents the inhibition of 
programmed death by blocking ligand-receptor binding, allowing the cytotoxic T-
cells to selectively target and kill tumour cells. Individuals being treated with  
immune-checkpoint immunotherapies have been demonstrated to be at an 
increased risk of developing autoimmune disease (Barroso-Sousa et al., 2018, 
Cukier et al., 2017), including Type 1 diabetes (Stamatouli et al., 2018). The 
expression of PDL1 in T1D was investigated by another PhD student in the 
group, Ms Jessica Hill, and was found to be upregulated in residual ICIs of 
individuals with T1D and not expressed in IDIs (Colli et al., 2018). Furthermore 
it was either absent or only expressed at very low levels in donors without 
diabetes (Colli et al., 2018). In collaboration with the group of Professor Decio 
Eizirik (University of Brussels), the regulation of PDL1 expression in T1D was 
then explored. Depending on the cell type, PDL1 is upregulated by different 
mechanisms; in cancer cells, PDL1 is expressed in response to IFNs, and in 
melanoma cells, the Jak-STAT1-IRF1 pathway is key to mediating PDL1 
upregulation (Garcia-Diaz et al., 2017) however, in macrophages, 
lipopolysaccharide (LPS) induces PDL1 expression via NK-κB activation (Loke 
and Allison, 2003). Colli et al. (2018) demonstrated that both IFN-α, and IFN-γ 
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can induce the expression of PDL1 in human beta cells in vitro. They further 
confirmed using siRNA knockdown studies that IFN signalling via IRF1 was 
important in regulating the expression of PDL1. In the context of T1D, IFNs can 
potentially be derived from at least two places, IFN-α from the endocrine cells 
themselves following an infection, and IFN-γ released from infiltrating immune 
cells. Given the association of immune cells with IRF1, it was investigated 
whether IRF1 and PDL1 were co-expressed in T1D. Pancreas sections from 
each of the 6 DiViD samples were immunostained for PDL1, IRF1 and insulin 
(Figure 3-27 (A)), and these data were combined with data regarding immune 
cell infiltration from serially stained sections in each of these samples, in 
collaboration with Dr Pia Leete. The presence or absence of PDL1 and IRF1 
was assessed in each residual ICI and correlated with the degree of immune 
cell infiltration (assessed by CD8 staining and cell counts, performed by Dr Pia 
Leete). In keeping with previous observations, both PDL1 and IRF1 expression 
were upregulated in the islets that contain insulin. Although they were frequently 
observed in the same islet, IRF1 expression could be observed in select islets 
where PDL1 was not expressed. By contrast however, PDL1 expression was 
never observed in the absence of IRF1 (Figure 3-27(B)). Importantly, the 
proportion of islets which were positive for both IRF1 and PDL1 were scored by 
two independent observers (JH and JC), and were associated with a higher 
degree of immune infiltration (CD8 staining and counts were performed by Dr 
Pia Leete, University of Exeter) (Figure 3-27 (C)). Taken together, these data 
suggest that there is a correlation between IRF1 and PDL1 expression and that 





Figure 3-27 Expression of IRF1, PDL1 and insulin in a residual insulin containing 
islet from an individual with T1D (DiViD1) 
Representative immunofluorescence images of (A) PDL1 (anti-PDL1; 
green) and IRF1 (anti-IRF1; red) (left) and PDL1, IRF1 and insulin (anti-
insulin; light blue) (right). The insets show magnified regions indicated by 
the white box. (B) 15 islets from each DiViD sample were selected at 
random and analysed for the proportion of islets that were immunonegative 
for both PDL1 and IRF1, or were immunopositive for PDL1 alone, IRF1 
alone or both PDL1 and IRF1. The proportion of islets that were 
immunonegative for PDL1 and IRF1 was scored in relation to islet 
inflammation (measured as the mean number of CD8+ T-cells present in 
each individual studied. The mean values ± SEM are shown.  




3.3.3 Analysis of PPP1R1A expression in human pancreas   
Given the preliminary findings presented in sections 3.1.1.2 and 3.1.1.3, 
expression of PPP1R1A was assessed in pancreas samples from a further 8 
donors with T1D and 7 donors without T1D. The expression of PPP1R1A in 
donors with no diabetes was initially characterised, followed by the expression 
of PPP1R1A in donors with T1D. When analysing the expression of PPP1R1A 
in samples from donors with T1D, the donors were segregated into two groups 
based on age of diagnosis; individuals diagnosed <7 years of age, and those 
diagnosed >13 years of age. The decision to do this was based on recent 
findings illustrating that the extent of immune invasion and the immune profile 
between the two age groups differ (Leete et al., 2016, Leete et al., 2020), and 
this could impact on the response being assessed here. 
3.3.3.1 PPP1R1A expression in pancreatic islets of individuals with and without T1D 
To explore which cell type(s) PPP1R1A was expressed in, PPP1R1A was co-
stained with insulin and glucagon – to determine if expression was localised to 
β- and/or α- cells, respectively; or somatostatin, combined with a hormone 
cocktail of insulin and glucagon – to determine if PPP1R1A was present in δ-
cells (SST+) or other endocrine cell types (cells which are insulin / glucagon / 
somatostatin negative).  
3.3.3.2 PPP1R1A expression in donors without diabetes 
To investigate the endocrine cell type(s) PPP1R1A was expressed in pancreas 
samples from 11 donors (Table 3-1 and Table 3-2) without diabetes were 
studied. It was found that PPP1R1A expression was restricted solely to the 
endocrine cell compartment, it was not expressed in the exocrine pancreas. 
Within the islets, PPP1R1A was highly expressed in β-cells (Figure 3-28). In 
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contrast, PPP1R1A was only weakly observed in select α- or δ- cells, and were 
not observed in cells that were negative for insulin, glucagon (Figure 3-28) or 
SST (data not shown). To determine whether the age of the donor impacted on 
the expression and / or cellular distribution of PPP1R1A the expression profile 
of PPP1R1A was assessed in a range of donors without diabetes (range: 1 
week – 80 years of age). PPP1R1A expression (in respect to both percentage 
of cells expressing PPP1R1A and PPP1R1A intensity) did not appear to be 





Figure 3-28 Expression of PPP1R1A in an islet from an individual without T1D 
(6099-06) 
Representative immunofluorescence images of (A) PPP1R1A (anti-
PPP1R1A; green), (B) Insulin (anti-insulin; light blue) (C) PPP1R1A, and 
insulin (D) overlay of PPP1R1A and glucagon (anti-glucagon; red), (E) 
overlay of PPP1R1A, glucagon and insulin, (F) Overlay of all channels, 
including nuclei (DAPI; dark blue). (G) Zoomed in image of PPP1R1A 
glucagon and insulin showing PPP1R1A positively stained β-cells (white 
arrows) and PPP1R1A negative α-cells (yellow arrows) 
Scale bar 25 μM 
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3.3.3.3 PPP1R1A expression in individuals diagnosed <7 years old, with a short-
duration of T1D 
PPP1R1A expression was assessed in 3 T1D donors diagnosed <7y with a 
short-duration of disease (range: at onset – 3 weeks; Table 3-2). Similar to 
donors without T1D, expression of PPP1R1A was restricted to β-cells. 
However, in select β-cells PPP1R1A expression was either much reduced or 
completely depleted (Figure 3-29). The majority of α- and δ- cells remained 





Figure 3-29 Expression of PPP1R1A in an islet from an individual with T1D, 
diagnosed <7 (SC41b) 
Representative immunofluorescence images of (A) PPP1R1A (anti-
PPP1R1A; green), (B) Insulin (anti-insulin; light blue) (C) PPP1R1A, and 
insulin (D) overlay of PPP1R1A and glucagon (anti-glucagon; red), (E) 
overlay of PPP1R1A, glucagon and insulin, (F) Overlay of all channels, 
including nuclei (DAPI; dark blue). (G) Zoomed in image of PPP1R1A 
glucagon and insulin showing PPP1R1A positively stained β-cells (white 
arrows) and PPP1R1A negative α-cells (yellow arrows), also PPP1R1A 




3.3.3.4 PPP1R1A expression in individuals diagnosed >13 years old, with a short-
duration of T1D 
The expression of PPP1R1A was assessed in 3 donors diagnosed >13y, with 
short-duration of diabetes (range: recent onset – 16 weeks; Table 3-2). 
PPP1R1A expression was restricted to β-cells, however, compared to 
individuals diagnosed <7 years old, there was a higher percentage of β-cells 
which had complete obsolete expression of PPP1R1A, and those that had 
retained PPP1R1A expression had much reduced intensity of PPP1R1A 
compared to controls (Figure 3-30). The β-cells which retained the highest 
expression of insulin had the weakest staining, or no positive staining for 





Figure 3-30 Expression of PPP1R1A in an islet from an individual with T1D, 
diagnosed >13 (E261) 
Representative immunofluorescence images of (A) PPP1R1A (anti-
PPP1R1A; green), (B) Insulin (anti-insulin; light blue) (C) PPP1R1A, and 
insulin (D) overlay of PPP1R1A and glucagon (anti-glucagon; red), (E) 
overlay of PPP1R1A, glucagon and insulin, (F) Overlay of all channels, 
including nuclei (DAPI; dark blue). (G) Zoomed in image of PPP1R1A 
glucagon and insulin showing PPP1R1A positively stained β-cells (white 
arrows) and PPP1R1A negative α-cells (yellow arrows), also PPP1R1A 
negative β-cells (pink arrows) Scale bar 25 μM 
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3.3.3.5 PPP1R1A expression in individuals diagnosed >13 years old with long duration 
T1D 
Expression of PPP1R1A was analysed in 2 T1D pancreas samples obtained 
from donors who had had T1D for a longer duration (range: 18 months – 7 
years; Table 3-1 and Table 3-2), PPP1R1A was not expressed in a vast 
majority of β-cells, with only very few residual β-cells in each islet retaining 
expression of PPP1R1A, furthermore, β-cells which retained PPP1R1A 
expression stained more weakly for PPP1R1A than donors without T1D. 
Unexpectedly, PPP1R1A was expressed in most α-cells of residual ICIs (Figure 





Figure 3-31 Expression of PPP1R1A in an islet from an individual with T1D, 
diagnosed >13 (6070-06) 
Representative immunofluorescence images of (A) PPP1R1A (anti-
PPP1R1A; green), (B) Insulin (anti-insulin; light blue) (C) PPP1R1A, and 
insulin (D) overlay of PPP1R1A and glucagon (anti-glucagon; red), (E) 
overlay of PPP1R1A, glucagon and insulin, (F) Overlay of all channels, 
including nuclei (DAPI; dark blue). (G) Zoomed in image of PPP1R1A 
glucagon and insulin showing PPP1R1A positively stained β-cells (white 
arrows) and PPP1R1A negative α-cells (yellow arrows), also PPP1R1A 




Figure 3-32 Summary of islet PPP1R1A expression 
Tables A and B summarise the expression of PPP1R1A in donors without 
diabetes (A) and with T1D (B). PPP1R1A score refers to the staining 
intensity of PPP1R1A where a score of 0 is no PPP1R1A and a score of 4 
represents strong PPP1R1A expression, β- and α-cell scores refer to the 
average percentage of α- or β- cells within each islet which stain positively 
for PPP1R1A (0=absent, 1=<25%, 2=25-50%, 3=50-75% and 4=>75%). 
Graph (C) plots the α- and β- cell scores from the tables, where each dot 
is the mean score of each islet analysed within a donor, and the bar 
represents the mean (± SEM). Green bars represent the β-cell score and 
red bars represent α- cell score.  




3.3.3.6 Subcellular distribution of PPP1R1A 
Using confocal microscopy, the subcellular distribution of PPP1R1A was 
explored. Intriguingly, PPP1R1A was identified in areas of the cells where 
insulin was not (Figure 3-33), i.e. insulin and PPP1R1A did not colocalise within 
the same subcellular compartments, thus PPP1R1A is not localised to the 
insulin granules, but is present in the cytoplasm of β-cells. PPP1R1A appeared 
to form mesh-type structures within the cell cytoplasm, around the insulin 
granules. Furthermore, confocal microscopy verified that PPP1R1A was present 
in the nucleus of β-cells. These observations were reflected in the expression of 




Figure 3-33 Expression of PPP1R1A in an islet from an individual without T1D 
(6099-06) 
Representative confocal immunofluorescence images of (A) PPP1R1A 
(anti-PPP1R1A; green), (B) Insulin (anti-insulin; light blue), (C) Glucagon 
(anti-glucagon; red), (D) Overlay of all channels, including nuclei (DAPI; 
dark blue), (E) Inset of overlay of all channels, insulin showing PPP1R1A 
positively stained β-cells (white arrows) and PPP1R1A negative α-cells 
(yellow arrows). PPP1R1A and insulin do not colocalise within the same 





It has been previously demonstrated that evidence of viral infection is more 
commonly identified in individuals with T1D, compared to those without (Figure 
3-5), regardless of detection method (immunostaining or PCR) (Richardson et 
al., 2009, Moya-Suri et al., 2005). Despite evidence of enteroviral infection 
being more commonly observed in T1D, evidence can be found in individuals 
without T1D. Because of this, identifying enteroviruses as triggering agents of 
T1D is challenging to show, and is still under much debate (Graves et al., 2003, 
Fuchtenbusch et al., 2001). Gathering further direct (VP1 staining) and indirect 
(PRRs and proteins encoded by ISGs) evidence would help broaden the 
understanding of how a viral infection might trigger the development of T1D in 
some people.  
The study of enteroviral infection indicators in the blood, for example, 
assessment of neutralising antibodies to EVs (which demonstrate history of 
previous infection) (Mustonen et al., 2018); or direct analysis of EV genome via 
RT-PCR analyses (which is suggestive of a current infections) (Salvatoni et al., 
2013), combined with analyses of host responses such as interferon signatures 
(Ferreira et al., 2014, Kallionpaa et al., 2014) are helpful, but do not directly 
inform what is happening at the active site of T1D, in the pancreatic islets of 
Langerhans. Studies described in this chapter have utilised precious human 
pancreas samples to shed light on potential anti-viral host response 
mechanisms occurring in the islets themselves, and how this differs between no 
diabetes, AAb+ but no diabetes, and T1D pancreata.  
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3.4.1 Similarities and differences between virally infected no diabetes islets, and T1D 
islets 
All cases used in this study were selected as they had evidence of VP1 positive 
cells in previous analyses (Richardson 2013; unpublished data – nPOD-V 
working group). To confirm this, serial sections from each donor were stained 
for the pattern recognition receptor, PKR. It has been previously demonstrated 
the PKR positivity can only be identified in VP1 positive cells in donors with T1D 
(Richardson et al., 2013), and this was verified in the larger study that this was 
part of (Laiho.J.E. et al, unpublished). VP1 positive cells specifically upregulate 
PKR expression and this is indicative of those cells sensing and responding to 
infection. The upregulation of PKR was observed in donors both with and 
without T1D, which suggests that this intracellular (within the same cells) 
response to viral infection is common across all donor types. However, the 
expression of PKR was the only similarity between donors with and without 
diabetes. Examination of the expression of other ISGs, i.e. MxA and STAT1, 
revealed profound differences between samples obtained from donors with 
diabetes and those without, including AAb+ donors. The expression of ISGs has 
not previously been directly compared between VP1 positive donors with T1D 
and those without. Individuals without T1D (controls and AAb+) showed very 
little or no upregulation of MxA. Importantly, MxA cannot be upregulated by 
virus directly (Haller and Kochs, 2011), but is specifically upregulated by Type I 
or type III interferons (Holzinger et al., 2007, Haller et al., 2015). The expression 
of MxA is so tightly controlled by interferons that it can be used as a surrogate 
marker for type I IFN (Roers et al., 1994, Yahya et al., 2017, Engelmann et al., 
2015). The absence of MxA positivity in no diabetes and AAb+ pancreata 
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indicates that they have a much reduced IFN response to virus, compared to 
donors with T1D. 
To further investigate whether the intercellular (between cells) response e.g. 
through release and response to interferons, differs between individuals with 
T1D, and those without, expression of additional protein products encoded by 
ISGs were examined, these were HLA-ABC and STAT1. It is largely accepted 
by the diabetes research community that HLA-ABC hyperexpression is a 
hallmark feature of T1D, and this has been widely published (Richardson et al., 
2016, Foulis et al., 1987, Pujol-Borrell et al., 1986). It has been previously 
reported that islets that hyperexpress HLA-ABC, also have elevated STAT1 
(Richardson et al., 2016), however, the expression of STAT1 was not 
investigated in VP1+ AAb+ (no diabetes) or AAb- no diabetes donors. In the 
present study, it was confirmed that STAT1 and HLA-ABC are both upregulated 
in residual ICIs in T1D. Furthermore, it was demonstrated that STAT1 was not 
expressed in islets from no diabetes or AAb+ donors, despite PKR positivity in 
these donors. STAT1 is key to regulating the interferon response (Figure 3-1) 
(Marroqui et al., 2015, Moore et al., 2011, Eizirik et al., 2008), which further 
indicated that interferon signalling is exacerbated in T1D, but not in AAb- or 
AAb+ donors without T1D, despite the presence of PKR and VP1 positive cells.  
By considering the expression of PKR, MxA, and STAT1, it can be 
hypothesised that the intracellular response to viral infection is similar between 
the different donor groups, since all respond to virus by upregulating PKR; 
however, MxA and STAT1 are only expressed in the islets of T1D donors. Since 
MxA and STAT1 are upregulated by interferons, this suggests that interferon 
signalling and the intercellular response is heightened in T1D, but is low / 
absent in virally infected islets from donors with no diabetes. The reason for this 
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is unclear, but may be linked to the genetic background / susceptibility of 
individuals.  
One of the genes associated with increased risk of T1D is IFIH1. IFIH1 encodes 
the pattern recognition receptor MDA5, and as illustrated earlier in this chapter, 
MDA5 expression is increased in β-cells in T1D (Figure 3-7) (Leete et al., 
unpublished). The IFIH1 SNP rs1990760 (A946T) is associated with increased 
T1D risk. In the forward orientation of the gene, TT is associated with highest 
risk, whereas CT is heterozygous protective, and CC is protective (Domsgen et 
al., 2016). In the total population, the frequency of the C allele is 0.426315, and 
the T allele is 0.573684 
(https://www.ncbi.nlm.nih.gov/snp/rs1990760#frequency_tab accessed 
24/7/20), however these are more disproportionate in distinct populations. In the 
African population, the C allele is far more common, with a frequency of 0.8095, 
and the T allele just 0.1905, similarly to the Asian population where the C allele 
has a frequency of 0.814 and the T allele 0.186. However, the frequencies in 
the South Asian population, are more similar to the total population, where the 
C allele has a frequency of 0.4631 and the T allele, 0.5369 
(https://www.ncbi.nlm.nih.gov/snp/rs1990760#frequency_tab accessed 
24/7/20). 
It is hypothesised that IFIH1 SNPs alter the likelihood of enteroviral infection 
(Cinek et al., 2012). The presence of enterovirus infection was increased in 
blood from individuals with the TC genotype (14.4%), compared to the risk TT 
genotype (9.5%) and the CC protective genotypes (7%) (Cinek et al., 2012). It is 
also reported that the A946T variant of IFIH1, the T (risk) allele is associated 
with the presence of anti-dsRNA antibodies in serum (Robinson et al., 2011). 
Interestingly though, it was also associated with lower serum IFN-α, but 
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increased ISG expression (Robinson et al., 2011). This raises the question of 
why there is increased ISG expression, with lower circulating IFN-α. A potential 
explanation of this is that the T (risk) allele is causing MDA5 to trigger an 
alternative IFN signature, and a different pattern of ISGs. The A946T variant is 
located in a region important for MDA5 filament formation (Domsgen et al., 
2016), which is essential for initiation of interferon signalling (Figure 3-3). MDA5 
filament formation occurs prior to MAVS (adapter protein) binding. MAVS is 
canonically localised to the mitochondria, however can also be localised to 
peroxisomes. If the MDA5 A946T SNP affects filament formation, this could 
potentially impact the cellular localisation that MDA5 binds to MAVS, i.e. if 
peroxisomal MAVS is preferred over mitochondrial MAVS. Depending on the 
cellular compartment which MAVS is localised to, a differential interferon 
signature is produced (Dixit et al., 2010). It is hypothesised that peroxisomal 
MAVS results in a TIII IFN signature, whereas mitochondrial MAVS results in a 
combined TI and TIII IFN signature (Ding and Robek, 2014). Furthermore, 
peroxisomal MAVS has been associated with IRF1 activation, whereas 
mitochondrial MAVS has been associated with IRF3 and NF-κB activation 
(Domsgen et al., 2016, Ding and Robek, 2014, Dixit et al., 2010). Following on 
from these interesting hypotheses, and the observation that IRF1 is upregulated 
at the mRNA level in laser-captured microdissected (LCM) islets in T1D 
(Lundberg et al., 2016), the expression of IRF1 was investigated in samples 




3.4.2 Expression of IRF1 
Interferon Regulatory Factor 1 (IRF1) was first identified by Fujita et al. (1988), 
as a regulator of IFN-β transcription. It is now clear that IRF1 impacts 
transcription of more genes than just IFN-β (Pine et al., 1990, Yu-Lee et al., 
1990, Taniguchi et al., 2001), although the profile of genes which are 
transcribed by IRF1 are likely cell type dependent (Taniguchi et al., 2001).  
IRF1 binds a specific DNA element, IRF-E, which has the consensus sequence: 
G(A)AAAG/CT/CGAAAG/CT/C (Tanaka et al., 1993), this sequence is subtly 
different, but still similar to the interferon-stimulated response elements ISRE 
(A/GNGAAANNGAAACT), and the gamma-activated sites (GAS) 
(TTNCNNNAA) elements (Darnell et al., 1994). The ISRE and GAS elements 
are bound by STAT dimers to activate transcription of specific genes. 
Canonically, STAT1 homodimers bind GAS, whereas STAT1/STAT2 
heterodimers bind ISRE, (Figure 3-1). When the cytokine, IFN-γ binds the IFN-γ 
receptor, JAK1 and JAK2 are activated (Michalska et al., 2018). Type I and type 
III IFN receptors are associated with TYK2 and JAK1, which following ligand 
binding, trigger phosphorylation of STAT1 and STAT2, resulting in heterodimer 
formation. STAT1 and STAT2 heterodimers then associate with IRF9 to form 
the ISGF3 complex, which promotes gene expression by binding to ISRE 
(Majoros et al., 2017). This canonical signalling pathway is summarised in 
Figure 3-1. Depending on which DNA binding element is activated, a different 
profile of ISGs is transcribed (Majoros et al., 2017). Due to sequence binding 
similarity, it might be postulated that IRF1 and STAT1 are co-expressed and 
drive expression of each other, as they are both products of ISGs themselves, 
or on the other hand, it may be postulated that they are competitors for the 
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same DNA binding sites, thus are not co-expressed in the same cells, although 
there are no published data to support this currently. 
Unlike other ISGs which are upregulated in T1D e.g. MxA, STAT1 and HLA-
ABC, IRF1 is not uniformly upregulated across the whole islet, it is often 
concentrated in a small cluster cells. These observations that STAT1 and IRF1 
are not elevated synchronously, suggests that the upregulation of these 
proteins is potentially mediated by different factors. It has been suggested by 
some reports that expression of IRF1 is driven by STAT1 activation (Zenke et 
al., 2018, Abou El Hassan et al., 2017), however this is unlikely to be the case 
in T1D given that STAT1 could be detected in the absence of IRF1, and that 
IRF1 and STAT1 localise to different areas of the same islet. Even though 
STAT1 and IRF1 may not have an impact on total expression levels of one-
another, IRF1 may promote the phosphorylation of STAT1 (Zenke et al., 2018), 
thus enhancing the activity (DNA binding) of STAT1.  
3.4.2.1 IRF1 and viral proteins 
It has been reported that IRF1 can inhibit the replication of numerous viruses, 
including Hepatitis E virus (Xu et al., 2016), Hepatitis C virus, yellow fever virus, 
West Nile virus, chikungunya virus, Venezuelan equine encephalitis virus and 
human immunodeficiency virus type-1 (Schoggins et al., 2011). These viruses 
mentioned are all positive sense, ssRNA viruses, as are enteroviruses; thus it 
may not be inconceivable to hypothesise that IRF1 may inhibit enteroviral 
replication also, although there is no evidence for this currently. Inhibiting viral 
replication may be an integral role of IRF1 in type 1 diabetes, as it could aid in 
the driving of a low-level persistent infection, which is hypothesised to be a 
potential trigger for the development of T1D (Alidjinou et al., 2014). This 
hypothesis could be tested using in vitro experiments in which IRF1 expression 
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can be manipulated, either using CRISPR-Cas technology, or an inducible 
expression system e.g. Flp-In T-REx (discussed in chapter 4), and the 
maintenance of a persistent infection documented. Interestingly, in cadaver 
pancreas tissue, IRF1 was not necessarily expressed in VP1 positive cells 
(Figure 3-19 and Figure 3-20). This suggests that IRF1 is probably not involved 
in enteroviral persistence in T1D. Nonetheless, VP1 positivity indicates cells 
which are actively producing viral proteins, however there may be other islet 
cells which are infected with virus, but not producing viral proteins. Staining for 
the presence of IRF1 with dsRNA (a by-product of viral infection) would further 
indicate whether infected cells express IRF1. 
3.4.2.2 IRF1 and negative regulators of immune cells 
Regardless of the trigger for elevated IRF1 expression, whether that be T1 or 
TIII IFN secreted from β-cells, or TII IFN secreted from immune cells, the role of 
IRF1 in mediating β-cell destruction is unknown. As presented and discussed 
previously in this chapter, pancreatic β-cells upregulate a variety of interferon-
stimulated genes, including HLA-ABC. Upregulation of these genes which 
enhance IFN signalling e.g. STAT1 and MxA, can perpetuate the pro-
inflammatory response, increasing immune infiltration to the islets. Upregulation 
of HLA-ABC on the cell surface, provides more opportunity for intracellular 
proteins to be presented to cytotoxic T-cells (CD8+ immune cells). If the passing 
immune cells recognise an antigen presented by the HLA-ABC molecule as 
being foreign, then providing they are already activated, or there are the other 
co-stimulatory signals also presented on β-cells, the passing immune cells will 
have the licence to kill the cell on which the antigen is presented.  
It is unclear whether IRF1 expression can enhance these pro-β-cell killing 
mechanisms or whether IRF1 aids in defence against infiltrating immune cells. 
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Pancreatic β-cells upregulate a variety of immune cell negative regulators 
(Wyatt et al., 2019, Colli et al., 2018), it is plausible that IRF1 may mediate the 
expression of these negative regulators. Intriguingly, the expression of IRF1 
correlated with β-cell PDL1 expression (Colli et al., 2018). In islets where PDL1 
was upregulated, so too was IRF1, however, there were some islets where 
IRF1 was expressed in the absence of PDL1, which indicates that IRF1 may be 
driving PDL1 expression in some cells. Expression of PDL1 on the cell surface 
acts as an inhibitory signal to prevent immune mediated killing of the cell, when 
it binds PD-1 on the immune cell. Other inhibitory molecules are also 
upregulated on β-cells in T1D, those being HLA-E, -F and –G. As discussed 
previously in this chapter, IRF1 and HLA-F expression did not correlate. HLA-E 
and HLA-G are also upregulated in residual ICIs in T1D (Wyatt et al., 2019), 
however, the expression of these has not been extensively studied in the 
context of T1D. Although HLA-E and –G are upregulated in more select cells, 
rather than across the islet, like HLA-F, the expression in not restricted to a 
cluster, like the polar expression of IRF1, despite IRF1 being a transcriptional 
regulator of HLA-F, but not of HLA-E or HLA-G (Gobin and van den Elsen, 
2000). 
3.4.2.3 IRF1 and immune cell subsets 
A correlation between the presence of IRF1 in islets and the presence of 
infiltrating immune cells (indicated by presence of CD45+ cells in / around the 
islet periphery) was observed. This was true in all samples studied including 
donors with no diabetes or T1D. IRF1 was always in close proximity to CD45+ 
immune cells, but IRF1 and CD45 were not both present in the same cells. This 
is true both in T1D and in no T1D, although presence of both CD45 and IRF1 
was infrequent in controls, if they were expressed, they were always in 
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neighbouring cells to each other, and only in the exocrine tissue i.e. not in the 
islets. The significance of this observation is as yet, undetermined. It is unclear 
whether IRF1 expression attracts CD45+ immune cells somehow, or whether 
CD45+ immune cells are driving the expression of IRF1 in surrounding cells. 
CD45 is a pan-immune cell marker, therefore the specific subset of immune cell 
neighbouring IRF1+ cells is unclear. More specific immune cell markers such as 
CD4, CD8 and CD20 would label the most frequently observed immune cells in 
human T1D; T-helper cells, cytotoxic T-cells and B-cells, respectively. It has 
been demonstrated that IFNγ can induce expression of IRF1 (Colli et al., 2018). 
If the neighbouring CD45+ cells are T-cells, they could be secreting IFNγ, which 
could be driving IRF1 expression.  
IRF1 knockout mouse studies have been carried out to shed light on the 
relationship between IRF1 and immune cell expansion in response to viral 
infection. IRF1 knockout (KO) mice were infected with West Nile Virus (WNV), 
and it was found that compared to WT mice, they exhibit a more systemic viral 
infection, suggesting that IRF1 can limit viral spread. Furthermore, IRF1 KO 
mice had more CD8+ T-cells, compared to WT WNV infected mice (Brien et al., 
2011), which suggests that IRF1 is important in clonal expansion of CD8+ T-
cells. Another study using IRF1 KO C57BL/6 mice investigated the effects of 
IRF1 on cyclophosphamide administration. Cyclophosphamide is an 
immunomodulatory chemotherapy drug, used to treat some autoimmune 
conditions, as well as cancer (Al-Homsi et al., 2015, Hughes et al., 2018, Teles 
et al., 2017). They found that cyclophosphamide administration in WT mice 
induced the expansion of Th1 cells, and reduced Treg cell percentages, 
whereas in IRF1 KO mice, these observations were not made (Buccione et al., 
2018), suggesting IRF1 is pivotal in immune cell expansion. These reports 
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(Buccione et al., 2018, Brien et al., 2011) indicate that IRF1 may have various 
roles in regulating different T-cell subsets (reducing CD8 and Treg clonal 
expansion, but enhancing Th1 clonal expansion) in mice. It must be 
remembered that these are animal models, therefore it is unclear whether IRF1 
plays the same roles in human T-cell regulation, and in the context of T1D.  
3.4.3 IRF1, STA1 and MxA conclusions 
From the studies described in this chapter, it could be hypothesised that HLA-
ABC, STAT1 and MxA are all driven by common stimuli, whereas IRF1 has an 
alternative stimulus. HLA-ABC, STAT1 and MxA expression are restricted to 
residual ICIs in donors with T1D. Islet endocrine cells are encapsulated by a 
basement membrane (Bogdani et al., 2014), protecting them from the exocrine 
pancreas, this could also be restricting the distribution of IFNs to the exocrine 
cells, and limiting the spread of IFNs to the rest of the pancreas. It is likely that 
the β-cells in the islets are responding to viral infection by secreting T1 and / or 
TIII IFN (Marroqui et al., 2017), this results in upregulation of HLA-ABC, STAT1 
and MxA within the islet, however there is very little IFN leaving the islet, 
passing through the basement membrane, which restricts the spread. Evidence 
of upregulated HLA-ABC and STAT1 can be identified in islets which are not 
surrounded by infiltrating immune cells (Foulis et al., 1986, Krogvold et al., 
2016, Richardson et al., 2016), suggesting that STAT1 and HLA 
hyperexpression precede immune infiltration. Since MxA and STAT1 are 
strongly correlated with each other, it can also be hypothesised that MxA 
expression preceded immune cell infiltration. Once β-cells have been destroyed 
by immune cells, hyperexpression of HLA-ABC and STAT1 is lost (Foulis et al., 
1986, Richardson et al., 2016). IRF1 on the other hand is highly correlated with 
the presence of CD45+ immune cells, and as such is more highly expressed in 
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islets which have immune cell infiltration or immune cells surrounding the islet. 
This suggests that IRF1 is likely driven by IFNγ, potentially secreted from 
immune cells. The significance of IRF1 expression driven by IFNγ is unclear in 
T1D, and it is unknown whether IRF1 is upregulating inhibitory and / or 
stimulatory signals, to send immune cells away, or to activate them to kill.  
The expression of IRF1 is intriguing, and warrants farther study to better 
understand its role in T1D. Creating a conditional expression or IRF1 knock-out 
β-cell line where the expression of IRF1 can be manipulated would provide a 
tool to study the impact IRF1 has on cellular response to viral infection, or 
different cytokines, e.g. T1, II or III IFN. Further immunostaining, with more 
specific immune cell markers would help clarify the identity of immune cell 
subsets which associate with IRF1 expression. Moreover, if IRF1 expression is 
related to the immune profile, as is hypothesised above, it would be beneficial to 
investigate the expression of IRF1 in individuals that were diagnosed <7 or >13 
years of age, as these correspond to T1DE1 and T1DE2 (Leete et al., 2020). 
Those diagnosed <7 (T1DE1) have a more aggressive immune phenotype, 
compared to those diagnosed older (T1DE2), as well as having more CD20 
positive immune cells (B-cells) in T1DE1 (Leete et al., 2016) surrounding the 
islets. As well as increasing the age range of donors examined, the duration of 
T1D may also impact the expression of IRF1, especially, if its expression is 
related to immune cell infiltration. In long duration T1D, after the β-cell 
destructive phase has passed, where there is little evidence of immune cells 
(In't Veld, 2011), it may be hypothesised that there would also be no IRF1. 
Understanding the role of IRF1, may provide insights into mechanisms of 
disease pathogenesis, which is important to understand if a specific treatment is 
to be developed.      
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3.4.4 PPP1R1A expression in pancreata 
In earlier sections of this chapter, evidence implicating an exaggerated immune 
response to viral infection in T1D is described. Reasons for this inappropriate 
immune response are as yet unclear, however genetic predisposition could be a 
contributing factor. SNPs in the gene encoding MDA5 (IFIH1) are associated 
with T1D onset. The polymorphism rs1990760, A946T (discussed earlier in 
section 3.4.1), confers increased risk for developing T1D (Smyth et al., 2006, 
Domsgen et al., 2016, Liu et al., 2009), however there are 4 further known 
polymorphisms in IFIH1 which confer protection against development of T1D 
(Nejentsev et al., 2009), suggesting that IFIH1 and its protein product, MDA5, 
may play a role in T1D development. Additionally, there are studies which have 
shown that reduced overall expression of MDA5 is protective against T1D 
(Lincez et al., 2015).  
3.4.4.1 Regulation of MDA5 
Given that MDA5 has the potential to play a pivotal role in T1D development, 
and expression of MDA5 is increased in β-cells in T1D (Leete et al. 
unpublished), understanding its regulation could be critical to understanding the 
development of T1D in ‘at-risk’ individuals. As mentioned in the introduction of 
this chapter, MDA5 must be dephosphorylated in order for it to be active, and 
trigger IFN signalling upon detection of intracellular dsRNA (Wies et al., 2013, 
Wallach and Kovalenko, 2013). It is very important that the activation of MDA5 
is regulated, not only to trigger an immune response proportional to viral 
infection, but because mitochondrial dsRNA can also trigger antiviral signalling 
via MDA5. If mitochondrial dsRNA ‘leaks out’ into the cell cytoplasm (Dhir et al., 
2018), it can be detected by MDA5, which would be unfavourable for the cell, as 
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it would trigger unnecessary IFN signalling. To restrict MDA5 activation, MDA5 
is held in its phosphorylated state. 
Due to the mounting evidence of a heightened immune response in T1D, it was 
hypothesised that MDA5 is being more readily activated. For MDA5 to be in its 
active state, it must be dephosphorylated. In order for this to be the case, the 
phosphatase, PP1 must be active, which is mediated by reduced expression of 
the appropriate inhibitor. PP1 has a numerous collection of inhibitors (Fardilha 
et al., 2012), thus identifying the appropriate one in this scenario is of 
importance. One of the inhibitors of PP1 is PPP1R1A. It was demonstrated by 
Mesman et al. (2014) that in dendritic cells, PPP1R1A is key to regulating PP1 
activity in regards to MDA5 activity. The extremely high level of expression of 
PPP1R1A in β-cells, suggests it may also be important at regulating this 
pathway in these cells as well. The high expression of PPP1R1A in β-cells of 
donors with no diabetes would inhibit PP1, rendering it unable to 
dephosphorylate and activate MDA5, this would therefore limit the interferon 
release from cells via MDA5 triggered pathways. In situations where PPP1R1A 
is depleted from β-cells, such as in T1D, PP1 would be free to dephosphorylate 
and activate MDA5, resulting in increased secretion of Type 1 interferon. Given 
that PPP1R1A is expressed at higher levels in no diabetes, compared to T1D, 
the hypothesis that PPP1R1A regulates PP1 in the context of MDA5 activation 
in β-cells, warrants further investigation.  
3.4.4.2 PPP1R1A expression in the human pancreas 
Findings from this study demonstrated that PPP1R1A is most highly expressed 
in pancreatic β-cells in individuals without T1D. The expression of PPP1R1A 
was intriguing, as the β-cells which contained the most insulin, had the lowest 
degree of PPP1R1A staining (Figure 3-28 and Figure 3-33), and β-cells which 
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contained less insulin had the highest expression of PPP1R1A (Figure 3-28 and 
Figure 3-33). The depletion of PPP1R1A from select β-cells in T1D was curious, 
as some β-cells had much reduced PPP1R1A, whereas others retained 
PPP1R1A expression. The depletion of PPP1R1A was both in the overall 
number of cells which expressed PPP1R1A, but also, the cells which retained 
PPP1R1A expression exhibited much weaker immunostaining for PPP1R1A, 
suggesting that the expression was depleted. It was interesting to observe that 
PPP1R1A was depleted from more β-cells in individuals diagnosed >13, 
compared to children diagnosed <7 years of age. The significance of this 
remains unclear, but could be related to host response to viral infection. In cells 
where PPP1R1A is depleted, it would be hypothesised that there is a larger 
degree of MDA5 activation and more IFN release from these cells (Figure 3-4).  
3.4.4.3 Other components of antiviral and interferon signalling pathways which have 
been shown to be impacted by the phosphatase, PP1 
Dephosphorylation of MDA5 is not the only way in which PP1 could regulate the 
cellular response to viral infection. PP1 may also regulate protein translation, 
which is impacted upon PKR activation following dsRNA detection (Liao et al., 
2016), as well as proteins downstream of MDA5 signalling – the 
phosphorylation status of IRF3 and IRF7 (Dalet et al., 2017, Gu et al., 2014, 
Wang et al., 2016).  
When dsRNA is detected by PKR, PKR phosphorylates the translational 
regulator, eIF2α. When eIF2α is phosphorylated, cap-dependent protein 
translation is inhibited within the cell, this is beneficial during a viral infection as 
viruses rely on host machinery to replicate, so by the cell shutting off translation, 
the viral proteins cannot be translated (Garcia et al., 2006), thus viruses cannot 
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infect further cells. Despite inhibition of general protein translation when eIF2α 
is phosphorylated, transcription of a few select genes are upregulated (via cap-
independent translation), one of which is GADD34. GADD34 targets PP1 to 
dephosphorylate eIF2α and rescue cells from translational arrest. Liao et al. 
(2016) have demonstrated using HeLa and DF-1 chicken fibroblast cells, that 
during Newcastle Disease Virus infection, phosphorylated eIF2α translational 
arrest is dependent on PKR signalling, even at late infection time points. They 
further showed that PP1 is degraded at these late time points, counteracting an 
increase of GADD34, retaining cells in translational arrest, as eIF2α will remain 
phosphorylated if PP1 is not expressed, thus unable to dephosphorylate eIF2α. 
This could also be harmful to the cells, as it would limit the production of 
cytokine signalling to neighbouring cells. Dalet et al. (2017), however, propose 
that IFN production by infected cells is cyclical. They suggest that not all 
infected cells in a population will be producing IFN at all times, but that the 
expression of IFN is heterogeneous within a population. This implies that whilst 
some cells are in translational arrest, others are not, and these are the ones 
producing IFN. Interestingly, they show that GADD34 expression is also 
dependent on IRF3 activation, which is upregulated in response to antiviral and 
interferon signalling, and that cells continually cycle between the 
phosphorylation statuses of eIF2α, controlled by PKR and GADD34/PP1. This 
should give the cells a balance between antiviral signalling and controlling the 
translation of viral proteins. Dalet et al. (2017) are not the only research group 
to implicate IRF3 and PP1 in related pathways; Gu et al. (2014) propose that 
PP1 plays a more direct role in regulating IRF3 activity. They found that 
overexpression of PP1 inhibits IRF3 activity by dephosphorylating it at Ser385 
and Ser396. IRF3 must be phosphorylated to carry out its role as a transcription 
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factor, hence PP1 overexpression reduced IFN production from macrophages 
by reduced IFR3 phosphorylation. It has also been proposed that IRF7 activity 
is regulated by PP1 (Wang et al., 2016). They demonstrate that IRF7 has a PP1 
binding motif and that PP1 targets 4 phosphorylation sites of IRF7; serines 471, 
472, 477 and 479. Furthermore, it is shown that interferon treatment, Poly I:C 
treatment and toll-like-receptor (TLR) challenge can induce the expression of 
PP1, potentially acting as a counter-regulatory mechanism, as like IRF3, IRF7 
must be phosphorylated to have transcriptional control over interferons. Thus 
overexpression of PP1 negatively regulates IRF3 / IRF7 activity. Although PP1 
is necessary to induce antiviral signalling, as in the case of MDA5, it is also 
necessary to put a brake on antiviral signalling as in the case of IRF3 and IRF7. 
Expression of PP1 regulatory subunits, including PPP1R1A, will inevitably have 
an impact on PP1 function, however, whether PPP1R1A inhibits PP1 from all or 
any of these IFN signalling mechanisms is yet to be defined. The depletion of 
PPP1R1A may be to allow PP1 to dephosphorylate IRF3 and / or IRF7, 
minimising transcription of ISGs, however, increased PP1 as mentioned 
previously may increase MDA5 signalling and resultant IFN secretion.  
3.4.4.4 Viral evasion strategies involving PP1 and PPP1R1A 
Since it has been demonstrated that PP1 can have a handle on many aspects 
of antiviral signalling, it is not surprising that viruses have evolved strategies to 
evade the immune response by utilising PP1. Measles virus infects dendritic 
cells (DCs) initially, and does so by binding the DC-SIGN receptor on the 
surface of DCs (Mesman et al., 2014). Upon viral binding, Raf1 is activated, 
which in DCs induces the activation (and phosphorylation) of PPP1R1A, which 
enables it to bind and inhibit PP1, thus preventing the activation of MDA5. This 
means that the measles virus has an upper hand in the infected DC, as MDA5 
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is unable to trigger intracellular signalling and IFN release. Additionally, Davis et 
al. (2014) have demonstrated the V protein of Measles virus can directly interact 
with PP1, which prevented the dephosphorylation of MDA5. Measles virus isn’t 
the only virus however to develop evasion strategies, via PP1. The 2C protein 
of enteroviruses (including CVB3) forms a complex with PP1 and IκB Kinase 
(IKK) (Li et al., 2016), to dephosphorylate IKKβ, restricting NF-κB mediated 
signalling and activation, limiting IFN release. Since PPP1R1A is depleted from 
β-cells in T1D, it could be hypothesised that PP1 will be available for the 2C 
protein to form a complex with and thus restrict NF-κB mediated cytokine 
signalling. This hypothesis could be tested in Vitro using modified versions of 
CVB3 with mutated 2C proteins, and measuring NF-κB activation and 
confirming whether any changes were mediated by PP1 by investigating 
whether PP1 does in fact form a complex with enteroviral 2C proteins. 
3.4.4.5 PPP1R1A conclusions 
Although it is clear PP1 may play several roles in regulating viral infection, it 
must be taken into consideration that this may not be the case in all cell types, 
so the same may not hold true in pancreatic β-cells. Nonetheless, if PP1 does 
play a role in regulating the immune response to viral infection as described 
above, PPP1R1A may not be the regulatory (inhibitory) protein in some or any 
of the processes.  
Using immortalized human pancreatic β-cell models with inducible expression of 
PPP1R1A will help to determine the significance of PPP1R1A depletion in T1D. 
The main aim of my PhD, was to investigate the role of PPP1R1A in regulating 
MDA5 activity and β-cell responses to viral infection. Due to unforeseen 
obstacles described in chapters 4 and 5, this aim was unable to be carried out. 
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Possible other ramifications of PPP1R1A depletion from β-cells in T1D were 
investigated. The results of which are described in chapter 6.  
 
3.4.5 Final summary of results for this chapter 
Results presented in this chapter demonstrate an increased level of IFN 
signalling in donors with T1D, compared to donors without T1D (with or without 
autoantibodies). Importantly, each sample examined was obtained from donors 
who had confirmed viral infection by detection of the viral protein VP1 and the 
viral sensor protein, PKR. This statement is critical since the response to viral 
infection can be compared between donors. Donors with T1D displayed 
significant upregulation of MxA and STAT1 compared to VP1 positive donors 
without T1D. Furthermore, results presented in this chapter demonstrate 
elevated IRF1 in T1D. IRF1 displayed a different pattern of staining compared 
to the other ISGs examined, implying that IRF1 is upregulated in response to 
different stimuli to that of MxA and STAT1. MxA and STAT1 are likely to be 
upregulated by TI or TIII IFN, as MxA and STAT1 are localised to the islet, 
whereas IRF1 expression is not restricted to the islet, and is expressed around 
the periphery of islets as well as intra-islet. IRF1 displayed highest expression in 
inflamed islets. Taken together, it could be hypothesised that TI and / or TIII IFN 
can upregulate IRF1, but in addition, it is likely that TII IFN (IFNγ) plays a 
significant role in IRF1 expression. Elevated TI IFN signalling and resultant 
elevated ISG expression in the islets of donors with T1D may be due to 
dysregulated MDA5 signalling. MDA5 activity is highly regulated, however, as 
demonstrated in this chapter, MDA5 is elevated in the β-cells in T1D. MDA5 is 
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normally phosphorylated, and thus minimally active, however when it is 
dephosphorylated by PP1, MDA5 becomes active (Wies et al., 2013).  
As demonstrated in this chapter, a regulatory protein of PP1, PPP1R1A, is 
depleted from β-cells in T1D. PPP1R1A depletion may contribute to elevated 
MDA5-mediated IFN signalling, due to increased dephosphorylated (active) 
MDA5 as a result of increased PP1 activity. PPP1R1A was shown to be 
significantly depleted from β-cells in T1D donors diagnosed <7 years (T1DE1), 
but even more so from donors diagnosed >13 years (T1DE2). Individuals who 
have had T1D for a longer duration, have almost obsolete β-cell PPP1R1A 
expression, but instead, an increased number of α-cells expressed PPP1R1A. 
The significance of these findings remains unclear, however could influence 
MDA5 activity and resultant IFN signalling.   
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4 Generation of cells with inducible expression of PPP1R1A 
 
4.1 Introduction 
Common methods to investigate the role of a specific protein within cells are 
either by knockout studies, for example where the translation of protein from 
mRNA is interfered with by using short interfering RNA (siRNA), or by 
overexpression studies, where cDNA encoding the gene of interest is transiently 
transfected into cells resulting in overexpression of the protein. Both of these 
events are often transient occurrences, with siRNA and transient transfections 
often only lasting a few days at maximum. Additionally, transfections with siRNA 
or cDNA do not affect every cell in the population, this results in the generation 
of background ‘noise’ from these untransfected cells, and makes results harder 
to interpret. This chapter describes the generation of 1.1B4 cells which, upon 
exposure to tetracycline, express WT PPP1R1A, or T35A PPP1R1A (which is a 
phosphorylation null mutant) using the Flp-In T-REx system.  
This chapter describes the generation of 1.1B4 cells which, upon exposure to 
tetracycline, express WT PPP1R1A, or T35A PPP1R1A (which is a 
phosphorylation null mutant). This was achieved by using the Flp-In T-REx 
system (Invitrogen Cat# K650001). The use of these cells is described in 
chapter 6. 
4.1.1 History of tetracycline regulated gene transcription 
The regulation of gene expression by tetracycline responsive promoters was 
first described in 1992 by Gossen and Bujard (1992). The tetracycline repressor 
protein (isolated from E.coli) was fused with the activating domain of VP16 of 
Herpes simplex virus. This now tetracycline sensitive transactivation domain 
216 
 
was used to control the expression of luciferase in HeLa cells. This system was 
a ‘tet-off’ system, where the addition of tetracycline silenced gene expression. 
The ‘tet-on’ system was developed a few years later by Gossen et al. (1995), by 
mutating the original tetracycline repressor gene from the ‘tet-off’ system. The 
concentration of tetracycline needed to induce gene expression was ~10x more, 
than needed to induce gene silencing, which is okay for an immortalized cell 
line, such as HeLa’s (in which this system was developed and tested), but is 
more of an issue for in vivo studies, as the high doses necessary for induction 
of gene transcription were unfavourable for the animal. Urlinger et al. (2000) 
further developed the tetracycline repressor gene from the ‘tet-on’ system to 
have increased sensitivity to tetracycline and lower basal activity, which has 
been further characterised by Lamartina et al. (2002) for in vivo use. The 
generation of antibiotic-responsive promotors has been a useful tool to study 
protein specific roles within cells and animals. This is reflected by the fact that 
other antibiotic-mediated gene expressions now exist, such as streptogramin- 
regulated gene expression (Fussenegger et al., 2000), amongst others (Klock et 
al., 1987, Lessard et al., 2007).  
One of the disadvantages of the Flp-In T-REx system is that tetracycline 
responsive promoters can be ‘leaky’ (Roney et al., 2016), however the EV, WT 
and T35A cells described in this chapter were shown to have no detectable 
PPP1R1A when not exposed to tetracycline, therefore this was not a problem in 
the system developed presently. Leaky promotors are promoters which are not 
fully tetracycline responsive, and still can be active, even in the absence of 
tetracycline. This is unfavourable, as it results in background expression of the 
gene of interest. 
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Site specific recombination has been widely used in biological research 
settings. There are 2 key site specific recombination systems, the Cre-LoxP, 
and Flp-FRT. The main difference between these two recombination methods 
are the species in which they were isolated and first identified. The Cre-LoxP 
system was identified in the bacteriophage P1 and Escherichia coli (Sternberg 
and Hamilton, 1981), whereas the Flp-FRT system was identified in baker’s 
yeast, Saccharomyces cerevisiae (Cox, 1983). The Flp-In T-REx system utilizes 
the Flp-FRT method for site specific recombination. The theory behind the way 
in which both these methods work is that recombination of 2 homologous 
sequences (either LoxP or FRT) is mediated via a specific recombinase 
enzyme, Cre or Flp, respectively (Sauer and Henderson, 1988, Gronostajski 
and Sadowski, 1985). These recombination strategies have been useful for 
genetic, and functional studies both in vivo, including drosophila (Weasner et 
al., 2017), zebrafish (Carney and Mosimann, 2018) and mice (Hara and Verma, 
2019, Goodrich et al., 2018) and in vitro (Thomas et al., 2004, Tarasov et al., 
2006). 
4.1.2 Flp-In T-REx system – An overview 
The Flp-In T-REx system is an overexpression system developed by Invitrogen 
(Cat# K650001). The system is based on site specific Flp-frt recombination 
(Cox, 1983) and tetracycline inducible gene expression (Gossen et al., 1995). 
The Flp-In T-REx system is advantageous over constitutive overexpression of 
cDNA because it allows for tetracycline mediated, conditional overexpression. 
When the cells are incubated with tetracycline containing media they will 
transcribe the cDNA – termed ‘Tet-on’, and therefore express the protein of 
interest, however in the absence of tetracycline, they will not transcribe the 
gene of interest. Tetracycline induced gene expression has been widely used 
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for both in vivo and in vitro studies (Corbel and Rossi, 2002). Gene expression 
which is induced by the addition of tetracycline is termed ‘tet-on’ where as 
tetracycline can also be used to induce the silencing of genes, termed ‘tet-off’. 
Examples of the tetracycline mediated gene expression in vivo include the use 
of tetracycline inducible antisense RNA to down-regulate PDX-1 expression in 
transgenic mice (Lottmann et al., 2001) and more recently, a similar method has 
been used for the investigation of retinopathy in Type 2 diabetes in transgenic 
rats (Reichhart et al., 2017). In this model, diabetes was induced by 
tetracycline-mediated knockdown of the insulin receptor. In vitro studies using 
the ‘Tet-On’ system have been predominantly overexpression studies, rather 
than knockdown (‘Tet-off’) studies that have been carried out more frequently in 
vivo. A number of groups have successfully used the Flp-In T-REx system in 
the rat β-cell line, INS-1E. INS-1E Flp-In T-REx cells have been used to 
investigate the transcription factors HNF6, HNF4α and HNF1β (Thomas et al., 
2004) as well as mutations in the Kir6.2 ATP-sensitive K+ channel subunit 
(Tarasov et al., 2006). Furthermore INS-1E Flp-In T-Rex cells have been 
successfully used by others in the University of Exeter Medical School to study 
various aspects of β-cell biology (Welters et al., 2008, Welters et al., 2006, 
Russell and Morgan, 2011). All of these studies have successfully used the Flp-
In T-REx system, however, as mentioned, these studies were carried out in 
INS-1E cells, which are rat, and due to the differences between human and 
rodent β-cells, for these (and future studies) the Flp-In T-REx system needed to 
be established in a human β-cell line.  
To generate these cells, they were stably transfected with a number of plasmids 
(Figure 4-1) which all play a role in the development of the tetracycline 
responsive system (Figure 4-2). All plasmids will be transfected into cells using 
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liposomal based methods, and will incorporate randomly into the cells’ genome. 
Due to this, after each transfection cells must be sorted into single wells, and 
expanded from individual clones. Incorporation of plasmids into different 
genomic locations could affect the behaviour of cells, by incorporating into or 
disturbing genes.  
 
Figure 4-1 Flow chart describing the process for creating the Flp-In T-REx cells. 
1. Cells are transfected with linearized pFRT/LacZeo. 2. Stably transfected 
cells are selected by resistance to Zeocin antibiotics. 3. Colonies are 
screened by Southern Blotting. 4. A cell which is stably transfected with 
pFRT/LacZeo is transfected with linearized pcDNA6/TR. 5. Stably 
transfected cells are selected for by blasticidin and zeocin resistance. 6. 
One of the blasticidin and zeocin resistant colonies are co-transfected with 
pOG44 and pcDNA5/FRT/TO. 7. Successful integrants of 
pcDNA5/FRT/TO show a hygromycin resistant phenotype. 8. Addition of 
tetracycline to the cell media enables transcription pf the inserted gene of 




Figure 4-2 Diagram of how the tetracycline repression / induction system works in Flp-In T-REx cells. 
Modified from Flp-In T-REx manual (Invitrogen).  (1) Following stable transfection with pcDNA6/TR, the tetracycline repressor 
protein is constitutively expressed by the cells. (2) Tetracycline repressor protein homodimers bind to the TetO2 sequences 
in the pcDNA5/FRT/TO vector, which represses transcription of the gene of interest. (3) Addition of tetracycline binds the 
tetracycline repressor protein homodimers. (4) A conformational change in the Tetracycline repressor protein upon tetracycline 




Initially, the pFRT/lacZeo plasmid is transfected into cells. This contains a Flp 
Recombination Target (FRT) site which is important in ensuring the 
recombination of the gene of interest to a specific genomic location in later 
stages of Flp-In T-REx cell development. After expansion, and antibiotic-
selection of a single clone, a plasmid containing the cDNA sequence encoding 
the tetracycline repressor protein (pcDNA6/TR) is transfected into the cells. The 
tetracycline repressor cDNA is under the control of a constitutive promoter, 
thus, cells will transcribe the tetracycline repressor protein at all times. This 
plasmid will integrate randomly into the cells’ genome, irrespective of the 
pFRT/lacZeo plasmid, thus cells must be expanded from single clones again. 
Once cells have been stably transfected, and clones with both plasmids 
incorporated into the cells’ genome have been identified each clone should be 
screened by Southern blotting to check that the pFRT/lacZeo plasmid has only 
integrated into the genome of the cells once. Integrations of multiple copies of 
pFRT/lacZeo would result in multiple FRT sites being incorporated into the 
genome of the cells, which would be problematic in latter stages of Flp-In T-REx 
cell generation. Multiple FRT sites within cells could result in either multiple 
copies of the gene of interest incorporated, or a heterogeneous population 
where cells have the gene of interest incorporated into different genomic 
locations. Once these two plasmids have been stably transfected into cells and 
screened to identify a clone with a single FRT site incorporated, a parental Flp-
In T-REx host cell line has been generated. This parental Flp-In T-REx cell line 
can be used to create multiple cell lines with tetracycline inducible expression of 
a gene of interest. 
To make use of this Flp-In T-REx host cell line, the cDNA sequence encoding 
the gene of interest must be inserted into the multiple cloning site (MCS) of the 
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pcDNA5/FRT/TO plasmid. The MCS contains a number of restriction enzyme 
sites and is located just downstream of a hybrid human cytomegalovirus (CMV)/ 
tet operator 2 (TetO2) promoter. This hybrid promoter allows for tetracycline 
regulated gene expression. The CMV promoter is constitutive, however the 
TetO2 promoter is responsive to tetracycline. When the tetracycline repressor 
protein is bound to the promoter region, the promoter is not available for gene 
transcription. The hybrid CMV / TetO2 promoter provides constitutive gene 
transcription, but only when the tetracycline repressor protein is not bound to 
the TetO2 promoter. In cells which do not express the tetracycline repressor 
protein, the promoter will act constitutively. 
Also encoded in the pcDNA5/FRT/TO plasmid is an FRT site, which is 
immediately upstream of the hygromycin resistance gene. The hygromycin 
resistance gene does not have a promoter or ATG initiation codon; therefore 
hygromycin resistance will only be conferred to cells when the FRT sites 
(incorporated into the Flp-In T-REx host cells and pcDNA5/FRT/TO plasmid) 
recombine. The SV40 promoter and ATG initiation codon (which serves the 
hygromycin resistance gene) is incorporated into the Flp-In T-REx host cell line 
with pFRT/lacZeo. Through Flp-recombinase mediated integration of 
pcDNA5/FRT/TO at the FRT site in the Flp-In T-REx host cells, the hygromycin 
resistance gene is brought into frame with the SV40 promoter and ATG initiation 
codon. For successful integration of the pcDNA5/FRT/TO plasmid with the FRT 
sequence in the Flp-In T-REx host cells, the pcDNA5/FRT/TO plasmid must be 
co-transfected with pOG44, which encodes the flp recombinase enzyme (Figure 
4-3). Hygromycin resistant cells, should all be clones of each other, as the 
pcDNA5/FRT/TO plasmid will incorporate into the same location (FRT site) of 
each cell, so there is no need to single-cell sort and expand individual colonies. 
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For an overview of the process to generate the Flp-In T-REx cells, please see 
Figure 4-1.  
These 1.1B4 Flp-In T-REx host cells can be used to investigate the role of other 
proteins in future studies. Gene expression can easily be manipulated in these 
cells, and on a population wide scale without the need for single-cell sorting. 
 
Figure 4-3 Mechanism of site-directed recombination for insertion of the gene of 
interest into parental Flp-In T-REx cells.  
cDNA encoding the gene of interest is inserted into the multiple cloning 
site of the pcDNA5/FRT/TO vector. When this vector is co-transfected with 
pOG44 (which contains the Flp recombinase enzyme), the FRT sites in the 
Flp-In T-REx host cells re-combine with the FRT site in the 
pcDNA5/FRT/TO vector, which incorporates the gene of interest into a 






4.1.3 Choosing a cell line to generate the Flp-In T-REx system in 
The first part of this chapter describes the process for selecting the host cell line 
in which to generate the Flp-In T-REx cells. This was a crucial initial step in 
development, as selecting the correct host cell line could impact future 
experiments. The criteria for selection were; (a) the cell line needed to be of 
human origin, (b) the cell line should express no endogenous PPP1R1A, since 
this would minimise background noise, (c) the cell line should be able to 
maintain a persistent viral infection. 1.1B4 cells were selected as the Flp-In T-






All plasmids used in this chapter (other than pEZ-M02/PPP1R1A) were 
purchased as components of the Flp-In T-REx core kit (Invitrogen). pEZ-
M02/PPP1R1A was purchased from SourceBioscience.  
Plasmids were transformed into competent E.coli, colonies expanded, and DNA 
extracted as described (see section 2.4).  
4.2.2 Restriction digest and ligation 
Extracted DNA was cut by endonuclease digestion using appropriate restriction 
digest enzymes, and relevant buffers, as described in section 2.4.3. Products 
were electrophoresed and relevant fragments were extracted (see section 2.3). 
Compatible fragments were ligated as described in section 2.4.4.  
4.2.3 Mutagenesis 
The Q5 Site-directed mutagenesis kit was utilized to manipulate the 
phosphorylation site of PPP1R1A, Thr35. The primers used to achieve 
mutagenesis are described in Table 4-1. Mutagenesis of PPP1R1A is described 




Table 4-1 Details of the primers used, annealing temperature, number of PCR 
cycles and product size for PCR reactions described in this chapter  
 
Figure 4-4 PPP1R1A primer locations 
The primers that amplify all known PPP1R1A isoforms are indicated with 
the orange arrows. These primers span over exons 3 and 6, as these are 
present in all isoforms. Variant specific primers are indicated by blue 
arrows. The forward which specifically amplifies the full length PPP1R1A 
isoform span across the boundary over exons 5 and 6, the forward primer  
for variant 2 spans across the exon boundary between exons 3 and 6, and 
the forward primer for variant 4 spans over exons 4 and 6. The reverse 




4.2.4 Cell culture 
In these studies, the following cell lines were used: 1.1B4; EndoC-βH1; INS-1E; 
PANC1; BRIN-BD11 and Min6. The conditions of culture of each of these cell 
lines is described in section 2.1. Human Islet samples were also analysed by 
PCR.  
INS-1E cells routinely used in the group have the Flp-In T-REx system 
integrated already. For this reason, they were used as a positive control, for 
detection of components of the Flp-In T-REx system. 
4.2.5 PCR 
A PCR (as described in section 2.3) was carried out for detection of PPP1R1A 
and of the tetracycline repressor protein (TetR). For details of the primers and 
PCR conditions used, refer to Table 4-1 and Figure 4-4. 
In this chapter cDNA generated from human islets was also used in some PCR 
experiments. Human islets were provided to the laboratory by the Oxford Centre 
For Islet Transplantation. 
4.2.6 Transfections 
The transfection reagent used in these studies was Avalanche®-Omni (EZ 
Biosystems). In each transfection, 0.4 ul Avalanche was used per µg DNA 
transfected into cells, unless otherwise stated. Transfections are described in 
more detail in section 2.1.2. 
4.2.7 Single cell sorts 
1.1B4 cells were seeded as single cells into each well of a 96 well plate using a 
FACS Aria III (operated by Dr Mark Russell). Colonies were expanded and 
screened for insulin positivity, or antibiotic resistance.  
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4.2.8 Western Blotting 
Protein was harvested from cells, estimated and prepared for analysis by 
western blotting as described in section 2.6. 
4.2.9 ICC 
Cells were seeded at a density of 0.5x105 cells per well onto coverslips in a 24-
well-plate. They were left to adhere for 24 hours before being fixed onto the 
coverslips by using 4% PFA. Cells were immunostained for Insulin, Glucagon, 
PPP1R1A or PPP1R1A Thr35. Antibodies, and their conditions of use are 
detailed in Table 2-5 and Table 2-8 
4.2.10 Dot Blotting 
In order to select a colony for future transfections, their ability to operate with a 
tetracycline repression / expression system was investigated. Protein was 
extracted, and concentration was determined (as described in sections 2.6.1 
and 2.6.2). A square of nitrocellulose membrane (VWR) was marked out into a 
grid of 80 squares. 5 µg protein was added for each sample. The membrane 
was left to air dry before being blocked for 1 hour in 5% milk in 0.05% TBST at 
room temperature. The blot was then incubated with Rabbit-PPP1R1A (1/500) 
diluted in 5% milk overnight on a roller at 4°C, then for 1 hour at room 
temperature the following day. The membrane then washed 3 x in TBST, then 
incubated with AP conjugated - Goat-anti-Rabbit secondary antibody, for 1 hour 
at room temperature, followed by 3 x TBST washes, then incubated with the 
chemiluminescent reagent, CDP-Star, for 5 minutes. To visualise the blot, the 




4.3 Results – Construction of the 1.1B4 Flp-In T-REx cell line 
4.3.1 Selecting a host cell line 
When selecting a cell line in which to overexpress PPP1R1A via the Flp-In T-
REx system, there were a number of factors to consider. These factors include; 
endogenous expression of PPP1R1A; representation of human β-cells and 
practicalities of manipulating the cells to develop the Flp-In T-REx cells (e.g. is it 
possible to do a single-cell sort). To answer one of these questions, the 
pancreatic cell lines available in our laboratory were characterised for their 
PPP1R1A expression at the RNA level, and at the protein level, where possible. 
In addition, the cells were screened for insulin expression and practicalities of 
working with each cell line was considered. 
4.3.1.1 PPP1R1A expression at the RNA level 
The mRNA expression of PPP1R1A was assessed in the human pancreatic cell 
lines; 1.1B4, EndoC-βH1 and PANC1, as well as in human islets. PPP1R1A 
was found to be expressed in the EndoC-βH1 cells and in the human islet 
samples (Figure 4-5). Furthermore, all three characterised isoforms (full length, 
version 2 and version 4) were expressed in both human islets and EndoC-βH1 
cells (Figure 4-5), the identity of each band was confirmed by direct sequencing 
of the excised bands. 1.1B4 cells appeared to express the full length isoform, 
however results from version 2 and 4 primers were undefined. These data from 
1.1B4 cells may be inconclusive due to matters of species, discussed later in 
this chapter, and in greater detail in chapter 5. PANC1 cells appeared to 
express the full length isoform of PPP1R1A and version 2, however they did not 





Figure 4-5 Analysis of PPP1R1A isoform expression by RT-PCR 
mRNA extracted from EndoC-βH1, 1.1B4 and PANC1 cells was used to 
create cDNA. An RT-PCR using four primer sets was carried out. The 
primer sets used amplified all isoforms, full length (235 bp), version 2 (191 
bp) or version 4 (270 bp) of PPP1R1A. Products were run alongside 
MassRuler Express DNA ladder. 
231 
 
4.3.1.2 PPP1R1A expression at the protein level 
The protein expression of endogenous PPP1R1A was assessed in 1.1B4, 
EndoC-βH1, INS-1E and PANC-1 cells by Western blotting. This revealed that 
PPP1R1A was expressed in the EndoC-βH1 cells and in the INS-1E cells 
(Figure 4-6). Interestingly, the band appeared at slightly different molecular 
weights in the human EndoC-βH1 cells, compared to the rat INS-1E cells. This 
is probably due to the slightly different amino acid sequence (Figure 4-7) 
resulting in post-translational modification differences highlighted in Figure 4-8, 
Figure 4-9 and Figure 4-10, as the molecular weight of both the human and rat 
proteins is approximately the same (Figure 4-7). Despite 1.1B4 and PANC1 
cells expressing PPP1R1A at the mRNA level, this was not detectable at the 
protein level.   
 
Figure 4-6 Endogenous expression of PPP1R1A in cultured pancreatic cell lines 
by Western blotting 
Protein extracted from 1.1B4, EndoC-βH1, INS-1E or PANC1 cells was 
used for Western blotting and was probed for with an antibody raised in 
rabbit which recognises mouse, rat and human PPP1R1A protein (A). The 
secondary antibody used was an AP-conjugated anti-rabbit antibody, and 
the blot was incubated with the chemiluminescent reagent CDP-star 





Figure 4-7 Protein alignment of human, rat and mouse PPP1R1A 
Uniprot was used to align the human, rat and mouse protein sequences of 
PPP1R1A. Amino acids which are conserved between the three species 
are marked with * below.  
Known phosphorylation sites are highlighted and the PP1 binding motif is 





Figure 4-8 Human and rat PPP1R1A proteins have different glycation sites 
The protein sequences for human (A) and rat (B) PPP1R1A were entered 
into NetGlycate server (http://www.cbs.dtu.dk/services/NetGlycate/) to 
predict glycation sites in each protein. Rat PPP1R1A has 4 possible 
glycation sites, whereas human PPP1R1A only has three, only two of 
these sites are common between human and rat PPP1R1A. The common 




Figure 4-9 Human and rat PPP1R1A proteins have different ubiquitination sites 
The protein sequences for human (A) and rat (B) PPP1R1A were entered 
into BDM-PUB server (http://bdmpub.biocuckoo.org/prediction.php) to 
predict ubiquitination sites in each protein. Human PPP1R1A (A) and rat 
PPP1R1A (B) have different predicted ubiquitination sites, however rat 




Figure 4-10 Human and rat PPP1R1A proteins have different predicted 
sumoylation sites 
The protein sequences for human (A) and rat (B) PPP1R1A were entered 
into GSP-SUMO 1.0 software to predict sumoylation sites in each protein. 
Human PPP1R1A (A) and rat PPP1R1A (B) share a common predicted 
sumoylation site 14VPLLE18, however human PPP1R1A has an 





In the cell lines 1.1B4, PANC1, EndoC-βH1, BRIN-BD11, Min6 and INS-1E, the 
subcellular localization of PPP1R1A was investigated using ICC (Figure 4-11), 
and the expression of Insulin was also examined (Figure 4-11). 1.1B4 cells did 
not have any detectable PPP1R1A, nor did PANC1 or BRIN-BD11 cells. INS-
1E, and Min-6 cells had an abundance of PPP1R1A, with each cell in the 
population expressing the protein robustly. EndoC-βH1 cells had an interesting 
staining distribution of PPP1R1A. Not all EndoC-βH1 cells had detectable 
expression by ICC analysis, whereas others displayed high expression of 
PPP1R1A. In all cell lines where PPP1R1A was detected, it was identified as 
both nuclear and cytoplasmic.  
The results at the mRNA and protein levels do not completely correlate with one 
another, as 1.1B4 and PANC1 cells express PPP1R1A at the mRNA level, 
however not at the protein level. Western blotting and ICC results are 
concurrent with one another, with EndoC-βH1 and INS-1E cells expression 
PPP1R1A, and 1.1B4 and PANC1 cells lacking PPP1R1A expression. 
Examination of each of the cell lines for insulin content by ICC revealed that all 
cell lines, with the exception of PANC1 cells expressed insulin. This was 
expected, since PANC1 cells are of pancreatic ductal lineage, and not β-cell 
lineage. Each of the INS-1E, Min6 and EndoC-βH1 cells expressed insulin, 
whereas insulin staining in the 1.1B4 and BRIN-BD11 cells was not uniform, 
with some cells staining positively, and others negatively.  
As a result of these analyses it was decided that the 1.1B4 cells should be the 
cells in which the Flp-In T-REx system should be developed. 1.1B4 cells have 
many advantages including, no endogenous expression of PPP1R1A (at the 
protein level) – therefore, no unregulated PPP1R1A expression. Importantly, 
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they are a human β-cell model, they express insulin to a degree; and they can 




Figure 4-11 Subcellular localization of PPP1R1A in 6 different pancreatic cell 
lines 
The subcellular localization of PPP1R1A was investigated by ICC. Cells 
were seeded onto 13 mm round coverslips, and then fixed using 4% PFA. 
They were permeabilised and stained for insulin (anti-insulin; red) and 
PPP1R1A (anti-PPP1R1A; green), and nuclei were labelled with DAPI 
(blue). PPP1R1A was undetected in 1.1B4 (A), PANC1 (B) and BRIN-
BD11 cells (C), but was both cytoplasmic and nuclear in EndoC-βH1 (C), 
Min-6 (E) and INS-1E cells (F). Insulin was undetected in PANC1 cells and 
expression was low in 1.1B4 and BRIND-BD11 cells.  
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4.3.1.3 Insulin expression in 1.1B4 cells 
As discussed above, the 1.1B4 cells do not have a homogenous expression of 
insulin. It is unknown whether this is a cell cycle phenomenon, or whether this is 
a phenotype that is altered with the passaging of cells. In order to try and 
maximise the insulin expression in the Flp-In T-REx host cells, low passage 
1.1B4 cells were sorted by Dr Mark Russell as single cells into a 96 well plate 
using the FACS Aria III. Cells were expanded, resulting in 12 viable colonies. 
Each was screened for islet hormone (insulin and glucagon) expression by ICC 
(Figure 4-12). All 12 colonies stained negatively for glucagon and of these 12 
colonies, 10 were also completely negative for insulin expression. Despite 
single-cell sorting, in one colony (colony 2) the cells displayed a mixed staining 
profile for insulin, with some cells expressing insulin, whilst the majority of cells 
in this population were insulin negative, and only a very small number of insulin 
positive cells. The cells in colony 5 were mainly insulin positive. Only, a small 
percentage of the cells had no insulin, whereas a majority of the cells stained 
positively for insulin. In addition to the differences in insulin expression, the cells 
had a very different morphological appearance when viewed under a light 
microscope (Zeiss Primo vert, with an AxioCam ERc5s). Unsorted 1.1B4 cells 
had a ‘star-shaped’ morphology with a few projections, and the appearance of 
being adhered to the growth surface of the flask. This is also the case for the 
insulin negative colonies, as well as colony 2 (Figure 4-12). Colony 5 (the 
insulin positive colony), had a very different morphology. They were not the 
traditional ‘star-shape’, and they appeared much more rounded without any 
projections. They also appeared to be less adhered to the growth surface of the 
culture flask. Within the population of the insulin positive colony 5, cells with the 
morphology of the unsorted 1.1B4 cells (star-shaped) could be distinguished 
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from those that had the more rounded appearance. It is possible to speculate 
that those cells that had the ‘star-shaped’ morphology of 1.1B4 cells are those 
that had lower, or no insulin expression, whereas those that appeared more 
rounded were the ones with very high insulin expression (Figure 4-12). Due to 
this, the culture method of the 1.1B4 cells was adapted (Figure 4-13), with the 
aim to preserve the insulin positive cells, since it appeared they were less 
adherent. Before trypsinization of the cells, the media was collected, any cells 
within this were pelleted and seeded into a fresh culture flask. After isolating the 
non-adhered cells, trypsin was used to detach the adhered cells, which were 
pelleted and seeded into a fresh flask. A portion of the cells were seeded onto 
coverslips for the next 7 passages and were screened for insulin content. Over 
time, regardless of the culture method used, the cells gradually lost their insulin 
expression (Figure 4-14). Interestingly, there was also an increase in the 
percentage of ‘star-shaped’ cells within the population.  
Given these findings, low-passage, un-sorted 1.1B4 cells were chosen as the 





Figure 4-12 Morphology and insulin expression in single cell sorted 1.1B4 cells 
Single-cell sorted 1.1B4 cell colonies were expanded, and growth rate and 
morphology documented. Colonies 2 and 4 (upper left and middle, 
respectively) had traditional morphology of 1.1B4 cells, with a few 
projections and a “cobblestone appearance”, however colony 5 (upper 
right) appeared quite different with very few cells having the traditional 
1.1B4 morphology and many appeared to be much more rounded. The 
cells were not floating, as they were on the same focal plane as the ones 
that were adhered to the growth surface of the flask, and also they did not 
really move if the flask was moved, which they would if they were floating. 
Each cell line was seeded onto coverslips and stained by ICC (described 
in section 2.10) to assess expression of glucagon (green) and insulin (red). 
A majority of cells in colony 2 (lower left panel) do not express insulin, 
however a small number of cells do – always seen clustered together, 
never was there an insulin positive cell on its own. In colony 4 (lower middle 
panel) there were no insulin positive cells observed. In colony 5 (lower right 
panel) most of the cells stained positively for insulin, with very few staining 
negatively for insulin. The insulin distribution in colony 5 is very 
perinuclear, and not in the cell periphery, however this could be partly due 
to most of the cells being very rounded, and lacking any projections. None 





Figure 4-13 Colony 5 cells were split in such a way to try and maximise insulin 
expression 
Since colony 5 cells were mainly rounded, it was hypothesised that these 
may not be as adherent to the growth surface of the culture vessel as the 
cells which had the traditional 1.1B4 appearance. To test this hypothesis, 
the media was collected and cells were pelleted and seeded into a fresh 
culture vessel in addition to the remaining cells trypsinised pelleted and 
seeded into a separate flask. After each passage, a subset of each culture 




Figure 4-14 Insulin expression in colony 5 1.1B4 cells over a series of passages  
Colony 5 from the single-cell-sort was examined for insulin expression by 
ICC after each passage. No trypsin or trypsin refers to the previous 
passage, where the “no trypsin” cells are from the media, so cells that were 
not (or only very weakly) adhered to the flask. With increasing passage 
number, insulin positivity was reduced, as seen by the reduction of insulin 
positive cells. Also evident is that the cells collected after trypsinization (in 




4.3.2 Generating the Flp-In T-REx cells 
Flp-In T-REx cells were generated by a series of successful stable 
transfections, where transfected cells were selected by antibiotic resistance 
(Figure 4-1). 
4.3.2.1 Stage 1 – Insertion of the FRT site into the cells’ genome 
The pFRT/LacZeo plasmid contains a lacZ-Zeocin fusion gene which encodes a 
fusion protein of galactosidase and zeocin resistance. Importantly, the plasmid 
also contains an Flp Recombination Target (FRT) site, which is a 34 bp 
sequence for the binding and cleavage site of Flp recombinase. It was 
recommended in the Flp-In T-REx handbook (Invitrogen) that the pFRT/LacZeo 
plasmid was linearized before transfection into cells, to preserve the FRT site 
and the lacZ-Zeocin fusion cassette. To achieve this, the restriction enzyme 
ApaI (Promega) was used. ApaI recognises the sequence ‘GGGCCC’, and cut 
the backbone of the pFRT/lacZeo vector in the presence of Buffer A (promega) 
without disrupting the gene sequences. 10 ug of pFRT/lacZeo plasmid was cut 
as described in section 2.4.3, and the product was extracted from the gel as 
described in section 2.3.1.  
Low passage 1.1B4 cells were seeded into 3 x 6 well plates, at a density of 1 x 
105 cells per well and left to adhere to the plate overnight. The media was 
changed on the cells and they were transfected (section 2.1.2) with linearized 
pFRT/lacZeo plasmid the following day. Cells were either untransfected, or 
transfected with either 0.5 µg or 1 µg of DNA per well. These two 
concentrations of DNA were used to maximise transfection efficiency. 
Additionally, transfecting with a higher concentration of DNA is more likely to 
result in multiple insertions of the plasmid (which is unfavourable). 24 hours 
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after the transfection, the media was changed on the cells and 48 hours after 
the transfection, the cells were confluent in 6 well plates. For Zeocin selection to 
be successful the cells cannot be more than 25% confluent in their culture flask 
/ plate. For this reason, each well was re-seeded into 2 x T25 flasks, so that the 
cells were <25% confluent. The cells were seeded in Zeocin containing media, 
at 6 different concentrations; 0 µg/ml, 100 µg/ml, 250 µg/ml, 500 µg/ml, 750 
µg/ml and 1000 µg/ml. 72 hours post Zeocin addition the untransfected cells 
which had Zeocin on were no longer viable, which indicated that 1.1B4 cells are 
sensitive to Zeocin. In the population of cells transfected with pFRT/lacZeo, 
there were also quite a few floating (dead) cells. The zeocin-containing media 
was replaced and then refreshed every 72 hours. To increase the number of 
stably transfected cells, the 0 µg/ml Zeocin condition for each transfection was 
re-seeded into 6 new T25 flasks, and Zeocin was added at 0 µg/ml, 20 µg/ml, 
40 µg/ml, 60 µg/ml, and 80 µg/ml. After several weeks of selection, there was a 
single colony from the cells which were transfected with 0.5 µg pFRT/lacZeo 
that were grown in 100 µg/ml Zeocin. This colony was expanded until there 
were sufficient cells for DNA to be extracted and to be frozen down, this colony 
will be referred to as colony 100. There were also viable cells in the flasks from 
1 µg DNA transfected, grown in 40 and 60 µg/ml Zeocin, however there was not 
just a single colony in each flask – for this reason, the cells were seeded as 
single cells into each well of a 96-well plate, using the FACS Aria III. The 
integration of pFRT/lacZeo into the genome of the cells can happen in any 
random location of the cells’ genome, and more than one integration can occur. 
This is why it is important to have each colony as an individual clone. The cells 
were expanded and selected for with Zeocin containing media for several 
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additional weeks. DNA was extracted and cells were frozen down from colonies 
40.13, 40.15, 40.16, 40.18, 40.22, 60.2, 60.5, 60.7, 60.8, 60.11 and 60.13.  
4.3.2.1.1 Screening of colonies for a single integration of pFRT/LacZeo 
To check for a single integration of the pFRT/LacZeo plasmid, a Southern blot 
(as described in section 2.5) was carried out.  
For optimisation of the Southern Blotting protocol, 8 conditions were used – a 
pFRT/LacZeo vector and INS-1E gDNA were used as positive controls (since 
these cells have been previously stably been transfected with the vector), and 
for negative controls, 1.1B4 DNA and pcDNA 6/TR vector and ddH2O were 
used. 300 ng and 1 µg of digested DNA was loaded for each sample. After the 
DNA was electrophoresed, the gel was imaged as described in section 2.3 to 
check that the gel had been run for an appropriate length of time (Figure 4-15). 
After the completion of the transfer, the gel was re-imaged to check that all of 
the DNA was transferred to the membrane (Figure 4-16). The results from the 
Southern Blot were unexpected. There was a clear band in both of the 
pFRT/LacZeo lanes (Figure 4-17), however no bands in any of the other lanes, 
including the INS-1E lanes, which were used as positive controls. This suggests 
that it is probably a sensitivity issue, as the bands in pFRT/LacZeo were clear, 
this indicates that the probe works, and that it is specific, as there were no 
bands detected in the pcDNA6/TR lanes. The difference being that there are 
multiple copies of the sequence in the pFRT/LacZeo lanes, whereas there is 
only 1 copy in the INS-1E cells. For this reason, and due to time constraints a 





Figure 4-15 Gel electrophoresis of digested genomic DNA  
Products of digested genomic DNA extracted from 1.1B4 and INS-1E cells 
and digested DNA from pFRT/LacZ and pcDNA6/TR plasmids were 
electrophoresed on a 1% agarose gel to separate DNA fragments based 






Figure 4-16 Gel electrophoresis for Southern blotting, after transfer had 
completed 
The agarose gel that the digested DNA was run on was imaged after the 
transfer. The lack of signal suggests that the transfer was successful, and 





Figure 4-17 Southern blot result 
The DNA was hybridized with a tagged probe against the LacZ gene. The 
purple should indicate where the LacZ gene is present. The probe has 
detected the LacZ sequence in the pFRT/LacZ vector only, not in 
pcDNA6/TR plasmid, INS-1E cells or 1.1B4 cells. The lack of detection in 
the INS-1E cells suggests that if there is just one copy of LacZ within the 
genome (like there is in these cells) that the method is not sensitive enough 




4.3.2.2 Transfection with pcDNA6/TR 
The pcDNA6/TR plasmid contains the sequence encoding the tetracycline 
repressor protein, under a constitutively active promoter. It also contains a 
sequence encoding blasticidin resistance.  
Before transfection into cells, it is suggested that the pcDNA6/TR plasmid 
should also be linearized, as with the pFRT/LacZeo plasmid, linearization limits 
double integrants and preserves important sequences. To linearize 
pcDNA6/TR, SapI (NEB) was used with the CutSmart Buffer (NEB) to cut the 
backbone of the plasmid (as described in section 2.4.3). The linearized product 
was run on a 1% agarose gel, and the product was extracted (as described in 
section 2.3.1). 1.1B4 cells stably transfected with pFRT/lacZeo were seeded at 
a density of 1 x 105 cells per well. The 5 fastest growing stably transfected 
colonies, colony 60.5, 60.11, 60.13, 40.15 and 100 were selected for 
transfection. 945 ng plasmid was transfected (as described in section 2.1.2) into 
each well. 24 hours post-transfection media was refreshed, and 48 hours after 
transfection Blasticidin was added at a concentration of 5 µg/ml. Antibiotics 
were refreshed every 72 hours and cells were continually split when they 
reached 80% confluency and seeded into blasticidin containing media. After 
addition of blasticidin only the cells that have been transfected with pcDNA6/TR 
should be viable. Over time, only cells with the pcDNA6/TR plasmid stably 
incorporated into their genome would be resistant to the blasticidin in the media, 
which should result in an increase in cell death. However, these transfected 
cells did not exhibit this increase in cell death over time, suggesting that either 
the antibiotics were not working, or that the transfection was very successful. To 
investigate this, blasticidin was added to cells from each of the initial 
untransfected colonies (colonies 60.5, 60.11, 60.13, 40.15 and 100), all of which 
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were not viable after a couple of days incubation with 5 µg/ml blasticidin, 
suggesting that the transfection was very successful. To corroborate this, DNA 
was extracted from each of the colonies and a PCR was carried out with 
primers targeting the tetracycline repressor (Table 4-1). Colonies 60.5, 60.11, 
60.13, 40.15 and 100 were subject to the PCR, as well as DNA from INS-1E 
cells (Figure 4-18). A clear band of the expected size was observed in each of 
the colonies, indicating that pcDNA6/TR was successfully incorporated into the 
genome of all the colonies. As they have all been successfully transfected, 
colony 100 was chosen to host the future transfections. Colony 100 was the 
chosen colony since it was the only clone which arose from the transfection with 
0.5 µg pFRT/LacZeo plasmid, this is important because at this concentration of 
transfected plasmid it is less likely to result in more than 1 insertion of 
pFRT/LacZeo into the cells’ genome.  
Even though all the cells in colony 100 likely have the pcDNA6/TR plasmid 
stably inserted into their genome (which we can tell as they are resistant to 
blasticidin), the incorporation occurs at a random genomic location. To ensure 
that the Flp-In T-REx host cells are a single clone of one another (to limit 
variability), colony 100 was subject to single cell sort, again using the FACS 
Aria III, and 2 x 96 well plates were seeded with single cells. Once small 
colonies had begun to form, zeocin (100 µg/ml) and blasticidin (5 µg/ml) was 
added to the culture media, and this was refreshed every 72 hours. Colonies 
were expanded until they reached confluency in flasks, so that a subset of each 
colony could be frozen down. 35 colonies were viable in zeocin and blasticidin 
containing media. The growth rate of each of these colonies varied some-what, 
and this was documented.  
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These 35 colonies are now all potential Flp-In T-REx parental cell lines, which 
all contain an FRT site, and constitutively express the tetracycline repressor 
protein.  
 
Figure 4-18 RT-PCR for mRNA expression of the tetracycline repressor protein.  
mRNA was extracted from colonies 5, 11, 13 and 100 and INS-1E cells, in 
addition to the pcDNA6/TR vector. A PCR of the tetracycline repressor was 
carried out, with annealing temperature of 64°C and 35 cycles. Gel 
electrophoresis of the PCR products revealed that the tetracycline 
repressor sequence (256bp) was successfully amplified from each nucleic 
acid extract. This indicates that the transfection with the pcDNA6/TR 
plasmid was successful in each case. Products were run alongside 




4.3.2.3 Subcloning of PPP1R1A into pcDNA5/FRT/TO 
To take advantage of the Flp-In T-REx parental cells, the sequence encoding 
PPP1R1A must be subcloned into the multiple cloning site (MCS) of the 
pcDNA5/FRT/TO vector. A cloning strategy was devised to achieve this (Figure 
4-19). Initially, a double-digest was performed using the restriction enzymes 
XmnI (NEB) and XhoI (NEB) (in CutSmart Buffer (NEB)) to excise the 
PPP1R1A coding sequence from the pEZ-M02 vector (Figure 4-20). Alongside 
this, the MCS of pcDNA5/FRT/TO was cut with EcoRV (NEB) and XhoI (NEB) 
in Buffer 3.1. Cuts with XmnI and EcoRV create ‘blunt’ ends whereas XhoI cuts 
a ‘sticky’ end, therefore, despite being cut with a different pair of enzymes, the 
fragment can be ligated into the backbone. Digested products were separated 
by gel electrophoresis (as described in section 2.3 and Figure 4-21) and 
extracted from the gel (as described in section 2.3.1). The compatible fragments 
were then ligated (as described in section 2.4.4 and Figure 4-22) and 
transformed into competent E.coli (as described in section 2.4). Multiple 
colonies were picked and DNA extracted using the Qiagen Miniprep kit (as 
described in section 2.4). The DNA was analysed from several colonies by 
restriction digest and PCR (Figure 4-23). The insertion of the PPP1R1A coding 
sequence into the pcDNA5/FRT/TO plasmid was confirmed by direct 
sequencing in 6 of the colonies. One of the confirmed colonies was further 
expanded (as described in section 2.4) and DNA extracted using the MidiPrep 






Figure 4-19 Double digest strategy for Subcloning PPP1R1A coding sequence 
into pcDNA5/FRT/TO vector 
The restriction enzyme sites highlighted in yellow were used in double 
digests to cut the PPP1R1A coding sequence out of the pEZ-M02 vector, 
and to cut the MCS of pcDNA5/FRT/TO to make complimentary ends. XmnI 
and EcoRV create blunt cuts, whereas XhoI creates a ‘sticky’ end.  
  
 
Figure 4-20 Vector maps of pEZ-M02/PPP1R1A and pcDNA5/FRT/TO 
The restriction enzymes used to subclone PPP1R1A into pcDNA5/FRT/TO 
are highlighted in bold font. XmnI and EcoRV result in blunt ends whereas 
XhoI cut creates a sticky end. Using at least one restriction enzyme which 
results in a sticky end can help with ensuring the insert is inserted in the 




Figure 4-21 Products to be ligated after double digest 
pEZ-M02/PPP1R1A was digested with XmnI and Xho1 separately and as 
a double digest with the multicore buffer. The pcDNA5/FRT/TO vector was 
cut with EcoRV and Xho1 separately and as a double digest with Buffer D. 
Products were separated by gel electrophoresis and run alongside 
Generuler 1Kb ladder. The products outlined with the blue box were 
extracted using the Qiagen gel extraction kit, and ligated to produce the 





Figure 4-22 Placement of the PPP1R1A coding sequence within the 
pcDNA5/FRT/TO vector 
Sequence of PPP1R1A (highlighted in pink) under the control of a 





Figure 4-23 products of restriction and PCR, showing PPP1R1A sequence within 
the FRT/TO vector 
Restriction digest (a) using Xho1 and HindIII to cut the ligated 
pcDNA5/FRT/TO/PPP1R1A plasmids that were transformed into the 
competent E.coli, and extracted by miniprep. The restriction digest shows 
that products of the expected size were cut from each colony. PCR (b) of 
the same extracted DNA using primers against the full length PPP1R1A 
sequence (235bp). 35 cycles were run and an annealing temperature of 
58°C was used. Each of these samples were sent for sequencing, and it 





4.3.2.4 Generation of a PPP1R1A phosphorylation null mutant (T35A) 
Once it was confirmed that PPP1R1A was successfully inserted into the 
pcDNA5/FRT/TO vector, the vector was subject to mutagenesis to create a 
phosphorylation null variant of PPP1R1A. This was achieved by changing the 
amino acid at position 35 from threonine to alanine, a strategy which has been 
used by other investigators (Connor et al., 1998). The codon in PPP1R1A for 
threonine is ACC, and alanine is encoded by GCC, therefore a single base 
substitution was required. Using NEBase changer 
(https://nebasechanger.neb.com/) the sequence for PPP1R1A was inputted and 
the bases that needed substituting were highlighted (bases 103-105). The 
website generated primers that result in the change from ACC to GCC. The 
forward primer starts 10 bases before the substitution, but carries the required 
change, and the reverse primer is designed back-to-back with the forward 
primer, but will transcribe in the opposite direction way (anti-clockwise) around 
the circular plasmid, creating a linear product. For PCR details, refer to Table 
4-1. The primers were used in conjunction with the Q5 site directed 
mutagenesis kit. The kit contains components necessary for the PCR including 
mastermix (which contains polymerase enzyme and buffer and dNTPs). For the 
PCR, initially 1 µg plasmid was used with the annealing temperature of 72°C. 
The kit contains Kinase-Ligase-Dpnl Mix (KLD) which removes any template 
plasmid and allows efficient ligation/circularization of the amplified product. For 
successful mutagenesis of pcDNA5/FRT/TO/PPP1R1A, the recommendations 
in the kit handbook had to be optimised in three ways (1) the concentration of 
template DNA was reduced to 500 ng from 1 µg, (2) the annealing temperature 
for the PCR was lowered from 72°C to 71°C and (3) the incubation time with 
KLD was increased from 5 minutes up to 1 hour. Before transformation into 
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competent E.coli, KLD and non-KLD treated PCR products were 
electrophoresed (Figure 4-24) to check that there was some product remaining 
after the KLD treatment. If there was no product, it would suggest that the PCR 
was unsuccessful. Increasing the KLD incubation time should maximise the 
removal efficiency of the template. There was product in the KLD treated PCR 
mix, but this was much reduced compared to the non-KLD treated PCR mix 
(Figure 4-24), suggesting there was a lot of unamplified template remaining. 
The KLD-treated PCR mix was transformed into competent E.coli. The PCR 
products were transformed (as described in section 2.4.1) into competent E.coli. 
Colonies were expanded and DNA was extracted using the plasmid mini-kit. 
Sequencing revealed that the modifications were successful and there was 





Figure 4-24 KLD-treated or non-KLD-treated PCR mix after mutagenesis PCR 
KLD-treated and non-KLD-treated PCR mix. The agarose gel 
demonstrates that only a very little amount of vector was amplified during 
the mutagenesis PCR reaction, and most of the product was original 
plasmid, demonstrated by the much larger band in the non-KLD treated 
PCR mix. The KLD-treated PCR mix was transformed into competent 






Figure 4-25 Sequencing data after T35A mutagenesis 
To check whether the mutagenesis was successful, DNA was sent for 
sequencing. The base change highlighted in yellow (GA) translates to a: 
CAA  CAG is a coding variant of Glutamine, so is a non-synonymous 
SNP.   
The amino acid change from A  G was the target of mutagenesis. This 
amino acid base change causes a change from ACC  GCC, which 





4.3.2.5 Choosing a Flp-In T-REx host cell line 
From the 35 potential Flp-In T-REx parental cell lines, one needed to be 
selected. The parental cell line was chosen based on non-induced expression 
of PPP1R1A (‘leakyness’) and the level of PPP1R1A expression after 
incubation with tetracycline containing media.  
To establish which parental cell line had the most favourable characteristics, the 
tetracycline repression / expression system in each clone was investigated. This 
was achieved by transiently transfecting each clone with 
pcDNA5/FRT/TO/PPP1R1A vector (Figure 4-26) and assessing protein 
expression in the presence or absence of 1000 ng/ml tetracycline. Each colony 
was seeded into 2 x wells of a 6 well plate. One well for transfection minus 
tetracycline, the other for transfection plus tetracycline. 500 ng of 
pcDNA5/FRT/TO/PPP1R1A was transfected into each well. 24 hours after the 
transfection, media was replaced with fresh warmed media or media containing 
1000 ng/ml tetracycline to relevant wells. 24 hours after the media change, 
protein was harvested (as described in section 2.6.1), and protein concentration 






Figure 4-26 Tetracycline induced expression of PPP1R1A 
36 colonies of Flp-In T-REx cells that have been stably transfected up to 
the point of the pcDNA6/TR plasmid (parental Flp-In T-REx cell lines) were 
seeded into 2 x wells each of 6 well plates and transiently transfected with 
PPP1R1A. Each colony was grown with 1 well in non-tetracycline 
containing media and 1 well in tetracycline containing media. Protein was 
extracted from each well 24 hours after addition of tetracycline. 5 μg 
protein was loaded directly onto the nylon membrane per sample, and 
expression of PPP1R1A was determined. The blot is annotated to indicate 
which sample is which. The left hand number in each case is without 
incubation with tetracycline and the right hand number is with incubation 
with tetracycline. Absence of detected protein in the minus tetracycline 
samples indicates good tetracycline repression, and darker detected 
protein from the tetracycline incubated cells indicates tetracycline 
responsive promoter sequences. Colonies 4, 8, 23 and 29 are highlighted 
with blue boxes. These were deemed the most responsive and were 




The tetracycline regulated expression of PPP1R1A in these 35 parental T-REx 
colonies was analysed by dot blot. A dot blot was chosen because it allows a 
large number of protein samples to be analysed simultaneously. 5 µg protein 
was dotted onto the membrane for each sample, and probed for as described in 
section 4.2.10. The dot blot revealed that there was a mixed expression of 
PPP1R1A, most colonies were not ‘leaky’, and most colonies had inducible 
expression (Figure 4-26). Colonies 4, 8, 23 and 29 were the colonies that were 
least ‘leaky’ and had the best inducible expression with largest increase in 
PPP1R1A expression after incubation with tetracycline (Figure 4-26).  
To further investigate the efficiency of colonies 4, 8, 23 and 29, these four 
colonies were seeded into 2 wells each of a 6-well plate and transfected with 
pcDNA5/FRT/TO/PPP1R1A, with identical transfection conditions as described 
above. 24 hours post-transfection media (+ 1000 ng/ml tetracycline) was 
refreshed, and 24 hours post this, protein was extracted (as described in 
section 2.6.1) and analysed by Western blotting (as described in section 2.6) for 
this Western blot, 17 µg protein was loaded per well. The membrane was 
blocked in 5% milk for 1 hour at room temperature, then incubated with rabbit-
anti-PPP1R1A (1/1000) in 5% milk overnight at 4°C. Upon viewing, it was 
revealed that PPP1R1A expression could be induced in all four colonies after 
incubation with tetracycline, and that the tetracycline-responsive promoter was 
not too ‘leaky’ (Figure 4-27). The basal expression of PPP1R1A in colony 4 was 
slightly lower than in the other 3 colonies, so for this reason colony 4 was 






Figure 4-27 Tetracycline induced expression of PPP1R1A in 1.1B4 Flp-In T-REx 
cell colonies 4, 8, 23 and 29 
1.1B4 Flp-In T-Rex cell colonies 4, 8, 23 and 29 were seeded into media 
not containing tetracycline, or media containing 1000 μg/ml tetracycline for 
24 hours. PPP1R1A expression was assessed, and GAPDH detected as 




4.3.2.6 pOG44 and pcDNA5/FRT/TO/PPP1R1A 
Colony 4 was seeded into a 6 well plate at a density of 1 x 105 cells per well. 
Each well was co-transfected with pOG44 and either pcDNA5/FRT/TO (empty 
vector), pcDNA5/FRT/TO/PPP1R1A or pcDNA5/FRT/TO/T35A_PPP1R1A. 
pOG44 encodes Flp recombinase, and is only transiently transfected (i.e. not 
stably inserted into the cells’ genome). Flp recombinase is necessary for 
recombination of the FRT sites. Each well was transfected with 2000 ng DNA in 
total, with a 9:1 ratio of pOG44:pcDNA. Specifically, in each well, 1800 ng 
pOG44 and 200 ng pcDNA was transfected with 0.8 µl Avalanche®-Omni 
transfection reagent. 24 hours post transfection the media was refreshed, and 
24 hours after this, hygromycin B (ThermoFisher Scientific) was added to the 
media at 150 µg/ml, and this was refreshed every 48 – 72 hours. After several 
weeks there were sufficient cells for determination of which colony had the 
lowest basal expression and highest tetracycline-induced expression of 
PPP1R1A. In total, the transfection process generated 4 clones for EV, 3 clones 
for WT PPP1R1A and 5 clones for T35A PPP1R1A. 
To determine which colonies had the lowest basal expression of PPP1R1A, and 
could induce high expression of PPP1R1A upon addition of tetracycline, 2 x 
wells of each colony were seeded into a 6 well plate at a density of 1 x 105 cells 
per well. 24 hours after seeding the cells, media was refreshed and tetracycline 
added to relevant wells and incubated for a further 24 hours before protein was 
extracted and estimated (as described in sections 2.6.1 and 2.6.1). 48 µg 
protein was loaded into the gel per sample. The membranes were probed for 
PPP1R1A and GAPDH (Figure 4-28). There was very little difference between 
the colonies, all had very low basal expression of PPP1R1A, and all had high 
expression of PPP1R1A upon incubation with tetracycline. FRT/TO 2A, 
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PPP1R1A 2A and T35A 1 were selected as the cell lines utilised for future 
experiments. These will be referred to as EV (empty pcDNA5/FRT/TO), WT 
(pcDNA5/FRT/TO/PPP1R1A) and T35A (pcDNA5/FRT/TO/T35A_PPP1R1A).  
 
Figure 4-28 Selection a cell line stably expressing PPP1R1A, with addition of 
tetracycline.  
Flp-In T-REx host cells were co-transfected with pOG44 and 
pcDNA5/FRT/TO, pcDNA5/FRT/TO/PPP1R1A or 
pcDNA5/FRT/TO/T35A_PPP1R1A. Each successfully transfected 
(hygromycin (150 μg/ml) resistant) well from a 6 well plate was given a 
number, and expanded as an individual colony.  These colonies were then 
characterised for their basal PPP1R1A expression or the tetracycline 
(1000 ng/ml) induced expression of PPP1R1A. GAPDH was detected as 




4.3.3 Validation of the chosen Flp-In T-REx cell colonies 
Before the 1.1B4 Flp-In T-REx cells can be used to assess the role of 
PPP1R1A in β-cells, the tetracycline-regulated expression and functional 
properties of PPP1R1A e.g. phosphorylation, needed to be verified. All three 
1.1B4 Flp-In T-REx cell lines were used in experiments simultaneously, and 
treated in exactly the same way to each other unless otherwise stated. All cell 
lines were created at the same passage, and are maintained at the same 
passage as each other, to try and reduce variability. There was no difference in 
growth speed between the cell lines, and for general culturing, they were not 
incubated in tetracycline. 
4.3.3.1 Tetracycline induced expression of PPP1R1A 
Cells were seeded at a density of 2 x 105 cells per well into 6 well plates. 24 
hours after seeding of the cells, the media was replaced with tetracycline 
containing media. Tetracycline was added at concentrations ranging from 0 
ng/ml to 1500 ng/ml. After 24 hours incubation in tetracycline, protein was 
extracted (as described in section 2.6.1) and PPP1R1A expression was 
analysed by Western blotting (Figure 4-29). These results indicated that the EV 
cells do not express PPP1R1A under any conditions, as was expected. The WT 
and T35A cells express PPP1R1A at concentrations as low as 100 ng/ml of 
tetracycline. There was no increase in expression of PPP1R1A with increasing 






Figure 4-29 Concentration of tetracycline needed to induce expression of 
PPP1R1A in 1.1B4 Flp-In T-REx cells 
EV (A), WT (B) and T35A Flp-In T-REx cells (C) were incubated with 
increasing concentrations of tetracycline for 24 hours and PPP1R1A 
expression was analysed by western blot analysis. The EV cells (A) did 
not express PPP1R1A after incubation with any concentration of 
tetracycline, the WT (B) and T35A cells (C) both had low expression after 
incubation with 50 ng tetracycline, and had expression after incubation 
with 100 ng tetracycline. The intensity of the green PPP1R1A band did not 
significantly increase with increasing concentrations of tetracycline after 
100 ng/ml up to 1500 ng/ml. This could be due to the on/off system, rather 




For future experiments, 1000 ng/ml tetracycline was used to induce expression 
of PPP1R1A. This concentration was chosen since it did not promote a 




4.3.3.2 Stability of PPP1R1A 
To evaluate how quickly PPP1R1A expression could be induced after 
incubation with tetracycline, EV and WT cells were incubated with tetracycline 
for increasing lengths of time, for up to a maximum of 72 hours. Protein was 
extracted and a Western blot carried out (as described in section 2.6) to 
evaluate PPP1R1A expression. After 2 hours incubation with tetracycline, a 
small amount of PPP1R1A could be detected (Figure 4-30). PPP1R1A 
expression increased at 6 hours, and was maximal at 24 hours. There was no 
change in PPP1R1A expression at 48 or 72 hours. Therefore, 24 hours was 
used as the optimal time point for tetracycline induced expression of PPP1R1A. 
 
Figure 4-30 Time-course of tetracycline incubation with 1.1B4 Flp-In T-REx cells 
EV or WT Flp-In T-REx cells were incubated with tetracycline at a 
concentration of 1000 ng/ml for up to 72 hours. Protein was extracted and 
PPP1R1A expression was determined by western blotting. PPP1R1A 
expression was induced after 2 hours incubation with tetracycline, however 
this expression was very minimal. After 24 hours, PPP1R1A was highly 
expressed in the cells and this expression did not reduce, even after 72 




To establish how quickly PPP1R1A is recycled within the cells, tetracycline was 
added to cells for 24 hours (since maximal expression of PPP1R1A was 
achieved at this timepoint), then media was replaced with fresh media, without 
tetracycline. Protein was extracted from the cells; 0hr, 24, 48, 72 and 96 hours 
after tetracycline withdraw, and having not been exposed to tetracycline at all. 
The EV cells were only assessed with no exposure to tetracycline, and 24 hours 
with tetracycline (0 hours withdraw). All cell lines did not express PPP1R1A 
when not exposed to tetracycline (Figure 4-31), nor did the EV cells after being 
exposed to tetracycline for 24 hours (0hr withdraw). WT and T35A cells showed 
enhanced expression of PPP1R1A after 24 hours exposure to tetracycline (0hr 
withdraw). The expression remained high 24 and 48 hours after removal of 
tetracycline, however, the expression of PPP1R1A in the T35A cells was slightly 
reduced after 48 hours withdraw from tetracycline. Both WT and T35A cells had 
diminishing expression of PPP1R1A 72 and 96 hours after removal of 




Figure 4-31 PPP1R1A expression after tetracycline withdraw from 1.1B4 Flp-In 
T-REx cells 
1.1B4 Flp-In T-REx cells were incubated with tetracycline for 24 hours, 
then media was replaced with fresh, warmed media containing no 
tetracycline. Protein was extracted from the cells for up to 96 hours post 
tetracycline removal. There was a decrease in expression of PPP1R1A 
from 48 hours after induction in the T35A cells, but not in the WT cells. 
This could suggest that phosphorylation of PPP1R1A increases its stability 
within the cell. Even 96 hours after removal of tetracycline from the media 
PPP1R1A was still expressed in both WT and T35A cells. Protein was also 
extracted from EV, WT and T35A cells which had never been exposed to 
tetracycline, as well as cells which had been exposed to tetracycline for 24 





4.3.3.3 Phosphorylation of PPP1R1A after addition of Forskolin 
Various reports including (Huang and Glinsmann, 1976, Endo et al., 1996), 
amongst others indicate that Protein kinase A (PKA) phosphorylates PPP1R1A 
at Thr35, which is necessary for its inhibition of protein phosphatase 1 (PP1). 
To my knowledge, this phosphorylation event has never been shown in β-cells. 
To investigate whether this phosphorylation event occurs in the 1.1B4 Flp-In T-
REx cells, they were incubated with forskolin. Forskolin increases levels of 
cyclic adenosine monophosphate (cAMP) within cells by activating the enzyme 
adenylyl cyclase, which then activates the kinase, PKA, to phosphorylate target 
proteins. PPP1R1A phosphorylation was initially investigated by Western 
blotting. Each of the 3 cell lines were seeded into 4 x T25’s each at a density of 
5x105 cells per flask to maximise protein yield. Four conditions were used per 
cell line; (a) -Tetracycline -Forskolin; (b) -Tetracycline +Forskolin; (c) 
+Tetracycline –Forskolin and (d) +Tetracycline +Forskolin. 24 hours after 
seeding the cells, media was refreshed, containing tetracycline (1000 ng/ml) 
where necessary. 22 hours after this, forskolin (10 µM/ml) was also added to 
relevant flasks. 2 hours after forskolin addition, protein was extracted. 
PPP1R1A expression and phosphorylation status was analysed by western 
blotting (as described in section 2.6). As expected, the EV cells did not express 
PPP1R1A or PPP1R1A phosphorylated at Thr35. WT and T35A cells only 
expressed PPP1R1A when they were incubated with tetracycline containing 
media (Figure 4-32), and PPP1R1A was phosphorylated after the addition of 
tetracycline in the WT cells, but was increased after the addition of forskolin. 
This suggests that there is a high basal phosphorylation status of PPP1R1A in 
the 1.1B4 Flp-In T-REx cells. When the T35A cells were incubated with 
tetracycline and forskolin, PPP1R1A was expressed, but not phosphorylated. 
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These data also indicate that the PPP1R1A Thr35A antibody is specific for this 
phosphorylation residue, as well as validating the mutation at Thr35, and that 
increased cAMP levels phosphorylate PPP1R1A.  
 
Figure 4-32 Phosphorylation capacity of PPP1R1A in the 1.1B4 Flp-In T-REx 
cells 
Each of the Flp-In T-REx cell lines (EV, WT and T35A) were incubated with 
or without tetracycline for 24 hours and with or without forskolin for 2 hours.  
Phosphorylation of PPP1R1A (~19 kDa) was assessed by western blotting 
and was compared to total PPP1R1A (~19 kDa) and normalised to GAPDH 
(~37 kDa). Phosphorylated PPP1R1A could only be detected in WT cells 
in the presence of tetracycline, and the expression was increased after 2 
hours incubation with forskolin. Total PPP1R1A could only be detected 
after incubation with tetracycline and could be detected in WT and T35A 





The phosphorylation of PPP1R1A in EV and WT cells was also investigated by 
ICC. The same conditions were used as previously described; (a) -Tetracycline 
-Forskolin; (b) -Tetracycline +Forskolin; (c) +Tetracycline -Forskolin and (d) 
+Tetracycline +Forskolin. 24 hours after seeding the cells, media was 
refreshed, containing tetracycline (1000 ng/ml) where necessary. 22 hours after 
this, forskolin (10 µM/ml) was also added to relevant flasks. 2 hours after 
forskolin addition, cells were fixed onto coverslips (as described in section 
2.10). They were probed for total PPP1R1A and phosphorylated PPP1R1A. 
Phosphorylated PPP1R1A was not detected in EV cells under any condition 
(Figure 4-33). In the absence of tetracycline, phosphorylated PPP1R1A could 
not be detected in the WT cells (Figure 4-33), however, following tetracycline 
exposure (in the absence of forskolin) low levels of PPP1R1A phosphorylation 
was detected (Figure 4-34). Following incubation with both tetracycline and 
forskolin, phosphorylated PPP1R1A expression was increased (Figure 4-34).  
Two cell lines conditionally expressing PPP1R1A (WT or T35A), plus a third cell 
line to be used as an EV control have been generated and validated, which 
provide the opportunity to study the impact that PPP1R1A expression and 






Figure 4-33 Flp-In T-REx cells have inducible expression of PPP1R1A following 
exposure to tetracycline 
Flp-In T-REx cells were cultured in tetracycline-free or tetracycline-
containing media (1000 ng/ml) for 24 hours. For the final 2 hours before 
fixing cells on coverslips, forskolin (10 μM/ml) was added, where 
relevant.After cells were fixed they were probed for total PPP1R1A (anti-
PPP1R1A; green) and the nuclei were stained with DAPI (DAPI; dark 





Figure 4-34 Flp-In T-REx cells have inducible expression of phosphorylated 
PPP1R1A following exposure to tetracycline and forskolin 
Flp-In T-REx cells were cultured in tetracycline-free or tetracycline-
containing media (1000 ng/ml) for 24 hours. For the final 2 hours before 
fixing cells on coverslips, forskolin (10 μM/ml) was added, where relevant. 
After cells were fixed they were probed for phospho-PPP1R1A (anti-
pPPP1R1A; green) and the nuclei were stained with DAPI (DAPI; dark 





This chapter describes the process of generating and validating 3 conditional 
overexpression cell lines using 1.1B4 cells; WT PPP1R1A; T35A PPP1R1A, 
and EV.  
The pancreatic cell lines available in the lab were evaluated for their suitability 
to act as a host cell for the Flp-In T-REx system. They were each characterised 
for their appropriateness as a model of (human) β-cell e.g. by means of 
assessing insulin expression, and their endogenous expression of PPP1R1A. 
Each Flp-In T-REx cell line has been validated as a reliable system to 
manipulate expression of PPP1R1A.  
CRISPR-Cas9 technology is becoming increasingly popular to study the role of 
specific proteins within cells. However, CRISPR-Cas9 does not allow for the 
conditional expression of proteins, which is why the Flp-In T-REx system was 
utilised for the present studies.  
4.4.1 PPP1R1A expression in clonal β-cell lines 
Each of the human pancreatic cell lines were analysed for expression of 
PPP1R1A at the RNA level. There are three known isoforms of PPP1R1A, and 
the presence of each of these isoforms was established in EndoC-βH1 cells, 
PANC1 cells, 1.1B4 cells and human islets. Human islets and EndoC-βH1 cells 
expressed each of the 3 isoforms, which were validated by direct sequencing of 
the excised amplicons. There is little known about the alternative-splice variants 
of PPP1R1A, however all three isoforms retain the PP1 binding motif (aa 8-12; 
RKIQF) and the PKA phosphorylation site at Thr35, which suggests all maintain 
the inhibitory function of PP1. 
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At the protein level, the rodent β-cells (BRIN-BD11, Min6 and INS-1E) were 
included in analyses. Western blotting revealed, as the PCR did, that the 
EndoC-βH1 cells express PPP1R1A. By western blotting though, only one band 
could be detected. This could be a sensitivity issue, or it could be that the 
antibody used cannot recognise all isoforms. The antibody used in these 
studies against PPP1R1A recognises the first 100 aa in the protein, and only 
the first 60 are identical in all three isoforms, or the first 83 are the same 
between the full length isoform and one of the alternate splice isoforms. When 
analysed by ICC, not all of the cells in the population expressed PPP1R1A 
which could be to do with which phase of the cell cycle the cells were in 
(discussed in chapter 6). PPP1R1A expression by Western blot indicated a 
difference in band size of PPP1R1A between the EndoC-βH1 cells and the INS-
1E cells (Figure 4-6). This is probably due to differences in the amino acid 
sequence, causing different post-translational modifications between the human 
and rat protein (Figure 4-7). There are various different locations at which the 
proteins are predicated to be glycated, ubiquitinated, and sumoylated (these are 
highlighted in Figure 4-8, Figure 4-9 and Figure 4-10). These modifications, as 
well as other amino acid changes in protein sequence, could cause a shift in the 




The 1.1B4 cells were chosen as the host cell line in which to create the Flp-In T-
REx system for the reasons described in section 4.3.1. One of the main 
disadvantages of the 1.1B4 cells is their lack of insulin expression, which is 
contradictory to the publication describing the development of the 1.1B4 cells 
(McCluskey et al., 2011), where it is stated that 1.1B4 cells express insulin and 
secrete it in response to glucose, or other depolarising agents. A single-cell sort 
was carried out to try and maximise the insulin expression in the cell population. 
The insulin positive cells isolated from the population, had a very different 
phenotype compared to the insulin negative cells. As discussed previously in 
section 4.3.1.3, the insulin positive cells had a much more rounded shape 
(Figure 4-12) and appeared less adhered to the growth surface of the culture 
flask; this is one possible reason why over time the insulin positive cells are lost 
from the population, as they are being lost during the passaging of the cells. For 
this reason, the method used to passage the cells was altered, however there 
was only a slight decrease in the rate at which insulin positivity was lost from 
the cell population. Over time the insulin positivity in the cells is reduced, 
possibly due to a slower proliferation rate in insulin positive cells, or due to 
stress from passaging them, or an alternative reason. Therefore these insulin 
positive 1.1B4 cells were not used as the host cell line for the Flp-In T-REx 
system. There are reports that other insulin containing β-cell lines (such as Rin-
38, and Min-6) have reduced insulin expression over time (Clark et al., 1990, 
O'Driscoll et al., 2004), although the 1.1B4 cells were reported to maintain 
insulin content between passages 17 and 40 (McCluskey et al., 2011), however 
the cells described presently were sorted at passage 33 (the earliest passage 
available), and cultured until passage 50, where very few insulin positive cells 
were present (Figure 4-14). 
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4.4.2 Validation of the Flp-In T-REx cells developed 
The Flp-In T-REx cells described in this chapter were verified to have robust 
induction of PPP1R1A gene expression after addition of tetracycline to the 
media, and that protein is stably expressed for at least 48 hours after removal of 
tetracycline. As discussed, three Flp-In T-REx cell lines were developed; EV, 
WT and T35A. The EV cell line was developed as an important control. It 
controls for the random incorporation of vectors into the genome of the cells, but 
more importantly checks that any effect is not from the addition of tetracycline 
(or any other molecule) to the cells, but is a result of expression of PPP1R1A 
(WT or T35A). The validation process of the Flp-In T-REx cells indicated that 
the Flp-In T-REx system has been successfully established in the 1.1B4 cells, 
with good inducible expression of PPP1R1A. The cells do not express 
PPP1R1A when not exposed to tetracycline, which is one of the potential 
disadvantages of the system. When transiently exposed to tetracycline, 
PPP1R1A expression remains high 24 hours after removal of tetracycline, 
however is diminished after 48 – 72 hours, however remains detectable. 
Interestingly, PPP1R1A expressed in the WT cells remained strong after 48 
hours, and was only noticeably reduced after 72 hours, whereas the T35A 
PPP1R1A was reduced at 48 hours after removal of tetracycline, indicating that 
the phosphorylation site of PPP1R1A may help to stabilise the protein, as there 
is basal phosphorylation of PPP1R1A in these cells, and the WT PPP1R1A 
remained expressed at a higher level for longer than the T35A mutant. 
Although, there is no direct evidence to validate this from these studies.   
The parental 1.1B4 Flp-In T-REx host cells developed provide a useful platform 




4.4.3 Limitations of the development process of Flp-In T-REx cells 
There are important lessons that were learnt from the generation of these cells. 
This knowledge can be used to modify the protocol to improve future attempts 
of generating new Flp-In T-REx cell lines.  
Improving transfection efficiency in the host cell line would be desirable, as this 
would result in a larger number of colonies to screen, from which the best 
colony can be selected. 
Transfections of pFRT/LacZeo and pcDNA6/TR would be performed in 24 well 
plates, rather than in 6 well plates. This would limit the likelihood of having more 
than one colony in each well, and would mean that if there was just one colony, 
these would have originated from a single cell. This would mitigate the need to 
do a single cell sort, speeding up the process, and reducing the need to 
passage the cells so many times. 
It would have been desirable to screen the clones after transfection with the first 
plasmid, by Southern blotting. This would indicate whether there was only one 
FRT site, or multiple FRT sites inserted into the genome of the cells. Multiple 
FRT sites are unfavourable as it could result in various clones after the final 
transfection. Clones could either have PPP1R1A inserted into just one of the 
FRT sites, or PPP1R1A could be incorporated into each FRT site, resulting in 
multiple copies of PPP1R1A. This could differ across cell lines (EV, WT and 
T35A), however it could also differ within each cell line, as after the final 
transfection the cells are not expanded from a single clone (on the basis that 
PPP1R1A will incorporate into the same genomic location in each cell). As 
Southern blotting was unable to be carried out the cell line selection for 
subsequent transfections was based on the choosing the cell line which was 
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transfected with the lowest concentration of pFRT/LacZeo (0.5 µg/ml), which 
should limit the number of insertions of pFRT/LacZeo into the genome of the 
cells. 
These 1.1B4 Flp-In T-REx cells can now be used to study PPP1R1A in β-cells. 
Sadly, during the generation process, it was discovered that 1.1B4 cells are not 
of human origin, but are in fact rat cells. This will be detailed in chapter 5. This 
finding obviously has important connotations regarding the utility of the cells 
whose generation is described in this chapter. It has meant that these cells 
cannot be used to examine all aspects of PPP1R1A’s function, since some 
interacting proteins of PPP1R1A are not homologous between rat and human. 
In this context, the protein of interest which differs between rat and human, and 
is most relevant to this study, is melanoma differentiation-associated protein 5 
(MDA5). MDA5 is a viral sensor protein present in pancreatic β-cells (discussed 
in Chapter 3), which senses dsRNA, a bi-product of viral infection. Rat MDA5 
does not contain the phosphorylation site that PP1 dephosphorylates on human 
MDA5 (Figure 4-35), therefore, the effect of PPP1R1A on the cellular response 
to viral infection could not be studied in these cells. Despite this disappointing 
revelation, these cells were used in this study. In chapter 6, the role of 
PPP1R1A in regulation of cell cycle progression and in glucose stimulated 





Figure 4-35 Alignment of human, mouse and rat MDA5 protein 
The human, mouse and rat MDA5 protein sequences were aligned and 
sites of interest were highlighted. Amino acids highlighted in green show 
PP1 binding motifs [FXXR], pink indicates the recognition of the S88 MDA5 
antibody, turquoise indicates the s104 MDA5 antibody recognition site, the 
blue highlighted amino acid indicates the amino acid which is altered by 
the T1D risk SNP. 
The protein sequence is quite different between human and rodent, in 
particular antibody recognition sequences are quite different. Importantly, 
in relation to PPP1R1A, the serine residue that is dephosphorylated by 
PP1 in the human sequence is not a serine, and is asparagine in rodent 
MDA5 (highlighted in purple). For this reason in addition to the lack of 
antibodies that recognise rodent MDA5, the affect of PPP1R1A on MDA5 







5 Identification and characterisation of human cells isolated from 
1.1B4 cell cultures 
5.1 Introduction 
Immortalised cell lines play a vital role in the field of molecular biology research, 
and provide relevant models for many cell types in both health and disease. 
Since HeLa cells were first isolated in 1951 by George Otto Gey (Gey, 1952), 
they have been used routinely, and many advances in the understanding of 
cancer biology have been due to the use of these cells (Masters, 2002). When 
the American Type Culture Collection (ATCC) was established in 1962, 18 cell 
lines were deposited. In each of these, the expression of glucose-6-phosphate 
dehydrogenase and phosphoglucomutase 1 was characterised, as these are 
polymorphic enzymes. It was found that each of the 18 individual cell lines 
deposited all carried the same variant for each of the two enzymes, furthermore, 
the variant that was identified is exclusively expressed in African-American 
individuals. This and further evidence, indicated that all 18 cell lines, which had 
probably each started off as a unique cell line, had each become contaminated 
with HeLa cells (Gartler, 1968).  
Since many contaminated cell lines have subsequently been reported, the 
current register (https://iclac.org/databases/cross-contaminations/ accessed 
8/10/19 (Capes-Davis et al., 2010)) lists 529 contaminated cell lines, with HeLa 
cells being the most common contaminant; having 121 entries. 54 of the 
contaminated cell lines (~10%), are endowed with cells of a different species.  
Commonly used methods for authenticating cell lines include karyotyping, 
isozyme analysis, multi-locus DNA fingerprint analysis, short tandem repeat 
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(STR) profiling, PCR fragment analysis and sequencing of ‘DNA barcode’ 
regions. These are summarised in Table 5-1 (Capes-Davis et al., 2010). 
Table 5-1 Methods used to identify contaminated cell lines (adapted from Table 
3 from (Capes-Davis et al., 2010)) 
Commonly used methods used for identifying contamination in cell lines, a 
brief description of how they work, and what type of contamination they 
detect. 
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Following their derivation, 1.1B4 cells were proposed as a good model of 
human pancreatic β-cells for use in vitro, as they grow reliably, can be 
transfected, and readily sorted into single-cells. Furthermore they can support a 
persistent enteroviral infection. These characteristics made this cell line 
attractive for the studies proposed in my thesis. Additionally, in the original 
publication, the cells were found to be glucose sensitive and able to secrete 
insulin in response to various stimuli (McCluskey et al., 2011). However, over 
the course of a few years, members of our group using this cell line identified a 
number of instances where the data collected gave questionable results. These 
are described in more detail in later sections of this chapter but, given this 
background, the identity of the cells was investigated further.  
The method used for species identity in the present study was PCR analysis of 
the vomeronasal receptor, a process first described by Holder and Cooper 
(2011). This method uses species-specific primers which detect the species of 
origin in extracted DNA, and shows whether the sample contains DNA from a 
single species, or if DNA from multiple species is present. The 1.1B4 cells in our 
lab originated from two different sources. Initially, a clone of 1.1B4 cells was 
purchased from the European Collection of Authenticated Cell Cultures 
(ECACC) in 2012, however, it was found that these had very low insulin 
expression by ICC. Therefore, in February 2015, a further clone of 1.1B4 cells 
was received as a gift from the originating laboratory (at Ulster University). 
Since 2015, these are the cells that have been utilised for assays in our 
laboratory (and are those utilised for experiments described below, unless 
otherwise stated).  
Using the PCR analyses noted above (Holder and Cooper, 2011), I 
demonstrated that the 1.1B4 cell line (from both ECACC, and the originating 
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laboratory in Ulster) contained both rat and human sequences. Using a range of 
other assays it was established that the 1.1B4 cells provided to us were 
contaminated with rat cells and subsequent efforts were made to isolate pure 
human cells from the mixed population. The isolated human 1.1B4 cells were 
then further characterised to establish their characteristics. This chapter 
describes the process of identifying and confirming that the cells were 
contaminated, the isolation of human 1.1B4 cells and the subsequent 
characterisation of these cells. 
5.1.1 Preliminary results relevant to this chapter 
A growing body of data collected by various group members all indicated that 
the 1.1B4 cell line may not human, as was advertised, but may be contaminated 
with rat cells. These data are described below.  
5.1.1.1 A history of the data generated with our clones of 1.1B4 cells  
One of the key interests within our group is the role of a viral infection in 
triggering T1D (Richardson and Morgan, 2018, Morgan and Richardson, 2014) 
and this was originally intended as a key focus of my studies. To investigate 
how β-cells respond to viral infection, cells can be treated with type 1 interferon 
(T1IFN), which is typically released in response to a viral infection. The 
responses can then be assessed in various ways including by monitoring the 
expression of ISGs by Western blotting and RT-PCR, and activation of gamma-
interferon activation sites (GAS) by use of a luciferase reporter assay.  
5.1.1.1.1 1.1B4 cells respond to rat interferon γ not human interferon γ 
In studies performed by Dr Shalinee Dhayal in our team, HeLa, INS-1 832/13, 
PANC1 and 1.1B4 cells were treated with human IFNγ or rat IFNγ for 24 hours 
and gene expression from the GAS promoter was monitored by luciferase 
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assay. Interferons and their cognate receptors are species specific (Gibbs et al., 
1991) so, in theory, human cells are expected to respond to human IFNγ 
selectively, while rat cells should respond only to rat IFNγ. In confirmation of this 
prediction, rodent INS-1 832/13 cells failed to respond to human IFNγ but 
showed a robust activation of the GAS reporter after treatment with of rat IFNγ 
(Figure 5-1). HeLa and PANC1 cells are both of human origin and each 
displayed an increase in GAS activation after treatment with human IFNγ, but 
failed to respond to rat IFNγ. In marked contrast to expectation, the 1.1B4 cells 
did not display any GAS activation after treatment with human IFNγ, but did 
show a response upon treatment with rat IFNγ (Figure 5-1). These results 
indicate that 1.1B4 cells are not responsive to human IFNγ thereby questioning 




Figure 5-1 Treatment of cells with IFNγ is species specific (Dr Shalinee Dhayal). 
Cells were treated with 20 µg/ml human and 20 µg/ml rat IFNγ for 24 hours. 
Activation of the GAS promoter was measured using a luciferase reporter 
assay. HeLa cells (a) and PANC1 cells (b) had an increase in GAS 
promoter activity when they were treated with human IFNγ, but not when 
they were treated with rat IFNγ. INS-1 832/13 cells (c) did not show 
evidence of GAS reporter activity when exposed to human IFNγ, but did 
when they were exposed to rat IFNγ. 1.1B4 cells (d) showed minimal GAS 
reporter activity when treated with human IFNγ and a bigger response 
when they were treated with rat IFNγ. 
**** = P<0.0001 ; ns = not significant 
Determined by one-way ANOVA followed by Dunnett’s multiple 





5.1.1.1.2 Protein expression of ISGs following treatment with T1IFN in 1.1B4 cells 
In a second series of studies, Dr Mark Russell was investigating the effects of 
type I IFN treatment on pancreatic and non-pancreatic cells at the protein level. 
As part of this work, HeLa, PANC1, EndoC-βH1, 1.1B4 cells and isolated 
human islets were treated with 1000 Units/ml human type 1 IFN for 24 hours. 
The protein expression of various interferon-stimulated genes (ISGs) including; 
MDA5, IRF1, STAT1 (and its active form; phospho STAT1 (Y705)), ISG15 and 
PKR was compared between untreated cells and those exposed to the cytokine 
(Figure 5-2). The expression of all the ISGs (apart from IRF1) was increased 
across all cell lines except one (1.1B4 cells), including in isolated human islets. 
IRF1 was increased only in HeLa and EndoC-βH1 cells and remained 
undetectable in human islets and PANC1 cells. STAT1 was modestly increased 
in 1.1B4 cells after type 1 IFN treatment but all other ISGs remained 
undetectable after treatment with human type 1 IFN. Like Type II IFNs, Type I 
IFNs are also species specific (Higgins, 1984). Importantly, the STAT1 antibody 
used for Western blotting is able to detect both human and rat STAT1, whereas 
all the other antibodies used recognise only human proteins. This evidence 
therefore supports the idea that the 1.1B4 cell clones are not authentic but have 
evidence of rat cell contamination with, at best, a diminishing population of 





Figure 5-2 1.1B4 cells do not upregulate ISG products after treatment with 1000 
U/ml human type 1 interferon for 24 hours (Dr Mark Russell) 
HeLa, human islets, PANC1, EndoC-βH1 and 1.1B4 cells were exposed 
to Type 1 IFN (1000 U/ml) or media alone (control) for 24 hours and protein 
lysates were collected.  
HeLa, human islets, PANC1 and EndoC-βH1 cells all upregulate the 
proteins MDA5, STAT1, pSTAT1, ISG15 and PKR in response to human 
type 1 interferon, however the 1.1B4 cells did not. A modest increase in 
STAT1 expression was seen in the 1.1B4 cells. Of interest the antibodies 
that detect STAT1 are capable of recognising both human and rat STAT1 
protein. In contrast the other antibodies recognise only the human form of 





5.1.1.1.3 Amplification of rat gene sequence from 1.1B4 cell cDNA  
A third line of evidence came from work undertaken by Ms Katie Partridge 
(professional training year student) who was studying the role of IL-22 in various 
β-cells, including 1.1B4 cells. In these experiments, RT-PCR was used to 
identify the IL-22 receptor alpha subunit (IL-22Rα) using primers designed 
against human IL-22Rα sequence. The amplicon was extracted from the gel 
and sent for sequencing. Upon analysis of the sequence data, it was found that 
the amplified product matched the rat IL-22Rα sequence more closely than the 
equivalent human sequence (Figure 5-3).  
These data and others (such as inconsistent PCR results obtained when 
amplifying PPPR1A isoforms (discussed in chapter 4)) suggested that the 1.1B4 
cells are not a homogeneous clone of human cells but that the cultures contain 
significant contamination with cells having a rat origin. One possibility is that the 
cells are hybrid (human/rat) but it seems more likely that they represent a mixed 






Figure 5-3 1.1B4 cells express the rat version of the alpha subunit of the IL-22 
receptor (Ms Katie Partridge). 
RNA was extracted from the 1.1B4 cells and converted into cDNA. Human 
primers were used to amplify the alpha subunit of the IL-22 receptor (A). 
Upon sequencing of the extracted amplified product (indicated by the red 
box), it was found to align with the rat sequence, not the human sequence 
(B). Identical bases are marked with *. “N” in the sequence of the sample 





5.2.1 Cell and islet culture 
For these studies, the 1.1B4, EndoC-βH1, INS-1 832/13, PANC1 and HeLa 
cells, in addition to human islets were used. All cells were cultured as described 
in section 2.1 and Table 2-1.  
Where required, pseudoislets were formed from human 1.1B4 cells as 
described in section 2.1.3. 
5.2.2 Flow cytometry  
1.1B4 cells were treated for 24 hours with 1000 U/ml human Type I interferon 
(T1IFN). Cells were collected by trypsinization and pelleted at 200 g for 5 
minutes, then washed in FACS buffer, resuspended and pelleted again in FACS 
buffer. T1IFN treated or untreated cells were split between 2 tubes each. 1 tube 
was incubated with anti-HLA-ABC (W6/32)-RPE (C#R7000), the other tube was 
incubated with an isotype control, which was IgG2a-RPE (C#X0950). Tubes 
were incubated for 30 minutes, with limited exposure to light. Cells were 
pelleted (200 g; 5 minutes), and resuspended in FACS buffer to remove 
unbound antibody. Cells were analysed by flow cytometry using a BD FACS 
Aria III, and cells hyperexpressing HLA-ABC on their surface were seeded as 
single cells into 2 x 96 well plates.  
5.2.3 PCR 
PCRs were carried out (as described in section 2.3) to identify the species of 
cells, and to identify β-cell genes in EndoC-βH1, PANC1 and h1.1B4 cells and 
human islets. The primers used are detailed in Table 5-2.
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60 35 318 bp 







65 35 217 bp (Li et al., 2014) 
GLUT1 ACACGAGACCCACTTTTTCCG TGACGATACCGGAGCCAATG 60 35 283 bp 





65 35 336 bp 
(Zalzman et al., 
2005) 






65 35 456 bp (Li et al., 2014) 






65 35 429 bp (Li et al., 2014) 
CAR-SIV GGAAGTTCATCACGATATCAG AATCATCACAGGAATCGCAC 52 35 253 bp (Ifie et al., 2018) 
ACTB CGCACCACTGGCATTGTCAT TTCTCCTTGATGTCACGCAC 60 35 200 bp (Li et al., 2014) 
Table 5-2 Details of the primers used, annealing temperature, # of PCR cycles and product size for PCR reactions described in this chapter 
Primers used in this thesis. Primers to amplify ZNT8 were designed as described in section 2.2.5. 
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5.2.4 Hormone secretion assay 
Hormone secretion assays were carried out using h1.1B4, PANC1 and INS-1 
832/13 cells (as described in section 2.8) to examine the ability of cells to 
secrete in response to various stimuli, including glucose, IBMX, forskolin and 
KCl or combinations of these stimuli. The concentration of hGH in cell 
supernatants was measured using ELISA (section 2.9). Graphs were plotted as 
fold change from 0 mM glucose to emphasise the change in secretion from 
basal levels, additionally, it allowed for data from multiple experimental repeats 
to be plotted on the same graph. The fold change between experiments was 
concordant, however there was more variation in absolute concentration of hGH 
measured between experimental repeats, despite fold change from 0 mM 
glucose being consistent between repeats. Independent statistical tests on the 
raw data from each experimental repeat was carried out.   
5.2.5 Electrical activity of h1.1B4 cells 
The calcium channel blocker, nifedipine, was used in combination with glucose 
to investigate the calcium channel functionality of the h1.1B4 cells during 
hormone secretion studies. To further investigate the electrical activity of the 
h1.1B4 cells, patch-clamp readings and calcium imaging were carried out (as 
described in section 2.13) in collaboration with Dr Kyle Wedgwood (University of 
Exeter). 
5.2.6 Islet hormone (Insulin and glucagon) expression 
EndoC-βH1 and h1.1B4 cells were screened for islet hormone expression by 
ICC (as described in section 2.10) using the insulin and glucagon antibodies 
described in Table 2-8 and Table 2-5. The h1.1B4 cells were additionally 
investigated for insulin and proinsulin expression by electron microscopy 
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(prepared as described in section 2.12), courtesy of Professor Varpu Marjomӓki 
(University of Jyvӓskylӓ). 
5.2.7 H1.1B4 cell response to T1IFN 
Isolated h1.1B4 cells were treated with PIC (as described section 2.1.2), or with 
1000 U /ml human Type 1 interferon for 24 hours then western blotting was 
performed (as described in section 2.6) to detect various interferon-stimulated 




5.3.1 Confirmation of rat cells in the 1.1B4 cell population 
Primers described in Holder and Cooper (2011) were utilised to assess the 
species of origin of the 1.1B4 cells and of various other cell lines frequently 
used in our laboratory. The primers recognise species-specific sequences, and 
are designed to have relatively high annealing temperatures, to aid specific 
DNA binding. INS-1 832/13 cells were used as a positive control for rat 
sequences, and PANC1 and EndoC-βH1 cells were used as human positive 
controls. DNA was extracted from each of the different lines for analysis. 
The PCR results confirmed that the DNA isolated from INS-1 832/13 cells was 
entirely of rat origin (no product was observed in the PCR reaction using human 
primers) and that the PANC1 and EndoC-βH1 cells contained only human DNA 
(Figure 5-4). However, the 1.1B4 cells used in these experiments (which were 
received from the Ulster lab, and were also used in the studies described above 
for luciferase assay, Western blotting and PCR), yielded a product only when 
the rat primers were used, and not with primers targeting the human sequence 
(Figure 5-4). This confirmed that the 1.1B4 cells (at least those being grown at 
that time) were not of human origin. This was a critical conclusion but, at this 
point, it was not clear where the contamination had arisen and we were 
concerned that it may have occurred in our laboratory. To explore this, we 
thawed aliquots of the earliest passages from frozen stocks of the 1.1B4 cells 
made available to us from both sources (ECACC and Ulster) for examination. 
Cells from both sources contained amplicons when the human primers were 
used, but products were also observed with the rat primers (Figure 5-5). This 
suggests very strongly that the early passage 1.1B4 cells from both sources 
already contained a mixture of human and rat DNA at the time they were 
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received in our laboratory and that any contamination had arisen elsewhere. 
Interestingly, when cells were checked for species identity over a series of just 3 
serial passages (passages 32-34), the ratio of human : rat DNA decreased 
considerably.  
 
Figure 5-4 1.1B4 cells contain rat DNA 
Primers designed against either the rat or human vomeronasal receptor 
were used to amplify DNA extracted from INS-1E, EndoC-βH1 and 1.1B4 
cells. Both human and rat primers were used to amplify DNA extracted 
from each cell line. EndoC-βH1 cells amplified product exclusively when 
the human primer sets were used, whereas the INS-1E cells amplified 
product when the rodent primers were used. The 1.1B4 cells amplified a 
small amount of product when the human primers were used, however 
they amplified a large amount of product when rat primers were used. 
Amplicons outlined by red rectangles were excised and sent for 
sequencing. Sequencing confirmed that the bands were rat vomeronasal 
receptor sequence. 
R1 = rodent primer set 1; R2 = rodent primer set 2; H1 = human primer set 





Figure 5-5 Species of 1.1B4 cells from different origins 
The original early passages of 1.1B4 cells from both ECACC and the 
originating laboratory in Ulster were tested for species identity by PCR of 
extracted DNA. 1.1B4 cells from both sources were shown to contain both 
human and rat sequences. Increasing passage numbers decreased the 
amount of product amplified by the human primer set. 




The next questions which arose, were whether the cells are a hybrid of human 
and rat cells (noting that electrofusion was used to generate this line), or if they 
represent a mixed population of separable human and rats cells. In the latter 
case we reasoned that it was possible that a population of human cells might 
have been isolated by chance in one of the previous rounds of single cell 
sorting done when generating either the Flp-In T-REx clones (Chapter 4), or in 
experiments designed to maximise insulin expression (Chapter 4). To address 
this, all of the viable colonies from each of these earlier experiments were 
screened for expression of species-specific vomeronasal receptors. 
Unfortunately, amplified products were only detected when rat primers were 
used, and not with primers amplifying human sequences (Figure 5-6). These 
results suggest that the cells are not a hybrid of rat and human cells, but are a 
mixed population of rat and human cells. They further imply that the human 
cells are out-competed by overgrowth of rat cells during successive passaging. 
Nevertheless, despite the evidence that none of the previous cell sorting 
attempts had yielded a human clone, we sought to use this technology to isolate 






Figure 5-6 DNA extracted from 1.1B4 cell clones from previous single-cell sorts 
show all clones were rat 
Colonies from the first round of single-cell sorting during the generation of 
the 1.1B4 Flp-In T-REx cells all contained rat sequence, and no human 
sequence when analysed by vomeronasal PCR. 1.1B4 cells sorted based 
on insulin expression also contained no human DNA.  
Unsorted 1.1B4 cells also contained rat sequence, not human. Low 
passage 1.1B4 cells received from Ulster contained both rat and human 




5.3.2 Isolation of human cells from the 1.1B4 cell population 
As interferon responses are species specific (Figure 5-1 and Figure 5-2) the 
1.1B4 cells from ECACC (p32) were treated with human type 1 interferon and 
the expression of human leucocyte antigen (HLA) Class I on their surface was 
studied. The HLA class I antibody (HLA-ABC) used in this study uniquely 
recognises a subgroup of human HLA proteins and should not stain cells 
expressing equivalent rat proteins. After treatment with Type 1 interferon for 24 
hours, approximately 1% of the cell population was found to express human 
HLA-ABC (Figure 5-7) and these immunopositive cells were sorted using a 
FACS Aria (III) into single wells of a 96 well plate. From two such plates, 6 
colonies were expanded over a period of several weeks. Once these had been 
expanded in sufficient number, their species identity was investigated using the 
vomeronasal receptor PCR method. Colonies 1, 2, 5 and 6 yielded amplified 
product when human primers were used while colonies 3 and 4 produced 
products only when the rat primers were used (Figure 5-8). This suggested that 
4 human cells had successfully been isolated from the original mixed population 
used to seed the colonies. Colonies 1, 2, 5 and 6 were then expanded further 
and stocks frozen down. Colonies 3 and 4 were discarded.  
For further validation of species identity, colonies 1 and 2 were sent to ECACC, 





Figure 5-7 ~1% of the original 1.1B4 cells hyperexpress HLA-ABC on their 
surface after treatment with Type 1 interferon 
Low passage cells from the original stock of 1.1B4 cells from ECACC were 
treated with 1000 U/ml human Type 1 interferon for 24 hours. Cells were 
sorted based on expression of HLA-ABC on their surface, ~1% of the 
population were positive for elevated surface HLA-ABC. The population 
indicated with the purple box are the cells hyperexpressing HLA-ABC. The 
hyperexpressing cells were single cell sorted into 2 x 96 well plates.  
 
 
Figure 5-8 Species identity of the 6 isolated clones 
The 6 viable colonies out of 2 x 96 well plates were each tested for species 
identity by vomeronasal PCR. EndoC-βH1 and INS-1E cells’ DNA were 
used as human and rat positive controls, respectively.  Colonies 1, 2, 5 
and 6 were all human, whereas colonies 3 and 4 were rat. None of the 
colonies amplified product when both primer sets were used. R = Rat 




5.3.3 Characterisation of the human 1.1B4 cells 
Given this confirmation that human cells had been isolated from the original 
mixed population, the question of the identity (and characteristics) of these cells 
remained. One obvious possibility is that the cells might be identical to PANC1, 
as PANC1 cells were used in the generation of the 1.1B4 cell electrofusion 
hybrids. Alternatively, they might be another type of human cells such as a 
different endocrine cell type, or ideally, functional beta-like cells created by the 
electrofusion event between PANC1 and isolated human β-cells (McCluskey et 
al., 2011).  
5.3.3.1 Morphology of the human 1.1B4 cells 
Whilst culturing and expanding the FACS-sorted human clones, it was noted 
that their morphology differed significantly from the unsorted 1.1B4 population. 
Whereas the unsorted 1.1B4 cells had a clearly defined plasma membrane and 
a firmly “cobblestone morphology” in culture, with limited evidence of complex 
organelle structures and small membrane protrusions (Figure 5-9), the human 
clones were elongated, appeared to contain more complex organelle structures 
and frequently exhibited long membranous projections leading away from the 





Figure 5-9 Morphology of the h1.1B4 cells differs from that of the unsorted 1.1B4 
cells 
Human 1.1B4 cells (A, B and C) have longer projections and are much 





5.3.3.2 Expression of β-cell genes by RT-PCR 
To characterise these human cells further and to determine if they have relevant 
characteristics of β-cells, RT-PCR was performed to amplify a number of key 
genes expressed by β-cells including INS, GLUT1, ZNT8, NKX6.1, PC1/3, 
SUR1, GCK, CAR-SIV and β-actin, ACTB, as a loading control. RNA extracted 
from EndoC-βH1 cells and from isolated human islets were used as positive 
controls. PANC1 cells were also analysed. EndoC-βH1 cells expressed each of 
the selected genes at the level of mRNA, as did human islets (Figure 5-10). 
PANC1 cells expressed GLUT1, PDX1, and ACTB but none of the other “β-cell” 
genes (Figure 5-10), which is “as expected” for a pancreatic ductal cell line. 
Somewhat surprisingly, the clonally isolated human “1.1B4” cells each had a 
unique expression profile when compared with one another. Colony 1 clearly 
expressed ZNT8, PDX1, NKX6.1, and SUR1, while colony 2 expressed the 
greatest number of genes on the panel; INS, GLUT1, PDX1, NKX6.1, SUR1 
and the SIV isoform of CAR. Colony 5 expressed GLUT1, PDX1, NKX6.1, 
SUR1, and, among the tested genes, colony 6 only expressed GLUT1, NKX6.1, 
and SUR1. Colony 2 was selected for further characterisation studies as it 
demonstrated the greatest potential as a human β-cell line. Colony 2 is referred 





Figure 5-10 Expression of key β-cell genes in EndoC-βH1 cells, human islet 
samples, PANC1 cells and the isolated human 1.1B4 cells 
mRNA was extracted from each human cell line and the human 1.1B4 
clones, and converted to cDNA. The expression of β-cell related genes 
was assessed by RT-PCR. Human islets (A) expressed each gene 
examined, as did EndoC-βH1 cells (B). PANC1 cells (C) expressed very 
few of the genes examined, which was expected since they are a 
pancreatic ductal cell line. Colony 1 (D), Colony 2 (E), Colony 5 (F) and 
colony 7 (G) expressed different β-cell related genes. These are 
summarised in table (H). N/A in table (H) indicates that expression was not 
tested. * indicates that in repeats, the indicated gene was expressed.    
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It has been reported that, for some β-cell lines, pseudoislet formation can 
enhance their insulin secretion rate and improve their glucose-responsiveness 
(Green et al., 2015, Persaud et al., 2010). h1.1B4 cells were therefore cultured 
under conditions which promote pseudoislet formation, and the β-cell gene 
expression analysis was repeated from mRNA extracted from harvested 
pseudoislets (Figure 5-11). Pseudoislet formation led to an increase in the 
expression of a selection of target genes in the cells. When the cells were 
grown as pseudoislets, the expression of GCK was induced, however 
expression remained weak. Out of the nine β-cell genes examined (excluding 
ACTB), the only genes not expressed when the cells were configured as 
pseudoislets were ZNT8 and PC1/3. However, SUR1, GCK and INS were 
expressed at relatively low levels and were not always detected. The β-cell 
gene panel was studied on 4 separate occasions when cells were grown as 
monolayers and twice when configured as pseudoislets. An overview of which 
genes were expressed in each RT-PCR reaction is given in Figure 5-11 (table 
C), and it can be seen that there was some variability between repeats 





Figure 5-11 Colony 2 has variable expression of β-cell genes 
When RNA was extracted from colony 2 cells grown as a monolayer (A), 
they expressed fewer β-cell genes than when they were grown as 




5.3.3.3 Expression of β-cell markers at the protein level in h1.1B4 cells 
As insulin was expressed at the mRNA level in the sorted and cloned h1.1B4 
cells, the expression of both insulin and proinsulin was then assessed at the 
protein level by ICC. The expression of Chromogranin A, Synaptophysin, and 
PPP1R1A were also characterised using this approach. CAR-SIV is 
predominantly localised on the cell surface in most epithelial cells, as it is found 
in tight junctions (Raschperger et al., 2006), however in pancreatic β-cells, it is 
mainly localised to insulin secretory granules (Ifie et al., 2018), therefore the 
localisation of CAR-SIV was also investigated.  
Disappointingly, h1.1B4 cells did not express insulin at the protein level. By 
contrast, proinsulin was present, albeit at low levels. Moreover, its subcellular 
distribution was unusual. Unlike the situation in primary β-cells, in those h1.1B4 
cells where it was detected, proinsulin appeared to be localised to the nucleus 
(Figure 5-12). This unexpected distribution is unlikely to be explained by an 
issue with the specificity of the antibody as EndoC-βH1 cells were stained in 
parallel, as a positive control, and the expression of proinsulin was observed in 
the expected peri-nuclear and cytoplasmic localisation (Figure 5-12). 
Occasionally, some h1.1B4 cells also expressed small quantities of pro-insulin 





Figure 5-12 H1.1B4 cells do not express insulin at the protein level, but do 
express low levels of proinsulin 
H1.1B4 cells (A, B, C and D) and EndoC-βH1 cells (E) were 
immunostained for proinsulin (anti-proinsulin; red) and insulin (anti-insulin; 
light blue) and nuclei were stained with DAPI (dark blue). No insulin was 
detected in the h1.1B4 cells (B and D), however was detected in the 
EndoC-βH1 cells (E). Very few h1.1B4 cells express proinsulin, proinsulin 
expressing cells are indicated with white arrows (A and B). Proinsulin was 




Chromogranin A was expressed in discrete compartments of the EndoC-βH1 
cells, often in close proximity to, or co-localizing with, proinsulin (Figure 5-13). 
The h1.1B4 cells, on the other hand, expressed only minimal amounts of (or 
any) chromogranin A, with staining hard to distinguish from background 
fluorescence (Figure 5-13). Synaptophysin was expressed throughout the 
EndoC-βH1 cells, both in the nuclear and cytoplasmic compartments, whereas 
h1.1B4 cells expressed synaptophysin exclusively in the nuclei. CAR-SIV was 
expressed on the regions of surface membrane located between adjacent 
h1.1B4 cells (Figure 5-13) in keeping with its role as a tight junctional protein 
but it was not seen in a cytoplasmic (granular) location. The h1.1B4 cells did not 
express PPP1R1A.  
 
Figure 5-13 H1.1B4 cells do not have β-cell-like localisation of chromogranin A, 
synaptophysin or CAR-SIV 
H1.1B4 cells were immunostained for (A) Chromogranin A (anti-
chromogranin A; red), (B) synaptophysin (anti-synaptophysin; red) or (C) 
CAR-SIV (anti-CAR-SIV; red), nuclei were stained with DAPI (dark blue). 
EndoC-βH1 cells were also immunostained for chromogranin A (D) or 




To further examine the aberrant expression of proinsulin in h1.1B4 cells, 
samples were sent to Prof Varpu Marjomӓki and Dr Tino Kantoluoto 
(Jyväskylän yliopisto, Finland) for cryo-EM immunogold labelling. However 
neither insulin nor proinsulin were detected by electron microscopy in the 
samples sent to them (Figure 5-14). This could be explained by the fact that 
they received a later passage of cells from those originally assessed for insulin / 
proinsulin immunostaining in our laboratory. Indeed, subsequent RT-PCR 
results with the later passage cells suggested that the expression of insulin had 
declined. Alternatively, it is also possible that only a small percentage of the 
cells express proinsulin and these evaded detection at the (very high) resolution 
of the EM analysis. Taken together, these data imply that proinsulin expression 
is, at best, low and that the cells may not represent an ideal model for human β-
cells. These statements are supported by the RT-PCR analysis of colony 2, 
where insulin was not always detected, suggesting that the transcript, if present, 





Figure 5-14 Electron microscopy of h1.1B4 cells revealed they have no insulin 
granules.  
H1.1B4 cells were analysed by electron microscopy, and expression of 
insulin and proinsulin were analysed via immunogold labelling. Courtesy 




5.3.3.4 Secretory capabilities of the h1.1B4 cells 
Since h1.1B4 cells do not contain large quantities of endogenous insulin, it was 
not feasible to measure the rates of insulin secretion directly. Thus, an 
alternative approach was taken in which transfected human growth hormone 
(hGH) was used as a surrogate. When hGH is transfected into cells with a 
regulated secretory pathway, such as most β-cell models, hGH is sorted into 
granules routed to this pathway after golgi processing (da Silva Xavier et al., 
2003, Fisher and Burgoyne, 1999). Secreted hGH can then be collected in 
culture media and measured by ELISA.  
Encouragingly, there was a 3-fold increase (p ≤ 0.0005) in the extent of hGH 
secretion upon incubation of the cells with 20 mM glucose by comparison with 
those incubated in the absence of glucose (Figure 5-15). Treatment with the 
agents expected to raise intracellular cAMP levels (200 µM IBMX + 10 µM 
forskolin) did not lead to any increase in hGH release in the absence of glucose, 
however, when the cells were co-incubated with 200 µM IBMX + 10 µM 
forskolin + 20 mM glucose, hGH released was enhanced, (p ≤ 0.0001) 
marginally more than that achieved with 20 mM glucose alone. Surprisingly, 
incubation with 25 mM KCl did not facilitate hGH secretion (Figure 5-15). KCl 
was chosen as it is expected to depolarise the β-cell membrane and should 





Figure 5-15 Effect of glucose and the cAMP activators, IBMX and forskolin, on 
secretion of hGH from h1.1B4 cells 
H1.1B4 cells were transfected with hGH 48 hours prior to the secretion 
assay being carried out. For the secretion assay, cells were incubated with 
various secretagogues (20 mM glucose, 200 μM IBMX, 10 μM forskolin or 
25 mM KCl), and supernatant was collected. The concentration of hGH in 
the supernatant was determined by sandwich ELISA. p ≤ 0.005 ** ;p ≤ 
0.0005 *** ;p ≤ 0.0001 **** ;ns = not significant 




Since the cells displayed a clear secretory response when glucose levels were 
raised from 0 to 20 mM, the sensitivity to glucose was studied. Cells were 
treated with increasing concentrations of glucose, 0 mM, 0.5 mM, 2 mM, 8 mM, 
12 mM and 20 mM for 1 hour and the extent of hGH secretion monitored 
(Figure 5-16). Surprisingly, the cells significantly (p ≤ 0.005) responded to the 
initial rise in glucose concentration (between 0 and 0.5 mM) but failed to 
increase hGH secretion further as glucose levels were raised progressively 
beyond this (Figure 5-16). Thus, the cells were sensitive to glucose over a very 
narrow concentration range and did not show any further response over the 





Figure 5-16 H1.1B4 cells respond to 0.5 mM glucose  
H1.1B4 cells were transfected with hGH 48 hours prior to the secretion 
assay being carried out. For the secretion assay, cells were incubated with 
increasing glucose concentrations (0 mM – 20 mM) and supernatant was 
collected. The concentration of hGH in the supernatant was determined by 
sandwich ELISA.  




When allied with the observation that 25 mM KCl also failed to elicit hGH 
secretion from the cells in the absence of glucose, a question arises about the 
status of the electrical activity of the cells. To investigate this, cells were 
incubated with 0 mM or 20 mM glucose in the absence or presence of a Ca 
channel blocker, nifedipine. Nifedipine is an L-type calcium channel antagonist 
which normally restrains glucose-stimulated insulin secretion by restricting Ca 
influx under depolarising conditions. However, nifedipine did not affect the 
secretion of hGH from h1.1B4 cells (Figure 5-17), suggesting that they may not 
express functional calcium channels involved in control of regulated secretion. 
Therefore, a still more fundamental approach was taken and cells were 
incubated either in Ca replete medium (containing 2 mM CaCl2) or with Ca 
depleted medium supplemented with 0.1 mM EGTA. Incubation of cells under 
calcium depleted conditions (+EGTA) had no impact on hGH release from the 
h1.1B4 cells compared to complete KRB (Figure 5-18), indicating that calcium 





Figure 5-17 The calcium channel blocker nifedipine has no effect on hGH 
secretion from h1.1B4 cells 
H1.1B4 cells were transfected with hGH 48 hours prior to the secretion 
assay being carried out. For the secretion assay, cells were incubated in 
the presence of absence of glucose, with or without nifedipine and 
supernatant was collected. The concentration of hGH in the supernatant 
was determined by sandwich ELISA.  
ns = not significant 





Figure 5-18 H1.1B4 cells do not require an influx of calcium to secrete hGH in 
response glucose 
H1.1B4 cells were transfected with hGH 48 hours prior to the secretion 
assay being carried out. For the secretion assay, cells were incubated with 
either in complete (2 mM CaCl2) or deplete KRB, and stimulated with the 
secretagogues; 0 mM glucose, 20 mM glucose, 200 μM IBMX and 10 μM 
forskolin or 20 mM glucose and 200 μM IBMX and 10 μM forskolin  
The concentration of hGH in the supernatant was determined by sandwich 
ELISA.  




In parallel studies, similar experiments were also performed with PANC1 cells, 
which are not expected to display a regulated secretory pathway akin to that 
found in more classical endocrine cells. Indeed, to my knowledge, hGH 
secretion has not previously been assessed from transfected PANC1 cells. 
Unlike the situation with h1.1B4 cells, secretion of transfected hGH from PANC1 
cells was not altered by exposure to 20 mM Glucose (vs 0 mM glucose) but, in 
keeping with data from h1.1B4 cells, PANC1 cells also failed to respond to 25 
mM KCl (Figure 5-19). Interestingly, the absolute basal secretion rate of hGH 
was relatively high in PANC1 cells (Figure 5-19(B)) and was much higher than 




Figure 5-19 hGH secretion from PANC1 cells 
There was no increase in secretion of hGH when PANC1 cells were 
stimulated with 20 mM Glucose or 25 mM KCl, compared to 0 mM Glucose. 
Data presented as fold change from 0 mM glucose (A)  
The actual basal secretion was very high, as shown in graph (B).  





In view of these rather disappointing findings in 1.1B4 cells, it was felt important 
to verify that hGH can be used as an effective surrogate for insulin in a better-
defined β-cell line. For this purpose, the highly glucose-responsive INS-1 
832/13 cell line was chosen. These cells have an abundance of insulin and their 
secretion is regulated by a variety of physiological insulin secretagogues 
(Hohmeier et al., 2000, Salunkhe et al., 2016, Yang et al., 2004, Pedersen et 
al., 2014, Fernandez et al., 2008). In these studies, cell culture supernatant was 
collected from each well and used for analysis by hGH ELISA. The INS-1 
832/13 cells secreted minimal hGH when unstimulated, however, when 
incubated with 20 mM glucose they secreted hGH (Figure 5-20). When 
incubated with the cAMP activators, IBMX (200 µM) and forskolin (10 µM), there 
was a significant (p ≤ 0.05) increase in concentration of hGH secreted. This was 
further augmented when cells were treated with 20 mM glucose or 25 mM KCl 
in addition to the cAMP activators (p ≤ 0.005) (Figure 5-20). Other than a low 
non-significant increase in secretion following exposure to high glucose, this is 
the expected pattern of insulin secretion from β-cells, where and increase in 
intracellular cAMP or depolarisation of the cell by exposure to potassium should 
elicit secretion (Gromada et al., 1998, Pipeleers et al., 1985, Gembal et al., 





Figure 5-20 Effect of glucose and the cAMP activators, IBMX and forskolin, on 
secretion of hGH from INS-1 832/13 cells 
INS-1 832/13 cells were transfected with hGH 48 hours prior to the 
secretion assay being carried out. For the secretion assay, cells were 
incubated with various secretagogues (20 mM glucose, 200 μM IBMX, 10 
μM forskolin or 25 mM KCl), and supernatant was collected. The 
concentration of hGH in the supernatant was determined by sandwich 
ELISA. P ≤ 0.05 * ; p ≤ 0.005 ** ; ns = not significant 




5.3.3.5 Electrophysiological properties of the h1.1B4 cells 
To address the possibility that h1.1B4 cells lack the typical electrophysiological 
features of β-cells, direct measurements of membrane potential and calcium 
fluxes were made. Patch-clamp and calcium imaging were performed in 
collaboration with Dr Kyle Wedgwood (University of Exeter). Strikingly, no ion 
channel currents were recorded in these cells despite the application of 
increasing voltage steps or after a voltage ramp was delivered to the cells via 
whole cell patch clamp methods (Figure 5-21). Furthermore, calcium imaging 
using a calcium responsive dye (Fura-2) was employed to investigate whether 
calcium channels were active. The acetoxymethyl (AM) ester form of Fura-2 is 
incubated with a monolayer of cultured cells, to allow to dye to cross the cell 
membrane (Zanin et al., 2019). Calcium imaging revealed that the cells were 
not responsive to increasing glucose concentrations, or to KCl. Fura-2 indicates 
intracellular calcium concentrations by displaying a shift in excitation when it is 
bound to Ca2+ (Grynkiewicz et al., 1985), thus intracellular calcium 
concentrations are calculated by determining the ratio of ~340 nm (Ca2+ bound 
Fura-2) to ~380 nm (unbound Fura-2). Initially, h1.1B4 cells were pre-incubated 
with 2.5 mM glucose, before the glucose concentration was elevated to 16.8 
mM, however no calcium spikes were observed. The glucose concentration was 
then lowered back to 2.5 mM glucose for 3 minutes before it was supplemented 
with 30 mM KCl. No calcium spikes were recorded during exposure to any of 
these solutions.  
Since the h1.1B4 cells secreted hGH at maximal capacity when exposed to 0.5 
mM glucose (Figure 5-16), and increasing glucose concentrations did not 
enhance hGH secretion, further calcium imaging experiments were carried out 
after glucose starvation. In order to balance the osmolarity of the solutions 
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used, pre-incubations were carried out using 16.8 mM sucrose (for full details, 
refer to Table 2-3). In the first instance, cells were pre-incubated with the 
glucose free solution and Fura-2 (AM) for 45 minutes, followed by 3 minutes 
incubation with 0 mM glucose, 16.8 mM sucrose, before exposure to 2.5 mM 
glucose for the duration of the time (20 minutes). Further experiments following 
the same procedure, but exposing the cells to 16.8 mM glucose or 2.5 mM 
glucose and 30 mM KCl for 20 minutes did not evoke any calcium spikes 
(Figure 5-22). When the h1.1B4 cells were pre-incubated with glucose-free, 
16.8 mM sucrose solution prior to exposure to 16.8 mM glucose there were a 
few cells in the population which had fluctuating calcium levels however these 
fluctuations were apparent before exposure to glucose and did not correlate 





Figure 5-21 h11B4 cells have no detectable current 
Whole-cell patch clamp was performed on the h1.1B4 cells (A and B) and 
the EndoC-βH1 cells (C and D). Increasing voltage steps were passed 
through the cells and the current (I) inside the cell was measured. There 
was no observable current out of 9 x h1.1B4 cells patched, compared to 
the EndoC-βH1 cells, which had an increased current with increasing 
voltage step inputs. A voltage ramp (E) was also performed on the h1.1B4 
cells, no current (I) was observed (F). The mean current (pA/pF) inside the 
h1.1B4 cells (G) and EndoC-βH1 cells (H) were calculated, and plotted 




Figure 5-22 Calcium imaging of h1.1B4 cells following exposure to high glucose 
or KCl 
The calcium responsive dye, Fura-2, was used to detected intracellular 
calcium concentrations. H1.1B4 cells were incubated with the 
acetoxymethyl (AM) ester form of Fura-2 for 45 minutes (to allow the dye 
to enter the cells) in (A & B) 2.5 mM glucose solution, or (C-D) 0 mM 
glucose, 16.8 mM sucrose solution prior to washing with PBS. Cells were 
then exposed to (A & B) 16.8 mM glucose for 5 minutes, followed by 2.5 
mM glucose for 5 minutes, then 2.5 mM glucose and 30 mM KCl for 5 
minutes and imaged for the duration (A is a snapshot), and the ratio of Ca2+ 
bound (~340 nm) to Ca2+ unbound (~380 nm) Fura-2 was plotted (B) (C & 
D) cells were exposed to 2.5 mM glucose for 20 minutes (E & F) cells were 
exposed to 16.8 mM glucose (G & H) cells were exposed to 2.5 mM 
glucose + 30 mM KCl for 20 minutes. The small coloured circles in (A, C, 
E and G) identify individual cells, and correspond to a coloured line in (B, 
D, F and H, respectively). The large circle in (A, C, E and G) was identified 




5.3.3.6 Response to human Type 1 interferon 
Since a key focus of the current research in our team surrounds the responses 
of β-cells to viral infection, the responses of the h1.1B4 cells to human Type 1 
interferon (a common by-product of viral infection) were examined. As 
mentioned earlier in the chapter (section 5.1.1.1.2), we could not detect any of 
the ISGs in the original 1.1B4 cells, except STAT1 and they did not upregulate 
these at the protein level following exposure to Type 1 interferon. The h1.1B4 
cells were seeded into 4 x 25 cm3 tissue culture flasks and treated with medium 
alone (control), a mock-infection protocol (transfection reagent only), 0.1 mg / 
ml Polyinosinic:polycytidylic acid (PIC – a synthetic viral dsRNA mimic), or 1000 
U/ml human Type 1 interferon for 24 hours. HeLa cells were also seeded and 
treated in parallel, as a positive control. The h1.1B4 cells had low basal 
expression of each of the ISGs, including; MDA5, PKR, STAT1 (and the 
activated form of STAT1; pSTAT1), IRF1 and ISG15. However all of these were 
upregulated in response to PIC and / or IFN Tx (Figure 5-23). The same was 
also true in the HeLa cells. These results are very different to the previous data 
(collected by Dr Mark Russell) using the unsorted 1.1B4 cells (Figure 5-2) in 





Figure 5-23 H1.1B4 cells respond to Type 1 interferon and the viral mimic, Poly: 
IC 
HeLa and h1.1B4 cells were treated with either Mock infection (transfection 
reagent only), Poly IC, or type 1 IFN for 24 hours. Control cells are 
unstimulated cells. Seven interferon-stimulated genes were probed for by 
western blotting including MDA5, PKR, STAT1 (and the active form; 
pSTAT1), IRF1, ISG15, and Tyk2. Upregulation of all the proteins were 
detected following either Poly IC or Type 1 interferon treatment, in both the 





This chapter describes the discovery of contamination with rat cells in human 
1.1B4 cell stocks. Human cells were isolated from the mixed rat and human 
1.1B4 cell population, and these were verified to be human independently by 
ECACC. The h1.1B4 cells were characterised, and shown to robustly respond 
to human type 1 interferon by upregulating ISGs. The h1.1B4 cells express 
multiple β-cell genes and secrete in response to elevated glucose (although not 
in a regulated manner). Also disappointingly, they do not display the 
electrophysiological properties, characteristic of β-cells. Thus, these h1.1B4 
cells are not a very robust β-cell model.  
5.4.1 Cell line contamination 
Cross-contamination of cells in culture is a serious issue that can have profound 
effects on scientific research, and has been happening for decades (Gartler, 
1968, Korch and Varella-Garcia, 2018). Early cross-contaminations 
predominantly involved HeLa cells. Buehring et al. (2004) carried out a PubMed 
search to identify publications that contained data obtained from cell lines 
known to be contaminated with HeLa cells, and yielded 220 publication listings. 
These data indicate that cross contamination is not an uncommon event and is 
a worryingly frequent occurrence with considerable consequences. Many cell 
line contaminations happen early in the development of the cell line (MacLeod 
et al., 1999), meaning that subsequent users of a cell line may be unaware of 
any changes, as the cells were always (unknowingly) contaminated. Data 
presented in this chapter allow 1.1B4 cells to be added to this list. High impact 
chemistry journals require authors to specifically state the methods used to 
establish the purity of their starting materials, and to document the results 
informing the reader of their quality control analysis (Nims et al., 2010). There 
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have been calls for cell line authentication to be a condition when submitting 
research grant applications, or even paper submissions (Nardone, 2007, 
Stacey, 2000). Some journals including the Journal of Endocrinology, and the 
Nature Publishing Group (for a full list, please see this site: 
https://www.promega.co.uk/resources/pubhub/cell-line-authentication-
testing/?cs=y&tabset0=0) require authors to check the list of known 
contaminated cell lines, and justify the reasoning for using a contaminated line. 
In addition, authors are required to identify the source of cells and the method 
by which authentication was carried out, and when the cells were last 
authenticated (https://www.nature.com/documents/nr-reporting-life-sciences-
research.pdf). Although this is a step in the right direction, often cells are 
authenticated when deposited, and then not again thereafter. Taking 1.1B4 cells 
as an example, they were authenticated as human upon deposition to ECACC, 
therefore any data collected from these cells would theoretically be okay to 
publish. As highlighted in this chapter however, cell line authentication is worth 
carrying out independently, as different validation methods may identify different 
types of contamination.  
Cell line authentication is not as simple as it may sound. ECACC are a founding 
member of the International Cell Line Authentication Committee (ICLAC). 
Before selling and distributing the 1.1B4 cells, they performed authentication 
studies using ECACC’s (and ATCC’s) standard procedure of short tandem 
repeat (STR) profiling, and confirmed they were human. This is one of the gold 
standard procedures for recognising cross-contamination within human cell 
cultures (Dirks and Drexler, 2011, Nims et al., 2010, Group, 2010). STR 
profiling is a technique which simultaneously amplifies multiple microsatellite 
regions which covers repetitive DNA regions with varying numbers of repeats 
338 
 
(STR loci). Results are compared to other known samples, and cell line origin 
identified. Due to the nature of the assay, only human DNA will be amplified, 
thus the issue with this type of test is that it confirms that DNA from the 
expected species is present and if the cell line has been contaminated with 
another cell type of the same species but it fails to recognise whether the cells 
are contaminated with any additional species, so must be used alongside other 
validation methods (Nims and Reid, 2017). As a result of the cross-
contamination of 1.1B4 cells reported in this thesis, ECACC have now changed 
their standard practice when they accept a new cell line – they now also check 
for cross-species contamination, as well as intra-species contamination 
(https://www.phe-culturecollections.org.uk/technical/discontinued-ecacc-cell-
lines.aspx accessed: 5/3/2020). As a field we should make it common practice 
to check the identity of the cells before they are used and confirm that they have 
the expected characteristics, regardless of where the cells were obtained from 
e.g. purchased from a reputable source, or gifted from (the originating) 
laboratory. 
5.4.2 Identification of contamination in the 1.1B4 cells 
1.1B4 cells are commonly used in diabetes research (Vasu et al., 2013, Vasu et 
al., 2014, Mohan et al., 2018, Nekoua et al., 2019), however, in our hands, the 
data obtained from them became increasingly questionable over time. 
Inconsistencies in data collected by various group members became apparent 
from when the cells were first obtained in 2012, compared to data collected 
more recently. The cells lost their responsiveness to treatment with human 
interferon and we were unable to successfully amplify product when primers 
designed against human gene sequences were used (sections 5.1.1.1.1, 
5.1.1.1.2 and 5.1.1.1.3). Increasingly, RT-PCR, qPCR and antibodies were 
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yielding negative results in the 1.1B4 cells. A positive control (EndoC-βH1 cells) 
was run alongside the 1.1B4 cells, so this argued against there being any 
issues with each of the assays being tested. A combination of the data collected 
by Dr Shalinee Dhayal (reporter assays), Dr Mark Russell (Western blotting) 
and Ms Katie Partridge (RT-PCR and sequencing) suggested that the 1.1B4 cell 
stocks in the lab contained cells of rat origin. Species specific PCR assays were 
established (section 5.3.1) to confirm that the cultures contained rat DNA 
sequences. These experiments were conducted in 1.1B4 cells which had been 
passaged a number of times since their arrival. By examining the early passage 
frozen stocks it was clear that the initial small percentage of human cells in the 
1.1B4 cell population were out-competed by the contaminating rat cells over 
time, which was confirmed by PCR (Figure 5-4 and Figure 5-5). PCR data from 
unsorted 1.1B4 cells indicated that both human and rat DNA was present. From 
these data alone, it is unclear as to whether the cells were a hybrid of human 
and rat (since electrofusion was used to generate the cells), or if the 1.1B4 cell 
stocks were a mixed population containing some human cells, but 
predominantly rat cells. Data obtained from vomeronasal receptor PCR using 
genomic DNA extracted from clones of previous single cell sorts, such as Flp-In 
T-REx cell generation and optimising insulin expression in 1.1B4 cells, indicated 
that the 1.1B4 cells were a mixed population, as only primers against rat DNA 
yielded a PCR product. If the cells were a hybrid of human and rat, product 
would be amplified with each primer set.     
There was a concern that the contamination had occurred in-house through 
mis-labelling or careless tissue culture practice. This was considered because 
the 1.1B4 cells were still displaying some β-cell characteristics, such as insulin 
expression, suggesting that they were β-cells. The clonal rat β-cell lines, INS-
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1E, INS-1 832/13 and BRIN-BD11 cells are routinely handled in the lab, so 
conceivably the 1.1B4 cells could have been contaminated in our laboratory 
with one of these lines. It was important, therefore, that we understood the time 
frame of the contamination, to understand how confined, or widespread, the 
contamination might be. Knowing the point in time the contamination took place 
was vital not just for our own research, but additionally for other research 
groups that use 1.1B4 cells. Confirmation that our earliest stocks of 1.1B4 cells 
from both ECACC, and independently from the originating laboratory at Ulster 
University, were both contaminated with rat cells, suggested that our lab was 
not the source of contamination. It was much more likely that they were 
contaminated before we received them, early in the cell generation process; 
which is a more common situation than one would like (MacLeod et al., 1999). 
MacLeod et al. (1999) investigated the authenticity of cell lines obtained directly 
from the laboratory which established the cell lines, they found 45 out of 252 
(18%) cell lines were contaminated, although these were mainly intraspecies 
contaminations. Following the careful review of our findings by ECACC, and the 
implementation of their own testing they confirmed the contamination of the 
1.1B4 cells, and in addition they identified a second cell line, 1.1E7 (McCluskey 
et al., 2011), developed at the same time as the 1.1B4 cells that were also 
contaminated with rat cells (https://www.phe-
culturecollections.org.uk/technical/discontinued-ecacc-cell-lines.aspx accessed: 
5/3/2020).  
5.4.2.1 Isolation of human cells from the mixed human and rat population 
In the early stocks of the 1.1B4 cells that were stored (from both sources), a 
minority human population was observed, although the percentage of human 
cells rapidly declined with each passage (Figure 5-5). The proliferation rate of 
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the h1.1B4 cells was slower than that of the unsorted (predominantly rat) 1.1B4 
cells. This is a likely reason as to why the human cells were so quickly out 
competed, within a small number of passages, resulting in an entirely rat 
population. Additionally, the fastidious growth habits of the h1.1B4 cells, e.g. 
reliance upon cell-to-cell communication, could also have impacted the decline 
of human cells. Treating the early stocks of 1.1B4 cells with human Type 1 
interferon, triggered the specific upregulation of HLA-ABC onto the surface of 
responding human cells. In addition to the species specificity of the T1IFN 
treatment, the antibody raised against HLA-ABC only recognises the human 
form of the protein, and not the rat form. This additional level of human specific 
detection, allows for a double selection procedure for human cells. The small 
percentage of the population hyperexpressing HLA-ABC on their surface was 
reflected in the vomeronasal PCR from cells of the same passage number. In 
cells of the same passage number as those treated with human T1IFN, to verify 
that there were some human cells remaining in the population, and the 
determine the ratio of human : rat cells, the species was analysed by 
vomeronasal PCR, and it was verified that human cells existed in the 
population. Seeding 2 x 96 well plates with a single cell in each well only 
resulted in 6 viable colonies. This small number of viable colonies could reflect 
differences in viability and cell-to-cell contact dependence in the human cells, in 
comparison to the rat cells in the population. Sorting the cells into conditioned 
media may have increased the number of viable colonies obtained. Conditioned 
media was not used during the isolation process of the h1.1B4s to prevent the 
potential contamination (even after 0.2 µM filterisation) with rat cells. 
Following the expansion of these six clones, it was confirmed by vomeronasal 
PCR that 4 out of the 6 clones were human. The characteristics of these lines 
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were then examined in more detail. It was interesting to observe differences in 
both morphology and growth rate of the isolated human cells, compared to the 
original 1.1B4 cells. The isolated human 1.1B4 cells had a fast doubling time, 
and unlike the original 1.1B4 cells, if the h1.1B4 cells were seeded at a very low 
density, they survived but did not replicate. If the cells were re-seeded into 
smaller culture vessels, where they are in closer proximity to one another, they 
begin to proliferate again. Sub-culturing into a larger culture vessel was then 
possible, once they had begun to increase in confluency and number. The 
original 1.1B4 cells were not fastidious with regards to low seeding density, and 
when seeded at a low density, the cells continued to proliferate. These slow and 
contact-dependent growth habits of the h1.1B4 cells shed light on why the 
human cells in the population were so quickly out competed with the 
contaminating rat cells, which have a faster doubling time and are more easily 
cultured. The next crucial question was whether the isolated human 1.1B4 cells 
had characteristic features of β-cells.  
5.4.3 Suitability of the h1.1B4 cells as a model of human beta cells 
5.4.3.1 β-cell gene expression 
The expression of key β-cell specific genes was characterised in the four 
isolated human 1.1B4 clones. The genes examined include INS, GLUT1, ZNT8, 
PDX1, PC1/3, SUR1, GCK, CAR-SIV and ACTB. Pro-insulin, insulin, glucagon, 
synaptophysin and chromogranin A were studied at the protein level by ICC, 
additionally, insulin and pro-insulin were also studied by electron microscopy.  
5.4.3.1.1 Monolayer results 
The expression of each of the genes listed above was variable between the four 
isolated human 1.1B4 clones. Colony 6 expressed the fewest number of genes, 
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whereas colonies 1 and 5 had similar expression patterns to each other, and 
colony 2 expressed the greatest number of genes tested in the panel (Figure 
5-10). ZNT8 was not expressed in any of the cell lines, neither was PC1/3. The 
protein products of these two genes are necessary for insulin synthesis and 
maturation. ZNT8 is a zinc transporter protein, which allows the passage of zinc 
into insulin granules (Davidson et al., 2014) and PC1/3 (prohormone convertase 
1/3) cleaves the pro-insulin peptide to insulin (Guest, 2019). The passage of 
zinc into insulin secretory granules is critical for the formation of insulin 
hexamers, where 6 insulin molecules are complexed with 2 Zn2+ ions and one 
Ca2+ ion (described further in chapter 1.4.2.1). Taken together, the lack of 
expression of these two genes suggest that the cells are unable to package and 
process mature insulin. 
The mRNA expression of the studied genes in colony 2 was variable between 
replicates. A possible explanation for this variability is the confluency of the cells 
when RNA was extracted, since cell-to-cell contact has been shown to enhance 
gene expression and insulin secretion from β-cells (Persaud et al., 2010, 
Teraoku and Lenzen, 2017, Chowdhury et al., 2013, Hauge-Evans et al., 1999, 
Green et al., 2015). Across all replicates, GLUT1, PDX1 and CAR-SIV were 
detected, which suggest that these genes have high mRNA levels. INS was 
detected in all but one PCR reaction, and the PCR reactions where a band was 
detected, the bands were weak, which suggest that it has low mRNA 
expression. NKX6.1 and SUR1 were detected in 50% of the PCR reactions, 
suggesting their expression level is low or variable, possibly dependent on 
confluency. 
In extension to exploring the gene expression of insulin, the protein expression 
of insulin, proinsulin and glucagon was also investigated. The h1.1B4 cells were 
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negative for glucagon, however, disappointingly, they were also negative for 
insulin. The proinsulin expression in the h1.1B4 cells was intriguing, by ICC, 
proinsulin could be detected, however, the intracellular distribution of it was 
unexpected. Not all h1.1B4 cells expressed proinsulin, and in those where 
proinsulin was detectable, the staining was punctate, mainly localised around 
the nucleus, whereas the proinsulin expression in the EndoC-βH1 cells was 
more homogenous within the population, since all cells expressed it. 
Furthermore, proinsulin expression continued further from the nucleus and more 
into the cytoplasm of the cells.  
No mature insulin was detected, which was not surprising as the transcript level 
for INS was low; in addition, the cells do not express PC1/3 or ZNT8, which are 
both necessary for insulin synthesis and maturation (as discussed previously in 
this chapter and in section 1.4.2.1). The chromogranin A and synaptophysin 
staining corroborated that these cells may not be specialised secretory cells, 
given that chromogranin A and synaptophysin could not be detected. 
Chromogranin A is important in the regulation of secretion by targeting peptide 
hormones (e.g. insulin in β-cells or glucagon in α-cells) to granules of the 
regulated pathway (Hendy et al., 1995, Herold et al., 2018). Synaptophysin is 
expressed in the membrane of presynaptic vesicles in β-cells (Wiedenmann, 
1991, Wiedenmann et al., 1986). The absent expression of these proteins 
suggest that the h1.1B4 cells do not have insulin secretory granules. A further 
indication that the h1.1B4 cells may not be specialised secretory cells is their 
intracellular distribution of CAR-SIV staining. CAR-SIV is a protein typically 
involved in tight junction integrity between neighbouring epithelial cells 
(Raschperger et al., 2006). Within pancreatic islets, CAR-SIV has been shown 
to be exclusively expressed in pancreatic β-cells, specifically within the insulin 
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secretory granules (Ifie et al., 2018). The subcellular localisation of CAR-SIV in 
the h1.1B4 cells was not typical of human pancreatic β-cells, and was 
expressed on the membrane (Figure 5-13), between two neighbouring cells. 
This is where a tight junction protein is expected to be expressed and is 
expressed in other cell lines e.g. PANC1, however the cell surface is not where 
CAR-SIV is expected to be expressed in pancreatic β-cells. The expression of 
CAR-SIV in the h1.1B4 cells is not entirely unexpected, as if the cells do not 
express components for mature insulin granules (ZNT8, chromogranin, 
synaptophysin), CAR-SIV cannot localise to the granules. Additionally, no 
granules were detected via EM.   
5.4.3.1.2 Pseudoislet results 
There is evidence that the originally described 1.1B4 cells performed more 
efficient insulin secretion in response to the incretins, GLP-1 and GIP (incretin 
hormones), when the cells were grown in pseudoislets, rather than in 
monolayers (Green et al., 2015). Min6 and EndoC-βH1 cells also perform more 
efficient secretion when cultured as pseudoislets rather than as monolayers 
(Hauge-Evans et al., 1999, Persaud et al., 2010, Teraoku and Lenzen, 2017), 
however INS-1 cells do not have improved glucose sensitivity when cultured as 
pseudoislets compared to monolayers (Persaud et al., 2010). The originally 
described 1.1B4 cells showed an increase in expression of genes involved in 
insulin secretion (INS and PDX1 among others) when cells had formed 
pseudoislets rather than grown in monolayers (Green et al., 2015). These 
findings were similar to the data collected from the isolated h1.1B4 cells, where 
an increase in expression of β-cell specific genes was observed when mRNA 
was harvested from h1.1B4 pseudoislets (Figure 5-11). It is important to 
consider during data interpretation that other reports of data collected from 
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1.1B4 cells are probably contaminated with rat cells, although this cannot be 
known for sure.  
Pseudoislets are formed when cultured β-cells are grown in non-adherent 
flasks, which promote cells to form clusters and grow in suspension. When β-
cells are grown in suspension, they form clusters which encourage the cells to 
behave more like pancreatic islets, as cells are in closer proximity to each other 
and have formed 3-dimensional structures. To investigate (1) whether the 
h1.1B4 cells would form pseudoislets and (2) whether pseudoislet formation 
enhanced their β-cell properties, they were cultured as pseudoislets and mRNA 
was extracted once pseudoislets had formed (after ~4 days in culture). 
The mRNA expression of key β-cell genes was increased when cells were 
grown as pseudoislets, compared to when they were grown as monolayers. The 
only genes that were not expressed in any repeat when the cells were grown as 
pseudoislets were ZNT8 and PC1/3. All other genes examined were all 
expressed in at least one repeat; GLUT1, PDX1, NKX6.1 and CAR-SIV were all 
expressed in both repeats, however INS, SUR1, and GCK were only expressed 
in one of the repeats, which suggests that the mRNA expression is lower in 
these genes. This is not surprising, as NKX6.1, SUR1 and GCK were not 
reproducibly detected when the PCR was carried with RNA extracted from cells 
grown as monolayers. The overall expression of the number of key β-cell genes 
was increased when cells were grown as pseudoislets compared to 
monolayers. These data suggest that the h1.1B4 cells rely upon cell-to-cell 
communication, to enhance their β-cell characteristics.  
As discussed previously, having an additional human β-cell line would be 
beneficial to the β-cell research community. It is evident that the isolated human 
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cells described presently do not have the capacity to process insulin effectively, 
due to the absence of mature insulin at the protein level by ICC, or of insulin 
granules by electron microscopy. This could be explained by the lack of 
expression of ZNT8 or PC1/3 at the mRNA level, regardless of monolayer or 
pseudoislet culture, both ZNT8 and PC1/3 are necessary for the processing and 
maturation of insulin. ZNT8 is a zinc transporter protein, which allows the 
passage of zinc into insulin granules (Davidson et al., 2014) and PC1/3 
(prohormone convertase 1/3) cleaves the proinsulin peptide to insulin (Guest, 
2019). It is also interesting to note that the h1.1B4 cells express insulin mRNA, 
but not the mature insulin protein. Unexpectedly, they did appear to express 
pro-insulin in the nuclei of a small subset of h1.1B4 cells. The localisation of 
synaptophysin was also unexpected in these cells, with it too, being expressed 
exclusively in the nuclei of all cells, unlike in the EndoC-βH1 cells, where it is 
nuclear and cytoplasmic. The expression of CAR-SIV in the h1.1B4 cells is also 
not typical of pancreatic β-cells. In the h1.1B4 cells, CAR-SIV was found to be 
expressed on the membrane, between neighbouring cells, which is its expected 
localisation in polarised epithelial cells, as it is a transmembrane cell-adhesion 
protein. In pancreatic β-cells however, the expression of CAR-SIV co-localizes 
with insulin, ZnT8 and PC1/3 (Ifie et al., 2018). These data again, indicate that 
the h1.1B4 cells do not have features of canonical β-cells.  
5.4.3.2 Secretion patterns of hGH from the h1.1B4 cells 
Since the h1.1B4 cells do not express insulin, insulin secretion could not be 
directly measured. Therefore, as a surrogate, the secretion of hGH was 
measured. hGH was transfected into the h1.1B4, PANC1 or INS-1 832/13 cells 
(see section 2.1.2), and its secretion was measured after incubation with 
various insulin secretagogues.  
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Since the original 1.1B4 cells were created by electrofusion of PANC1 cells with 
isolated human β-cells, it was questioned whether the h1.1B4 cells were 
PANC1 cells. In order to answer this crucial question, the secretion of hGH from 
PANC1 cells was studied. The PANC1 cells displayed high levels of hGH 
secretion when they were incubated in the absence of glucose, suggesting high 
basal secretion (Figure 5-19). When incubated with 20 mM glucose or with 25 
mM KCl there was no increase in secretion, compared to 0 mM glucose (Figure 
5-19). These data suggest that the PANC1 cells are not glucose responsive 
(despite expressing GLUT1 mRNA, indicating glucose should be able to enter 
the cell), nor are they reliant upon potassium channel closure to trigger calcium 
channel opening and (hGH) secretion since secretion was not augmented 
following exposure to 25 mM KCl.  
Following exposure to 20 mM glucose there was a significant increase in 
concentration of hGH secreted from the h1.1B4 cells, compared to when they 
were incubated in a glucose deficient environment (Figure 5-15), this fold 
increase is similar to the report in the original characterisation of the 1.1B4 cells 
(McCluskey et al., 2011), although in this system insulin secretion was 
measured, so comparisons cannot be directly made.  
The h1.1B4 cells display a ~2-fold increase in secretion when incubated with 
0.5 mM glucose, but no further increase in secretion with increasing 
concentrations of glucose (Figure 5-16). These data suggest that hexokinase is 
the major kinase responsible for the initiation of glucose metabolism, of glucose 
to glucose-6-phosphate, rather than glucokinase. This is not what is expected in 
pancreatic β-cells. The Km for glucokinase is much higher than that of 
hexokinase, meaning that a lower concentration of glucose will elicit a response 
with hexokinase than glucokinase (Middleton, 1990). Glucokinase is expressed 
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in the liver and pancreas and plays a crucial role in glucose metabolism in 
pancreatic β-cells (German, 1993). The PCR data suggests that glucokinase 
expression is absent/ or present at very low levels in h1.1B4 cell monolayers, 
but is expressed at marginally higher levels when pseudoislets are formed. In 
the original characterisation of the 1.1B4 cells, it was found that glucokinase 
was expressed, however hexokinase was also expressed, and phosphorylating 
activity of both hexokinase and glucokinase were similar (McCluskey et al., 
2011). Studies by other members of the group carried out soon after the 1.1B4 
cells were available, showed that hexokinase was the predominant kinase in the 
1.1B4 cells. The hGH secretion data from the h1.1B4 cells support these 
observations (Figure 5-16), where increasing concentrations of glucose did not 
enhance the secretion of hGH from the cells, suggesting the hexokinase is 
predominant over glucokinase. Expression of hexokinase at the RNA and 
protein level of the h1.1B4 cells would further validate these findings.  
The h1.1B4 cells did not exhibit augmented secretion in response to 200 µm 
IBMX + 10 µM forskolin when combined with 20 mM glucose (Figure 5-15). 
These stimuli typically potentiate secretion of insulin from β-cells (Kalwat and 
Cobb, 2017) above incubation with 20 mM glucose alone. The combination of 
IBMX and forskolin elevates the intracellular cAMP concentrations. IBMX does 
this by preventing the breakdown of cAMP by inhibiting phosphodiesterases, 
and forskolin stimulates the enzyme, adenylate cyclase. The net effect of 
forskolin and IBMX incubated on the cells is a dramatic upregulation of cAMP, 
which would ordinarily stimulate the secretion of insulin (or hGH in cells which 
have a regulated secretion pathway), when also incubated with glucose. There 
are various theories as to how cAMP induces insulin secretion from pancreatic 
β-cells, it is unclear whether it acts at the level of the KATP or calcium channel, 
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with evidence supporting both (reviewed in (Kalwat and Cobb, 2017)). cAMP 
upregulation mimics the incretin induced insulin secretion from β-cells (Figure 
1-3). The G-protein coupled receptors, namely GIPR and GLP1R, elevate 
cAMP, when their specific ligands, the incretins GIP and GLP-1, respectively, 
bind to the extracellular component of their receptors, augmenting insulin 
secretion in the presence of high glucose. 
Exposure of β-cells to 25 mM KCl causes depolarisation of the membrane by 
inducing the closure of KATP channels, which triggers an influx of calcium into 
the cell and results in fusion of any docked insulin granules at the cell 
membrane for exocytosis of insulin, via the triggering pathway (Rorsman and 
Braun, 2013). The observation that KCl had no effect on hGH secretion from the 
h1.1B4 cells suggests that they do not contain the potassium or calcium 
channels necessary for depolarization of the cell membrane, which β-cells 
should possess. At the mRNA level, the h1.1B4 cells express a subunit of the 
KATP channel, SUR1, at variable levels. Further studies examining the protein 
expression of SUR1, and Kir6.2 (another KATP channel subunit) would validate 
these findings. 
The observation that hGH secretion is not increased by cAMP or KCl, suggests 
that the h1.1B4 cells do not have the capacity to secrete insulin via the 
canonical regulated pathway (Figure 1-2), neither the triggering or amplification 
pathways (Figure 1-3). This was further investigated using nifedipine. Nifedipine 
is an L-type calcium channel blocker, therefore incubating cells with nifedipine 
will block calcium channels. Calcium influx is necessary for insulin secretion via 
the regulated secretory pathway, therefore incubation with nifedipine will block 
(hGH) secretion, if calcium channels are necessary. When nifedipine was co-
incubated with either 0 mM or 20 mM glucose, there was no alteration in 
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secretion of hGH. These data imply that L-type calcium channels do not play a 
role in secretion by the h1.1B4 cells. Ordinarily, there is an influx of calcium 
through L-type calcium channels, after depolarization of the cell by closure of 
KATP channels (Rorsman and Braun, 2013) (Figure 1-3). If the h1.1B4 cells 
possessed these functional channels, there would be a decrease in secretion 
after incubation with 20 mM glucose + nifedipine, compared to 20 mM glucose 
alone, due to calcium being unable to enter the cells, however, these findings 
were not observed in this system (Figure 5-17).  
These data suggest that the h1.1B4 cells are not electrically active and do not 
possess the necessary protein components for canonical regulated insulin 
secretion.  
To further validate these findings, hGH secretion experiments were carried out 
using calcium free KRB, supplemented with EGTA, which will chelate any 
extracellular calcium, preventing calcium entry into the cells. Quenching the 
calcium should inhibit insulin secretion from β-cells, as calcium influx is 
necessary for insulin granules to fuse with the cell membrane and release 
insulin. The secretion of hGH from the h1.1B4 cells was not affected by the 
presence or absence of calcium (Figure 5-18). This further suggests that the 
h1.1B4 cells do not secrete via a regulated secretory pathway, and secrete via 
a constitutive secretory pathway. 
The h1.1B4 cells do increase secretion after incubation with 20 mM glucose, but 
this could be due to increased energy within the cells resulting in increased 
constitutive secretion from the cells, rather than triggering an insulin secretion 
pathway. This hypothesis was proposed since these data were collected; (1) 
secretion was not augmented by addition of IBMX or forskolin with glucose, (2) 
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they did not secrete in response to 25 mM KCl, (3) nifedipine had no effect on 
secretion, (4) calcium free KRB (+EGTA) did not affect secretion.  
To ensure that these observations were not due to the secretory pathway hGH 
was routed to (i.e. regulated vs constitutive; Figure 1-2), hGH was transfected 
into the INS-1 832/13 cells and supernatant was collected and analysed by hGH 
ELISA. If hGH is routed for regulated secretion, it should show the same 
secretory pattern as expected if insulin was measured by radioimmunoassay. 
The INS-1 832/13 cells are known to have regulated insulin secretion 
(Hohmeier et al., 2000, Salunkhe et al., 2016, Yang et al., 2004, Pedersen et 
al., 2014, Fernandez et al., 2008), thus can be used as a control measure of 
hGH secretion following exposure to insulin secretagogues. The INS-1 832/13 
cells displayed a different pattern of hGH secretion, compared to the h1.1B4 
cells. Increasing intracellular cAMP levels in INS-1 832/13 cells by incubation 
with IBMX and forskolin induced a significant increase hGH secretion, and this 
was further augmented by co-incubation with 20 mM glucose or 25 mM KCl 
(Figure 5-20). This is the expected pattern of secretion from β-cells (Gromada et 
al., 1998, Pipeleers et al., 1985, Gembal et al., 1992). These data, combined 
with previously published reports of hGH as a tool to measure regulated 
secretion (da Silva Xavier et al., 2003, Fisher and Burgoyne, 1999), indicate 
that the data obtained measuring hGH secretion from the h1.1B4 cells suggest 





5.4.3.3 Electrical activity of the h1.1B4 cells 
Pancreatic β-cells have similar electrical properties as nerve cells, where 
membrane potential is crucial to neurotransmitter exocytosis from nerve cells 
and insulin exocytosis from β-cells (Rorsman and Ashcroft, 2018). The resting 
membrane potential of mouse β-cells is ~ -80 mV, whereas the resting 
membrane potential of human β-cells is ~-70 mV. Human β-cells have no 
electrical activity when in low glucose environments, however, become 
increasingly active when exposed to increasing glucose concentrations. 
Interestingly, once a human β-cell is exposed to high glucose (above 22 mM), 
the reversal of electrical activity and action potential firing can take up to half an 
hour to return to normal (Rorsman and Ashcroft, 2018).  
Whole-cell patch clamping and calcium imaging experiments carried out on the 
h1.1B4 cells verified that the cells were not electrically active and showed no 
signs of having a membrane potential (Figure 5-21), despite being viable during 
the recordings. With increasing voltage applied to the cell, there was no change 
in intracellular current detected, which indicates that functioning ion channels 
are not present on the cell surface. The calcium imaging revealed that they do 
have some fluctuation of intracellular calcium levels, however these were not in 
response to any stimuli tested, and remained unchanged regardless of whether 
the cells were starved of glucose prior to calcium imaging and glucose 
stimulation or not (Figure 5-22). Taken together, these data suggest that the 
h1.1B4 cells do not have typical electrical properties of pancreatic β-cells.  
5.4.4 Future studies 
The h1.1B4 cells can be further characterised by growing them as pseudoislets, 
and investigating their secretion patterns. It could be speculated that culturing 
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the cells as pseudoislets would have no impact on their secretion, as they do 
not have a canonical glucose-regulated secretion pathway, dependent on the 
electrical conductance of the cell.  
Embedding pseudoislets of the h1.1B4 cells would enable the investigation as 
to whether this has an impact on subcellular localisation of pro-insulin, 
chromogranin or CAR-SIV. This would be interesting, as when h1.1B4 cells 
were grown as pseudoislets they expressed a greater number of β-cell genes, 
compared to when they were grown as monolayers. Additionally, qPCRs could 
be carried out in order to quantitate the mRNA expression of the genes.   
Overall, the h1.1B4 cells described here are by no means a perfect β-cell 
model, however they might prove to be a useful model for virus-related studies 
or investigating responses to interferon. They might also be useful to 
understand different aspects of secretion, as they do not have all the necessary 
components, but appear to be sensitive to glucose, and may elucidate discrete 
roles for proteins involved in other secretory pathways. These cells were used 
to investigate the role of PPP1R1A in secretion and cell cycle (described in 








6 Cellular functions of PPP1R1A (in cultured β-cells) 
6.1 Introduction 
Given the restricted tissue and cellular distribution of PPP1R1A expression 
(Martens et al., 2011, Jiang et al., 2013) and its depletion from β-cells in 
individuals with Type 1 diabetes (discussed in Chapter 3), understanding the 
role of PPP1R1A in pancreatic β-cells is of importance. In this chapter, two 
potential roles of PPP1R1A in β-cells were explored, namely, in the regulation 
of cell cycle progression and insulin secretion. Using the 1.1B4 Flp-In T-REx 
cells described in Chapter 4, h1.1B4 described in Chapter 5, 1.2B4 and EndoC-
βH1 cells, these potential roles for PPP1R1A were investigated, and this 
chapter describes the findings.  
Since the early 1990’s, Protein phosphatase 1 (PP1) has been identified as an 
essential component of mitosis in Drosophila (Axton et al., 1990). There are 
over 120 PP1 interacting proteins, including PPP1R1A (Fardilha et al., 2012), 
thus understanding whether PPP1R1A plays a role in regulating any 
documented functions of PP1, such as cell cycle regulation, requires careful 
assessment. Pancreatic β-cells seldom replicate once fully mature, one 
exception being in pregnancy, where there is an increase in β-cell mass to 
comply with β-cell demand. There is a larger pool of evidence for this response 
in rodents, where increased β-cell replication is seen (Genevay et al., 2010) but 
on the contrary, the limited studies in humans suggest that there is no increase 
in β-cell proliferation in pregnancy. This leads to the hypothesis that the 
increased β-cell mass in pregnant women is due to β-cell neogenesis, rather 
than replication (Butler et al., 2010), or due to adaptive responses by β-cells to 
a change in circulating hormones, such as prolactin and other placental 
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lactogens, and kisspeptin (Bowe et al., 2019). There is however, evidence for β-
cell proliferation in newly diagnosed individuals with T1D (Willcox et al., 2011, 
Willcox et al., 2010) which indicates that β-cells do have the capacity to 
replicate when exposed to the necessary stimuli. Given that PPP1R1A is 
depleted from β-cells in Type 1 diabetes (discussed in Chapter 3) and that there 
is an increase in proliferation of β-cells in this disease, it was investigated 
whether PPP1R1A is necessary for regulating cell cycle progression in 
pancreatic β-cells. The role of PPP1R1A in regulating cell cycle progression 
was assessed by manipulating the expression of PPP1R1A in cell lines and 
examining the effects on cell cycle stages. Additionally, pancreas tissue 
sections were analysed for the basal phosphorylation status of PPP1R1A, the 
proliferation marker Ki67, the senescence marker p21 and PPP1R1A 
expression.  
In the literature, there is evidence that PPP1R1A expression is linked to the 
secretory capacity of pancreatic β-cells (Dorrell et al., 2016) and may play a role 
in augmenting insulin secretion (Taneera et al., 2015). The mechanism by 
which PPP1R1A influences insulin secretion remains unclear. The role of 
PPP1R1A in hormone secretion was therefore assessed using three 





6.2.1 Cell culture 
Three 1.1B4 Flp-In T-REx cell lines were developed and cultured as described 
(in Chapter 4) in media supplemented with 150 µg/ml hygromycin B for 
continued selection of stably transfected cells. The 1.1B4 Flp-In T-REx cells 
either express WT PPP1R1A, T35A PPP1R1A (non-phosphorylatable) or empty 
vector (EV; as a control) upon addition of 1000 ng/ml tetracycline to the media. 
Human 1.1B4 cells were isolated and cultured as described in Chapter 5. 1.2B4 
and EndoC-βH1 cells were cultured as described in section 2.1.  
6.2.2 Cell cycle analysis 
1.1B4 Flp-In T-REx cells were seeded into 6 well plates at a density of 2x105 
cells per well, or in 24 well plates on coverslips at a density of 0.5x105 cells per 
well. Cells were incubated with 1000 ng/ml tetracycline where necessary and 
were treated with 10 µM forskolin for the required length of time. Cells were 
harvested and cycle stage was analysed by flow cytometry or ICC (sections 2.7 
and 0). The cells on coverslips were stained for total or phosphorylated 
PPP1R1A and Ki67.  
Protein expression in pancreas tissue was detected via immunofluorescence 
staining (section 2.11.2 and 2.11.3). FFPE pancreas sections were stained for 
phosphorylated PPP1R1A and either total PPP1R1A, P21 or Ki67 with insulin 
and DAPI, using antibody conditions described in Table 2-8 and Table 2-5. The 
donor details are described in Table 6-1.  
6.2.3 Secretion 
Since the 1.1B4 Flp-In T-REx cells, h1.1B4 and 1.2B4 cells do not express 
large amounts of insulin, the effects of PPP1R1A on insulin secretion could not 
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be directly measured. As a surrogate for insulin, hGH was transfected into the 
cells (sections 2.1.2 and 0), and secretion was measured via ELISA (section 
2.9). Results were normalised to 0 mM glucose, and presented as fold change 
against 0 mM glucose, thus allowing for comparison between cell lines or cells 
expressing PPP1R1A mutants. Statistical analyses were carried out on the raw 
data collected from each experimental repeat. 
6.2.4 Immunofluorescence studies 
FFPE pancreas tissue sections (Table 6-1) were immunostained as described 
in section 2.11.2 and 2.11.3. Antibodies used are detailed in Table 2-8 and 
Table 2-5. Citrate (pH6) was used for HIER and 5% NGS was used as the 
blocking reagent for all the antibodies.  
Sample CRN Identity Age (years) Sex 
6014-03 PH 14-073 NDC 2 Male 
6103-04 PB 11-243 NDC 1.5 Male 
6022-03 PT 14-073 NDC 75 Male 
6012-04 PT 14-005 NDC 68 Female 
6010-08 PT 19-145 NDC 47 Female 
6011-10 PH 19-145 NDC 46 Female 
Table 6-1 Details of nPOD samples utilised in the study 
The first 4 digits of the sample number are the patient ID, the second 2 
numbers indicate the block number. PH = Pan head, PB = Pan body and 




6.3.1 PPP1R1A and cell cycle progression 
Whilst validating the EV, WT and T35A Flp-In T-REx clones (described in 
Chapter 4), cells were seeded onto coverslips and incubated with 1000 ng/µl 
tetracycline for 24 hours, and / or 10 µg forskolin for 2 hours. These 
experiments were performed to validate that an increase in intracellular cAMP 
resulted in the phosphorylation of PPP1R1A at threonine 35, and that this was 
detectable via ICC. Each of the cell lines were analysed for the p-Thr35 form 
and total PPP1R1A, under 4 different conditions; no addition, tetracycline alone, 
forskolin alone and tetracycline plus forskolin. Regardless of clone or condition, 
P-Thr35 PPP1R1A could be detected in the nuclear region, concentrated 
around the nuclear membrane, in a subset of cells (Figure 6-1). This was very 
unexpected because validation studies of these cells by western blotting 
(section 4.3.3) had shown that PPP1R1A could not be detected, except in 
stably transfected cells upon addition of tetracycline. The sub-population of cells 
which expressed p-Thr35 PPP1R1A when analysed via ICC appeared to be 
undergoing mitosis, as the DAPI staining of these cells matched literature 
reports of DAPI staining during mitosis (Figure 6-2) (He and Davie, 2006). The 
DAPI staining in cells which are in G0 phase of the cell cycle is more evenly 
distributed across the nucleus, whereas the DAPI staining in cells in the mitotic 
stages of the cell cycle, the DAPI staining is more punctate. This is due to the 
target of DAPI, Adenine-Thymine rich regions of DNA (Kapuscinski, 1995), 
which is condensed during mitosis, giving more punctate DAPI staining. These 
data suggest that PPP1R1A is transiently expressed (and phosphorylated) 
during cell division, even in cells where it is otherwise absent. Total PPP1R1A 
could not be detected in any Flp-In T-REx cells, other than when WT or T35A 
361 
 
cells had been incubated with tetracycline (‘tet-on’ WT) (Figure 4-32). These 
observations led to further investigation of the role of PPP1R1A in cell cycle 
progression.  
 
Figure 6-1 Phospho PPP1R1A is expressed in a subset of cells which do not 
express PPP1R1A  
To validate PPP1R1A phosphorylation in the Flp-In T-REx cells, cells were 
seeded on 13 mm round coverslips and cultured in tetracycline (1000 
ng/ml) supplemented media for 24 hours. In addition, cells were exposed 
to 10 µM forskolin for 2 hours to induce PKA mediated PPP1R1A 
phosphorylation. Cells were then stained for Phoshpo PPP1R1A (anti-
pPPP1R1A; green), nuclei were stained with DAPI (dark blue). pPPP1R1A 
was unexpectedly expressed in a subset of EV (A) and T35A (B) Flp-In T-





Figure 6-2 staining pattern of DAPI during different phases of the cell cycle  
Images lifted from the report by He and Davie (2006) which served as a 




Initially, to ensure that this was not a cell type specific observation, EndoC-βH1 
cells were co-stained for Ki67 with either phosphorylated or total PPP1R1A. 
Ki67 is a commonly used proliferation marker (Sales Gil and Vagnarelli, 2018, 
Sobecki et al., 2017). In cells which are in either the G1, S, G2 or mitotic phases 
of the cell cycle, Ki67 is expressed, however is absent from cells which are in 
G0 (Scholzen and Gerdes, 2000). When EndoC-βH1 cells were co-stained for 
Ki67 with total PPP1R1A, there was no indication that Ki67 expression was 
correlated with PPP1R1A expression (Figure 6-3), this was consistent with 
other cell lines such as INS-1 832/13 and h1.1B4 cells. However, when Ki67 
was co-stained with p-Thr35 PPP1R1A, there was a clear correlation in 
expression (Figure 6-3). Phosphorylated PPP1R1A was only expressed in Ki67 
positive cells, however, phosphorylated PPP1R1A was not expressed in all Ki67 
positive cells, which suggests that PPP1R1A expression and phosphorylation is 





Figure 6-3 Phosphorylated PPP1R1A, but not total PPP1R1A correlates with 
Ki67 expression in EndoC-βH1 cells  
EndoC-βH1 cells were seeded onto coverslips, fixed and probed for Ki67 
(anti-Ki67; green) and PPP1R1A (anti-PPP1R1A; red) or Ki67 and 
phosphorylated PPP1R1A (anti-pPPP1R1A; red). Scale bar = 50 µm for 





6.3.1.1 Expression of phosphorylated PPP1R1A in pancreata 
Co-staining of phosphorylated PPP1R1A with total PPP1R1A was carried out in 
human pancreas tissue samples from non-diabetic individuals to assess the 
basal level of phosphorylated PPP1R1A present in pancreatic β-cells. 
Phosphorylated PPP1R1A is expressed more highly in pancreatic Islets of 
Langerhans, compared to the exocrine pancreas, however, is detected in the 
nuclei of some exocrine cells, where total PPP1R1A is not detected (Figure 
6-4). Unlike total PPP1R1A, which is predominantly cytoplasmic, 
phosphorylated PPP1R1A is nuclear, with some β-cells having stronger 
expression than others (Figure 6-4). The expression level of phosphorylated 
PPP1R1A did not necessarily correlate with the expression of total PPP1R1A. 
This discrepancy between the expression of PPP1R1A forms could be to the 





Figure 6-4 Expression of PPP1R1A (total and phosphorylated) in an islet from an 
individual without T1D (6010-08) 
Representative immunofluorescence images of (A) PPP1R1A (anti-
PPP1R1A; green), (B) overlay of total PPP1R1A and pPPP1R1A (C) 
pPPP1R1A (anti-pPPP1R1A; red) (D) insulin (anti-insulin; light blue), (E) 
overlay of total PPP1R1A, pPPP1R1A and insulin, (F) Overlay of all 
channels, including nuclei (DAPI; dark blue). (G) Zoomed in image of total 
and phosphorylated PPP1R1A with insulin showing dual total and 
phosphorylated PPP1R1A positive β-cells (white arrow) and total 
PPP1R1A negative, phosphorylated PPP1R1A positive β-cells (yellow 




6.3.1.2 Relationship between PPP1R1A and Ki67 in human pancreas tissue 
Due to the observation in cultured cells of the correlation between Ki67 and 
phosphorylated PPP1R1A, it was questioned whether this also held true in 
human pancreas tissue. Previously described in this chapter was the finding of 
phosphorylated PPP1R1A expression in a subset of β-cells within the islets. For 
studies investigating the relationship between Ki67 and pPPP1R1A, pancreata 
obtained from young donors were utilised, since β-cells seldom replicate, 
although replicate more commonly in children under the age of 2 years. In the 
cases studied (Table 6-1), cells in the pancreatic Islets of Langerhans 
(determined by insulin staining) which stained positively for Ki67, 
phosphorylated PPP1R1A is not observed (Figure 6-5). Occasionally, double 
positive Ki67 and phosphorylated PPP1R1A cells were observed in the exocrine 
pancreas (Figure 6-6), however this observation was rare. The infrequent 
observation of Ki67 positive β-cells was unsurprising. Phosphorylated 
PPP1R1A was frequently detected in the nuclei of cells, and staining was 
stronger within islets, compared to the exocrine pancreas. Within the islets, 
pPPP1R1A was more commonly and strongly expressed in β-cells. This is a 
different pattern to that in cultured β-cells, where pPPP1R1A is not restricted to 





Figure 6-5 Expression of Ki67 and pPPP1R1A in the pancreas from a young 
door (6014-03) 
Representative immunofluorescence images of (A) Ki67 (anti-Ki67; 
green), (B) pPPP1R1A (anti-pPPP1R1A; red) and (C) Insulin (anti-insulin; 
light blue). Overlay of Ki67, pPPP1R1A and Insulin (D). (E) Overlay with 
all channels, including nuclei (DAPI; dark blue). (F) Zoomed in image of 
Ki67, pPPP1R1A and insulin showing a Ki67 positive pPPP1R1A negative 





Figure 6-6 Expression of Ki67 and pPPP1R1A in the pancreas from a young 
door (6103-04) 
Representative immunofluorescence images of (A) Ki67 (anti-Ki67; 
green), (B) pPPP1R1A (anti-pPPP1R1A; red) and (C) Insulin (anti-insulin; 
light blue). Overlay of Ki67 and pPPP1R1A (D). (E) Overlay with all 
channels, including nuclei (DAPI; dark blue). (F) Zoomed in image of Ki67 
and pPPP1R1A showing double Ki67 and pPPP1R1A positive cells. White 
arrows indicate Ki67 and pPPP1R1A positive cells in the exocrine 
pancreas. Data are representative of images from 2 donors. Yellow arrows 
indicate Ki67 positive, pPPP1R1A negative cells. Scale bar 50 μM 
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6.3.1.3 Relationship between PPP1R1A and p21 in human pancreas tissue 
As a means to study whether PPP1R1A may play a role in cellular senescence 
or cell cycle arrest, pancreas sections from elderly non-diabetic donors were co-
stained for phosphorylated PPP1R1A and the G1/S phase inhibitor, p21. Cells 
which express p21 are arrested in the cell cycle at G1/G0 (Vasavada et al., 
2007), p21 prevents the phosphorylation of Rb (Karimian et al., 2016), thus 
preventing cell cycle progression. Cells which stained positively for p21 were 
often intra-islet (Figure 6-7). There was no clear relationship between p21 and 
phosphorylated PPP1R1A, although both are nuclear and both were stronger 
within pancreatic islets. Occasionally, p21 positive cells were also positive for 
phospho PPP1R1A, however there was no clear relationship between the 





Figure 6-7 Expression of p21 and pPPP1R1A in the pancreas from an adult 
donor (6012-04) 
Representative immunofluorescence images of (A) p21 (anti-p21; green), 
(B) pPPP1R1A (anti-pPPP1R1A; red) and (C) Insulin (anti-insulin; light 
blue). Overlay of p21, pPPP1R1A and Insulin (D). (E) Overlay with all 
channels, including nuclei (DAPI; dark blue). (F) Zoomed in image of p21, 
pPPP1R1A and insulin showing an assortment of p21 positive and 
pPPP1R1A positive β-cells. Yellow arrows show pPPP1R1A positive, p21 
negative cells, white arrows show p21 positive, pPPP1R1A negative cells 
and orange arrows show double p21 and pPPP1R1A positive cells. Data 




6.3.1.4 Cell cycle analysis in cultured cells 
To investigate whether PPP1R1A plays a role in cell cycle progression, the 
1.1B4 Flp-In T-REx cells were used. Cell cycle stages (Figure 6-8) were 
analysed by flow cytometry to determine whether induced expression and / or 
phosphorylation of PPP1R1A affected the proportion of cells in each stage of 
the cell cycle.  
 
Figure 6-8 Schematic diagram of the cell cycle. 
During G1, cells grow and prepare for the S phase, where DNA replication 
takes place. Once the cell has passed through G1 and S phases, the cells 
enter G2 and prepare for mitosis. The mitotic (M) phase is then entered, 
where it is further divided into Prophase, Metaphase, Anaphase and 
Telophase, where two daughter cells are formed. In order to exit mitosis, 
Rb must be dephosphorylated by PP1. After mitosis, cells can enter G0, 




Phosphorylation of PPP1R1A was induced in 1.1B4 Flp-In T-REx cells by 
addition of 10 µM forskolin after induction of PPP1R1A via tetracycline-
supplementation of the culture media. Initially, two time points were examined; 2 
and 24 hours after addition of forskolin. 2 hours was chosen since at this time it 
has been validated that PPP1R1A is phosphorylated following forskolin 
exposure (Figure 4-32), 24 hours was chosen since this is the approximate 
doubling time of the 1.1B4 cells. Interestingly, there was a significant increase 
(p<0.0001) in the percentage of apoptotic cells in the population when ‘tet-on’ 
WT cells were treated with forskolin for 24 hours (30.99%), compared to ‘tet-on’ 
WT with no forskolin treatment (3.43%) (Figure 6-9 and Figure 6-10). The ‘tet-
on’ T35A cells, had no alterations in the apoptotic population of cells (5.94%) 
when treated with forskolin for 24 hours, as compared to no forskolin treatment 
(p=0.9589). This increase in the percentage of apoptotic ‘tet-on’ WT cells which 
had been treated with forskolin for 24 hours was accompanied by a significant 
reduction in the proportion of cells in G0/G1 phase compared to T35A PPP1R1A 
or EV cells in G0/G1 phase treated with tetracycline and forskolin for 24 hours 
(p<0.0001). These effects were only observed in the ‘tet-on’ WT cells, whereas 
in the absence of tetracycline, the proportion of cells was similar across all 
stages of the cell cycle, irrespective of their transfection state. Importantly, the 
effects on cell cycle were not due solely to incubation with tetracycline and/or 
forskolin, as ‘tet-on’ EV and T35A cells which had also been exposed to 
forskolin for 24 hours showed no change in cell cycle progression compared to 
unstimulated cells (Figure 6-9 and Figure 6-10). These data show that 
sustained phosphorylation of PPP1R1A has an adverse effect on cell viability 






Figure 6-9 Phosphorylation, but not absolute expression of PPP1R1A induces 
apoptosis in cells 
1.1B4 Flp-In T-REx cells were seeded into 6-well plates and cultured in the 
absence (- tetracycline) or presence of 1000 ng/ml tetracycline (+ 
tetracycline) for 24 hours. Cells were also exposed to 10 µM forskolin for 
either 0, 2 or 24 hours.  
Cells were collected, and the percentage of cells in each stage of the cell 
cycle were analysed by flow cytometry. 25,000 events were analysed per 
sample. M6 represents fragmented DNA (apoptotic cells). 






Figure 6-10 Phosphorylation, but not absolute expression of PPP1R1A reduces 
cell viability 
Values from Figure 6-9 are plotted separately to highlight that the increase 
in apoptotic ‘tet-on’ WT cells which have been exposed to forskolin for 24 
hours, has resulted in a decrease in the percentage of cells in the G0/G1 
phases of the cell cycle. Results are presented as mean ± SEM. **** 
P<0.0001; determined by 2-way ANOVA with tukey follow up. 
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To examine whether WT PPP1R1A remained phosphorylated for the full 24 
hours, and to confirm that T35A PPP1R1A was not phosphorylated during 
forskolin treatment, Western blotting was performed. This revealed that 
phosphorylation of WT PPP1R1A was sustained for 24 hours, although the 
maximal response was achieved within 2 hours (Figure 6-11). Furthermore, 




Figure 6-11 PPP1R1A phosphorylation is sustained over 24 hours 
1.1B4 Flp-In T-REx cells were seeded into 6-well plates and cultured in 
1000 ng/ml tetracycline supplemented media for 24 hours. Cells were also 
exposed to 10 µM forskolin for either 0, 2, 6, 10 or 24 hours.  
Protein was extracted, and analysed by Western blotting. The membrane 
was probed for total PPP1R1A, phosphorylated PPP1R1A and GAPDH 




Due to these findings, it was then questioned at what time point PPP1R1A 
phosphorylation has an adverse effect on cell viability. ‘Tet-on’ WT and T35A 
cells were treated with forskolin for 0, 2, 6, 10 or 24 hours, and cell cycle stages 
were analysed by flow cytometry and ICC by co-staining for total- or 
phosphoThr35 PPP1R1A in parallel with Ki67. By flow cytometry, an increase in 
the percentage of apoptotic WT cells was observed after 6 hours of incubation 
with forskolin. This increased further at 10 and 24 hours of incubation (Figure 
6-12). There also appeared to be an increase in the proportion of ‘tet-on’ WT 
cells with increasing durations of forskolin treatment in G2/M phases and a 
significant reduction of cells in G0/G1 phases. There was no change in the 





Figure 6-12 6 hours of sustained PPP1R1A phosphorylation induces cell death 
1.1B4 Flp-In T-REx cells were seeded into 6-well plates and cultured in 
1000 ng/ml tetracycline supplemented media for 24 hours. Cells were also 
exposed to 10 µM forskolin for either 0, 2, 6, 10 or 24 hours.  
Cells were collected, and the percentage of cells in each stage of the cell 
cycle were analysed by flow cytometry. 25,000 events were analysed per 
sample. 




These results were reflected in ICC, where from 2 hours incubation with 
forskolin, the ‘tet-on’ WT cells appeared stressed, evidenced by some cells 
displaying signs of chromosomal bridges (Figure 6-13). These structures were 
not visible in EV or T35A cells. PPP1R1A expression did not correlate with the 
expression of Ki67. Furthermore, Ki67 positive EV cells did not express 
PPP1R1A. After 24 hours incubation in forskolin (10 µM) containing media, EV 
and T35A cells did not have any change in morphology, either in non-mitotic or 
mitotic cells (Figure 6-13). The WT cells exposed to forskolin for 24 hours 
however, had elongated and fragmented DAPI staining, which was reflected in 
the Ki67 staining (Figure 6-13). These morphological changes in Ki67 
localisation suggest that chromosomal bridges may have formed (Pampalona et 
al., 2016). 
Phosphorylated PPP1R1A was observed in the whole population of WT cells 
after 2 hours incubation with forskolin, confirming that PPP1R1A is 
phosphorylated by forskolin after 2 hours incubation (Figure 6-14). 
Phosphorylated PPP1R1A was also observed in EV and T35A cells, however, it 
was only ever observed in the same cells as those that were Ki67 positive 
(Figure 6-14). Additionally, not all Ki67 cells were phospho PPP1R1A positive, 
but all phospho PPP1R1A cells were Ki67 positive in the EV and T35A cell 
populations, regardless of incubation with tetracycline and / or forskolin (Figure 
6-14). These results mirror the staining pattern in the EndoC-βH1 cells, where 
all phospho PPP1R1A positive cells were also Ki67 positive, however not all 





Figure 6-13 Forskolin exposure in ‘tet-on’ WT Flp-In T-REx cells results in 
incomplete mitosis – distribution of total PPP1T1A 
EV, WT or T35A Flp-In T-REx cells were cultured in media supplemented 
with 1000 ng/ml tetracycline for 24 hours. Cells were also exposed to 10 
µM forskolin for 0, 2 or 24 hours before being fixed on coverslips. They 
were then stained for Ki67 (anti-Ki67; green) and PPP1R1A (anti-
PPP1R1A; red). Nuclei were labelled with DAPI (dark blue).  (B) shows EV 
(+ tet, + forskolin for 24 hours) mitotic (Ki67 positive) cells (white arrows), 
(C) shows mitotic WT (+ tet, + forskolin for 24 hours) cells with 




Figure 6-14 Forskolin exposure in ‘tet-on’ WT Flp-In T-REx cells results in 
incomplete mitosis – distribution of pPPP1R1A 
EV, WT or T35A Flp-In T-REx cells were cultured in media supplemented 
with 1000 ng/ml tetracycline for 24 hours. Cells were also exposed to 10 
µM forskolin for 0, 2 or 24 hours before being fixed on coverslips. They 
were then stained for Ki67 (anti-Ki67; green) and phospho PPP1R1A (anti-
pPPP1R1A; red). Nuclei were labelled with DAPI (dark blue).  (B) shows 
EV (+ tet, + forskolin for 24 hours) mitotic (Ki67 positive) cells (white 
arrows), (C) shows mitotic WT (+ tet, + forskolin for 24 hours) cells (white 





6.3.1.5 PPP1R1A and cell viability 
To understand whether it is the sustained phosphorylation of PPP1R1A which is 
detrimental to cell viability, forskolin was added to the culture media of 1.1B4 
Flp-In T-REx cells for an initial period of 2 hours, the media was then refreshed 
to remove the forskolin from half of the cells, while the other half were cultured 
in forskolin-containing media. Cell cycle analysis was carried out 24 hours after 
the initial addition of forskolin. Transient phosphorylation of PPP1R1A (by 
addition of forskolin to WT cells for 2 hours, before refreshing the media) had no 
detrimental effect on cell cycle progression (Figure 6-15), whereas 24 hours 
incubation with forskolin caused a strong effect, and a big increase in the 
proportion of apoptotic cells. None of the treatment conditions had any effect on 
the EV or T35A cells (Figure 6-15). These data suggest that sustained 
phosphorylation of PPP1R1A (caused by a long-term increase in intracellular 
cAMP) is detrimental to cell viability. Whereas a long-term increase in 






Figure 6-15 Cells can be rescued from cells death after transient 
phosphorylation of PPP1R1A 
1.1B4 Flp-In T-REx cells were seeded into 6-well plates and cultured in the 
absence (- tetracycline) or presence of 1000 ng/ml tetracycline (+ 
tetracycline) for 24 hours. To investigate whether transient phosphorylation 
of PPP1R1A was sufficient to result in mitotic arrest, cells were exposed 
to 10 µM forskolin for 2 hours, then media was replenished with fresh 
media (+ or – tetracycline) (forskolin exposure for 2 hours) or media was 
not refreshed, and cells remained exposed to forskolin (+ or – tetracycline) 
(forskolin exposure for 24 hours).  
Cells were collected, and the percentage of cells in each stage of the cell 






6.3.2 PPP1R1A and hormone secretion 
Previous studies have reported that knockdown of PPP1R1A in INS-1 832/13 
cells reduced insulin secretion in response to 16.7 mM glucose (Taneera et al., 
2015), this implies that PPP1R1A expression is necessary for efficient insulin 
secretion from these cells.  
6.3.2.1 PPP1R1A and hormone secretion from the Flp-In T-REx cells 
Initially, the 1.1B4 EV, WT and T35A Flp-In T-REx cells were used to 
investigate the relationship between changes in expression of PPP1R1A and 
hormone secretion. 1.1B4 cells are reported to secrete insulin in response to 
glucose and agents which elevate cAMP (Green et al., 2015, McCluskey et al., 
2011), however, since the Flp-In T-REx cells do not express insulin as 
discussed previously (Chapter 4), hGH was used as a surrogate. Secreted 
human Growth hormone was measured (using the sandwich ELISA method 
(section 2.9)) after cells were incubated with 0 mM glucose, 20 mM glucose, 
200 µm IBMX + 10 µM forskolin, 200 µm IBMX + 10 µM forskolin + 20 mM 
glucose or 25 mM KCl. In each case, WT cells had the smallest fold change in 
hGH secretion, across all conditions, compared to 0 mM glucose (Figure 6-16). 
EV, WT and T35A cells had similar secretion patterns to one-another, with no 
significant differences observed between the cell lines, however, there was a 
tendency for the EV cells to have the highest fold change in secretion. These 
results were unexpected, as they were conflicting with the report from Taneera 
et al. (2015) where knockdown of PPP1R1A in INS-1 832/13 cells reduced 
insulin secretion in response to glucose, suggesting that overexpression of 
PPP1R1A should augment insulin secretion. Due to the conflicting results, the 
h1.1B4 cells were used to investigate effects of PPP1R1A on secretion of hGH. 
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Human 1.1B4 cells were used since these are human cells and increase 
secreted hGH in response to elevated glucose.  
 
Figure 6-16 Effect of PPP1R1A expression on hGH secretion from 1.1B4 Flp-In 
T-REx cells 
1.1B4 Flp-In T-REx cells were cultured in tetracycline containing medium 
(1000 ng/ml) for 24 hours before being transfected with hGH (1 μg DNA / 
well in a 24 well plate). 24 hours post transfection, media was refreshed (+ 
tetracycline), and cells were cultured for a further 24 hours. A secretion 
assay was then carried out, using the following secretagogues; 0 mM 
glucose, 20 mM glucose, 200 μM IBMX and 10 μM forskolin or 20 mM 
glucose and 200 μM IBMX and 10 μM forskolin or 25 mM KCl. The 
concentration of hGH in the supernatant was determined by sandwich 
ELISA. There was no statistical significance between the cell types. 




6.3.2.2 PPP1R1A and hormone secretion from the h1.1B4 cells 
PPP1R1A and hGH were co-transfected into h1.1B4 cells for 24 hours, then 
media was refreshed for a further 24 hours before secretion experiments were 
carried out. The results from these experiments revealed that PPP1R1A had no 
effect on secretion when stimulated with 20 mM glucose, 200 µM IBMX + 10 µM 
forskolin or 25 mM KCl independently (Figure 6-17). However, when the 
stimulant was 20 mM glucose combined with 200 µM IBMX + 10 µM forskolin, 
there was a profound reduction in the amount of hGH secreted (p=0.0036) 
(Figure 6-17) compared to when 20 mM glucose alone as a stimulant. These 
data are interesting, as hGH secretion was not decreased in response to the 
same stimulus when T35A PPP1R1A was transfected into the cells (p=0.6545). 
Thus suggesting that phosphorylation of PPP1R1A (induced by an increase in 
intracellular cAMP, driven by forskolin and IBMX) inhibits secretion from these 
cells. These data may imply that phosphorylation of PPP1R1A inhibits PP1 from 
dephosphorylating a target protein, critical to secretory pathways. It does 
however need to be remembered that these cells are not electrically active, and 
do not secrete via the canonical insulin secretion pathway, as discussed in 
Chapter 5. Due to the limitations of the h1.1B4 cells, the experiment was 




Figure 6-17 Effect of PPP1R1A expression on hGH secretion from h1.1B4 cells 
H1.1B4 cells were cultured for 24 hours before being transfected with hGH 
(0.5 μg DNA / well in a 24 well plate) +/- EV, WT PPP1R1A or T35A 
PPP1R1A. 24 hours post transfection, media was refreshed, and cells 
were cultured for a further 24 hours. A secretion assay was then carried 
out, using the following secretagogues; 0 mM glucose, 20 mM glucose, 
200 μM IBMX and 10 μM forskolin or 20 mM glucose and 200 μM IBMX 
and 10 μM forskolin or 25 mM KCl. The concentration of hGH in the 
supernatant was determined by sandwich ELISA.  






6.3.2.3 PPP1R1A and hormone secretion from the 1.2B4 cells 
PPP1R1A and hGH were co-transfected into 1.2B4 cells for 24 hours, then 
media was refreshed for a further 24 hours before secretion experiments were 
carried out. The concentration of secreted hGH from the 1.2B4 cells was a lot 
lower than in the other cell lines utilised, particularly compared to the h1.1B4 
cells (Figure 6-18). The 1.2B4 cells had augmented secretion in response to 
each stimuli, however was maximal with 20 mM glucose or with 200 µM IBMX, 
10 µM forskolin and 20 mM glucose. PPP1R1A did not significantly alter the 
secretion patterns observed in the 1.2B4 cells (Figure 6-18), however cells 
transfected with WT PPP1R1A had marginally lower secretion, compared to EV 





Figure 6-18 Effect of PPP1R1A expression on hGH secretion from 1.2B4 cells 
1.2B4 cells were cultured for 24 hours before being transfected with hGH 
(0.5 μg DNA / well in a 24 well plate) +/- 0.5 μg EV, WT PPP1R1A or T35A 
PPP1R1A DNA. 24 hours post transfection, media was refreshed, and 
cells were cultured for a further 24 hours. A secretion assay was then 
carried out, using the following secretagogues; 0 mM glucose, 20 mM 
glucose, 200 μM IBMX and 10 μM forskolin or 20 mM glucose and 200 μM 
IBMX and 10 μM forskolin. The concentration of hGH in the supernatant 
was determined by sandwich ELISA. No significant differences in hGH 
secretion were identified between cell lines.  





This chapter describes investigations into the role(s) of PPP1R1A in β-cells, 
using the models developed and described in Chapters 4 and 5, with validation 
of the findings in human pancreas tissue.  
6.4.1 PPP1R1A and cell cycle 
Mature pancreatic β-cells are considered to be terminally differentiated and 
irreversibly arrested, such that they do not proliferate at a very high rate, with 
only 1.1±0.3% islets having Ki67 positive cells in non-diabetic controls (Willcox 
et al., 2010). In recent onset Type 1 diabetes, however, there is an increase in 
islets with Ki67 positive staining (10.88±2.5%) (Willcox et al., 2010). The rate of 
β-cell proliferation is highest in the first 2 years of life, but remains low beyond 
this age, as optimum β-cell mass is reached and retained (Bonner-Weir et al., 
2016, Basile et al., 2019). Since Type 1 diabetes arises from the autoimmune 
destruction of pancreatic β-cells, β-cell proliferation after the destructive phase 
would be desirable in order to increase β-cell mass. There is a focus on efforts 
to identify agents or methods which promote β-cell proliferation (Ackeifi et al., 
2018, Karakose et al., 2018, Shaklai et al., 2018). In Type 1 diabetes, β-cell 
expression of PPP1R1A is depleted. Findings described in this chapter suggest 
that PPP1R1A has a role to play in regulating cell cycle progression. Given the 
decrease in PPP1R1A expression and increase in cell proliferation in T1D, it is 
plausible that these two events may be synchronous, and the depletion of 
PPP1R1A may affect the progression of cell cycle in pancreatic β-cells in Type 
1 diabetes.  
The data collected from in vitro cell studies presented in this chapter, suggest 
that PPP1R1A plays a role in cell cycle progression in the pancreatic β-cell. 
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PPP1R1A becomes phosphorylated transiently during the mitotic phase of the 
cell cycle, this was observed in all cell lines studied, which included the human 
cell lines EndoC-βH1, h1.1B4 and the rodent Flp-In T-REx EV, WT and T35A 
cell lines (Figure 6-3 and Figure 6-14). This phenomenon was also observed in 
human exocrine pancreas (Figure 6-6). In in vitro cell studies, where untreated 
cells were stained, phosphorylated PPP1R1A was only observed in Ki67 
positive cells, however not all Ki67 positive cells were phospho PPP1R1A 
positive. Indicating that PPP1R1A phosphorylation (and expression) is transient, 
however these data also imply that this event may be critical for cells to undergo 
mitosis. It is also interesting to note that total PPP1R1A bore no correlation with 
Ki67 expression in cultured cells. This is likely due to the epitope that the total 
PPP1R1A antibody recognises. The total PPP1R1A antibody recognises the 
first 100 amino acids of the protein sequence, meaning that the Thr35 
phosphorylation site and PP1 binding site (aa 8-12) will be within the recognised 
sequence. Since PPP1R1A phosphorylation dramatically increases its binding 
efficiency to PP1, it can be assumed that phosphorylated PPP1R1A is bound to 
PP1. Under these circumstances, the epitope which the total PPP1R1A 
antibody recognises may be masked by phosphorylation and / or PP1 binding. 
This is also the likely reason for the discordance between total and pPPP1R1A 
staining in human pancreas tissue.   
The observations between Ki67 and phosphorylated PPP1R1A in vitro were not 
mirrored in the islets in cadaver pancreas sections. Despite observing a number 
of Ki67 positive β-cells, these cells were not also positive for phosphorylated 
PPP1R1A, whereas most Ki67 negative β-cells were positive for 
phosphorylated PPP1R1A. The correlation between total PPP1R1A and Ki67 
expression was not established in human pancreas tissue sections. There was 
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no parallel between total PPP1R1A and Ki67 expression in EndoC-βH1 cells, a 
commonly used model of pancreatic β-cells, therefore it can be postulated that 
there is no detectable correlation between Ki67 and total PPP1R1A in pancreas 
sections. Furthermore, the total PPP1R1A antibody did not detect PPP1R1A in 
mitotic cells, suggesting that the antibody is unable to recognise the epitope, 
due to reasons described previously. The absence of phosphorylated PPP1R1A 
and Ki67 co-expression in the β-cells of human pancreas sections could be due 
to the very transient co-expression, where the phenomenon was not observed 
in the small number of proliferating cells, as β-cell proliferation is infrequent in 
vivo. This is unlikely to be the situation in clonal β-cells which replicate 
efficiently. The co-expression of phosphorylated PPP1R1A and Ki67 was 
seldom observed in the exocrine pancreas (Figure 6-5 and Figure 6-6), where 
Ki67 staining and proliferation is a more frequent occurrence. The timing for 
phosphorylation of PPP1R1A is thus transient during cell cycle progression.  
Progression through the cell cycle is tightly regulated, with a number a check 
points. The expression level of cyclins, activates or deactivates cyclin 
dependent kinases (Cdks) (Table 6-2). Kinases (in particular, Wee1) and 
phosphatases (in particular, Cdc25) further regulate the activity of cyclin-Cdk 
complexes. Many other proteins are involved in cell cycle regulation, and much 
of the protein activity is regulated by phosphorylation and dephosphorylation. 
There are three checkpoints during mitosis; G1/S checkpoint, G2/M, and 
Metaphase-to-anaphase checkpoint. The purpose of the G1/S checkpoint is to 
determine whether the environment is favourable, as this is the point where the 
cell will commit to cell cycle progression, by entering the S phase, where new 
DNA is synthesised for the daughter cell. The G2/M checkpoint is necessary to 
ensure that DNA is replicated, and again checking that the environment is 
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favourable. At this point the cell will enter mitosis. The metaphase-to-anaphase 
checkpoint ensures that all the chromosomes are attached to the spindle 
appropriately, for anaphase to be triggered, and cytokinesis to be successful. 
These checkpoints are in place to ensure mitosis is carried out successfully, if 
the conditions are not favourable at any of the checkpoints the cell will not 
progress through the cell cycle (Alberts B, 2008). 
Cell cycle phase Cyclin Cdk partner 
G1 Cyclin D Cdk4, Cdk6 
G1/S Cyclin E Cdk2 
S Cyclin A Cdk2, Cdk1 
M Cyclin B Cdk1 
Table 6-2 Elevated cyclins and Cdks in different stages of the cell cycle 
Table was adapted from page 1063 Alberts B (2008) 
 
During early mitosis, PP1 is supressed by binding to PPP1R1A (Wu et al., 
2009). PP1 has a much stronger binding affinity for PPP1R1A when PPP1R1A 
is phosphorylated at Thr35, which is achieved via PKA. Although there have 
been no direct studies, this suggests that PPP1R1A is phosphorylated during 
early mitosis. PP1 is thought to be supressed during early mitosis in order to 
prevent the dephosphorylation of phosphoproteins (such as Rb) being 
premature, thus exiting mitosis too early. Wu et al. (2009) suggest that after 
cyclin B degradation, Cdk1 levels drop. This drop in Cdk1 leads to the auto-
dephosphorylation of PP1 at its Cdc2 phosphorylation site (Thr320), allowing 
partial PP1 activation. Depending on the cell type, dephosphorylation of 
PPP1R1A at Thr35 is mediated by either PP1 (after partial activation of PP1 by 
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reduced Cdk1 expression) in embryonic mitotic cells, or by PP2A and / or 
calcineurin in cardiac myocytes or renal medulla (El-Armouche et al., 2006, 
Higuchi et al., 2000). The phosphatase responsible for the dephosphorylation of 
PPP1R1A in β-cells is yet to be elucidated, however it is clear that the timing of 
PPP1R1A phosphorylation is crucial for the successful completion of mitosis, 
and that sustained phosphorylation of PPP1R1A leads to apoptosis, based on 
the findings presented in this chapter. This apoptosis could be due to the 
inability of cells to exit mitosis, and reach the necessary cell cycle checkpoint. 
The coverslip staining described in this chapter of Ki67 with phopsho Thr35 
PPP1R1A suggests that when phosphorylation of PPP1R1A is sustained, the 
cells are unable to successfully complete anaphase (Figure 6-13 and Figure 
6-14), and two daughter cells are unable to be formed. This hypothesis could be 
tested by introducing a phosphomimetic change (T35D) which would act as 
constitutively phosphorylated. If cells expressing this PPP1R1A mutant were 
unable to divide, this would confirm the findings. This conclusion was drawn 
since the appearance of chromosome bridges were observed in WT cells which 
had been exposed to forskolin, and chromosome bridges result after 
unsuccessful completion of cytokinesis.  
The phosphorylation status of Rb is also crucial to progression through the cell 
cycle. When Rb is either not phosphorylated, or is hypophosphorylated, it can 
bind E2F transcription factors, which block the transcription of genes required 
for mitosis, Rb is maintained in this hypophosphorylated state in G0 and early 
G1 phase (Hirschi et al., 2010), thus keeping cells from entering mitosis. Cyclin 
dependent kinases keep Rb hyperphosphorylated, all through late G1 to M 
phases, meaning Rb is inactive, and unable to bind E2F transcription factors, 
allowing for the transcription of genes required for cell cycle progression and 
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DNA synthesis (Hirschi et al., 2010). PP1 is key to the dephosphorylation of Rb, 
and dephosphorylates Rb in anaphase (Ludlow et al., 1993). This occurs late in 
mitosis and allows cells to exit mitosis by restricting E2F transcription factors. 
The activity of PP1 is controlled by many regulatory proteins, and it is unclear 
whether PPP1R1A is critical in regulating cell cycle progression in β-cells.  
The results obtained from the cell cycle analysis by flow cytometry and ICC 
mirror the observation that cells are suspended in mitosis (by an increase in 
Ki67 staining and cells within the G2/M phase %), and then ultimately die (an 
increase in apoptotic cell % and amorphous Ki67 and Thr35 PPP1R1A 
staining). The amorphous structures observed in cells which had induced 
sustained phosphorylation of PPP1R1A could be chromosomal bridges. During 
the S phase of the cell cycle, DNA is replicated (Pampalona et al., 2016). Sister 
chromatids then bind via kinetochores to the mitotic spindle and line up along 
the metaphase plate (equator of the cell), before they are pulled apart in 
anaphase (Pampalona et al., 2016). Before the sister chromatids can be pulled 
apart and anaphase can commence, the chromosomes must undergo several 
changes. The newly synthesised chromosomes from S phase must condense, 
and decatenate (untangle), aided by the enzyme, topoisomerase II. Sister 
chromatids are held together by cohesion complexes, and to allow for 
separation of the two sister chromatids, the cohesion complexes must be 
removed. Defects in any of these three processes (condensation, decatenation 
or removal of cohesion complexes) result in sister chromosomes that cannot 
separate, and the formation of chromosome bridges. Chromosome bridges 
occur during anaphase and telophase, and result in uneven distribution of 
chromosomes between two daughter cells (aneuploidy, or polyploidy) 
(Pampalona et al., 2016). 
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The unsuccessful completion of mitosis under conditions of induced sustained 
PPP1R1A phosphorylation, and the production of chromosome bridges may be 
caused by the inability of PP1 to dephosphorylate Rb (resulting in cells unable 
to restrict E2F transcription factors) or an alternative target mitotic protein of 
PP1 (Figure 6-19), since phosphorylation of PPP1R1A inhibits PP1. The net 
outcome of sustained PPP1R1A phosphorylation would be increased overall 
intracellular phosphorylation of PP1 substrates. Although the target of PP1 
dephosphorylation has not been identified in the studies described in this 
chapter, the phosphorylation status of PPP1R1A has been shown to be of 
paramount importance. There are data to suggest that PP1 is also necessary 
for the entry of cells into mitosis (Margolis et al., 2006), therefore the high 
expression of PPP1R1A in β-cells could restrict cell cycle entry, by restricting 
PP1 activity. PP1 induces cell cycle entry by dephosphorylating Cdc25 at 
Ser287 in Xenopus Oocytes (Margolis et al., 2006), although it is unclear if this 
is also true in human cells. The high expression level of PPP1R1A in β-cells 
could be achieved to inhibit PP1 from aiding entry into mitosis. This does not 
seem to be the case in the Flp-In T-REx cells however, where only the mitotic 
exit was affected by phosphorylated PPP1R1A. It does have to be taken into 
account though, that the Flp-In T-REx cells are immortalized, and may have a 
different regulatory mechanism for cell cycle progression than human 
pancreatic β-cells in vivo. An alternative possible explanation as to why cells 
can enter mitosis, but cannot exit, could be that the role PP1 plays in regulating 
the early progression into cell cycle may not be regulated by PPP1R1A, but 




Figure 6-19 Schematic diagram of the cell cycle, and what might happen if 
sustained phosphorylation of PPP1R1A was induced 
During G1, cells grow and prepare for the S phase, where DNA replication 
takes place. Once the cell has passed through G1 and S phases, the cells 
enter G2 and prepare for mitosis. The mitotic (M) phase is then entered, 
where it is further divided into Prophase, Metaphase, Anaphase and 
Telophase, where two daughter cells are formed. In order to exit mitosis, 
Rb must be dephosphorylated by PP1. If the phosphorylation of PPP1R1A 
is induced, this inhibits PP1 from dephosphorylating Rb, thus cells are 
‘stuck’ in mitosis. After mitosis, cells can enter G0, where they are 





6.4.1.1 PPP1R1A and P21 
Cellular senescence is defined as a state of irreversible growth arrest, and lack 
of proliferative potential (Kuilman et al., 2010). P21 is an inhibitor of the cell 
cycle at the G1/S phase, thus cells expressing p21 are arrested in cell cycle at 
G1/G0 (Vasavada et al., 2007). p21 expression prevents the phosphorylation of 
Rb by binding to cyclin A/CDK2, cyclin E/CDK2 and cyclin D1 or D2/CDK4 
(Karimian et al., 2016), which is necessary for cell cycle progression. P21 
transcription is regulated by p53. P53 can be activated by various cellular 
stresses, including DNA damage and oxidative stress (Karimian et al., 2016). 
There are various studies which have identified a role for cellular senescence in 
the pathogenesis of both Type 1 and Type 2 diabetes (Thompson et al., 2019, 
Aguayo-Mazzucato et al., 2019, Tian et al., 2019), despite the two forms of 
diabetes displaying distinct pathophysiological differences. In mouse models 
and human islets from both classifications of diabetes, senescent β-cells were 
identified in a larger proportion compared to controls for each study (Tian et al., 
2019).  
Since p21 can restrict the phosphorylation of Rb, and PP1 dephosphorylates Rb 
in healthy cell cycle progression, it was investigated whether phosphorylation of 
PPP1R1A is associated with p21 expression in human pancreas samples from 
donors >68 years old. It was found that the expression of p21 and 
phosphorylated PPP1R1A were both more highly expressed in pancreatic islets, 
however there was no commonality between p21 and phosphorylated 
PPP1R1A (Figure 6-7). This suggests that PPP1R1A expression does not 
influence p21 induced cellular senescence in pancreatic β-cells.  
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6.4.2 PPP1R1A and hormone secretion 
The primary function of pancreatic β-cells is to secrete insulin in a regulated 
manner, in response to elevated blood glucose levels. Pancreatic β-cells have 
multiple secretion pathways, the regulated secretion pathway and the 
constitutive secretion pathway, which are outlined in the introduction, Figure 1-2 
and Figure 1-3. Insulin is routed through the regulated secretory pathway 
(Guest, 2019), where the protein is packaged and the mature secretory 
granules are docked behind a mesh of F-actin, before the final stimuli of 
elevated glucose triggers fusion of the granule with the cell membrane resulting 
in insulin release from the cell. Other secreted proteins from pancreatic β-cells 
are routed through the constitutive secretory pathway. The constitutive 
secretory pathway is present in most cell types, and the rate limiting step in 
secreted protein via this pathway is the rate of transcription (Revelo et al., 
2019). The three cell lines utilised in the present study (Flp-In T-REx, h1.1B4 
and 1.2B4) do not have endogenous insulin expression. For this reason, hGH 
was transfected into the cells, and secreted hGH was measured. In cells which 
have a regulated secretory pathway, hGH is routed in this pathway, however, if 
there is no such pathway in the cells, it is secreted via the constitutive secretion 
pathway (Fisher and Burgoyne, 1999, da Silva Xavier et al., 2003).   
Taneera et al. (2015) found that silencing the expression of PPP1R1A in INS-1 
832/13 cells resulted in a significant reduction in insulin secretion in response to 
16.7 mM glucose, compared to cells which did not have PPP1R1A expression 
silenced, suggesting that PPP1R1A is necessary for optimal insulin secretion 
from pancreatic β-cells. In an attempt to build on these results, the expression 
of PPP1R1A was manipulated in three different cell lines (Chapter 4) to help 
understand the role PPP1R1A may play in secretory pathways of pancreatic β-
400 
 
cells. In all three cell lines utilised, PPP1R1A was not expressed endogenously, 
therefore no accountability had to be considered for basal PPP1R1A 
expression, and any affect observed was from exogenous, transfected 
PPP1R1A.  
The effect PPP1R1A exerted on secretory capabilities was cell line-dependant. 
In the 1.1B4 Flp-In T-REx cells and the 1.2B4 cells there was no significant 
change in hormone secretion between cells overexpressing WT or T35A 
PPP1R1A compared to those not expressing PPP1R1A under any stimulatory 
conditions (Figure 6-16 and Figure 6-18). The 1.1B4 Flp-In T-REx cells had a 
marginal increase in hGH secretion in response to 20 mM glucose, however 
they also displayed increased overall secretion when stimulated with an 
intracellular increase in cAMP, which was chemically induced by incubation with 
IBMX and forskolin. Secretion was significantly potentiated by co-stimulation 
with 20 mM glucose, IBMX and forskolin. KCl also exerted an increase in 
secretion in the 1.1B4 Flp-In T-REx cells, which was comparable to secretion 
induced by 20 mM glucose. The net effect of WT PPP1R1A on hGH secretion 
from the 1.1B4 Flp-In T-REx cells was that overexpression of PPP1R1A had no 
influence on insulin secretion (Figure 6-16). Secretion from the 1.2B4 cells was 
also similar between groups, with secretion augmented by stimulation with 20 
mM glucose by 2 – 3 fold compared to 0 mM glucose. Artificially increasing 
intracellular cAMP levels with IBMX and forskolin also stimulated secretion, 
however this was further increased when cells were stimulated with IBMX, 
forskolin and 20 mM glucose (Figure 6-18). These findings that PPP1R1A 
overexpression has no influence on hormone secretion are contradictory to 
results from other groups where PPP1R1A has been shown to be necessary for 
insulin secretion (Taneera et al., 2015, Solimena et al., 2018). In both of these 
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previously published reports, PPP1R1A was knocked down in INS-1 832/13 
cells, whereas in the findings described presently, PPP1R1A was 
overexpressed, which could explain the difference in results.  
The most unexpected result however, was when PPP1R1A was overexpressed 
in the h1.1B4 cells, and secretion was studied. It must be noted that the h1.1B4 
cells do not have a glucokinase regulated metabolism of glucose (Figure 5-16), 
nor do they rely on calcium channels for glucose stimulated insulin secretion 
(Figure 5-17 and Figure 5-18). Furthermore, they have no detectable electrical 
activity (Figure 5-21 and Figure 5-22). These findings implicate that the h1.1B4 
cells do not have a canonical regulated hormone secretion pathway. This 
hypothesis is further confirmed in that they do not secrete hormone in response 
to elevated intracellular cAMP levels (200 µM IBMX and 10 µM forskolin), or to 
25 mM KCl, which, as observed in the 1.2B4 and 1.1B4 Flp-In T-REx cells, is 
expected to result in secretion from pancreatic β-cells. Due to these findings, it 
can be argued that the h1.1B4 cells do not have a regulated secretion pathway 
and only have a constitutive secretion pathway (this is described in more detail 
in Chapter 5). The h1.1B4 cells displayed minimal secretion when exposed to 0 
mM glucose, however when exposed to glucose, whether that be 0.5 mM or 20 
mM glucose, the cells secreted hormone to a similar level. This is probably not 
a glucose-stimulated response per se, but rather likely just a result of increased 
energy availability to the cells. WT or T35A PPP1R1A had no effect on hormone 
secretion when cells were exposed to 20 mM glucose alone. In response to 
elevated intracellular cAMP in the absence of glucose, the cells do not secrete 
hormone above the levels of 0 mM glucose, speculatively due to the lack of 
energy available to the cells, however, if h1.1B4 cells are incubated with 20 mM 
glucose under conditions of elevated intracellular cAMP (by co-incubating with 
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200 µM IBMX and 10 µM forskolin), the cells secreted hGH to similar levels as 
with 20 mM glucose alone (Figure 6-17). That is only true however, when the 
h1.1B4 cells were co-transfected with growth hormone alone, growth hormone 
and empty vector, or growth hormone and the phosphorylation null PPP1R1A 
mutant. The h1.1B4 cells co-transfected with growth hormone and WT 
PPP1R1A, showed ~50% reduction in secretion of hGH (Figure 6-17), 
compared to when they were exposed to elevated glucose in the absence of 
cAMP elevators. As discussed and demonstrated in other sections of this 
thesis, elevated cAMP levels result in PKA-mediated phosphorylation of 
PPP1R1A at position Thr35. Secretion of hGH was dramatically reduced when 
WT PPP1R1A was transfected into h1.1B4 cells, and cells were incubated with 
cAMP activators and elevated glucose. However when T35A PPP1R1A was 
transfected into h1.1B4 cells, there was no reduction in secretion under the 
condition of elevated glucose and cAMP. These findings implicate that 
PPP1R1A can regulate constitutive secretion, more specifically, that 
phosphorylation of PPP1R1A dramatically reduces constitutive secretion. 
Pancreatic β-cells ordinarily have high levels of PPP1R1A, and additionally, 
within this chapter, the expression of phosphorylated PPP1R1A in human 
pancreas was characterised and discussed. Pancreatic β-cells have variable 
expression of phosphorylated PPP1R1A, ranging from low expression to very 
high expression, however it is predominantly nuclear. It could therefore be 
hypothesised that PPP1R1A is present in pancreatic β-cells in order to regulate 
secretion. In T1D, where PPP1R1A is downregulated (Chapter 3), it could be 
speculated that this results in an increase in molecules secreted via the 
constitutive secretion pathway. In Type 1 diabetes, where there is evidence of 
increased IFN signalling (discussed in Chapter 3), a reduction of PPP1R1A 
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expression would enhance the secretion of cytokines, such as IFNs routed 
through the constitutive pathway.  
Data published from other labs is contradictory to the data presented in this 
chapter. These discrepancies could be due to the difference in approach to 
manipulate PPP1R1A expression levels, as in the current study, PPP1R1A (WT 
or T35A) was overexpressed, whereas in other reports, PPP1R1A was knocked 
down. There are three known isoforms of PPP1R1A, the full length version, 
version 2 and version 4 (discussed in more detail in the Introduction, Chapter 
1). The form of PPP1R1A overexpressed in the studies described in this 
chapter was the full length isoform, or the phosphorylation null mutant of the full 
length isoform. Where PPP1R1A has been knocked down in other studies 
(Solimena et al., 2018, Taneera et al., 2015), the expression of different 
isoforms was not verified. Depending on the primer sets used for validation of 
PPP1R1A knockdown, the various isoforms may not have been detected. The 
role(s) of each of the different PPP1R1A isoforms has not been elucidated, 
however all contain the PP1 binding region, and phosphorylation site at 




6.4.3 Study limitations 
There are several limitations to the studies described in this chapter.  
Cell cycle regulation may be altered in immortalised cell lines to allow for infinite 
mitotic cycles, therefore findings should be taken cautiously and be further 
investigated in other models, such as primary human islets. 
It has not been possible to directly study the role PPP1R1A has on insulin 
secretion from pancreatic β-cells, as none of the cell lines used have 
endogenous insulin. To overcome this hurdle, human growth hormone was 
transfected into the cells, and secretion of this was measured. This is a 
commonly used surrogate method to secretion patterns in vitro. Although there 
are cell lines available which express endogenous insulin, such as the rodent 
cell line INS-1 832/13 or the human cell line EndoC-βH1, both of these also 
have endogenous PPP1R1A (Chapter 4). The INS-1 832/13 cells are a good 
model, however they are a rodent model of pancreatic β-cells, therefore the 
findings may not be translatable to human β-cell physiology. The EndoC-βH1 
cells are notoriously challenging in which to manipulate gene expression, 
therefore knocking down the expression of PPP1R1A in them may not be very 
efficient. Additionally, the expression of PPP1R1A is heterogeneous across the 
population of EndoC-βH1 cells (as described in Chapter 4), which makes 
studying the role of PPP1R1A in secretion challenging. Furthermore, as with the 
INS-1 832/13 cells, studying the role of phosphorylation of PPP1R1A on 
secretion would be challenging, due to endogenous PPP1R1A that may not be 
efficiently silenced, and may override the transfected T35A PPP1R1A, although 




Two potential roles of PPP1R1A have been discussed in this chapter; the 
regulation of cell cycle progression and the regulation of hormone secretion. It 
has been demonstrated that sustained phosphorylation of PPP1R1A results in 
mitotic catastrophe, which ultimately results in chromosomal bridge formation 
and apoptosis. Nonetheless, the phosphorylation of PPP1R1A is necessary for 
cells during mitosis, but the timing of the phosphorylation is critical to successful 
mitosis and cell survival. It remains unclear whether the restricted tissue 
distribution of PPP1R1A, and very high expression levels in pancreatic β-cells, 
could be a feature of their replicative quiescence. 
It has also been demonstrated in this chapter that PPP1R1A may play a role in 
regulating constitutive secretion. This chapter discussed the difference on effect 
of secretion PPP1R1A exerts on three different cell lines. In two cell lines with 
glucose regulated secretion (1.1B4 Flp-In T-REx and 1.2B4), PPP1R1A 
expression did not significantly affect the secretion of hormone from the cells. 
However, in a cell line which does not have a regulated secretion pathway 
(h1.1B4 cells), PPP1R1A dramatically reduced secretion, but only when the 
phosphorylation of PPP1R1A was induced.  
One further possible role of PPP1R1A is regulation of the cellular response to 
viral infection. It would be interesting to manipulate the expression (and 
phosphorylation) of PPP1R1A, to investigate whether loss of PPP1R1A results 
in a heightened IFN response, as discussed in Chapter 3. Hypothetically, 
reduced expression of PPP1R1A would result in increased activity of MDA5, 








7 Summary of findings 
The new findings reported in this thesis cover three topics: firstly; the role of a 
viral infection in triggering the development of T1D, secondly; islet expression of 
PPP1R1A and its role in β-cell function and, thirdly; the utility of 1.1B4 cells as a 
model for study of β-cell function. 
7.1 The role of a viral infection in triggering T1D development 
7.1.1 Interferon-stimulated genes are upregulated in pancreatic β-cells in Type 1 
diabetes 
Despite the large body of evidence implicating viral infections as a potential 
factor mediating the autoimmunity culminating in T1D (Gamble et al., 1969, 
Dunne et al., 2019), the argument that viral infection directly triggers T1D is 
challenging to make, since not everyone harbouring an enteroviral infection 
develops T1D. Nevertheless, it is clear that many more donors with T1D have 
detectable EV proteins in their pancreas than control subjects, suggesting that 
there is a link between viral infection and T1D. The studies described in Chapter 
3 revealed that the host response to viral infection is different in donors with 
T1D, compared to control donors without T1D. It was revealed that in T1D, the 
protein expression of ISGs (previously unstudied in the context of T1D) are 
elevated, and that this response is restricted only to those with clinical disease. 
Therefore it may not be the existence of a pancreatic viral infection that is of 
critical importance (since this can occur both in those with T1D and those 
without) but the way in which the host responds that is critical in contribution to 
T1D development. The development of T1D is likely to reflect a complex 
interplay between the establishment and persistence of an enteroviral infection, 
the way in which the host responds to this infection (probably influenced by 
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genetic predisposition), and the immune system (Figure 7-1). It is also likely that 
different factors influence islet autoantibody generation and the clinical 
progression to symptomatic T1D since the role of enteroviral infection appears 
to differ in these two states.  
 
Figure 7-1 Likely factors which culminate in T1D 
In order for Type 1 diabetes to develop, a complex interplay between three 
factors; enteroviral infection, host response to infection and generation of 





The islet cell expression of IRF1 was investigated for the first time in human 
islet studies in situ, in this study. Unexpectedly, this protein displayed a different 
pattern of staining when compared to other, more widely studied, ISGs (such as 
STAT1, MxA, HLA class I) which suggests that a different stimulus may be 
involved (Figure 7-2). IRF1 levels correlated much more closely with the 
presence of infiltrating CD45+ cells than was the case for other ISGs, 
suggesting that a product elaborated from immune cells (such as IFNγ) may 
drive IRF1 expression. Since IFNα is considered to mediate the response to 
other ISGs in islets, it seems likely that IRF1 is controlled by a different 
cytokine. In support of this, it is known that hyperexpression of several ISGs, 
(including HLA-ABC and STAT1 (and thus also MxA)) can be detected in the 
absence of immune cell infiltration (Foulis et al., 1986, Krogvold et al., 2016, 
Richardson et al., 2016), whereas increases in IRF1 were most commonly seen 
in the vicinity of CD45+ immune cells. IRF1 expression correlated with the 
expression of the immune checkpoint inhibitor, PDL-1 (discussed in chapter 3). 
PDL-1 upregulation on β-cells is protective against immune mediated cell death, 
thus it may be postulated that IRF1 upregulation is protective for β-cells. The 
significance of IRF1 upregulation in T1D beyond the correlation in expression 





Figure 7-2 Proposed interferon signalling in T1D 
A normal response to a viral infection is to produce type 1 interferon, 
however, excessive type 1 IFN will result in exaggerated ISG expression 
(e.g. STAT1, MxA and HLA-ABC). Expression of these cytokines and ISGs 
act as a trigger for immune cells to hone in on. Certain immune cell subsets 
secrete IFNγ, which I hypothesise may augment STAT1 and HLA-ABC 
expression, but additionally, induces the expression of IRF1, adding to the 





7.2 Islet expression of PPP1R1A and its role in β-cell function 
7.2.1 Islet expression of PPP1R1A and its role in β-cell function 
The initial rationale for investigating PPP1R1A in the β-cell was its strikingly 
restricted tissue distribution according to literature reports and our independent 
confirmation in house, that PPP1R1A is robustly expressed in pancreatic islets 
(Dhayal et al, unpublished). Immunofluorescence staining further revealed that 
PPP1R1A expression is restricted to β-cells in human islets and that, in donors 
with no diabetes, PPP1R1A is highly expressed in the majority of these cells. In 
T1D however, the expression of PPP1R1A in β-cells is much reduced. It was 
depleted from some β-cells in donors who were diagnosed <7 years of age, but 
was even more dramatically depleted in donors diagnosed >13 years of age. In 
donors who had T1D with a longer duration, residual insulin containing β-cells 
did not express PPP1R1A, however α-cells in these residual ICIs unexpectedly 
became immunopositive (Figure 7-3). The reason for α-cell immunopositivity of 
PPP1R1A was not explored in further detail, but may be due to β-cell trans-
differentiation from β- to α-cells. Further to these findings, the role of PPP1R1A 
in pancreatic β-cells was examined.  
 
Figure 7-3 Summarised expression pattern of PPP1R1A  
Summarised expression pattern of PPP1R1A in donors with no diabetes 





7.2.1.1 PPP1R1A and regulation of anti-viral responses 
An original aim of my project was to investigate whether the depletion of 
PPP1R1A from β-cells in T1D impacted their responses to viral infection. 
However, this could not be achieved as the work had to be undertaken in rodent 
cells since (as discussed in Chapter 5) the human 1.1B4 clone proved 
problematic. Somewhat surprisingly, the amino acid sequence of MDA5, the key 
downstream target whose activity is controlled by PPP1R1A, differs between 
humans and rodents and there is a unique phosphorylation site in the human 
protein (at Ser 88) which is regulated in a reversible manner but is missing from 
the rodent protein (Wallach and Kovalenko, 2013, Wies et al., 2013). Thus, it 
was not feasible to monitor PPP1R1A mediated MDA5 regulation, as no 
appropriate cellular model was available to do so. This was disappointing 
because our hypothesis was centred around the concept that the elevated 
expression of PPP1R1A in β-cells donors without T1D would maintain MDA5 in 
an inactive conformation and minimise IFNα generation. By contrast, when 
PPP1R1A is depleted from β-cells (in donors with T1D) MDA5 activation would 
ensue leading to markedly increased TI IFN-signalling. This apparent “over 
activation” of MDA5 would then contribute to the increased expression of HLA-
ABC, STAT1 and MxA (Figure 7-4) all of which occur in the islets of people with 
T1D. Confirmation of these mechanisms in cellular studies would have been 




Figure 7-4 Proposed mechanism of PPP1R1A regulated IFN release from virally 
infected pancreatic β-cells 
In the presence of PPP1R1A, the activity of PP1 is regulated leading to the 
activation of MDA5, resulting in an appropriately controlled type 1 IFN 
response (left). In the absence of PPP1R1A however (right), PP1 activity 
will be dysregulated, and available to dephosphorylate and activate MDA5. 
More active MDA5 will result in increased type 1 IFN release and increased 




7.2.1.2 PPP1R1A and regulation of cell cycle progression 
Pancreatic β-cells seldom replicate beyond the earliest years of life and 
investigating the role of PPP1R1A in cell cycle progression was not an original 
aim of my study. However, interesting and unexpected observations of 
endogenous PPP1R1A phosphorylation were made in mitotic cells (which do 
not ordinarily express detectable PPP1R1A). Furthermore, the same 
phenomenon was observed in multiple cell lines available in the lab. Follow-up 
studies showed that sustained PPP1R1A phosphorylation was detrimental to 
cell viability, and suggested that the cells were unable to successfully complete 
mitosis (Figure 7-5). When sustained phosphorylation of PPP1R1A was induced 
for over 6 hours, there was a significant increase in the proportion of apoptotic 
cells within the population (Figure 7-5). Moreover, daughter cells appeared to 
retain connections which I suspect may be retained chromosomal bridges, 
which is indicative of incomplete mitosis.  
Despite the links between PPP1R1A (phosphorylation) and cell cycle 
progression observed in multiple clonal β-cell lines, the same patterns were not 
observed in the β-cells of donor pancreas samples. Mitotic cells in the exocrine 
pancreas were identified as having elevated phosphorylated PPP1R1A, so the 
phenomenon may not be β-cell specific. Rather, it may be a requirement for all 
cell types to transiently upregulate and phosphorylate PPP1R1A at a critical 





Figure 7-5 Schematic diagram showing the proposed phosphorylation changes 
of PPP1R1A during cell cycle progression 
PPP1R1A is rapidly phosphorylated during prophase and metaphase, and 
then for successful completion of mitosis, PPP1R1A must be 
dephosphorylated during anaphase. If there is no decrease in 
phosphorylated PPP1R1A, then cells will enter a phase of mitotic 







7.2.1.3 PPP1R1A and secretion 
The findings described in Chapter 6 were interesting as they are different from 
outcomes reported by other research groups (Dorrell et al., 2016, Taneera et 
al., 2015). It had been previously shown that PPP1R1A is critical for glucose 
stimulated release of insulin from pancreatic β-cells (Taneera et al., 2015). 
However, the findings reported in Chapter 6 suggested a minimal role for 
PPP1R1A in regulating insulin secretion in response to glucose, or other insulin 
secretagogues, in my studies.  
Interestingly I found that, PPP1R1A, or more specifically, PPP1R1A 
phosphorylation, may be pivotal in regulating constitutive secretion. In the non-
β-like-h1.1B4 cells, where regulated secretion was not observed, PPP1R1A 
phosphorylation inhibited (constitutive) secretion of human growth hormone 
(Figure 7-6). It seems possible, therefore, that in healthy β-cells, PPP1R1A 
expression (and phosphorylation) may also inhibit constitutive secretion. In 
situations where PPP1R1A is depleted from β-cells (such as in T1D), a larger 





Figure 7-6 Differences between the rate of constitutive secretion  when 
unphosphorylated, vs. phosphorylated PPP1R1A is overexpression in cells 
Overexpression of PPP1R1A in cells had negligible effects on secretion, 
however inducing phosphorylation of PPP1R1A, dramatically reduced the 
rate of secretion from cells expressing only the constitutive secretory 
pathway. This indicates that a critical substrate of PP1 may exist and that 
must be maintained in a dephosphorylated state in order to sustain 
constitutive secretion.  




7.3 Contamination of human 1.1B4 cells with rodent cells 
7.3.1 H1.1B4 cells 
My discovery that purportedly “human” 1.1B4 cells were contaminated with rat 
cells, presented not only challenges, but also answers to explain why various 
assays had yielded unexpected results when these cells were used. My 
experience should provide an important lesson to the wider scientific 
community, in that thorough cell line authentication should be carried out before 
cell lines are distributed by recognised cell banks and checks for authenticity 
should be made regularly. As a result of the 1.1B4 cell contamination, 
international guidelines have now been changed on hybrid cell line 
authentication. In particular, ECACC and the international cell authentication 
committee now recommend that cells should be tested not only to verify the 
reported species of origin (which as the previous situation) but also to confirm 
(or deny), the presence of additional species. DNA profiling of mouse, rat, 
Chinese hamster and African green monkey will be carried out in validation of 
cell lines in the future (https://www.phe-
culturecollections.org.uk/media/177519/authenticating-hybrid-cell-lines.pdf 




7.4 Limitations of studies 
Inevitably, my studies have certain limitations and, among these, are the 
following: 
 The 1.1B4 Flp-In T-REx cells are now confirmed as rat rather than 
human cells (as originally supposed), thus not all outcomes may 
translate to the human situation.  
 My studies have focussed on the role of full length native and non-
phosphorylated mutant forms of PPP1R1A. The role(s) of the various 
isoforms of PPP1R1A have not been investigated. Given that I have 
shown that all three isoforms are expressed in human islets, 
understanding of the role(s) of each isoform could help determine the 
role of PPP1R1A in pancreatic β-cells.    
 When examining responses in pancreas sections recovered from human 
donors, a relatively small sample size was used. Thus, expanding the 
data to include a wider range of cases would be advisable.  
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7.5 Future work 
 A study of the effects of PPP1R1A on cellular response to enteroviral 
infection would be beneficial. Developing a suitable cell model in which 
such experiments can be carried out is crucial. Currently, there are no 
human β-cell lines that can be readily manipulated in such a way that 
PPP1R1A expression can be controlled while sustaining a persistent 
enteroviral infection. A potential way around this might be to use 
CRISPR-Cas9 technology to silence PPP1R1A in human EndoC-βH1 
cells (which is feasible with new technologies), and to compare anti-viral 
responses in WT and PPP1R1A KO cells. This may be a challenge, 
however, as PPP1R1A expression in EndoC-βH1 cells appears to be 
heterogeneous despite the claim that these represent a clonal cell 
population. It is also unclear whether EndoC-βH1 cells can-maintain a 
persistent enteroviral infection in tissue culture.  
 Further validation that PPP1R1A may exert an impact on the constitutive 
pathway of secretion is also an important objective. Assuming that this 
conclusion is verified, then understanding the mechanisms involved 
would also be of interest. There are limitations to this as inducing 
phosphorylation of PPP1R1A (which is necessary for inhibition of 
constitutive secretion) for more than a couple of hours in tissue culture 
results in cell death by apoptosis (discussed in Chapter 6).  
 The studies described in this thesis have investigated the effects of WT 
(full length) PPP1R1A and a full length non-phosphorylatable mutant. 
However, additional isoforms of PPP1R1A are present in pancreatic β-
cells, at least at the mRNA level, and it will be important to explore 
whether these are translated to yield functional protein isoforms. Creating 
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the alternatively spliced mutant forms of PPP1R1A, and overexpressing 
these in β-cells to observe their effects (if any) on responses to persistent 
enteroviral infection, cell viability or secretion, would be interesting.  
 Given my discovery that IRF1 has a different expression pattern 
compared to other ISGs in T1D, further studies into the role of IRF1 in 
regulating immune cell infiltration in T1D could be beneficial. This may 
help in understanding whether IRF1 acts to promote and sustain immune 




7.6 Concluding remarks 
The findings reported in this thesis provide strong support for the hypothesis 
that a viral infection is associated with the development of Type 1 diabetes. 
These findings highlight that it may not be the viral infection per se which is 
determinant of Type 1 diabetes development but the way in which the host 
responds to a viral infection. The evidence presented illustrates that a more 
exaggerated immune response to virus is present in individuals with Type 1 
diabetes, than is evident in those without the condition. These findings thus 
provide evidence to support the hypothesis that an enteroviral vaccine could 
work as a potential prevention strategy for individuals at risk of developing Type 
1 diabetes. This work also provides a clear road map for future mechanistic 
studies into how a viral infection of β-cells may trigger Type 1 diabetes 
development and how this response differs in people without Type 1 diabetes 
susceptibility. Therefore the potential impact of this work may be considerable.  
Other novel findings in this thesis implicate PPP1R1A as an important β-cell 
protein. Its marked depletion from β-cells in Type 1 diabetes may be critical to 
their loss of function as insulin secreting cells. The data described provides 
grounds to elaborate on the role of PPP1R1A in β-cells further. Understanding, 
whether PPP1R1A is involved with regulation of MDA5 activity in β-cells, and 
resultant response to viral infection, or other cell functions e.g. regulation of 
constitutive secretion, cell cycle progression or another role, will be important if 
dysregulation of this protein is indeed a key driver of β-cell function and 
susceptibility to viral infection. These findings justify further studies into the role 
of PPP1R1A, and may impact future treatments for T1D, especially since 
PPP1R1A has a very selective expression profile. 
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In addition to the impact this work may ultimately have on understanding the 
course and implications of viral infections in β-cells in Type 1 diabetes, perhaps 
the finding which may have the biggest impact on the diabetes research 
community, as well as all research communities which use human cell lines, is 
the identification of contamination in the 1.1B4 cell line. As a result of this 
finding, International cell line authentication guidelines have been changed. Cell 
lines are now not only checked to be the species which they indicate they are, 
but additionally, cell lines are validated to not contain evidence of any other 
species. This important finding will ensure that cell lines which previously were 
not known to be contaminated (such as the 1.1B4 cell line), will now be 
identified as contaminated, and thus, contaminated cell lines will not be used. 
This will result in increased confidence that cell lines are as they say they are, 
and not contaminated. Going forward, this will benefit the research community, 
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